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ABSTRACT 
 
 E. coli biotin ligase (BirA) catalyzes the site-specific ligation of biotin to the 
lysine within its 15-amino acid peptide substrate (AP).  We harnessed the high peptide 
substrate specificity of BirA to develop a general methodology for site-specific protein 
labeling with biophysical probes.  We synthesized an isosteric ketone analog of biotin 
and discovered that BirA also ligates it to the AP with similar kinetics while retaining the 
high peptide specificity of the native reaction.  Because ketones are absent from native 
cell surfaces, recombinant AP-fused cell surface proteins can be tagged with the ketone 
analog, and then specifically conjugated to hydrazide- or hydroxylamine-functionalized 
molecules.  We demonstrated this two-step protein labeling methodology on purified 
protein, in the context of mammalian cell lysate, and on epidermal growth factor receptor 
expressed on the surface of live HeLa cells. Both fluorescein and a benzophenone 
photoaffinity probe were incorporated, with total labeling times as short as 20 minutes. 
To develop new protein labeling methodology, we synthesized azide analogs of 
biotin, but found that BirA did not accept them as substrates.  Our efforts to rationally 
design mutations in the active site to accommodate these analogs met with little success.  
We thus investigated in vitro compartmentalization as a platform for re-engineering the 
substrate specificity of BirA through in vitro evolution.  Selections did not enrich for 
BirA mutants that could catalyze ligation of the azide analog to the AP, but instead 
highlighted the technical difficulties of our in vitro compartmentalization strategy.    
 We used phage display to engineer a new and orthogonal biotin ligase-acceptor 
peptide pair for site-specific protein labeling. Yeast biotin ligase (yBL) does not 
biotinylate the AP, but we discovered a new 15-amino acid substrate for yBL, which we 
call the yeast acceptor peptide (yAP).  The yAP is not biotinylated by BirA, and thus we 
were able to specifically label AP and yAP fusion proteins co-expressed in the same cell 
with differently colored quantum dots.  We fused the yAP to a variety of recombinant 
proteins and demonstrated biotinylation by yBL at the N-terminus, C-terminus, and 
within a flexible internal region. yBL is also very sequence-specific, as endogenous 
proteins on the surface of yeast and HeLa cells are not biotinylated. This new 
methodology expands the scope of biotin ligase labeling to two-color imaging and yeast-
based applications.  
 
Thesis Supervisor:  Alice Y. Ting 
Title:  Pfizer-Laubach Associate Professor of Chemistry 
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Chapter 1:  Introduction 
Part 1:  Methodologies for site-specific labeling of proteins in live cells 
 
 
The majority of the information presented in Part 1 was published in:   
Chen, I. and Ting, A. Y.  Site-specific labeling of proteins with small molecules in live 
cells.  Curr. Opin. Biotechnol. 16, 35-40 (2005). 
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The use of reporters such as fluorescent proteins (FP), β-lactamase, β-
galactosidase, and luciferase has revolutionized cell biology by conferring the ability to 
visualize, monitor, and quantify proteins in living cells with high spatial and temporal 
resolution1.  Although powerful, these reporter proteins are limited by their large size, 
which can alter the structure and function of the protein to which they are fused2,3; their 
potential interference with endogenous processes such as polyubiquitination4; and their 
restriction to optical imaging applications.  As our understanding of cell signaling 
improves, researchers are increasingly interested in probing the more sophisticated 
functions of proteins in their natural habitats.  For example, photocaging groups could be 
used to temporally regulate protein activity; photoaffinity probes could reveal detailed 
molecular information about protein-protein interactions; magnetic resonance imaging or 
positron emission tomography probes could allow imaging of tissue in live animals; and 
electron microscopy probes could provide much higher resolution spatial information 
after cell fixation.   
However, the principal barrier to the utilization of these probes in the cellular 
context has been the shortage of robust site-specific protein labeling methodology.  
Whereas the strength of reporters like the FPs lies in the perfect labeling specificity and 
technical simplicity of genetic fusion, the chemoselective reaction of a small molecule 
probe with a single functional group on a single protein poses an enormous chemical 
problem, particularly inside living cells where thousands of other proteins, DNA, RNA, 
carbohydrates, and small molecules present the same range of functional groups.  
Biochemists have typically exploited the unique reactivities of the cysteine sidechain, 
which reacts with maleimide- or haloacetamide-functionalized molecules, and the amino 
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group at the protein N-terminus, which has a reduced pKa compared to that of the lysine 
sidechains, for labeling proteins with small molecules in vitro.  These strategies cannot be 
applied inside cells because nearly all proteins have cysteine residues or a free  
N-terminus.  To circumvent the specificity challenge posed by the cellular environment, 
labeling can be performed in vitro and the labeled protein can then be introduced into the 
cell by microinjection5.  This strategy, however, is technically challenging and frequently 
alters the natural distribution of the protein. 
Therefore, various methods have been developed to target small molecule probes 
to recombinant proteins expressed in their native cellular environment.  The goal of all of 
these labeling methods has been to target diverse small molecule probes to the proteins 
with comparable specificity as FP fusion6,7.  Most strategies for achieving specificity 
have generally relied upon unique combinations of amino acids, which we refer to as 
“recognition sequences,” that recruit the small molecule probe.  These recognition 
sequences are genetically fused to the protein and can be either full-length proteins or 
small peptides.  In some cases the information contained in the recognition sequence 
alone is sufficient to confer specificity (Figures 1A and 1B).  In other cases, an enzyme is 
necessary to mediate the conjugation of the probe to the target sequence (Figure 1C).  
Other methods do not require the use of recognition sequence tags, as the introduction of 
the probe is accomplished through engineered protein translational machinery (Figure 
1D). 
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In Part 1 of this first chapter, we evaluate existing labeling methods on the basis 
of several criteria, with a particular focus on applicability to live cell imaging.  First, we 
consider the specificity of the method.  In evaluating specificity, we consider not only the 
chemoselectivity of the strategy for probe recruitment, but also the presence of any side 
Figure 1.  Strategies for site-specific labeling of recombinant proteins with small molecules in live 
cells.  (A) Small molecule labeling using protein tags.  The protein of interest (white oval) is 
expressed, fused to a protein tag (e.g. DHFR or hAGT, blue) that is able to bind noncovalently or 
covalently to a small molecule (e.g. methotrexate or O6-benzylguanine conjugate, red).  (B) Small 
molecule labeling using peptide tags.  The protein of interest is expressed, fused to a peptide tag 
(e.g. tetracysteine motif, blue) that is able to bind to a small molecule (e.g. fluorogenic biarsenical, 
red).  (C) Small molecule labeling using enzyme-mediated covalent attachment to a peptide tag 
(e.g. acceptor peptide, blue).  An enzyme (e.g. biotin ligase, grey) labels the peptide tag with the 
small molecule (red) directly or with a functional handle to which the small molecule probe ligates 
through a chemoselective reaction.  (D) Probe incorporation by unnatural amino acid mutagenesis.  
An amber stop codon (UAG) is introduced by site-directed mutagenesis within the gene encoding 
the protein of interest.  During protein translation, a tRNA bearing the antibodon AUC, which has 
been aminoacylated with the unnatural amino acid (red), suppresses the stop codon and enables 
production of the full-length protein containing the unnatural amino acid.   
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reactions or other mechanisms of probe retention that may result in high background for 
imaging applications.  We also consider any undesired side effects of application of these 
methods in live cells, such as the invasiveness of the recognition sequence and potential 
toxicity of any of the labeling reagents.  We also evaluate the generality of the method by 
identifying any restrictions on cell types and cellular compartments that can be labeled, as 
well as any restrictions on the probe structures that can be conjugated.  Lastly, we also 
consider the stability of probe attachment to the recognition sequence and the timescale 
of labeling, which are critical factors in determining the types of biological processes that 
can be studied.  Table 1 at the end of this section summarizes the relative merits and 
disadvantages of existing labeling methods.  The majority of the information presented in 
this section of Chapter 1 has already been discussed in a recent review by Chen and 
Ting6. 
 
Small molecule labeling using protein recognition sequences 
The most straightforward method for targeting a small molecule to a protein 
sequence is to use a binding interaction (Figure 1A).  In this approach, the protein of 
interest is genetically fused to a protein tag that is capable of binding to a probe-
conjugated ligand.  The binding interaction should be sufficiently tight so that a good 
signal-to-noise ratio can be achieved over background nonspecific interactions.  In one of 
the first demonstrations of this concept, Farinas and Verkman used single-chain antibody 
tags fused to localization signal sequences to target various hapten-fluorophore 
conjugates to specific subcellular compartments of the secretory pathway in live cells8.  
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However, antibodies do not serve as good, general protein recognition sequences because 
they express poorly outside of the oxidizing environment of the secretory pathway.   
More recent approaches have employed Escherichia coli dihydrofolate reductase 
(DHFR) and the F36V mutant of FK506 binding protein 12 (FKBP12 F36V) as protein 
tags.  DHFR binds to methotrexate with a dissociation constant (Kd) of 25 pM9, and 
FKBP12 F36V binds to the synthetic ligand for FKBP12 (SLF´) with a Kd of 94 pM10.  
Appending various biophysical probes to these small molecule ligands is synthetically 
straightforward and does not reduce the binding affinity for the protein targets.  Nuclear- 
and plasma-membrane localized DHFR fusion proteins were labeled in DHFR-deficient 
Chinese hamster ovary (CHO) cells using a membrane-permeable Texas Red-
methotrexate conjugate11.  Similarly, a fluorescein-SLF´ conjugate was used to label 
several FKBP12 F36V fusion proteins in NIH-3T3, COS-7, Jurkat, and HeLa mammalian 
cell lines12.   
Labeling with these tags is fast and highly specific, due to the high affinity of the 
protein-ligand interactions.  Both methods enable labeling with probes of diverse 
structures due to the modularity in the design of the ligand-probe conjugate.  However, 
like the FPs, these protein tags are large; DHFR and FKBP consist of 157 and 108 amino 
acids, respectively.  Furthermore, as a result of the noncovalent probe recruitment, ligand 
dissociation causes the signal to deteriorate over time.  For example, the Texas Red-
methotrexate conjugate remains localized to DHFR fusion proteins for only about one 
hour after washout of unbound methotrexate conjugate11.  DHFR-methotrexate labeling 
has the additional disadvantage of high background in mammalian cells stemming from 
the labeling of endogenous DHFR, unless DHFR-knockout cell lines are used.  In 
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contrast, the SLF´ ligand has a >1000-fold preference for the F36V mutant over wild-type 
FKBP12.  The background staining of mammalian DHFR can be reduced significantly by 
using probe conjugates to trimethoprim, which binds to E. coli DHFR 250-fold times 
better than it binds to mammalian DHFR13,14.  
The extremely high-affinity interaction between avidin and biotin (Kd = 1 fM15) 
can also be exploited for labeling with minimal signal attenuation.  Recombinantly 
expressed chicken avidin has been targeted to various compartments of the secretory 
pathway and labeled with biotin-fluorescein conjugates of various pKa values, in order to 
measure the pH values within those compartments16,17.  Besides its large size, other 
drawbacks of using avidin as a protein tag include its tetrameric nature and its potential 
toxicity through essentially irreversible biotin sequestration.   
Stabilizing the protein-small molecule binding event with a subsequent covalent 
reaction also eliminates the problem of signal loss via ligand dissociation.  Johnsson and 
co-workers exploited the alkylation of Cys145 of human O6-alkylguanine transferase 
(hAGT) with various O6-benzylguanine suicide substrates to covalently label nuclear, 
cytosolic, cytoskeletal, and cell surface recombinant proteins with fluorophores in E. coli, 
yeast, and hAGT-deficient mammalian cells18-20.  Similarly, the HaloTag™ protein 
(Promega), a bacterial haloalkane dehalogenase that has been engineered to form 
covalent enzyme-substrate adducts, has been used as a protein tag to enable the covalent 
attachment of various chloroalkane-bearing fluorophores21 and quantum dots22.  
In a separate approach, covalent probe ligation to the protein recognition sequence 
requires the presence of an enzyme catalyst.  The Burkart, Walsh, and Johnsson labs have 
independently developed labeling methodologies employing a phosphopantetheine 
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transferase enzyme (PPtase) to label an ~80-amino acid protein recognition sequence 
derived from either peptide carrier protein (PCP) 23,24 or acyl carrier protein (ACP)25.  
PPtases covalently transfer 4′-phosphopantetheine-linked probes from coenzyme A 
(CoA) to one specific serine sidechain of either ACP or PCP.  This enzyme-mediated 
ligation has been used for fluorophore tagging of the α-agglutinin receptor Aga2p25 and 
Sag1p cell wall protein in yeast26, as well as the human G protein-coupled receptor NK125 
and transferrin receptor27 in mammalian cells. 
The hAGT, HaloTag™, and ACP/PCP labeling methods all have excellent 
specificity.  The specificities of hAGT and HaloTag™-mediated probe ligation derive 
from initial binding interactions that orient the reactive groups and ensure site-specific 
ligation.  The ACP or PCP-tagging method capitalizes on the inherent sequence-
specificity of the PPTase enzyme to ensure specific probe ligation.  All three methods are 
also versatile because the derivatization sites on the benzylguanine, chloroalkane, and 
CoA cores are permissive, and nearly any biophysical probe can be appended without 
affecting the specificity or rate of the ligation chemistry.  Labeling times with these 
methods are short; fluorescent benzylguanine, chloroalkane, or CoA probes are typically 
administered to cells for only 5-10 minutes before washout of the unreacted probe.  The 
development of fluorogenic probes, which become fluorescent only after ligation to the 
target sequence, would further reduce the labeling time because the “invisibility” of the 
unreacted probe eliminates the need for a washout step. 
The principal drawback of these three methods is the large tag size:  207 amino 
acids for hAGT, ~300 amino acids for HaloTag™, and ~80 amino acids for ACP or PCP. 
In addition, background labeling is observed for the hAGT method, since hAGT is 
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naturally found in mammalian cells.  To partially address this problem, mutant hAGTs 
have been engineered that react with the benzylguanine probes up to twenty times faster 
than endogenous hAGT28.  Ironically, despite the covalent attachment of the probe, signal 
attenuation is still a problem with hAGT labeling, because Cys145-alkylated hAGT is 
targeted for degradation at a rate of ~10%  per hour19.  Unlike the other two methods, 
PPtase-mediated labeling is currently restricted to the labeling of cell surface proteins in 
yeast and mammalian cells because of the membrane impermeability of the CoA 
conjugates.  Metabolic delivery of a coumarin fluorophore onto carrier protein fusions 
expressed in the cytoplasm has been demonstrated in living E. coli and suggests a 
possible strategy to extend PPtase-mediated labeling to intracellular applications23. 
 Lastly, we consider the use of temporary protein recognition sequences such as 
inteins and split inteins.  Inteins can be cleaved “tracelessly” via protein splicing or 
deubiquitination to produce a protein with an N-terminal cysteine.  The resulting N-
terminal cysteine is then derivatized via native chemical ligation with a thioester-
functionalized probe29.  Specific probe attachment is achieved because of the rarity of N-
terminal cysteines on endogenous proteins and the inherent chemoselectivity of native 
chemical ligation for N-terminal cysteines over internal cysteines of proteins.  This 
method is also versatile for probe structure and should work in any cell type, but the 
precursor intein and ubiquitin fusions are still large, even if temporary.  In addition, the 
rates of splicing and thioester ligation are slow, restricting the methodology to the study 
of biological processes that take place over several hours.  Moreover, intracellular 
cysteine and cysteamine compete with the target protein for reaction with the thioester, 
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reducing the labeling efficiency and necessitating extensive washouts to reduce 
background in imaging applications.   
Protein trans-splicing has also been used to tracelessly ligate a synthetic molecule 
to a protein expressed inside living cells.  The protein of interest Is expressed as a fusion 
to one half of the naturally occurring Ssp DnaE split intein.  The other half of the intein, 
conjugated to a synthetic molecule, is introduced inside the cell using a protein 
transduction domain.  Upon reconstitution of the intein, protein splicing is triggered, 
resulting in the simultaneous ligation of the synthetic molecule to the protein of interest 
and excision of the intein.  This strategy was used to ligate the FLAG epitope to green 
fluorescent protein expressed in live CHO cells30, but in principle it should be 
straightforward to apply this strategy to specifically and covalently attach diverse other 
probes.  For imaging applications, high background may be a concern as a result of the 
anticipated difficulty of washing out unreacted probe-split intein conjugate.  Like the 
strategies employing intein and ubiquitin tags, this method suffers from the large size of 
the temporary split intein tag (123 amino acids) and the slow kinetics of protein splicing.   
 
Small molecule labeling using peptide recognition sequences 
 Peptide recognition sequences represent a much less invasive option than protein 
recognition sequences due to their much smaller size.  As with proteins, small molecules 
can be targeted to peptides via high affinity binding interactions (Figure 1B).  
Streptavidin-binding peptides and bungarotoxin-binding peptides have been used as tags 
to recruit their fluorophore-labeled protein binding partners to the protein of interest31.  
However, the large size of the streptavidin- and bungarotoxin-probe conjugates partially 
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defeats the purpose of using a small peptide tag, and the membrane impermeability of the 
proteins restricts applications of this method to cell surface labeling applications.  Peptide 
tags that bind fluorophores directly have also been used for live cell labeling.  For 
instance, Nolan and co-workers have evolved a 38-amino acid peptide (“fluorette”) that 
binds with a Kd of 25 pM to the Texas Red fluorophore.  Labeling of this sequence in 
cells was demonstrated on a plasma membrane- localized GFP construct 32.  Even though 
the measured in vitro binding affinity is quite high, there is a background problem for live 
cell imaging because the Texas Red dye tends to localize in mitochondria.  Another 
drawback is that a new peptide partner must be evolved for every new probe of interest, 
which limits the versatility of the method.  Imperiali and co-workers have also developed 
genetically encodable peptide tags that bind with nanomolar affinity to lanthanide ions, 
which are interesting probes not only for fluorescence imaging but also for x-ray 
scattering and NMR33,34 .  Proteins fused with the lanthanide-binding peptide have been 
labeled in vitro, delivered inside mammalian cells through the protein transduction HIV-
Tat peptide, and imaged using fluorescent microscopy35.  To date, however, there have 
been no reports of lanthanide-labeling performed on proteins expressed in live cells.  The 
ultraviolet excitation wavelength of lanthanide ions and their potential toxicity may limit 
applications of this methodology on live cells. 
Several labeling methods have been developed based on the affinity of 
oligohistidine sequences for nickel (II) nitrilotriacetic acid (Ni-NTA) complexes.  The 
first labeling strategies employed a hexa- or decahistidine tag that bound a single 
fluorophore-derivatized Ni-NTA complex with very modest affinity (Kd ~1-20 µM)36,37.  
The affinity was improved by about four orders of magnitude by binding three Ni-NTA 
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complexes per oligohistidine sequence, which enabled the imaging of the type I 
interferon receptor subunit ifnar2 on live Sf9 insect cells38.  Besides the typical 
drawbacks of non-covalent probe recruitment, the Ni-NTA/oligohistidine methodologies 
also suffer from quenching of the fluorescence by the paramagnetic Ni2+ ion (although 
not observed by Lippard and co-workers37) and the toxicity of Ni2+ to cells.  These 
deficiencies of Ni-NTA have been partially addressed by the recent development of a 
fluorescein dizinc compound that binds with nanomolar affinity to hexahistidine 
sequences39.    
 The use of the Tsien laboratory’s fluorogenic biarsenical (FlAsH) compounds to 
label a six-amino acid tetracysteine peptide (CCPGCC) is probably the most widely used 
alternative to genetic fusion to FPs40,41.  The probes are membrane-permeable and 
become intensely fluorescent upon binding to the tetracysteines.  The binding interaction 
(Kd ~ 2-4 pM) is significantly stronger than all of the other binding interactions that have 
been described above, so the signal deterioration problem observed with other non-
covalent probe targeting strategies is not as pertinent in this case.  Recent improvements 
to the original methodology have greatly enhanced its utility.  New biarsenical 
compounds that span the visible spectrum have been developed42; dyes that can also 
moonlight as photosensitizers to polymerize diaminobenzidine have been useful for 
electron microscopy imaging43; and dyes that generate singlet oxygen to inactivate 
protein function have also been reported44.   
Unlike most of the other methods described in this chapter, the FlAsH 
methodology has already begun making significant contributions to cell biology.  These 
probes have been applied to study connexin43, AMPA receptor45, VP4046, and 
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synaptotagmin I47 trafficking in live mammalian cells and Drosophila, often by 
employing a clever two-color pulse-chase labeling strategy that distinguishes younger 
protein from older protein.  However, several drawbacks still limit its utility.  The 
biarsenical compounds retain a significant affinity for isolated thiols.  Thus, lengthy (>1 
hour) and complex washouts with the olfactorily unpleasant 1,2-ethanedithiol reagent are 
required to compete away arsenic-monothiol interactions, even though the probes are 
fluorogenic.  In many cases, even the extensive washing does not fully eliminate 
background staining48.  New tetracysteine sequences that bind with higher affinity to the 
biarsenical probes have improved the specificity of the method49,50.  Other limitations of 
this method include the toxicity of arsenic and the requirement for the cysteines to be in 
reduced form for probe attachment, thus preventing applications in the secretory pathway 
and at the cell surface. 
In principle, peptide recognition sequences are more desirable than protein-based 
recognition sequences because their small size minimizes perturbation to the target 
protein.  Generally, the binding interactions of probes with peptides are weaker than 
those with full-length proteins, perhaps because of the limited amount of surface area that 
can be presented by peptides.  As a result, the use of peptides as probe recognition 
sequences is often accompanied by lower labeling specificity and greater signal 
attenuation, compared to the use of protein recognition sequences.   
 
Covalent small molecule labeling using peptide recognition sequences and enzymes 
Our laboratory has championed the use of enzymes to catalyze the attachment of 
small molecule probes to a genetically fused peptide recognition sequence51 (Figure 1C).  
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We have capitalized on the extraordinary sequence specificity of the enzyme E. coli 
biotin ligase (BirA) for its 15-amino acid acceptor peptide substrate (AP).  BirA catalyzes 
the ligation of biotin to the lysine residue within the AP, but we have found that a ketone 
analog of biotin can efficiently substitute for biotin in the reaction51.  As ketones are 
absent from cell surfaces, the enzymatically introduced ketone can be selectively 
derivatized with diverse hydrazide- or hydroxylamine-functionalized probes (Chapter 
3)51,52.  In principle, the combination of a small tag, covalent and diverse probe 
attachment, and extremely high labeling specificity distinguish BirA/ketone-mediated 
labeling from other methods that also employ peptide recognition sequences.  However, 
BirA/ketone labeling is currently limited to cell surface applications because of the 
incompatibility of ketone-hydrazide (or hydroxylamine) ligation with intracellular 
applications.  A detailed discussion of the development of this methodology, its 
advantages, its drawbacks, and suggestions for future improvement is presented in 
Chapters 2 and 3 of this thesis.   
Several other examples of enzyme-mediated labeling have been reported.  Some 
of these methods also use the same two-step labeling strategy of BirA/ketone-mediated 
labeling.  In a very similar approach, Bertozzi and co-workers have shown that an 
aldehyde can be site-specifically introduced within a six-amino acid peptide tag using the 
formylglycine-generating enzyme.  Derivatization of the aldehyde with diverse 
hydrazide- or hydroxylamine-containing probes has been accomplished in vitro, but 
labeling has not yet been demonstrated on live cells.53  Our laboratory has recently 
developed new labeling methodology using the lipoic acid ligase (LplA)-catalyzed 
ligation of an unnatural azide probe to a 22-amino lipoic acid peptide tag54.  The azide is 
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then chemoselectively derivatized with a cyclooctyne-conjugated probe55.  Although 
successful labeling has only been reported for cell surface proteins, LplA-mediated 
labeling has the potential to work inside cells, because the azide and cyclooctyne 
functionalities are completely absent from cells.  
Transglutaminase has also been harnessed by our laboratory to ligate diverse 
amine-containing probes to a specific glutamine residue within a 7-amino acid peptide 
tag expressed on the cell surface56.  An advantage of transglutaminase-mediated labeling 
over BirA- and LplA-mediated labeling is the single-step probe attachment to the peptide 
tag, which is enabled by transglutaminase’s wide tolerance for structurally diverse amine 
substrate.  However, transglutaminase does not exhibit the same degree of sequence 
specificity for its peptide substrate as BirA or LplA, so intracellular labeling applications 
would likely suffer from high background due to the presence of endogenous protein 
substrates of transglutaminase inside a cell.  Another method that enables single-step 
labeling is Sfp PPtase-catalyzed ligation of diverse CoA derivatives to the yBBR peptide 
tag57,58.  Like transglutaminase, Sfp PPtase possesses wide small molecule substrate 
tolerance, but it shares the same high specificity for its peptide substrate possessed by 
BirA and LplA.  As mentioned above for ACP/PCP labeling, the membrane 
impermeability of CoA derivatives restricts Sfp PPtase/yBBR labeling to cell surface 
proteins.   
Enzyme-mediated labeling represents a promising new strategy that retains the 
minimal invasiveness of peptide recognition sequences but improves the specificity and 
stability of probe recruitment.  We note that none of these enzymatic strategies have yet 
been applied to intracellular labeling.  A unique advantage of all of these enzyme-
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mediated methods is that the labeling can be spatially controlled through genetic targeting 
of the labeling enzyme.  For example, we are working on targeting BirA to the 
presynaptic surface of neurons, in order to specifically label the subpopulation of proteins 
that traffic to the postsynaptic surface.  This degree of spatial control is not attainable 
with other labeling methods where the probe recruitment is independent of a protein 
catalyst. 
 
Small molecule labeling through unnatural amino acid mutagenesis 
Unnatural amino acid mutagenesis via amber codon suppression has been used to 
label proteins in living cells59 (Figure 1D).  Biophysical probes such as benzophenone60 
and aryl azide61crosslinkers have been incorporated, as well as fluorophores such as 
dansylalanine62 and 7-hydroxycoumarin63.  Like BirA and LplA-mediated labeling, the 
versatility of this method is enhanced through the use of cell-compatible chemoselective 
ligation reactions.  For instance, unnatural amino acids bearing ketones64, azides61, or 
alkynes65 have been incorporated, allowing further derivatization using hydrazone 
formation, Staudinger ligation66, and azide/alkyne cycloaddition ligation reactions55,67,68.   
The major advantages of unnatural amino acid labeling are the perfect specificity, 
the diversity of probes that can be introduced, and the minimum possible structural 
perturbation to the protein of interest.  Unnatural amino acid mutagenesis has generally 
been restricted to applications in bacteria and yeast cells, although recent improvements 
have enabled broader applicability in mammalian cells69.  One concern regarding this 
method is that the ribosomes do not readily tolerate highly polar amino acids or amino 
acids considerably larger than tryptophan, which therefore places a limit on the types of 
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probe structures that can be directly introduced.  Also, a new orthogonal tRNA 
synthetase/tRNA pair needs to be evolved for every new probe.  Both of the above 
concerns can be addressed by the use of two-step labeling procedures employing 
chemoselective ligation reactions.  Another serious concern is that a large amount of 
truncated protein product is inevitably generated as a result of the competition between 
unnatural amber suppressor tRNA and the release factors that normally terminate protein 
synthesis at the amber stop codon.  This can lead to a dominant negative effect, especially 
if the protein of interest is multimeric in its functional state.   
 
Conclusions 
 Imperfect site-specific labeling methods represent the major bottleneck to 
utilization of small molecule probes in the cellular context.  The methods described here 
illustrate various approaches to addressing this difficult chemical problem.  Among the 
existing techniques, there is generally a trade-off between tag size and labeling 
specificity, although this can be surmounted through the use of additional mediating 
factors, such as enzymes or the cell’s translation machinery.  All of the discussed 
methods were developed for labeling recombinant proteins, but not endogenous proteins.  
Methods exist to label endogenous cell surface proteins on live cells through the use of 
fluorescent ligands and antibodies70, but these strategies suffer from probe dissociation, 
limits in scope, and invasiveness, particularly in the case of antibody labeling.  The 
unnatural amino acid labeling method is notable for its minimal tag size, but future 
approaches that enable introduction of probes onto endogenous, unmodified proteins will 
be highly desirable.  For future work, it is useful to look at creative methods that have 
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been developed for in vitro protein labeling and explore the feasibility of extending these 
to cell labeling applications, such as selenocysteine labeling71, sortase-mediated 
ligation72, or epoxide-based labeling73. 
 
Method Tag sizea 
Sources of 
background labeling Restrictions Other comments 
Protein recognition sequences     
Single-chain antibody ~230 None Oxidizing cellular compartments Protein-ligand dissociation 
DHFR 157 Endogenous DHFR None Protein-ligand dissociation 
FKBP12 (F36V) 108 None None Protein-ligand dissociation 
Avidin 128 None Oxidizing cellular compartments 
Tetramerization, toxicity 
from biotin sequestration 
hAGT 207 Endogenous hAGT None  
HaloTag™ ~300 None None  
ACP/PCP and PPtase 77 None Cell surface  
Intein/native chemical ligation 
(NCL) ~150→1
b Competition with 
cysteine during NCL 
Reducing 
environment NCL and splicing are slow 
Split intein/trans splicing ~123→1b 
Unreacted probe 
conjugate to one half of 
split intein 
Reducing 
environment trans-splicing is slow 
Peptide recognition sequences     
Streptavidin- and bungarotoxin-
binding peptides 13 None Cell surface  
Probe conjugates are large, 
ligand dissociation 
Texas Red binding peptide 23-38 Texas Red localization to mitochondria Texas Red only Ligand dissociation 
Lanthanide-binding tags 15-25 None Unknown 
Labeling not yet 
demonstrated in live cell 
context, ligand dissociation, 
UV excitation of lanthanide 
ion, lanthanide toxicity  
Oligohistidine/Ni-NTA 6-10 None Generally cell surface  
Ni2+ quenches fluorescence 
and is toxic, ligand 
dissociation 
Oligohistidine/fluorescein dizinc 6 None Cell surface  
tetracysteine 6-10 Significant affinity for monothiols 
Reducing 
environment 
Fluorogenic, long labeling 
times, possible residual 
arsenic toxicity 
Enzyme-mediated labeling of peptide sequences      
Biotin ligase/ketone 15 One natural substrate in E. coli Cell surface Two-step labeling 
Formylglycine-generating enzyme 6 None Unknown, but likely cell surface 
Not yet applied in live cells, 
two-step labeling 
Lipoic acid ligase/azide 22 Three natural substrates in E. coli Cell surface 
Two-step labeling, potential 
for intracellular labeling 
transglutaminase 6-7 
Can label endogenous 
proteins under forcing 
conditions 
Cell surface One-step labeling 
Sfp PPTase 11 One natural substrate B. subtilis  Cell surface One-step labeling 
Other methods     
Unnatural amino acid mutagenesis 0 None None Dominant negative effect due to truncations 
Table 1.  Different methods for labeling recombinant proteins with small molecule probes in live cells and 
their relative attributes.  a The tag size is given as the number of amino acids.  b The tag is temporary and is 
cleaved off inside the cell. 
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Biological function of BirA and other biotin ligases  
The enzyme E. coli biotin ligase (BirA) catalyzes the post-translational 
attachment of biotin to a specific lysine residue of its only natural substrate, the biotin 
carboxyl carrier protein subunit (BCCP) of acetyl coenzyme A carboxylase.  The 
mechanism of biotin transfer proceeds in two distinct steps and is analogous to that of 
tRNA charging catalyzed by aminoacyl-tRNA synthetases (Figure 2).  First, the enzyme 
catalyzes the formation of the biotin adenylate ester (biotin-AMP) from biotin and ATP 
and releases pyrophosphate (PPi) in the process.  Then, the reactive intermediate is 
attacked by the lysine residue of BCCP to effect biotin transfer.  The steady-state kinetics 
of BirA-catalyzed biotin transfer to BCCP have been measured.  The kcat value is 0.16 ± 
0.09 s-1, and the Km values for biotin, ATP, and BCCP are 0.49 ± 0.07 µM , ~0.3 mM, 
and 4.39 ± 0.37 µM, respectively74.  
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Post-translational biotinylation catalyzed by the biotin ligases is necessary for the 
function of the carboxylase, decarboxylase, and transcarboxylase enzymes, and it is 
generally believed that a single biotin ligase is responsible for the activation of all biotin-
dependent enzymes of the organism75.  These enzymes play a key role in the synthesis of 
cellular metabolites during fatty acid synthesis, gluconeogenesis, lipogenesis, amino acid 
Figure 2.  Site-specific biotin transfer catalyzed by the biotin ligases.  (A) Structure of biotin.  (B) 
Two-step reaction mechanism of biotinylation.  In the first step, the carboxylic acid of biotin is 
activated by reaction with ATP to form the biotin adenylate ester (biotin-AMP).  In the next step, the 
reactive lysine of the substrate attacks biotin-AMP, effecting biotin transfer .  
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metabolism and energy transduction75.  Biotin is an essential cofactor for these enzymes 
and serves as the carrier of an activated form of carbon dioxide for transfer to and from 
various organic acids.  Following biotin attachment to the carboxylases, carboxylate 
(CO2-) is fixed onto one of the ureido nitrogens of biotin through an enzyme-catalyzed 
reaction with bicarbonate ion.  The carboxylate group is then transferred from biotin to an 
organic acid in reactions catalyzed by the carboxylases (e.g. the formation of malonyl 
CoA from acetyl CoA that is mediated by acetyl CoA carboxylase).  The reverse transfer 
of carboxylate from organic acid to biotin is catalyzed by the decarboxylases.   
Some biotin ligases additionally function in gene regulation.  The complex of 
BirA bound to biotin-AMP (BirA-biotin-AMP) also moonlights as a transcriptional 
repressor of the biotin operon genes encoding enzymes involved in biotin biosynthesis.  
In the absence of protein substrate, BirA-biotin-AMP homodimerizes, binds 
cooperatively to the biotin operon DNA, and shuts down transcription76.  Repressor 
function is dependent on dimerization and the presence of bound biotin-AMP.  Thus, 
through the buildup of the BirA-biotin-AMP complex, biotin biosynthesis is coupled to 
the intracellular biotin concentration and BCCP substrate supply.  When the intracellular 
concentration of biotin is low or BCCP levels are high, all of the biotin-AMP is 
transferred to BCCP, and there is no buildup of BirA-biotin-AMP to shut down 
transcription of the biotin biosynthetic genes.  However, when the intracellular 
concentration of biotin is high or BCCP levels are low, the BirA-biotin-AMP complex 
accumulates and shuts down biotin biosynthesis.  A model has been proposed suggesting 
that binding of BirA to BCCP and BirA homodimerization are mutually exclusive, and 
thus, competition between BCCP and another BirA molecule for the same interface on 
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BirA-biotin-AMP effects the switch from biotin ligase to repressor activity (and vice 
versa)77.   
It is believed that other bifunctional biotin ligases, such as the enzymes from 
Bacillus subtilis and Methanosarcina barkeri, switch between ligase and repressor 
activity using the same mechanism as BirA78.  Other prokaryotic biotin ligases, such as 
the Methanococcus jannaschii and Pyrococcus horikoshii enzymes, lack DNA-binding 
domains and thus only have ligase activity78.  Eukaryotic biotin ligases do not possess 
DNA-binding domains, but it is believed that these enzymes still play a role in regulating 
transcription in response to changes in biotin levels79,80.  Gravel and co-workers have also 
demonstrated an additional role for mammalian biotin ligase in histone biotinylation, 
suggesting that mammalian biotin ligase could play a significant role in controlling 
general gene expression, like histone (de)acetylases and (de)methylases81.  
 
Protein domain structure of BirA 
 BirA has been the most biochemically and structurally characterized biotin ligase 
enzyme.  Four crystal structures of BirA have been reported with at least 2.8 Å 
resolution:  unliganded BirA (PDB:  1BIA)82, BirA bound to biotinyl-lysine (PDB:  
1BIB)82, BirA bound to biotin (PDB:  1HXD)83, and BirA bound to biotinol-adenylate, a 
non-hydrolyzable analog of biotin-AMP (PDB:  2EWN)84.  The former two structures are 
monomeric, whereas the latter two are dimers.   
 The structures all show that BirA consists of three distinct domains (Figure 3).  
The N-terminal domain (orange) is the DNA-binding domain, as evidenced by the 
characteristic helix-turn-helix motif.  The central domain (grey) contains the catalytic 
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active site.  The ureido group of biotin makes hydrogen bond contacts with the sidechains 
of Ser89, Thr90, and Gln112 and the protein backbone at Arg116.  The bottom thiophane 
ring and the valeric acid tail of biotin interact with a hydrophobic pocket that includes the 
Lys-Trp-Gln-Pro motif found in avidin82.  The ATP binding site has not yet been 
identified; a Gly-Arg-Gly-Arg-Arg-Gly loop was originally proposed to serve this 
function, but subsequent mutational studies have shown that the loop is involved with 
biotin and biotin-AMP binding instead85.  The β strand Val189-Lys194 that is proposed 
to interact with BCCP or another BirA molecule is also contained in this domain.  The 
function of the C-terminal domain (blue) is not exactly known, but mutational studies 
suggest a role in ATP and BCCP binding86.  From the structures, the N-terminal domain 
makes few contacts with the rest of protein.  Not surprisingly, a BirA mutant lacking this 
domain is still able to synthesize biotin-AMP from biotin and transfer biotin-AMP to 
BCCP with the same efficiency as the wild-type enzyme, although biotin and biotin-AMP 
binding to the enzyme is compromised87. 
 
 
 
 
Figure 3.  Structure of BirA showing the three distinct domains (PDB:  1HXD).  The N-terminal DNA-
binding domain is colored orange, the central catalytic domain is shown in grey, and the C-terminal 
domain is shown in blue.  Biotin (yellow) is also shown. 
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 The only other biotin ligase for which crystal structures have been determined is 
the P. horikoshii biotin ligase (unliganded, bound to biotin, ADP, and biotin-AMP).   
Comparison of the structures of the catalytic and C-terminal domains of P. horikoshii and 
E. coli biotin ligase suggests significant differences, which is perhaps not surprising 
because P. horikoshii biotin ligase lacks DNA-binding activity.  However, the features of 
the biotin binding site appear to be well conserved84.  Few eukaryotic biotin ligase 
enzymes have been cloned, but the yeast (Saccharomyces cerevisiae), human, and plant 
(Arabidopsis thaliana) biotin ligases have been characterized88-90.  The yeast and human 
enzymes (690 and 726 amino acids, respectively) are at least double in size compared to 
BirA (322 amino acids).  The C-terminal regions of these eukaryotic biotin ligases show 
homology with BirA. The function of the N-terminal domain is unknown, although in the 
yeast enzyme it was shown to be required for biotinylation activity88.  Interestingly, the 
N-terminal domain could be deleted in the human enzyme without abolishing 
biotinylation activity91.  
 
Characteristics of BirA desirable for site-specific protein labeling 
 The choice of enzyme is critical in developing new labeling methodology based 
on an enzyme-catalyzed reaction.  We generally look at enzymes that naturally catalyze 
the ligation of a small molecule onto a polypeptide, such as those that catalyze post-
translational modifications.  The most important attribute we look for in an enzyme is 
tremendous sequence specificity for its polypeptide substrate.  Ideally, the enzyme 
already has a known peptide substrate (25 amino acids or less).  The enzyme must 
possess some degree of tolerance with regards to small molecule substrate, so that 
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potentially useful analogs can be incorporated without extensive re-engineering of the 
active site.  Furthermore, the ligation of unnatural substrates must not compromise the 
enzyme’s natural specificity for the polypeptide.  
 The extraordinary sequence specificity of BirA makes it an ideal enzyme to use 
for site-specific labeling.  BirA has only one natural substrate in E. coli, BCCP.  Biotin 
ligases from other species are also very specific, only biotinylating between one and five 
proteins within their respective organisms.  We preferred using BirA because it had the 
highest specificity and also because there was wealth of experimental, structural and 
biochemical data available to us to guide any engineering efforts.  Also, BirA has been 
expressed inside mammalian cells without compromising its activity92 and sequence 
specificity (Mark Howarth and Alice Y. Ting, unpublished results). 
 Most importantly, unlike for the other biotin ligases, a peptide substrate already 
existed for BirA at the outset of this project.  This unnatural 15- amino acid peptide 
substrate (AP), with sequence GLNDIFEAQKIEWHE, was isolated from peptide 
panning of a randomized peptide library fused to the lacI DNA-binding protein93.  
Although it is biotinylated by BirA with similar kinetics (kcat/Km  = 10,000 ± 500 M-1 s-1 
for AP, kcat/Km  = 11,900 ± 400 M-1 s-1 for BCCP)94, the properties of this peptide 
substrate are very different than BCCP.  It is well known that the biotin ligases from 
different species can biotinylate the biotin acceptor domains (from the carboxylase 
enzymes) of other organisms.  In fact, functional complementation of BCCP biotinylation 
in an E. coli strain possessing a temperature-sensitive BirA mutant has been used for 
cloning the enzymes from yeast95, B. subtilis96, humans89, and A. thaliana97.  By contrast, 
the AP seems to be a substrate only for BirA, as we and others have subsequently 
46 
discovered that the B. subtilis, M. jannaschii, P. horikoshii, yeast98, Spodoptera 
frugiperda99, and mammalian biotin ligases92 all do not biotinylate the AP, at least within 
the detection limits of the reported assays (Sarah A. Slavoff and Alice Y. Ting, 
unpublished results).   
 Previous efforts to truncate the natural biotin acceptor proteins have led to 
minimal domains 70-80 amino acids in length75, because biotin ligases recognize a stably 
folded structure.  Structures of three of these acceptor proteins suggest a conserved 
tertiary structure, in which the lysine biotinylation site is presented at the tip of a tight 
hairpin loop100-102.  It is difficult to recapitulate such a three-dimensional structure in a 
peptide sequence, and it is probably for this reason that the AP mostly likely interacts 
with the BirA active site (Km ~ 25 µM94) in a different manner than BCCP. 
The high specificity of BirA and the small size of the AP have made site-specific 
biotinylation an important tool for protein purification in vitro, in living bacteria103, and 
in mammalian cells92.  Others in our laboratory have applied site-specific biotinylation to 
target streptavidin-conjugated fluorophores and quantum dots to cell surface proteins for 
cellular imaging104,105.   
The goal of my thesis was to develop new site-specific small molecule labeling 
methodology by expanding the chemistry of BirA beyond biotinylation.  The active site 
of BirA could be extensively re-engineered to ligate small molecule probes directly to the 
AP, but we favored the more conservative approach to investigate biotin analogs 
possessing functional handles that could enable covalent probe attachment through a cell-
compatible chemoselective reaction.  At the outset of this project, the small molecule 
substrate tolerance of BirA was largely unknown.  Only the biotin analogs oxybiotin106, 
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α-dehydrobiotin107, and desthiobiotin108 had been conclusively demonstrated to be 
substrates of bacterial biotin ligases.  Thus, a significant portion of this thesis is dedicated 
to syntheses of novel small analogs of biotin and our explorations of the substrate 
tolerance of BirA and its mutants with them. 
 We successfully developed two new methodologies for site-specific labeling of 
proteins on live cells, using unnatural substrates of biotin ligases.  In Chapter 2, we 
describe the synthesis of an isosteric ketone analog of biotin where the ureido nitrogens 
have been replaced with methylene groups.  We then demonstrated that the ketone analog 
is utilized by wild-type BirA as a substrate.  Using this new enzymatic chemistry we 
developed a new methodology to label cell surface proteins on live cells with diverse 
small molecule probes (Chapter 3).  To address the limitations of the methodology 
developed in Chapters 2 and 3, we synthesized several azide analogs of biotin in Chapter 
4, but we found that the wild-type enzyme did not accept any of them as a substrate.  We 
attempted to re-engineer the active site for these azide analogs using crystal structure-
guided rational design, but these attempts were unsuccessful.  We then sought to develop 
a platform for re-engineering the BirA active site through in vitro evolution, which is 
described in Chapter 5.  Lastly, in Chapter 6 we engineered an unnatural peptide substrate 
for yeast (S. cerevisiae) biotin ligase through phage display, thus expanding the scope of 
biotin ligase-mediated labeling to two-color imaging and yeast-based applications.   
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Chapter 2:  Total synthesis of a ketone analog of biotin 
 
 
The work presented for the thiolactone approach to ketone 1 is unpublished.  A 
portion of the work described for the sulfoxide route to ketone 1 was published in:   
Chen, I., Howarth, M., Lin, W., and Ting, A. Y.  Site-specific labeling of cell surface 
proteins with biophysical probes using biotin ligase.  Nat. Methods 2, 99-104 (2005).  
The work described for the Pauson-Khand route to ketone 1 was performed in 
collaboration with Eric McNeill, an undergraduate researcher in the Ting laboratory.  The 
majority of the Pauson-Khand work has been published in:  McNeill, E., Chen, I., and 
Ting, A. Y.  Synthesis of a ketone analogue of biotin via the intramolecular Pauson-
Khand reaction.  Org. Lett. 8, 4593-4595 (2006). 
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Introduction 
 In this chapter we describe the total synthesis of ketone 1, an isosteric analog of 
biotin where the ureido nitrogens have been replaced with methylene groups (Figure 1).  
Three synthetic approaches to ketone 1 are described, with two of them being ultimately 
successful. 
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In developing a synthetic strategy for ketone 1, we first drew inspiration from the wealth 
of information provided by past syntheses of biotin.  Over 60 total syntheses of both 
racemic and enantiopure biotin have been achieved by both academic and industrial 
scientists over the past 60 years1.   
Our first approach was based on the landmark thiolactone strategy that was 
originally developed by Hoffman-La Roche in 1946 (Figure 2, top)1.  Efforts to install the 
valeric acid sidechain by palladium-catalyzed Fukuyama coupling or Grignard addition to 
the analogous thiolactone precursor proved to be unsuccessful, causing us to abandon this 
approach.  Our next strategy was inspired by Marquet’s approach to biotin (Figure 2, 
bottom)2, employing stereoselective alkylation of sulfoxides to couple the sidechain to 
the bicyclic core.  This successfully yielded ketone 1 in 14 steps from commercially 
available starting materials, but in only 0.79% overall yield.  A portion of this work has 
been described in a recent publication by Chen, Howarth, Lin, and Ting3.    
 
Figure 1. Structures of ketone 1 and biotin. 
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 A more efficient synthesis of ketone 1 became desirable after we successfully 
demonstrated its utility as a protein labeling reagent in conjunction with E. coli biotin 
ligase (Chapter 3)3.  Capitalizing on the specific carbon framework of the bicyclic core, 
we developed a novel approach based on the Pauson-Khand [2+2+1] cycloaddition 
reaction.  This route yielded ketone 1 in six fewer steps and three-fold higher yield than 
our sulfoxide approach.  Furthermore, this route would allow expedient access to a wide 
variety of ketone 1 analogs, which could serve as valuable tools to probe the active site 
geometry and chemistry for both biotin ligases and the high affinity biotin-binding 
protein, streptavidin.  The majority of this work has been described in a recent 
publication by McNeill, Chen, and Ting4. 
Figure 2.  Previous synthetic approaches to biotin.  (top) In the thiolactone approach to biotin, both 
palladium-catalyzed Fukuyama coupling and Grignard addition have been used to couple the 
sidechain to the thiolactone 2.  (bottom) In another approach, the sidechain is introduced by 
alkylation of the sulfoxide 3.  
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Results and Discussion 
 
The thiolactone approach to ketone 1 
Our first retrosynthetic analysis was inspired by syntheses of biotin that installed 
the sidechain by Fukuyama coupling5 or Grignard addition6 to the thiolactone 2 (Figure 2, 
top).  The synthesis of thiolactone 11, the analogous precursor for ketone 1, proceeded in 
eight steps from commercially available cis-1,2,3,6-tetrahydrophthalic anhydride, 
beginning with a slight modification of a known reaction sequence (Figure 3)7.    
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First, ring opening of the anhydride to the dibenzyl ester 4 was accomplished by 
refluxing with benzyl alcohol (BnOH) and a catalytic amount of para-toluenesulfonic 
acid (p-TsOH) in toluene and azeotropically removing water with a Dean Stark trap.  
Following oxidative cleavage of the olefin by sodium periodate and catalytic potassium 
permanganate, the cyclization precursor 5 was obtained.  Decarboxylative cyclization to 
afford 6 was achieved in 57% yield by refluxing 5 and sodium acetate (NaOAc) in acetic 
anhydride (Ac2O).  Protection of the ketone as an ethylene ketal and cleavage of the 
Figure 3.  Synthesis of the thiolactone precursor to ketone 1.  a.  BnOH, cat. p-TsOH, PhCH3, reflux.  
b.  NaIO4, cat. KMnO4, K2CO3, t-BuOH/H2O.  c.  NaOAc, Ac2O, reflux.  d.  ethylene glycol, cat. p-
TsOH, PhCH3.  e.  H2, cat. Pd/C, MeOH.  f.  EDC, CH2Cl2.  g.  NaBH4, THF.  h.  KSAc, DMF, 150 
°C.  All chiral compounds were synthesized as a racemic mixture.  
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benzyl protecting groups by hydrogenation cleanly afforded the diacid 8 (95% in two 
steps from 6).  The diacid 8 was then cyclized by treatment with one equivalent of 1-
ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) to afford the 
anhydride 9.  Reduction of 9 by sodium borohydride afforded the racemic lactone 10 in 
only 36% yield, despite analytical thin-layer chromatography (TLC) showing complete 
consumption of the starting anhydride.  Finally, we cleanly converted lactone 10 to the 
thiolactone 11 by thionation with potassium thioacetate (KSAc).   
We also attempted to synthesize lactone 10 in enantiopure form by 
desymmetrization of the meso anhydride 9 with chiral reducing reagents.  We first tried 
chiral reduction with lithium aluminum hydride-ethanol-1,1′-bi-2-naphthol complex 
(BINAL-H), but the reaction was sluggish and yielded 10 in less than 9% yield.  By 
contrast, in a previous synthesis of biotin, BINAL-H reduction was used efficiently (76% 
yield, >90% enantiomeric excess (ee) ) to desymmetrize the analogous meso anhydride8.  
In another reported synthesis of biotin, desymmetrization of the highly related meso 
imide was accomplished very efficiently (92% yield, >96% ee) using a chiral 
oxazaborolidine catalyst derived from (1S,2S)-(+)-threo-1-(4-nitrophenyl)-2-amino-1,3-
propanediol9.  However, we never investigated this alternative strategy to eventually 
synthesize optically pure ketone 1.   
 Installation of the sidechain proved to be unexpectedly problematic.  We first 
attempted Fukuyama coupling of 11 with the organozinc reagent derived from ethyl 
iodovalerate (Figure 4). 
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Ethyl iodovalerate (12) was synthesized in one step from δ-valerolactone following the 
literature procedure (Figure 4A)5.  The organozinc reagent 13 was then generated by 
oxidative insertion of zinc, using 1,2-dibromoethane and trimethylsilyl chloride (TMSCl) 
as initiators.  However, when we treated thiolactone 11 with the zinc reagent 13 in the 
presence of 10 mol% bis(triphenylphosphine) palladium(II) chloride, we observed no 
reaction (Figure 4B).  Repeating the reaction on the unprotected ketone and/or changing 
the catalyst to palladium on charcoal10 also failed to yield any product.  At the time, the 
complete lack of reactivity of thiolactone 11 under these conditions was surprising, 
because the same conditions were used to couple 13 to thiolactone 2 in 86-94% yield5,10.  
A later personal communication with Dr. Masahiko Seki of Tanabe Seiyaku Corporation, 
who co-developed the Fukuyama coupling reaction for biotin synthesis, revealed that the 
N-benzyl protecting groups of thiolactone 2 are unexpectedly necessary for successful 
Fukuyama coupling; the reaction failed to proceed at all with deprotected 2.  It has been 
suggested that the benzyl groups may accelerate the reaction by stabilizing the 
palladacycle intermediate following oxidative insertion of palladium into the thioester10.     
Figure 4.  Attempts to install the sidechain via Fukuyama coupling.  (A) Synthesis of the 
organozinc reagent (13) from δ-valerolactone.  (B) All attempts to effect the Fukuyama coupling of 
11 and 13 failed, leading only to recovery of 11. 
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 Following the strategy employed by Chen et al. in their recent synthesis of biotin6, 
we also tried to install the sidechain through Grignard addition to thiolactone 11 (Figure 
5).  The Grignard reagent 16 was prepared from 1-methylcyclopentanol by retro-Barbier 
fragmentation, ketalization of the resulting bromoketone, and insertion of magnesium 
(Figure 5A).  Quenching studies with deuterated solvents and anisaldehyde confirmed the 
reactivity of our prepared Grignard reagent.  However, we again failed to observe any 
conversion to product after refluxing 11 and 16 together (Figure 5B), although the same 
reaction between 16 and thiolactone 2 was reported to proceed in 82% yield6.  A test 
reaction of thiolactone 11 with isopropyl magnesium chloride yielded an addition 
product, demonstrating that Grignard addition to thiolactone 11 is possible.  Although 
deprotonation at the ring junction should not be facile because of the ring strain of the 
resulting [3.3.0] bicycle, we nevertheless hypothesize that deprotonation alpha to the 
carbonyl by the Grignard reagent happens first and thwarts nucleophilic addition.  
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Figure 5.  Attempts to couple the sidechain via Grignard addition.  (A) Synthesis of the Grignard 
reagent (16)  from 1-methylcyclopentanol.  (B) All attempts to effect the coupling of 11 and 16 failed, 
leading only to recovery of 11. 
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Technical issues aside, it is not immediately obvious why the reactions that 
proceeded so efficiently with thiolactone 2 failed to work at all with thiolactone 11.  
Subtle conformational differences or fortuitous stabilization of reaction intermediates by 
the benzyl protecting groups may explain the grossly different reactivities of thiolactones 
2 and 11.  Our inability to install the sidechain by nucleophilic attack on the thiolactone 
forced us to abandon this synthetic route to ketone 1 and pursue a new retrosynthetic 
analysis. 
 
The sulfoxide approach to ketone 1 
 Our new retrosynthetic analysis was inspired by Marquet’s racemic synthesis of 
biotin, which installed the sidechain by stereoselective alkylation of sulfoxide 3 (Figure 
2, bottom)2.  The analogous precursor to ketone 1, sulfoxide 25, has been synthesized 
before11, conveniently using many of the same reactions used in our previous approach.   
We synthesized 25 in eight steps from cis-1,2,3,6-tetrahydrophthalic anhydride (Figure 
6A).  Protected dimethyl ester 20 was afforded using the same reaction sequence to 
synthesize the analogous dibenzyl ester 7, with some procedural modifications.  
Reduction of 20 with lithium aluminum hydride cleanly afforded the diol 21.   
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We encountered some difficulties in obtaining the diiodide 23 in good yield.  
Iodination of diol 21 proceeded in only 27% yield, with the major isolated product being 
the furan 22 (50%) that arose from competitive intramolecular cyclization of the mono 
iodide intermediate.  In theory, the furan 22 could be recycled to 23 in a three-step 
sequence involving deprotection of the ketal, furan ring-opening by heating with red 
phosphorous and hydroiodic acid, and reprotection of the ketone12.  We also tried 
activating the diol to a ditosylate, but we only isolated the monotosylate and 22 from the 
Figure 6.  Synthesis of ketone 1 via sulfoxide alkylation.  All chiral compounds were synthesized as 
racemic mixtures, and the configurations at each stereocenter are shown.  For atom numbering, see Figure 
7.   (A) a. MeOH, cat. p-TsOH, reflux.  b. KMnO4, H2O.  c. NaOAc, Ac2O.  d. ethylene glycol, cat. p-
TsOH, benzene, reflux.  e. LiAlH4, THF, 0 °C to rt.  f. I2, PPh3, imidazole, PhCH3.  g. Na2S, DMF.   
h. NaIO4, MeOH/H2O.  i. MeLi, THF/HMPA, 78°C, then 29, -30 °C.  j. PPh3, CCl4, reflux.  k. AcOH,  
aq. HCl, reflux.  l. pentafluorobenzyl bromide, DIPEA, CH2Cl2, then HPLC purification.  m. LiOH, 
THF/MeOH/H2O.  (B) Synthesis of tert-butyl iodovalerate (29).   
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reaction.  Despite its successful application in Marquet’s biotin synthesis, we never 
investigated mesylation of 21 as an alternative to iodination, instead choosing to proceed 
forward with the diiodide.  Double displacement of the diiodide with sodium sulfide was 
accomplished cleanly to afford the sulfide 24.  Oxidation of the sulfide with one 
equivalent of sodium periodate afforded the sulfoxide 25 as predominantly the cis 
(sulfoxide oxygen atom is on the same face as the ring junction protons) isomer. 
Installation of the sidechain was successfully achieved by alkylation of the 
carbanion of 25 with tert-butyl iodovalerate (29), which we synthesized in two steps from  
δ-valerolactone (Figure 6B).  Treatment of sulfoxide 25 at -78 °C with methyllithium in a 
2.5:1 mixture of tetrahydrofuran (THF) and hexamethylphosphoramide (HMPA) 
generated a carbanion that was then reacted with tert-butyl iodovalerate (29) at -30 °C.  
Following workup and quick silica gel chromatography to remove unreacted 25 and 29, 
the desired adduct 26 was reduced by refluxing with triphenylphosphine (PPh3) in carbon 
tetrachloride and then subsequently hydrolyzed to afford ketone 1 as an inseparable 
mixture of diastereomers (1-mix).      
The diastereoselectivity of the alkylation of sulfoxide 25 ranged from 1:2 to 1:5 in 
favor of the desired diastereomer.  The relative stereochemical configuration of the major 
product was confirmed by NOE (Nuclear Overhauser Effect) difference studies, which 
showed a 5% enhancement in the signal of the C-3 proton when the C-2 proton was 
irradiated (Figure 7; the atomic numbering scheme of ketone 1 is analogous to that 
reported for biotin13).  Moreover, we concomitantly observed no NOE enhancement of 
any of the protons at C-3′, which we would have expected for the undesired diastereomer 
possessing the opposite configuration at C-2.   
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As in Marquet’s precedent, the inherent preference for sulfoxide alkylation to occur trans 
to the S→O bond outweighs the preference for the alkylating agent to approach from the 
less sterically congested convex face of the bicycle, favoring the desired stereochemical 
consequence2.  We found that the diastereomers could be resolved by derivatization of  
1-mix to the pentafluorobenzyl ester and high-performance liquid chromatography 
(HPLC) purification on a semipreparative silica column.  Following basic hydrolysis of 
27, diastereomerically pure ketone 1 was afforded.  We also obtained small quantities of 
each enantiomer of ketone 1 by separating the enantiomers of 27 on a semipreparative 
chiral HPLC column and hydrolyzing each isolated enantiomer to the free acid. 
Our sulfoxide approach to diastereomerically pure ketone 1 requires 14 steps from 
commercially available starting material, and proceeds in 0.79% overall yield.  We 
obtained >100 mg of ketone 1 after three scale-ups of this route, which has been more 
than enough to satisfy our laboratory’s research needs over the past four years, even after 
distribution of the compound to other labs. 
    
The Pauson-Khand approach to ketone 1 
With our successful demonstration of the utility of ketone 1 for site-specific 
labeling using E. coli biotin ligase (Chapter 3)3, we became interested in developing a 
Figure 7.  Confirmation of the relative stereochemical configuration of the desired diastereomer by 
NOE difference studies.   Irradiation of the C-2 proton yielded a 5% signal enhancement of the C-3 
proton but no signal enhancement of any proton at C-3′.  The numbering of atoms is analogous to that 
reported for biotin (reference 13). 
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higher yielding and less time-consuming synthesis.  We would also like to make analogs 
of ketone 1, as part of our continued efforts to probe the active site geometry and 
chemistry for both E. coli BirA and the high affinity biotin-binding protein streptavidin.  
However, the low yield of ketone 1 via the sulfoxide route precludes access to ketone 1 
analogs through further chemical derivatization.  Furthermore, the nature of the reactions 
comprising this synthetic sequence does not permit facile access to analogs.  Therefore, 
we desire a shorter and higher yielding synthesis that would also permit access to a wider 
variety of ketone 1 analogs.   
In collaboration with Eric McNeill, an undergraduate student researcher in the 
Ting Laboratory, we designed a new synthesis of 1 that was not based on any previous 
synthesis of biotin.  Our approach centered around the intramolecular Pauson-Khand 
reaction, a [2+2+1] cycloaddition that has proven to be an effective methodology for 
accessing bicyclo-[3.3.0]-oct-5-en-7-ones from 1,6-enynes14,15, including allyl propargyl 
sulfides16,17.  In contrast to biotin, the carbon framework of the [3.3.0] bicycle of ketone 
biotin lends itself well to construction by this powerful reaction, which simultaneously 
forms two rings and three carbon-carbon bonds.  Our retrosynthetic analysis is shown in 
Figure 8.   
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We envisioned that ketone 1 would derive from 30 after reduction of the α,β-unsaturated 
carbonyl and hydrolysis of the methyl ester.  Pauson-Khand cyclization of 31 would yield 
Figure 8.  Retrosynthetic analysis for the Pauson-Khand approach to ketone 1. 
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the cyclopentenone 30.  The Pauson-Khand precursor 31 could be obtained after addition 
of acetylene to methyl 6-oxohexanoate 32, complexation with octacarbonyldicobalt, and 
displacement of the propargylic alcohol with allyl mercaptan.  Aldehyde 32 could be 
synthesized in one step from cyclohexene according to a literature procedure.    
The synthesis of ketone 1 (Figure 9) proceeded in eight steps.  Ozonolytic 
cleavage of cyclohexene in the presence of methanol (MeOH) afforded terminally 
differentiated aldehyde 32 after workup with acetic anhydride and triethylamine (NEt3)18.   
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Addition of in situ-generated lithium trimethylsilylacetylide to 32 under anhydrous 
conditions led to the formation of the known propargyl alcohol 3319.  Attempts to 
synthesize only the desired R enantiomer of 33 using Carreira addition of 
trimethylsilylacetylene20 led to almost exclusive formation of aldol self-condensation 
products, presumably because of the lack of alpha substitution of the aldehyde.  Removal 
of the trimethylsilyl (TMS) protecting group with potassium carbonate in methanol 
afforded 34 in 66% yield from 32.  Following literature precedent16, we next formed the 
Figure 9.  Synthesis of ketone 1 via the Pauson-Khand reaction.  All chiral compounds were 
synthesized as racemic mixtures, and the configurations at each stereocenter are shown.  For atom 
numbering, see Figure 7.  a. O3, MeOH/CH2Cl2, -78°C, then Ac2O, NEt3.  b. lithium TMS-acetylide, 
THF, -78°C.  c. K2CO3, MeOH.  d. Co2(CO)8, CH2Cl2.  e. BF3.Et2O, 78°C, then allyl mercaptan, 78°C 
to rt.  f. PhCH3, reflux.  g. CuI, MeLi, DIBAL-H, THF/HMPA, -42°C to 0°C; HPLC separation of the 
diastereomers.  h. LiOH, MeOH/H2O.     
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hexacarbonyldicobalt complex of 34 by reaction with octacarbonyldicobalt in 
dichloromethane.  Complexation of the alcohol to boron trifluoride diethyl etherate 
(BF3.Et2O), followed by nucleophilic displacement with allyl mercaptan, formed the 
Pauson-Khand cyclization precursor 31, which was not isolated due to concerns about air 
stability. 
When run at 70 °C in toluene, the Pauson-Khand reaction was found to proceed in 
55% yield in three steps from 34.  However, the product formed, 30-mix, was an 
inseparable mixture of diastereomers 30a and 30b, with the desired diastereomer 30b 
comprising only 25% of the total product as determined by 1H NMR analysis.  The 
cobaltacyclic Pauson-Khand intermediate 36b that places the valeric acid sidechain on 
the more sterically congested concave face is disfavored relative to the intermediate 36a 
where the sidechain is on the convex face of the bicyclic ring structure, leading to 
preferential formation of product 30a  (Figure 10)21.   
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Figure 10.  Cobaltacyclic intermediates 36a and 36b leading to products 30a and 30b, respectively, 
during the Pauson-Khand cyclization of enyne 31.  36b is destabilized by an  unfavorable steric 
interaction between the acetylenic proton and the valeric acid side chain.
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We found that carrying out the reaction in refluxing toluene rather than at 70 °C 
increased the proportion of 30b to 35% of the total product formed, while still affording 
57% total yield (in three steps from 34) of cyclization products.  
Reducing the double bond of 30-mix proved to be more difficult than we had 
anticipated.  Attempts at reduction using Pd/C or PtO2 failed, even at high catalyst 
loadings and elevated temperatures and H2 pressures.  In light of this, we turned to 
copper-mediated 1,4-reduction of the α,β-unsaturated carbonyl.  A procedure in which 
30-mix was reacted with an in-situ-generated copper hydride complex proved to be 
effective, giving the reduced product in 73% yield as a mixture of diastereomers22.  The 
desired diastereomer 35 was isolated after semipreparative HPLC on a silica column, and 
the methyl ester was hydrolyzed with lithium hydroxide to afford diastereomerically pure 
ketone 1 in 7.6% yield in two steps from 30-mix.  The low overall yield for this final set 
of steps stemmed from the desired diastereomer only comprising 35% of the mixture and 
the recovery after HPLC purification being surprisingly inefficient (<50%). 
Our Pauson-Khand approach afforded ketone 1 in eight steps and 2.5% overall 
yield.  This synthesis is six steps shorter and three-fold higher in yield than our 
previously described sulfoxide approach, despite the Pauson-Khand cyclization favoring 
the undesired diastereomer.  Moreover, with this approach we can access oxygenated, 
nitrogenated, or carbocyclic analogs of ketone 1 by intramolecular Pauson-Khand 
reactions on the analogous allyl propargyl ethers, allyl propargyl amines, and 1,6-enynes, 
which all have precedent in the literature14.  Our previous synthetic approach cannot 
access these analogs because the sulfoxide is necessary to enable carbanion generation 
for sidechain installation.  Moreover, the Pauson-Khand cyclization of internal alkynes 
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and olefins can afford analogs derivatized at C-1′ and C-3′, while 1,4-addition of cuprate 
nucleophiles to the Pauson-Khand product (e.g. cyclopentenone 30) can accomplish 
derivatization at C-3.  Therefore, this new synthetic sequence greatly aids our efforts to 
probe the active sites of BirA and streptavidin by providing expedient access to a wide 
variety of ketone 1 analogs. 
Our synthesis would be more efficient and elegant if the desired diastereomer 30b 
were the major product after Pauson-Khand cyclization.  Unfortunately, the cobaltacyclic 
intermediate that yields 30b is disfavored relative to the one that yields 30a (Figure 10).  
Another personal communication with Dr. Seki of Tanabe yielded an alternative Pauson-
Khand cyclization strategy that could afford the desired diastereomer as the major 
product (Figure 11).  
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This strategy is based on the intramolecular Pauson-Khand cyclization of 1,6-diynes, a 
reaction with precedent for dipropargyl sulfides23.  Thus, we should be able to obtain 
cyclopentadienone 38 following Pauson-Khand cyclization of dipropargyl sulfide 37.  
The bulky silyl groups are necessary to prevent further dimerization of 38 via a Diels-
Alder reaction.  Reduction of 38 should proceed on the less sterically hindered face to set 
the desired relative stereochemistry at C-2, C-3, and C-4.  Implementation of this new 
Figure 11.  Proposed synthesis of ketone 1 via Pauson-Khand cyclization of the dipropargyl sulfide (37).
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Pauson-Khand strategy could greatly increase the overall yield of ketone 1 from 
cyclohexene and enhance our ability to synthesize more analogs.   
 
Conclusions 
 Three routes to ketone 1 were presented in this chapter.  The first route ultimately 
failed because all attempts to attach the valeric acid sidechain through Fukuyama 
coupling or Grignard addition proved to be futile.  Our second route, proceeding through 
a sulfoxide intermediate, successfully yielded ketone 1 in 14 steps from a commercially 
available starting material, but in only 0.79% yield.  To improve the efficiency of  
ketone 1 synthesis, we also devised a Pauson-Khand approach to access the [3.3.0] 
carbocyclic skeleton of ketone 1.  Although the Pauson-Khand cyclization favored the 
formation of the undesired diastereomer, this new synthesis reduced the number of steps 
by almost half and increased the yield three-fold compared to our sulfoxide approach.  
The Pauson-Khand approach also allows expedient access to a wide variety of ketone 1 
analogs that could be useful to probe the active site chemistries of biotin ligase and 
streptavidin.  
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Experimental 
 
General Methods.  
All chemicals were purchased from Sigma-Aldrich or Alfa Aesar and used 
without further purification, unless otherwise stated.  Anhydrous tetrahydrofuran (THF) 
was distilled from sodium benzophenone ketyl and transferred with oven-dried syringes 
and cannulae.  Analytical thin-layer chromatography (TLC) was performed using 0.25 
mm silica gel 60 F254 plates and visualized with p-anisaldehyde or potassium 
permanganate.  Flash chromatography was carried out using 70-230 mesh silica gel (ICN 
SiliTech 32-63D).  Solvents for chromatography are described as percent by volume.   
Infrared (IR) spectra were recorded on a Perkin-Elmer Model 2000 FT-IR 
spectrometer.  Proton nuclear magnetic resonance (1H NMR) spectra were recorded using 
a Varian Unity 300 (300 MHz) or Varian Mercury 300 (300 MHz).  Chemical shifts are 
reported in delta (δ) units, parts per million (ppm) referenced to the deuterochloroform 
singlet at 7.27 ppm or the deuterated methanol (CD3OD) quintet at 3.31 ppm.  Coupling 
constants (J) are reported in Hertz (Hz).  The following abbreviations for multiplicities 
are used:  s, singlet; bs, broad singlet; t, triplet; dd, doublet of doublets; ddd, doublet of 
doublet of doublets; dt, doublet of triplets; q, quartet; quin, quintet; m, multiplet.  Carbon 
nuclear magnetic resonance (13C NMR) spectra were recorded with broadband 
decoupling using a Varian Mercury 300 (75 MHz) spectrometer.  Chemical shifts are 
reported in delta (δ) units, parts per million referenced to the center line of the 
deuterochloroform triplet at 77.0 ppm.  High resolution mass spectra (HRMS) were 
obtained on a Bruker Daltonics APEXII 3 Tesla Fourier Transform Mass Spectrometer 
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using electrospray ionization.  Low resolution electrospray ionization mass spectra (ESI-
MS) were obtained on an Applied Biosystems 200 QTRAP Mass Spectrometer. 
 
Thiolactone approach to ketone 1 (Figures 3-5) 
 
CO2Bn
CO2Bn
 
Cyclohex-4-ene-1,2-dicarboxylic acid dibenzyl ester (4) 
cis-1,2,3,6-tetrahydrophthalic anhydride (7.00 g, 46.0 mmol), benzyl alcohol 
(10.5 g, 10.0 mL, 96.6 mmol), and 88 mg of p-TsOH were taken up in 200 mL of 
toluene.  The flask was fitted with a Dean-Stark trap, and the reaction was refluxed 
overnight.  The reaction was concentrated and partitioned between ethyl acetate (EtOAc) 
and 5% sodium carbonate.  The aqueous layer was re-extracted once with EtOAc.  The 
combined organic layers were dried over magnesium sulfate (MgSO4) and concentrated 
in vacuo to afford 12.4 g (77%) of 4 as a yellow oil.  Compound 4 is known in the 
literature24.   1H NMR (CDCl3, 300 MHz):  δ 7.25-7.37 (m, 10H), 5.69 (t, J = 1.5, 2H), 
5.04 (s, 4H), 3.14 (dd, J = 4.7, 1.9, 1H), 3.12 (dd, J = 4.7, 1.7, 1H), 2.54-2.64 (m, 2H), 
2.34-2.41 (m, 2H). 
 
HO2C
HO2C
CO2Bn
CO2Bn 
3,4-Bis-benzyloxycarbonyl-hexanedioic acid (5) 
To a solution of sodium periodate (31.4 g, 147 mmol) in 520 mL of water was 
added potassium permanganate (499 mg, 3.16 mmol), potassium carbonate (2.47 g,  
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18.0 mmol), and 130 mL of tert-butyl alcohol.  A solution of olefin 4 (5.70 g, 16.2 mmol) 
in 130 mL of tert-butyl alcohol was added, and the resulting mixture was stirred at room 
temperature for two hours.  The reaction was quenched by adding 3.9 mL of ethylene 
glycol and stirred for another two hours.  The mixture was acidified to pH 1-2 by the 
addition of concentrated hydrochloric acid (HCl) and extracted three times with 50% 
THF/EtOAc.  The combined organic layers were dried over MgSO4 and concentrated in 
vacuo to afford 6.55 g (97%) of 5 as an off-white solid.  1H NMR (CDCl3, 300 MHz):  δ 
7.26-7.35 (m, 10H), 5.03 (s, 4H), 3.41 (m, 2H), 2.80 (dd, J = 16.9, 9.6, 2H), 2.40 (dd,  
J = 16.9, 4.1, 2H).  ESI-MS (found) 415.32 [M+H]+.  Required for C22H23O8:  415.14. 
 
O
CO2BnBnO2C  
4-Oxo-cyclopentane-1,2-dicarboxylic acid dibenzyl ester (6) 
A suspension of diacid 5 (9.50 g, 22.9 mmol) and anhydrous sodium acetate (1.5 
g, 18.3 mmol) in 27 mL of acetic anhydride was refluxed for 40 minutes.  The reaction 
was cooled gradually to room temperature and then stored overnight at 4 °C.  The 
precipitated sodium acetate was filtered off.  Acetic anhydride was removed by 
distillation under high vacuum.  During distillation, the temperature of the oil bath never 
exceeded 45 °C, in order to prevent epimerization to the undesired trans isomer.  The 
remaining black oil was dissolved in EtOAc, and the solution was washed twice with 
saturated bicarbonate.  The organic layer was dried over MgSO4 and concentrated.  
Purification of the crude black oil on silica gel ( 25-30% EtOAc/hexanes (Hex) ) afforded 
4.61 g (57%) of the cis cyclopentanone dibenzyl ester 6 as an orange-yellow solid.  1H 
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NMR (CDCl3, 300 MHz):  δ 7.27-7.38 (m, 10H), 5.05 (d, J = 12.1, 2H), 4.96 (d, J = 12.1, 
2H), 3.49 (m, 2H), 2.79 (ddd, J =19.2, 4.6, 1.6, 2H), 2.51 (ddd, J = 19.2, 6.8, 2.3, 2H).  
ESI-MS (found) 375.18 [M+Na]+.  Required for C21H20O5Na :  375.12.   
 
CO2BnBnO2C
OO
 
4-Oxo-cyclopentane-1,2-dicarboxylic acid dibenzyl ester ethylene ketal (7) 
A round-bottomed flask was charged with 6 (2.92 g, 8.30 mmol), ethylene glycol 
(644 mg, 0.58 mL, 10.4 mmol), p-TsOH (16 mg), and 50 mL of toluene.  The flask was 
fitted with a Dean-Stark trap and the mixture was refluxed for 12 hours.  The reaction 
was concentrated in vacuo, and the residue was purified on silica gel (25% EtOAc/Hex) 
to afford 3.15 g (96%) of the product 7 as a clear oil.  1H NMR (CDCl3, 300 MHz):  δ 
7.27-7.38 (m, 10H), 5.04 (d, J = 12.3, 2H), 4.94 (d, J = 12.3, 2H), 3.90 (s, 4H), 3.27 (m, 
2H), 2.39 (ddd, J = 13.7, 6.1, 1.9, 2H), 2.18 (ddd, J = 13.5, 6.3, 2.3, 2H).  ESI-MS 
(found) 419.22 [M+Na]+.  Required for C23H24O6Na :  419.15. 
 
OO
O
OH
O
OH  
4-Oxo-cyclopentane-1,2-dicarboxylic acid ethylene ketal (8) 
A solution of 7 (3.14 g, 7.92 mmol) in 25 mL of methanol (MeOH) was added to 
a stirring suspension of 792 mg palladium on carbon in 25 mL of MeOH.  The flask was 
flushed with nitrogen and then hydrogen.  The reaction mixture was stirred under an 
atmosphere of hydrogen overnight.  The reaction mixture was filtered through a plug of 
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Celite.  The filtrate was concentrated in vacuo to afford 1.69 g (99%) of diacid 8 as a 
white solid.  
 
OO
OO O 
Tetrahydro-cyclopenta[c]furan-1,3,5-trione ethylene ketal (9) 
The diacid 8 (928 mg, 4.29 mmol) and EDC (822 mg, 4.29 mmol) were taken up 
in 40 mL of dichloromethane (DCM).  The mixture was stirred at room temperature for 
1.5 hours and concentrated.  The residue was taken up in EtOAc, and washed twice with 
water.  The organic layer was dried over sodium sulfate (Na2SO4) and concentrated to 
afford 731 mg (86%) of a white solid.  Due to concerns about stability, the anhydride 9 
was used immediately in the next reaction. 
  
O O
OO
 
Tetrahydro-cyclopenta[c]furan-1,5-dione ethylene ketal (10) 
Achiral reduction of 9 with borohydride 
To a solution of meso-anhydride 9 (731 mg, 3.70 mmol) in 37 mL of anhydrous 
THF was added sodium borohydride (139 mg, 3.70 mmol).  The reaction was stirred for 
one hour at room temperature and partitioned between EtOAc and 1 M HCl.  The organic 
layer was dried over MgSO4, concentrated in vacuo, and purified on silica gel (50% 
EtOAc/Hex) to afford 243 mg (36%) of the racemic lactone 10 as crystals.  Compound 10 
is known in the literature25.  1H NMR (CDCl3, 300 MHz):  δ 4.49 (dd, J = 9.3, 8.2, 1H), 
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4.17 (dd, J = 9.4, 2.9, 1H), 3.92-3.94 (m, 4H), 3.06 (m, 2H), 2.08-2.25 (m, 3H), 1.79 
(ddd, J = 13.7, 3.4, 1.8, 1H). 
  
Desymmetrization of 9 by chiral reduction with BINAL-H  
A round-bottomed flask was charged with lithium aluminum hydride (119 mg, 
2.98 mmol) and 4.2 mL of anhydrous THF.  The resulting grey suspension was cooled to 
0 °C, and a solution of anhydrous ethanol (EtOH) (137 mg, 173 µL, 2.97 mmol) in 4.2 
mL of anhydrous THF was added dropwise.  The mixture was stirred at 0 °C for 10 
minutes, then a solution of (R)-(+)-1,1′-bi-2-naphthol (BINOL) in 12.8 mL of anhydrous 
THF was added dropwise.  The resulting mixture was gradually warmed to room 
temperature and stirred for two hours.  The reaction was cooled to -78 °C, and a solution 
of meso-anhydride 9 in 4.2 mL of anhydrous THF was added dropwise over seven 
minutes.  The reaction mixture was stirred at -78 °C for four hours, gradually warmed to 
room temperature, and stirred overnight.  The reaction was quenched with 1 M HCl.  The 
aqueous layer was extracted three times with chloroform.  The combined organic layers 
were washed twice with 5% sodium carbonate and once with water and dried over 
MgSO4.  Concentration in vacuo and purification on silica gel (50% EtOAc/Hex) 
afforded 11 mg (9%) of 10 as a clear oil.   
 
OO
S O 
Tetrahydro-cyclopenta[c]thiophene-1,5-dione ethylene ketal (11) 
The lactone 10 (63 mg, 0.342 mmol) and potassium thioacetate (117 mg, 1.03 
mmol) were taken up in 3.4 mL of N,N-dimethylformamide (DMF) and heated to 150 °C 
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for four hours.  The reaction was partitioned between EtOAc and water.  The aqueous 
layer was re-extracted twice with EtOAc.  The combined organic layers were washed 
once with saturated brine, dried over MgSO4, and concentrated.  Purification of the 
residue on silica gel (37.5% EtOAc/Hex) afforded 62 mg (91%) of the thiolactone 11 as a 
yellow oil.  1H NMR (CDCl3, 300 MHz):  δ 3.92 (m, 4H), 3.61 (dd, J = 11.5, 7.1, 1H), 
3.22 (dd, J = 11.5, 2.7, 1H), 3.14 (m, 1H), 2.99 (m, 1H), 2.30 (dd, J = 14.2, 4.6, 1H), 2.19 
(ddd, J = 14.3, 9.5, 1.5, 1H), 2.13 (m, 1H), 1.94 (dd, J = 13.4, 9.2, 1H).  ESI-MS (found) 
223.02.  Required for C9H12O3SNa:  223.04. 
 
I
CO2Et  
Ethyl iodovalerate (5-iodo-pentanoic acid ethyl ester, 12) 
Ethyl iodovalerate (12) was synthesized according to the literature procedure5.  To 
a solution of δ-valerolactone (4.86 g, 4.4 mL, 48.6 mmol) in 24 mL of acetonitrile was 
added sodium iodide (8.02 g, 53.5 mmol), followed by TMSCl (5.81 g, 6.8 mL, 53.5 
mmol).  The mixture was stirred overnight at room temperature.  EtOH (9.7 mL) was 
added and the resulting mixture was stirred for six hours.  The reaction was concentrated 
in vacuo, and the residue was partitioned between EtOAc and water.  The organic layer 
was washed once with 10% sodium thiosulfate and once with water.  After drying over 
MgSO4 and concentration in vacuo, the residue was purified on silica gel (0-5% 
EtOAc/Hex) to afford 7.67 g (77%) of ethyl iodovalerate (12).  1H NMR (CDCl3, 300 
MHz):  δ 4.14 (q, J = 7.2, 2H), 3.20 (t, J = 6.8, 2H), 2.33 (t, J = 7.2, 2H), 1.69-1.92 (m, 
4H), 1.27 (t, J = 7.2, 3H). 
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Preparation of the organozinc reagent for Fukuyama coupling (13) 
Zinc powder was activated according to the procedure of Knochel et al26.  A flask 
was charged with zinc powder (1.12 g, 17.1 mmol), 1,2-dibromoethane (130 mg, 59 µL, 
0.69 mmol), and 2.3 mL of anhydrous THF, and heated to reflux for one minute.  After 
cooling to room temperature, TMSCl (56 mg, 65 µL, 0.26 mmol) was added, and the 
mixture was stirred at room temperature for 30 minutes.  Then, a solution of 12 (4.16 g, 
16.2 mmol) in 9 mL of anhydrous THF was added, and the resulting suspension was 
stirred vigorously at 45 °C for nine hours, clearing in the process.   
 
Attempted Fukuyama coupling to thiolactone 11 
To a solution of thiolactone 11 (56 mg, 0.280 mmol) in 2.0 mL of toluene and 
0.15 mL of DMF was added bis(triphenylphosphine) palladium(II) chloride (20 mg, 
0.028 mmol).  The resulting mixture was stirred at room temperature for two minutes, 
while flushing with nitrogen.  Then, 0.65 mL of the solution of zinc reagent 13 (0.84 
mmol) was added dropwise.  The reaction mixture was stirred for 12 hours at room 
temperature.  Analytical TLC showed very little conversion of the starting material. 
 
Br
O
 
6-Bromo-hexan-2-one (14) 
6-Bromo-hexan-2-one was synthesized according to the literature procedure27.  To 
a chilled suspension of 1-methyl-cyclopentanol (2.54 g, 25.4 mmol) and potassium 
carbonate (21 g, 152 mmol) in 83 mL of chloroform was added bromine (20.3 g, 6.5 mL, 
127 mmol).  The resulting mixture was stirred at 0 °C for two hours.  The reaction 
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mixture was washed twice with 10% sodium thiosulfate and once with water.  The 
organic layer was dried over MgSO4 and concentrated to afford 4.24 g (93%) of a slightly 
yellow oil.  1H NMR (CDCl3, 300 MHz):  δ 3.41 (t, J = 6.6, 2H), 2.48 (t, J = 7.1, 2H), 
2.15 (s, 3H), 1.67-1.78 (m, 2H), 1.81-1.91 (m, 2H). 
 
Br
OO
 
6-Bromo-hexan-2-one ethylene ketal (15) 
6-Bromo-hexan-2-one (14) (4.24 g, 23.7 mmol), ethylene glycol (4.45 g, 4.0 mL, 
71.7 mmol), and p-TsOH (45 mg, 0.237 mmol) were taken up in 80 mL of toluene.  The 
flask was fitted with a Dean-Stark trap and heated to reflux for 20 hours.  The reaction 
was concentrated and purified on silica gel (20% EtOAc/Hex) to afford 4.46 g (85%) of a 
pale yellow oil.  Compound 15 is known in the literature28.  1H NMR (CDCl3, 300 MHz):   
δ 3.94 (m, 4H), 3.42 (t, J = 6.8, 2H), 1.88 (quin, J = 7.1, 2H), 1.63-1.70 (m, 2H), 1.49-
1.60 (m, 2H), 1.32 (s, 3H). 
 
Preparation of Grignard reagent (16) 
To a solution of 15 (450 mg, 2.02 mmol) in 3.5 mL of anhydrous THF was added 
132 mg (5.43 mmol) of magnesium turnings and 10 µL of 1,2-dibromoethane.  The 
mixture became slightly exothermic and was stirred at room temperature for 30 minutes.  
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Attempted Grignard addition to thiolactone 11 
To a solution of thiolactone 11 (37 mg, 0.185 mmol) in 0.65 mL of anhydrous 
THF was added 0.65 mL of the solution of Grignard reagent 16.  The reaction was 
refluxed for four hours.  Analytical TLC showed no conversion of the starting material.   
 
Sulfoxide approach to ketone 1 (Figure 6) 
 
CO2Me
CO2Me
 
 
Cyclohex-4-ene-1,2-dicarboxylic acid dimethyl ester (17) 
Cyclohexene dimethyl ester 14 was synthesized following the literature 
procedure29.  A suspension of cis-1,2,3,6-tetrahydrophthalic anhydride (20.0 g, 131 
mmol) and p-TsOH (250 mg, 1.31 mmol) in 40 mL of MeOH was refluxed overnight.  
Toluene (20 mL) was added to the resulting clear solution, and 30 mL of solvent were 
removed by distillation.  MeOH (30 mL) was added, and 30 mL of solvent were distilled 
off.  Toluene (15 mL) and MeOH (30 mL) were added, 45 mL of solvent were distilled 
off, and the remaining solvent was removed in vacuo.  The remaining oil was dissolved 
in 100 mL of EtOAc and washed once with 5% sodium carbonate.  The aqueous layer 
was extracted once more with EtOAc.  The combined organic layers were dried over 
MgSO4 and concentrated to afford 23.0 g of a pale yellow oil (88%).  1H NMR (CDCl3, 
300 MHz):  δ 5.68 (t, J = 1.8, 2H), 3.69 (s, 6H), 3.06 (dd, J = 4.8, 1.8, 1H), 3.04 (dd,  
J = 4.8, 1.5, 1H), 2.56 (m, 2H), 2.36 (m, 2H).           
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HO2C
HO2C
CO2Me
CO2Me  
3,4-Bis-methoxycarbonyl-hexanedioic acid (18) 
The synthesis and spectral characterization of diacid 18 have been reported in the 
literature30.  To an ice-cold and well-stirred solution of potassium permanganate (61.7 g, 
390 mmol) in 230 mL of water was added compound 17 (25.7 g, 130 mmol).  The 
resulting thick, brown suspension was stirred overnight at room temperature.  A total of 
61.2 g of sodium sulfite and 115 mL of concentrated HCl were added portionwise, 
turning the thick brown mixture into a pink solution with lots of white precipitate.  The 
aqueous solution was extracted four times with 50% THF/EtOAc.  The aqueous layer was 
filtered, and the pH was readjusted to below 2.0 by the addition of concentrated HCl.  
The aqueous layer was then re-extracted four times with 50% THF/EtOAc.  The 
combined organic layers were dried over MgSO4 and concentrated in vacuo to give  
33.3 g (98%) of 18 as a white solid. 1H NMR (CD3OD, 300 MHz):  δ 3.69 (s, 6H), 3.25, 
(m, 2H),  2.70 (dd, J = 17.1, 9.6, 2H), 2.48 (dd, J = 17.1, 4.2, 2H).         
 
O
CO2MeMeO2C  
4-Oxo-cyclopentane-1,2-dicarboxylic acid dimethyl ester (19) 
The synthesis and spectral characterization of cyclopentanone 19 have been 
reported in the literature30.  Following the same procedure for the synthesis of compound 
6, 14.0 g (71%) of 19 were isolated as an orange-yellow solid, starting from 25.9 g of 
diacid 18 (98.8 mmol).  1H NMR (CDCl3, 300 MHz):  δ 3.72 (s, 6H), 3.45 (m, 2H), 2.74 
(ddd, J = 19.2, 6.3, 1.7, 2H), 2.49 (ddd, J = 19.2, 6.7, 2.3, 2H).        
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4-Oxo-cyclopentane-1,2-dicarboxylic acid dimethyl ester ethylene ketal (20) 
The synthesis and spectral characterization of compound 20 have been reported in 
the literature30.  Following the same procedure for the synthesis of compound 7, except 
substituting benzene for toluene, 12.5 g (96%) of 20 were isolated as a yellow oil, starting 
from 10.7 g of compound 16 (53.4 mmol).  1H NMR (CDCl3, 300 MHz):  δ 3.92 (s, 4H), 
3.68 (s, 3H), 3.21 (m, 2H), 2.35 (m, 2H), 2.15 (m, 2H).         
 
OO
OH OH 
3,4-Bis-hydroxymethyl-cyclopentanone ethylene ketal (21) 
To a cooled suspension of lithium aluminum hydride (5.12 g, 128 mmol) in 130 
mL of anhydrous THF was added a solution of compound 20 (12.5 g, 51.3 mmol) in 76 
mL of anhydrous THF, via cannula transfer.  Following addition, the reaction mixture 
was gradually warmed to room temperature and stirred for two hours.  The reaction was 
cooled to 0 °C and 20 mL of water was added portionwise.  The mixture was filtered, and 
the solid was washed liberally with DCM.  The combined filtrate was concentrated and 
purified on silica gel (5% MeOH/DCM) to afford 7.72 g (81%) of the diol 21 as a clear 
oil.  Compound 21 is known in the literature31.  1H NMR (CDCl3, 300 MHz):  δ 3.89-3.91 
(m, 4H), 3.66-3.81 (m, 4H), 2.46 (m, 2H), 1.98 (dd, J = 13.7, 8.6, 2H), 1.71 (dd, J = 14.0, 
7.4, 2H).  
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OO
I I  
3,4-Bis-iodomethyl-cyclopentanone ethylene ketal (23) 
The diol 21 (7.72 g, 41.0 mmol), imidazole (11.2 g, 164 mmol), and 
triphenylphosphine (32.3 g, 123 mmol) were taken up in 310 mL of toluene.  Iodine (31.2 
g, 123 mmol) was added in one portion, and the resulting heterogeneous mixture was 
stirred for 20 minutes.  The liquid was decanted and washed with 10% sodium 
thiosulfate.  The organic layer was dried over Na2SO4 and concentrated in vacuo.  The 
crude product was purified on silica gel (10-40% EtOAc/Hex) to afford 4.58 g (27%) of 
the diiodide 23 as a clear oil.  Compound 23 is known in the literature32.  1H NMR 
(CDCl3, 300 MHz):  δ 3.89 (m, 4H), 3.15-3.29 (m, 4H), 2.58 (m, 2H), 2.12 (dd, J = 14.1, 
7.8, 2H), 1.94 (dd, J = 14.0, 7.1, 2H). 
 
OO
S  
Tetrahydro-cyclopenta[c]thiophen-5-one ethylene ketal (24) 
To a suspension of freshly recrystallized sodium sulfide (1.27 g, 16.2 mmol) in 54 
mL of DMF was added a solution of the diiodide 23 (4.59 g, 11.2 mmol) in 54 mL of 
DMF.  The reaction mixture was stirred overnight at room temperature.  More sodium 
sulfide (1.27 g, 16.2 mmol) was added to drive the reaction to completion.  After three 
more hours, the reaction was concentrated in vacuo and partitioned between EtOAc and 
water.  The organic layer was dried over MgSO4 and concentrated.  Purification of the 
crude residue on silica gel (8% EtOAc/Hex) afforded 1.73 g (83%) of the sulfide 24 as a 
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clear oil.  Compound 24 is known in the literature11.  1H NMR (CDCl3, 300 MHz):  δ 
3.90 (s, 4H), 2.80-2.94 (m, 4H), 2.59 (d, J = 8.7, 2H), 2.01 (m, 2H), 1.71 (dd, J = 12.4, 
7.5, 2H). 
 
S
O
OO
 
2-Oxo-hexahydro-2λ4-cyclopenta[c]thiophen-5-one (25) 
The synthesis and spectral characterization of sulfoxide 25 have been reported11.  
To a chilled solution of sodium periodate (2.18 g, 10.2 mmol) in 86 mL water was added 
a solution of sulfide 24 (1.73 g, 9.29 mmol) in 65 mL of MeOH.  The resulting mixture 
was stirred at 4 °C for five hours and filtered.  MeOH was removed in vacuo, and the 
remaining aqueous layer was saturated with salt and extracted four times with 
chloroform.  The combined organic layers were dried over MgSO4 and concentrated to 
afford 1.69 g (90%) of the sulfoxide 25 as a white solid.  Compound 25 is known in the 
literature.  Major isomer (cis) 1H NMR (CDCl3, 300 MHz):  δ 3.89 (s, 4H), 3.47 (m, 2H), 
3.24-3.31 (m, 2H), 2.65 (dd, J = 13.5, 9.3, 2H), 2.14-2.22 (m, 2H), 1.71 (dd, J = 13.5, 2.4, 
2H).    
 
I
CO2H 
Iodovaleric acid (5-iodo-pentanoic acid, 28) 
To a solution of δ-valerolactone (8.50 g, 84.9 mmol) in 42 mL of acetonitrile was 
added sodium iodide (14.0 g, 93.4 mmol) and TMSCl (10.1 g, 11.8 mL, 93.3 mmol).  The 
mixture was stirred overnight at room temperature before the addition of 8 mL of water.  
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The reaction was stirred at room temperature for one more hour and concentrated in 
vacuo.  The residue was partitioned between EtOAc and water, and the organic layer was 
washed once with 10% sodium thiosulfate.  The product was extracted into 5% sodium 
carbonate.  The aqueous layer was then acidified to pH=1 with concentrated HCl, and the 
product was extracted into EtOAc.  The organic layer was dried over MgSO4 and 
concentrated to yield 11.6 g (60%) of iodovaleric acid (28) as a yellow solid.  Compound 
28 is known in the literature33.  1H NMR (CDCl3, 300 MHz):  3.20 (t, J = 6.8, 2H), 2.40 
(t, J = 7.1, 2H), 1.70-1.93 (m, 4H). 
 
I
CO2t-Bu 
tert-Butyl iodovalerate (5-iodo-pentanoic acid tert-butyl ester, 29) 
To a solution of iodovaleric acid (28) (11.6 g, 50.7 mmol), pyridine (8.0 g, 8.2 
mL, 100 mmol), and tert-butyl alcohol (19.2 g, 24.7 mL, 258 mmol) in 150 mL of DCM 
was added phosphorous oxychloride (16 g, 9.5 mL, 100 mmol).  The reaction mixture 
was stirred overnight at room temperature and concentrated.  The residue was partitioned 
between EtOAc and water.  The organic layer was washed with 5% sodium carbonate 
and saturated brine and dried over MgSO4.  After concentration in vacuo, the crude 
product was purified on silica gel (30% EtOAc/Hex) to afford 6.36 g (44%) of tert-butyl 
iodovalerate (29) as a slightly yellow oil.  Compound 29 is known in the literature2.  
1H NMR (CDCl3, 300 MHz):  3.18 (t, J = 6.9, 2H), 2.24 (t, J = 7.2, 2H), 1.80-1.90 (m, 
2H), 1.63-1.73 (m, 2H), 1.44 (s, 9H). 
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 5-(2,5-Dioxo-octahydro-2λ4-cyclopenta[c]thiophen-1-yl)-pentanoic acid tert-butyl ester 
ethylene ketal (26) 
Under an atmosphere of dry nitrogen, a solution of sulfoxide 25 (590 mg, 2.92 
mmol) in 6.8 mL of anhydrous THF and 2.8 mL of hexamethylphosphoramide (HMPA) 
was cooled to -78 °C.  Methyllithium (2.2 mL of a 1.6 M solution in diethyl ether, 3.5 
mmol) was added dropwise.  The resulting yellow solution was stirred at -78 °C for 20 
minutes before dropwise addition of neat tert-butyl iodovalerate (29) (3.89 g, 13.7 
mmol).  The reaction was stirred at -30 °C for five hours before quenching with water.  
The product was extracted with DCM, and the organic layer was dried over Na2SO4 and 
concentrated in vacuo.  Purification on silica gel (0-6% MeOH/EtOAc) afforded the 
adduct 26 (800 mg, 76% crude yield) as a diastereomeric mixture. 
 
S CO2H
O
 
5-(5-Oxo-hexahydro-cyclopenta[c]thiophen-1-yl)-pentanoic acid (1-mix) 
Crude compound 26 (800 mg, 2.23 mmol) and triphenylphosphine (995 mg, 3.79 
mmol) were dissolved in 20 mL of carbon tetrachloride.  The resulting solution was 
heated at reflux for 2 hours.  The reaction mixture was decanted from the precipitated 
triphenylphosphine oxide and concentrated.  After purification on silica (5-10% 
EtOAc/Hex), the product was immediately dissolved in 6 mL of glacial acetic acid 
(AcOH) and 3 mL of water.  Three drops of concentrated HCl were added, and the 
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resulting solution was heated at reflux for 16 hours.  The reaction mixture was diluted 
with water, saturated with sodium chloride, and extracted with EtOAc.  The combined 
organic layers were dried over MgSO4 and concentrated in vacuo.  Purification on silica 
gel (20-50% EtOAc/Hex + 0.5% AcOH) afforded 181 mg (33%) of the product as a 
mixture of diastereomers (1-mix). 
 
S CO2CH2C6F5
O
 
5-(5-Oxo-hexahydro-cyclopenta[c]thiophen-1-yl)-pentanoic acid 
pentafluorophenylmethyl ester (27) 
To a solution of 1-mix (179 mg, 0.739 mmol) in 7 mL of DCM was added 
diisopropylethylamine (DIPEA) (0.14 mL, 0.80 mmol), followed by pentafluorobenzyl 
bromide (0.13 mL, 0.86 mmol).  The resulting solution was stirred at ambient 
temperature for 48 hours.  The reaction mixture was diluted with water, and the organic 
layer was separated.  The aqueous layer was re-extracted with DCM.  The combined 
organic layers were washed with brine, dried over MgSO4, and concentrated in vacuo.  
After purification on silica gel (10-20% EtOAc/Hex), the diastereomeric esters were 
separated on a semi-preparative silica HPLC column (Microsorb-MV 100 Si; 1.5% 
isopropanol/hexanes; 5.0 mL/min); retention times for the diastereomers were 12.0 
(undesired) and 13.1 (desired) minutes.  The desired diastereomer 27 was obtained as a 
white solid (142 mg, 46% yield).  1H NMR (CDCl3, 300 MHz):  δ 5.20 (s, 2H), 3.70 (dt,  
J = 8.2, 5.7, 1H), 2.87-3.16 (m, 3H), 2.17-2.57 (m, 7H), 1.32-1.71 (m, 6H).  
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5-(5-Oxo-hexahydro-cyclopenta[c]thiophen-1-yl)-pentanoic acid (ketone 1) 
Pentafluorobenzyl ester 27 (108 mg, 0.256 mmol) was dissolved in 0.8 mL of 
THF and 0.8 mL of MeOH.  A solution of lithium hydroxide (32.2 mg, 0.767 mmol) in 
0.8 mL of water was added dropwise.  The resulting yellow solution was stirred at 
ambient temperature for 12 hours.  The reaction was partitioned between EtOAc and 1 M 
HCl that had been saturated with sodium chloride.  The layers were separated and the 
aqueous layer was re-extracted with EtOAc.  The combined organic layers were dried 
over MgSO4 and concentrated in vacuo.  Purification of the crude oil on silica gel (40% 
EtOAc/Hex + 0.5% AcOH) afforded 45 mg (72%) of ketone 1 as a white solid.  IR 
(neat):  3300-2500 (broad), 2934, 1739, 1707, 1405, 1244, 1169, 949, 747 cm-1. 1H NMR 
(CDCl3, 300 MHz):  δ 10.58 (bs, 1H), 3.71 (dt, J = 8.2, 5.7, 1H), 2.88-3.17 (m, 3H), 2.18-
2.58 (m, 7H), 1.33-1.72 (m, 6H). 13C NMR (CDCl3, 75 MHz):  δ 217.2, 179.3, 52.1, 48.5, 
44.5, 44.5, 37.0, 36.0, 33.8, 32.6, 29.0, 24.5.  HRMS (found) 265.0875 [M+Na]+. 
Required for  C12H18O3SNa:  265.0869. 
 
HPLC separation of ketone 1 enantiomers.  
The enantiomers of pentafluorobenzyl ester 27 were resolved on a 
semipreparative Daicel CHIRALPAK AD-H column (10% isopropanol/Hex; 3.0 
mL/min).  The enantiomeric excess (ee) after separation was determined using an 
analytical Daicel CHIRALPAK AD column (10% isopropanol/Hex; 1.0 mL/min); 
retention times of the enantiomers were 15.7 minutes (most likely d, stereochemical 
92 
configuration:  2S,3S,4R) and 24.2 minutes (most likely l, stereochemical configuration:  
2R,3R,4S).  The d enantiomer of 27 was obtained in >99% ee, while the l-enantiomer was 
obtained in 85% ee.  Each enantiomer was subsequently hydrolyzed to its acid as 
described above.  The free acids d-ketone 1 and l-ketone 1 were purified using reverse-
phase HPLC (Microsorb-MV 300 C18; 10-43% acetonitrile/water with 0.1% 
trifluoroacetic acid (TFA) over 20 minutes; flow rate 4.7 mL/min; retention time of 
product is 16.0 minutes). 
 
Pauson-Khand approach to ketone 1 (Figure 9) 
 
H
O
CO2Me  
6-Oxo-hexanoic acid methyl ester (32) 
The aldehyde 32 was synthesized according to the literature procedure18.  A 
mixture of cyclohexene (6.16 g, 7.42 mL, 75.0 mmol) and sodium bicarbonate (2.0 g, 24 
mmol) in 50 mL of MeOH and 250 mL of DCM was cooled to -78 °C.  Ozone was 
bubbled through the resulting blue mixture for two hours.  The reaction mixture was 
filtered, and 80 mL of benzene was added to the filtrate.  The solution was concentrated 
in vacuo to a volume of ~50 mL, and then triethylamine (11.4 g, 16.0 mL, 113 mmol), 
acetic anhydride (23.0 g, 21.2 mL, 225 mmol), and 225 mL of DCM were added at 0 °C.  
The reaction mixture was warmed to room temperature and stirred for four more hours.  
The mixture was quenched with 150 mL of 0.1 M HCl, and the layers were separated.  
The organic layer was washed with 2 M sodium hydroxide (NaOH), washed with water, 
dried over MgSO4, and concentrated to afford 10.55 g (98%) of 32.  1H NMR (CDCl3, 
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300 MHz):  δ 9.77 (t, J = 1.5, 1H), 3.67 (s, 3H), 2.45-2.49 (m, 2H), 2.32-2.37 (m, 2H), 
1.64-1.69 (m, 4H). 
 
CO2Me
OH
TMS  
6-Hydroxy-8-trimethylsilanyl-oct-7-ynoic acid methyl ester (33) 
A stirring solution of TMS-acetylene (1.08 g, 1.56 mL, 11.0 mmol) in 20 mL of 
anhydrous THF under an inert atmosphere was cooled to -78° C.  Methyllithium (6.88 
mL of a 1.6 M solution in diethyl ether, 11.0 mmol) was added dropwise and the 
resulting mixture was stirred at -78 °C for 20 minutes.  This solution was added dropwise 
via cannula transfer to a stirring solution of methyl 6-oxohexanoate (32) (1.44 g, 1.28 
mL, 10.0 mmol) in 20 mL of THF at -78 °C.  The reaction was stirred for 30 minutes at  
-78 °C, then for 30 minutes at room temperature, then quenched with 30 mL saturated 
aqueous ammonium chloride (NH4Cl).  The layers were separated and the aqueous layer 
extracted twice with diethyl ether.  The combined organic layers were washed with brine 
and dried over MgSO4 before purification on silica gel (5-25% EtOAc/Hex) to afford 
1.94 g (80%) propargyl alcohol 33 as a pale yellow oil.  IR (neat):  3440, 2954, 2866, 
2171, 1739, 1438, 1366, 1249, 1093, 1016, 853, 761, 700, 649 cm-1.  1H NMR (CDCl3, 
300 MHz ):  δ 4.36 (t, J = 6.3, 1H), 3.66 (s, 3H), 2.33 (t, J = 6.9, 2H), 1.81 (bs, 1H), 1.72-
1.64 (m, 4H), 1.53-1.43 (m, 2H), 0.16 (s, 9H).  13C NMR (CDCl3, 75 MHz):  δ 174.3, 
106.8, 89.8, 62.8, 51.8, 37.5, 34.2, 24.9, 24.8, 0.1.  HRMS (found) 265.1232 [M+Na]+.  
Required for C12H22O3SiNa:  265.1230. 
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Methyl 6-hydroxyoct-7-yn-1-oate (34)    
To a stirring solution of 33 (300 mg, 1.24 mmol) in 3 mL of MeOH was added 
potassium carbonate (188 mg, 1.36 mmol).  The mixture was stirred at ambient 
temperature for 30 minutes, then concentrated in vacuo.  The resulting residue was taken 
up in saturated NH4Cl, which was extracted twice with EtOAc.  The combined organic 
layers were washed with brine, dried over MgSO4, and concentrated in vacuo.  
Purification on silica gel (25% EtOAc/Hex) afforded 34 as a colorless oil (157 mg, 0.92 
mmol, 74%).  IR (neat):  3435, 3289, 2950, 2867, 2113, 1734, 1438, 1368, 1201, 1091, 
1031, 853, 668, 555 cm-1.  1H NMR (CDCl3, 300 MHz):  δ 4.38 (dt, J = 6.3, 1.9, 1H), 
3.67 (s, 3H), 2.46 (d, J = 1.9, 1H), 2.34 (t, J = 7.2, 2H), 1.92 (bs, 1H), 1.77-1.62 (m, 4H), 
1.54-1.46 (m, 2H).  13C NMR (CDCl3, 75 MHz):  δ 174.3, 85.0, 73.3, 62.2, 51.8, 37.4, 
34.1, 24.8, 24.7.  HRMS (found) 193.0837 [M+Na]+.  Required for C9H14O3Na:  
193.0835. 
 
O
S CO2Me  
5-(5-oxo-3,3a,4,5-tetrahydro-1H-cyclopenta[c]thiophen-1-yl)-pentanoic acid methyl 
ester (30-mix)   
To a stirring solution of 34 (560 mg, 3.29 mmol) in 15 mL of DCM under argon 
was added octacarbonyldicobalt (1.24 g, 3.62 mmol).  The resulting maroon solution was 
stirred at room temperature for one hour.  The reaction was purified by filtration over a 
95 
silica gel plug (25% EtOAc/Hex, the product eluted as a deep red band) to afford a dark 
red solid, which was immediately taken up in 30 mL of DCM and cooled to -78 °C under 
an argon atmosphere.  Boron trifluoride diethyl etherate (549 mg, 490 µL, 3.87 mmol) 
was added via syringe, and the resulting solution was allowed to stir for 10 minutes at  
-78 °C.  Allyl mercaptan (246 mg, 265 µL, 3.32 mmol) was then added via syringe, and 
the reaction was allowed to warm to room temperature over one hour.  The mixture was 
purified on silica gel (0-7% EtOAc/Hex, product eluted as a deep red band) to afford 31 
as a dark red oil.  This oil was taken up in 120 mL of toluene and heated to reflux for 1.5 
hours.  The reaction mixture was purified on silica (20% EtOAc/Hex) to afford 480 mg 
(57%) of 30-mix as a colorless oil, in a 2:1 mixture of in favor of the undesired 
diastereomer.  IR (neat):  2933, 2861, 1735, 1713, 1627, 1437, 1365, 1312, 1256, 1197, 
1178 cm-1.  1H NMR (CDCl3, 300 MHz): δ 5.96 (s, 1H), 4.16 (t, J = 7.1, 0.35H), 4.07 (t, 
J = 7.2, 0.65H), 3.66 (s, 3H), 3.40 (m, 1H), 3.14 (t, 1H), 2.71 (dd, J = 18.6, 6.6, 0.65H), 
2.69 (dd, J = 18.6, 6.6, 0.35H), 2.53 (t, J = 10.5, 1H), 2.32 (t, J = 7.5, 2H), 2.21 (dd,  
J = 18.3, 2.7, 0.35 H), 2.19 (dd, J = 18.3, 2.7, 0.65 H), 1.86-1.58 (m, 4H), 1.56-1.36 (m, 
2H).  13C NMR (CDCl3, 75 MHz): δ 209.5, 186.4, 174.0, 126.2, 51.8, 46.1, 45.9, 41.8, 
38.0, 34.7, 33.9, 27.5, 24.5.  HRMS (found) 277.0869 [M+Na]+.  Required for 
C13H18O3SNa: 277.0869. 
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5-(5-oxo-hexahydrocyclopenta[c]thiophen-1-yl)-pentanoic acid methyl ester (35) 
To a stirring mixture of CuI (46 mg, 0.24 mmol) in 10 mL of anhydrous THF 
under argon at -42 °C was added methyllithium (161 µL of a 1.6 M solution in diethyl 
ether, 0.26 mmol), HMPA (2.67 mL) and diisobutylaluminum hydride (2.84 mL of a 1.0 
M solution in hexanes, 2.84 mmol).  The mixture was stirred at -42 °C for 1.5 hours, and 
then 30-mix (480 mg, 1.87 mmol) in 3 mL of anhydrous THF was added.  The reaction 
mixture was allowed to warm to 0 ° C over four hours.  The reaction was quenched with 
5 mL of 1 M HCl.  The layers were separated and the aqueous layer extracted twice with 
diethyl ether.  The combined organic layers were washed with 1 M HCl, water, and brine, 
dried over magnesium sulfate and concentrated in vacuo.  Purification on silica gel (25% 
EtOAc/Hex) afforded 353 mg (73%) of the product as a mixture of diastereomers (1:2 in 
favor of the undesired diastereomer).  The diastereomers were separated on a semi-
preparative silica HPLC column (Microsorb-MV 100 Si; 8% isopropanol/Hex; 5.0 
mL/min); retention times for the diastereomers were 15.5 (undesired, major) and 17.0 
(desired, minor) minutes.  Following HPLC purification, the recovery of the desired 
diastereomer 35 was 9.5% from 30-mix.  IR (neat):  2934, 1739, 1436, 1197, 1175 cm-1.  
1H NMR (CDCl3, 300 MHz): δ 3.71 (m, 1H), 3.68 (s, 3H), 3.3-2.9 (m, 4H), 2.54 (m, 2H), 
2.4-2.2 (m, 5H), 1.7-1.4 (m, 8H).  13C NMR (CDCl3, 75 MHz): δ 217.5, 174.1, 52.2, 51.8, 
48.7, 44.7, 37.2, 36.1, 35.2, 34.0, 32.8, 29.2, 24.9.  HRMS (found) 279.1013 [M+Na]+.  
Required for C13H20O3SNa:  279.1025. 
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5-(5-Oxo-hexahydro-cyclopenta[c]thiophen-1-yl)-pentanoic acid (ketone 1)   
A total of 20 mg (0.078 mmol) of 35 was dissolved in 2 mL of MeOH.  A solution 
of lithium hydroxide (10 mg, 0.23 mmol) in 0.6 mL of water was added dropwise, and 
the resulting yellow solution was allowed to stir for 20 hours at room temperature.  The 
reaction mixture was partitioned between EtOAc and 1 M HCl saturated with brine.  The 
aqueous layer was extracted twice with EtOAc, and the combined organic layers were 
dried over MgSO4 and concentrated in vacuo.  Purification on silica gel (50% EtOAc/Hex  
+ 0.5% AcOH) afforded 15.1 mg (80%) of ketone 1 as a white solid.   
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Chapter 3:  Site-specific labeling of cell surface proteins using  
a ketone substrate for E. coli biotin ligase 
 
 
The majority of the work discussed in this chapter has been published in:     
Chen, I., Howarth, M., Lin, W., and Ting, A. Y.  Site-specific labeling of cell surface 
proteins with biophysical probes using biotin ligase.  Nat. Methods 2, 99-104 (2005).  
Cell surface labeling was performed in collaboration with Mark Howarth and Alice Y. 
Ting.  The benzophenone-biotin hydrazide probe was designed and synthesized by 
Weiying Lin, with the assistance of Eric McNeill.   
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Introduction 
The re-directing of natural enzyme-catalyzed reactions represents a promising 
new strategy for the site-specific labeling of proteins.  Enzyme-catalyzed small molecule 
attachment to a peptide substrate retains the minimal invasiveness of a small genetically 
encodable tag, while improving the specificity and stability of probe recruitment.  Our 
laboratory was interested in capitalizing on the extraordinary sequence specificity of the 
enzyme E. coli biotin ligase (BirA).  BirA catalyzes the ATP-dependent transfer of biotin 
to the lysine sidechain within an unnatural 15-amino acid peptide substrate, the “acceptor 
peptide” (AP).  BirA has only one natural substrate in E. coli, and as a result, it has 
become a widespread tool for the site-specific biotinylation of AP fusion proteins in vitro 
and in living bacteria1 and mammalian cells2-4.  To harness the sequence specificity of 
BirA for ligation of other small molecule probes to proteins, we sought to re-engineer the 
biotin binding site to accommodate various biotin analogs.  We were particularly 
interested in ketone 1, a biotin isostere with the ureido nitrogens replaced by methylene 
groups (Figure 1).   
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Because the ketone group is absent from natural proteins, carbohydrates, and lipids, it can 
be selectively derivatized on the cell surface with hydrazide- or hydroxylamine-bearing 
probes under physiological conditions to form stable hydrazone or oxime linkages, 
respectively5.  
Figure 1. Structures of ketone 1 and biotin. 
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BirA-catalyzed transfer of ketone 1 to a genetically fused AP tag would represent 
another chemoenzymatic strategy for engineering ketone functionality into proteins.  By 
feeding cells a ketone analog of N-acetylmannosamine, the Bertozzi group exploited the 
native substrate promiscuity of enzymes involved in sialic acid biosynthesis to decorate 
the extracellular glycoproteins of live cells with ketones5.  The Hsieh-Wilson group 
modified a β-1,4-galactosyltransferase to transfer a ketone analog of galactose onto O-
linked β-N-acetylglucosamine residues of a protein6.  Schultz and co-workers showed that 
ketones can also be introduced site-specifically in proteins of live cells through unnatural 
amino acid mutagenesis7.  Of these existing methods, only unnatural amino acid 
mutagenesis site-specifically introduces the ketone into one protein and can be applied 
for live cell imaging.  Introduction of a ketone group through unnatural amino acid 
mutagenesis enabled the imaging of outer membrane protein LamB on living E. coli, 
after conjugation to membrane-impermeable fluorophore hydrazides8.  However, 
hydrazide labeling was performed overnight at 4 °C, and after labeling the cells were 
washed in a buffer containing 10% N,N-dimethylformamide to remove the nonspecific 
interaction of the dyes with the cell membrane.  While E. coli are hearty enough to 
withstand these conditions, mammalian cells are far more delicate and likely would not 
survive.  Thus, at the outset of this project, a labeling methodology for mammalian cell 
imaging based on the site-specific introduction of ketones did not exist.   
In this chapter we describe the development of new protein labeling methodology 
(Figure 2) based on the observation that wild-type BirA uses ketone 1 efficiently in place 
of biotin.  We discovered that BirA ligates this probe to the AP with slightly reduced 
kinetics but with the high substrate specificity of the native reaction.  Proteins 
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enzymatically tagged with ketone 1 can be further derivatized using the chemoselective 
ligation with hydrazide- or hydroxylamine-functionalized molecules.  We demonstrated 
this two-stage protein labeling methodology on purified protein, protein in mammalian 
cell lysate, and proteins expressed on the surfaces of live HeLa cells.  Both fluorescein 
and a benzophenone photoaffinity probe were incorporated (Figure 3), with total labeling 
times as short as 20 minutes.  The majority of the work in this chapter has been described 
in a recent publication by Chen, Howarth, Lin, and Ting9. 
 
 
 
 
 
 
Figure 2.  General method for labeling acceptor peptide (AP)-tagged recombinant cell surface 
proteins with biophysical probes using ketone 1.  Biotin ligase (BirA) catalyzes the ligation of ketone 
1 to the AP (blue); a subsequent bio-orthogonal ligation between ketone and hydrazide (or 
hydroxylamine) introduces the probe (green circle).  Figure reproduced from reference 9.  
Figure 3.  Structures of the fluorescein hydrazide (FH) and benzophenone-biotin hydrazide 
(BP) probes used in this chapter.  Figure reproduced from reference 9. 
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Results 
 
Wild-type BirA ligates ketone 1 to the AP 
The synthesis of ketone 1 as a racemic mixture is discussed in detail in Chapter 
29,10.  Using the reported crystal structure of BirA bound to biotin,11 we designed some 
mutants that could possibly better accommodate the binding of ketone 1 (Figure 4).  
 
Gln112
Ser134
Thr90
Asn91
Ser89
Gly115
Arg116
 
 
 
Replacement of the ureido nitrogens with methylene groups destroys the hydrogen 
bonding interactions with the backbone carbonyl at Arg116 and the sidechains of Thr90 
and Gln112.  The introduction of the sp3-hybridized carbons in place of the sp2-
hybridized nitrogens is also expected to alter the orientation of the carbonyl group within 
the binding pocket.  To compensate for these changes, the amino acids closest to the 
ureido group were targeted for mutagenesis.  We sought to make the binding pocket more 
hydrophobic and slightly larger to accommodate the introduction of the methylene 
groups.  
Figure 4.  Amino acids targeted for mutagenesis to accommodate ketone 1.  Amino acids that contain 
atoms within 4 Å of the ureido group in the BirA-biotin crystal structure (PDB:  1HXD) are shown.  
Carbon atoms are colored grey, oxygen atoms are colored red, nitrogen atoms are colored blue, and 
sulfur atoms are colored orange.   
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We constructed the genes for the single and double mutants Thr90Val, Thr90Ala, 
Gly115Ala, Gln112Met, Thr90Val + Asn91Leu, and Thr90Ala + Asn91Leu using 
Quikchange™ site-directed mutagenesis.  We overexpressed and purified each enzyme 
from E. coli JM109.  Because we thought it unlikely that a single point mutation or two  
conservative mutations would completely abolish biotin binding, we assayed for properly 
folded enzymes through their ability to catalyze the biotinylation of a synthetic acceptor 
peptide substrate.  Biotinylation reactions of the synthetic AP were analyzed using 
reverse-phase HPLC, and biotinylated products were confirmed by matrix-assisted laser 
desorption/ionization time of flight (MALDI-TOF) mass spectrometry.  At a catalyst 
loading of 1-2 mol%, wild-type BirA and all of the designed single mutants were able to 
catalyze the complete conversion of 100 µM of synthetic AP to a single biotinylated 
product within six hours of reaction at room temperature (Table 1).  On the other hand, 
the double mutants completely converted the AP into multiple products, which we 
confirmed by MALDI-TOF to be the AP conjugated to multiple biotin molecules (Table 
1).  This nonspecific biotinylation was also observed with the BirA double mutants that 
we designed to accommodate an azide analog of biotin (Chapter 4).  We hypothesize that 
these more substantial alterations to the active site lead to poorer binding of the biotin 
adenylate ester intermediate, which is subsequently released and trapped locally by the 
additional lysines of our synthetic AP.  
 Using the same HPLC assay, we next tested our collection of enzymes for their 
ability to utilize ketone 1 as a substrate under the same conditions.  When we combined 
wild-type BirA, ketone 1 (racemic), and ATP with the synthetic AP, we observed 
complete conversion to a new product peak within six hours at room temperature or two 
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hours at 30 °C.  Omission of ATP or BirA from the reaction eliminated this peak, proving 
that it was the product of the enzymatic reaction (Figure 5A).  MALDI-TOF analysis 
confirmed that the product had the expected molecular weight for ketone 1 attached to the 
AP (calculated [M+Na]+ 2541.3 g/mol; observed 2542.3 g/mol) (Figure 5B).  Ketone 1 
was also separated into its constituent enantiomers by semipreparative chiral HPLC 
(Chapter 2), and we verified that only one enantiomer was accepted by BirA (data not 
shown), which we presume has the same d configuration as biotin. 
 
 
  
When we tested the other mutants under the same conditions, we found that only 
Gly115Ala and Gln112Met could also could catalyze the complete conversion to the AP-
ketone 1 conjugate (Table 1).  The Thr90 single mutants showed a pronounced reduction 
in ketone 1 ligation activity relative to the wild-type enzyme, and the double mutants 
failed to utilize it at all.  When we re-assayed the three most active enzymes under shorter 
Figure 5.  BirA-catalyzed ligation of ketone 1 to the AP.  (A) HPLC traces showing BirA- and ATP-
dependent ligation of ketone 1 to a synthetic acceptor peptide (KKKGPGGLNDIFEAQKIEWH; 
acceptor lysine underlined). (B) MALDI-TOF spectrum confirming the mass of the purified AP-
ketone conjugate.  Figure was reproduced from reference 9. 
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reaction times, we found that the wild-type enzyme was the best catalyst for ketone 1 
ligation (Table 1).  Thus, all of our strategically introduced mutations actually impaired 
the ability of the wild-type enzyme to utilize ketone 1, which highlights the difficulty of 
rational redesign of enzyme substrate specificity.  Even with the aid of a crystal structure, 
a detailed understanding of the relationship between protein sequence and function 
remains elusive.   
 
 
 
 
 
 
 
 
To quantitatively compare the efficiency of ketone 1 ligation and biotin ligation 
catalyzed by BirA, we measured the rates of product formation for both reactions under 
identical conditions using the HPLC assay (Figure 6).  The initial rate for ketone 1 
ligation (0.258 ± 0.024 µM/min) was only 3.7-fold less than that for biotin ligation (0.954 
± 0.018 µM/min, matching the previously reported rate for BirA biotinylation of its 
natural substrate, biotin carboxyl carrier protein12).   
Mutant Conversion to AP-biotin Conversion to  AP-ketone 1 
Thr90Ala 100% 25% 
Thr90Val 100% 10% 
Gln112Met 100% 100% 
Gly115Ala 100% 100% 
Thr90Ala + Asn91Leu 100%, but nonspecific biotinylation 0% 
Thr90Val + Asn91Leu 100%, but nonspecific biotinylation 0% 
wild-type 100% 100% 
Table 1.  Summary of biotin and ketone 1 incorporation by the BirA mutants used in this study.  
Reactions were incubated for six hours at room temperature under the following conditions:  100 µM 
AP, 1-2 µM enzyme, 1 mM biotin or racemic ketone 1, 4 mM ATP, 5 mM magnesium acetate in 50 
mM bicine pH 8.3.  The reactions were analyzed using reverse-phase HPLC.   
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However, while the biotin ligation rate remained constant until > 50% conversion, the 
ketone ligation rate slowed markedly after ~100 enzyme turnovers.  This suggested that 
product inhibition might be occurring, possibly through Schiff base formation with lysine 
sidechains involved in catalysis.  In order to avoid any such inhibition, we used > 0.01 
equivalents of BirA relative to protein substrate in all subsequent labeling experiments. 
 
Labeling of AP fusion proteins in vitro 
To test the use of BirA and ketone 1 for the labeling of a recombinant protein, we 
generated a test substrate by fusing the AP to the C-terminus of cyan fluorescent protein 
(CFP-AP).  Purified CFP-AP was first enzymatically labeled with ketone 1, and then 
fluorescein hydrazide (FH; Figure 3) was added to derivatize the ketone.  The resulting 
hydrazone adduct was reduced with sodium cyanoborohydride to improve its stability for 
SDS-PAGE analysis.  We originally had problems with nonspecific sticking of FH to 
Figure 6.  Time course of biotin () and ketone 1 () ligation to synthetic AP using 0.091 µM BirA. 
Reactions were incubated at 30 °C under the following reaction conditions:  100 µM AP, 0.091 µM 
BirA, 1 mM biotin or 2 mM racemic ketone 1, 4 mM ATP, 5 mM magnesium acetate in 50 mM 
bicine pH 8.3.  Aliquots were removed at the indicated times, quenched with EDTA, and analyzed by 
HPLC.  Each data point represents the average of three experiments (error bars, std).  Figure 
reproduced from reference 9. 
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CFP-AP, but we found that precipitation of the protein with trichloroacetic acid before 
SDS-PAGE was the most effective way to purify the protein away from the excess FH.  
The labeling reactions were resolved using SDS-PAGE, and the gels were analyzed by 
fluorescence to detect labeling and stained with Coomassie Blue to verify equal loading 
of protein (Figures 7A and 7B, respectively).  
 
 
 
 
Fluorescein is conjugated to CFP-AP only when ATP is present in the first step, 
indicating that the conjugation is dependent on the enzymatic ligation of ketone 1.  To 
serve as a negative control for specificity, we mutated the acceptor lysine of the AP to an 
alanine, creating the CFP-Ala construct.  We observed no fluorescein conjugation when 
this mutant protein was subjected to the same two-step labeling procedure, demonstrating 
that the labeling is site-specific for the lysine of the AP. 
To test the specificity of the BirA/ketone 1-mediated labeling reaction in a more 
demanding environment, we spiked HeLa cell lysate with CFP-AP (or CFP-Ala) and 
subjected the mixture to the same two-stage labeling procedure above.  We initially 
encountered problems with proteolytic degradation of the AP by proteases present in the 
cell lysate, but we eventually found that hypotonic lysis greatly reduced protease release.  
Figure 7.  Labeling of recombinant CFP-AP with fluorescein hydrazide (FH).  (A) Fluorescence gel 
image of denatured CFP-AP protein samples (fused AP sequence:  GLNDIFEAQKIEWHE; acceptor 
lysine underlined) labeled by ketone 1 and then fluorescein hydrazide.  Omission of ATP (second lane) 
eliminates labeling, as does mutation of the acceptor lysine (CFP-Ala; third lane).  (B) Coomassie-
stained image of gel in (A), verifying equal loading of proteins in all lanes.  Figure was reproduced 
from reference 9. 
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Lysate labeling reactions were analyzed by SDS-PAGE as described above (Figures 8A 
and 8B).  Only CFP-AP is labeled with fluorescein (Figure 8A), even in the presence of 
endogenous mammalian proteins at similar concentration (as seen by Coomassie stain, 
Figure 8B).  Like for purified CFP-AP, labeling is dependent on the presence of ATP and 
the lysine of the AP.   
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We also performed the same two-step fluorescent labeling procedure on lysates 
generated hypotonically from human embryonic kidney (HEK) 293T cells expressing a 
cytoplasmic CFP-AP construct.  Figures 9A and 9B show that successful labeling is again 
dependent on the presence of ATP and specific for CFP-AP.  Thus, from the collective 
results of the two lysate labeling experiments, we conclude that wild-type BirA accepts 
ketone 1 as a cofactor without compromising its exceptional specificity for the peptide 
substrate. 
 
Figure 8.  Labeling of CFP-AP protein with ketone 1 and FH in the presence of HeLa cell lysate.  (A) 
Fluorescence image of a gel showing labeling of only the CFP-AP protein, despite the many other 
proteins present in the lysate.  Omission of ATP, or replacement of CFP-AP by CFP-Ala, eliminates 
labeling.  (B) Coomassie stained image of the gel in (A), showing all of the proteins present in the 
lysate.   
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We also assessed the sensitivity of our labeling method by comparing it to 
antibody detection.  Because the CFP-AP construct expressed in the HEK cells has an  
N-terminal hexahistidine tag, we could compare the detection of the CFP-AP in the lysate 
using either ketone 1/FH conjugation or immunoblot with a mouse anti-pentahistidine 
primary antibody and a fluorescein-conjugated secondary antibody.  Figure 10 shows that 
our method is considerably more sensitive than anti-pentahistidine antibody labeling for 
detection of CFP-AP in lysate. 
Figure 9.  Labeling of lysates from HEK cells expressing CFP-AP.  A. Fluorescence image of a gel 
showing the labeling of lysates with ketone 1 and FH.  Only CFP-AP is labeled. Omission of ATP 
(second lane) eliminates labeling, and no labeling is seen when HEK cells are not transfected with the 
CFP-AP plasmid.  B. Coomassie stained image of the gel in A.  Figure reproduced from reference 9.   
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Labeling of cell surface proteins  
Because ketones are absent from native cell surfaces, BirA-catalyzed introduction 
of ketone 1 should permit the site-specific conjugation of hydrazide or hydroxylamine 
probes onto AP-tagged cell surface proteins.  Because FH is known to penetrate the 
plasma membrane of E. coli8, we decided to label cells with these membrane- 
impermeable fluorophores:  Alexa Fluor 488 hydrazide, Alexa Fluor hydroxylamine, and 
Texas Red hydrazide.  To highlight how the use of a single ketone handle can direct the 
conjugation of diverse biophysical probes, we also designed and synthesized a custom 
photoaffinity probe, which we called benzophenone-biotin hydrazide (BP, Figures 3 and 
11).  BP possesses a hydrazide functional group for conjugation to ketone 1, a 
benzophenone photocrosslinker, and a biotin moiety to enable sensitive detection with 
streptavidin conjugates.  The design and synthesis of BP was performed by Weiying Lin 
and Eric McNeill of our laboratory according to the reaction sequence in Figure 11. 
Figure 10.  Comparison of our labeling method (ketone 1 followed by FH) to antibody detection 
(anti-pentahistidine mouse monoclonal followed by fluorescein-conjugated secondary antibody) for 
visualization of CFP-AP in lysate.  A fluorescence image of denatured protein samples transferred to 
nitrocellulose membrane is shown.  Our method generates a significantly stronger signal than 
antibody detection.  Figure reproduced from reference 9.  
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We created an artificial cell surface protein by fusing the AP and CFP to the 
extracellular side of the transmembrane (TM) domain of the platelet-derived growth 
factor (PDGF) receptor (Figure 12).  The TM domain targets the entire construct to the 
cell surface, while the CFP marker allows facile identification of transfected cells. This 
construct, called AP-CFP-TM, was efficiently expressed in HeLa cells after 12-24 hours.  
Biotinylation with extracellularly added BirA, biotin, and ATP resulted in distinct 
membrane labeling of the transfected cells after staining with streptavidin-Alexa 568.  
This confirmed that the AP tag was expressed on the cell surface and sterically accessible 
to BirA (data not shown).  In our initial experiments, weak labeling persisted even when 
biotin or ATP was omitted from biotinylation reaction, but no labeling was observed 
when BirA was omitted from the reaction.   We suspected that this unwanted labeling 
was a result of the transfer of residual biotin adenylate ester (biotin-AMP) that remained 
bound to BirA after purification from E. coli.  BirA binds tightly and stably to  
Figure 11.  Synthesis of benzophenone-biotin hydrazide (BP).  a.  2,2-dimethoxypropane, 
concentrated hydrochloric acid, rt.  b.  biotin N-hydroxysuccinimidyl ester, DIPEA, DMF, rt.  c.  
hydrazine, ethanol, reflux.   
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biotin-AMP (koff ~ 2.7×10-4 s-1, Kd ~ 50 pM13), and the complex has been reported to 
survive gel filtration chromatography14.  In a process we call “recycling BirA,” we 
removed the bound biotin-AMP by incubating BirA with a three-fold molar excess of 
synthetic AP at room temperature for three hours and re-purifying the hexahistidine-
tagged enzyme on nickel-nitrilotriacetic acid (Ni-NTA) resin.  Using recycled BirA 
(rBirA), we observed membrane labeling of transfected cells only when both biotin and 
ATP were additionally present in the biotinylation media.  Because we were concerned 
about the possible toxicity of extracellular ATP, we separately examined the growth rate 
of HeLa cells incubated for 24 hours with various amounts of ATP; we observed no 
effect at concentrations below 5 mM.  Therefore, 1 mM ATP was used for all our cellular 
experiments. 
In collaboration with Mark Howarth, we first attempted to label HeLa cells 
expressing the AP-CFP-TM construct with a fluorophore.  To initiate labeling, the cell 
media was replaced with Dulbecco's phosphate buffered saline pH 7.4 (DPBS) containing 
0.2 µM rBirA, 1 mM ketone 1 (racemic), 5 mM magnesium chloride, and ATP.  The 
ketone ligation was allowed to proceed for 60 minutes at 32 °C.  The cells were then 
rinsed to remove excess ketone 1, and the fluorophores were added at a final 
concentration of 100-200 µM in slightly acidic media (DPBS pH 6.2)15, which is known 
to accelerate hydrazone or hydroxylamine formation.  After incubation for 60 minutes at 
32 °C, the cells were washed and imaged.  Under these conditions we did not detect any 
specific labeling, instead observing nonspecific sticking of the fluorophore to the surfaces 
of all cells and significant amounts of internalization of the fluorophore.  To reduce the 
amount of nonspecific sticking, we tried lower concentrations of fluorophore and shorter 
116 
hydrazide (or hydroxylamine) conjugation times, but we still observed no specific 
labeling of the transfected cells.  We then tried performing the hydrazide conjugation at 
16 °C to slow endocytosis of the fluorophore and the ketone-labeled AP-CFP-TM.  
Endocytosis of the ketone-labeled protein not only reduces the number proteins available 
for imaging, but also slows down the overall rate of the ketone-hydrazide reaction at the 
cell surface.  Even with this modification to the protocol, we still never successfully 
detected specific labeling of AP-expressing cells with the fluorophores.  We believe that 
the kinetics of hydrazone formation are not fast enough to achieve a level of conversion 
that is detectable above the nonspecific sticking of fluorophore to the cell surface.  The 
inability to introduce small molecule fluorophores on cell surfaces represents one current 
limitation of BirA/ketone 1 labeling. 
We then initiated efforts to detect the specific labeling of HeLa cells with BP.  To 
detect the biotin handle on the BP probe, we planned on using a streptavidin-Alexa 568 
conjugate, but we first had to confirm that the streptavidin conjugate would not bind to 
our ketone analog of biotin.  When HeLa cells expressing the AP-CFP-TM construct 
were labeled with ketone 1 using rBirA and stained with streptavidin-Alexa 568, we 
observed no labeling of the cells, suggesting that streptavidin does not bind to ketone 1.  
Through isothermal titration calorimetry it was determined that streptavidin does bind 
ketone 1 weakly with Kd = 0.9 µM (Markku Kulomaa, personal communication), but this 
interaction is apparently not strong enough to survive our washing conditions. 
To perform labeling with BP, HeLa cells expressing the AP-CFP-TM construct 
were labeled with ketone 1 as described above.  After washing away excess ketone 1,  
1 mM of BP in DPBS pH 6.2 was added to the cells at 16 °C, to minimize endocytosis, 
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and the cells were incubated at that temperature for 10 to 60 minutes.  The cells were then 
stained with streptavidin-Alexa 568 to detect the biotin handle of BP.  The fluorescence 
and differential interference contrast (DIC) images of the labeled cells are shown in 
Figure 12.   
 
 
 
 
Cells transfected with AP-CFP-TM display distinct membrane labeling by the BP probe, 
indicated by the streptavidin-Alexa 568 staining pattern, whereas neighboring 
untransfected cells remain unlabeled (Figure 12A).  No membrane labeling was observed 
when ketone 1 was omitted from the BirA reaction (Figure 12B), showing that BP 
Figure 12.  Site-specific labeling of AP-CFP-TM expressed on the surface of live HeLa cells with a 
benzophenone–biotin hydrazide (BP) probe. Cells expressing the construct were labeled with ketone 
1 for 60 minutes, followed by BP for 60 minutes. The probe was then detected via its biotin handle 
using streptavidin-Alexa 568. The left columns show the CFP images (false-colored cyan) merged 
with the DIC images. The right columns show the Alexa 568 images (false-colored orange).  (A) 
HeLa cells transfected with AP-CFP-TM are labeled with ketone 1 and BP, while neighboring 
untransfected cells are not.  (B) Negative control with ketone 1 omitted.  (C) Negative control with 
cells expressing the Ala-CFP-TM point mutant.  Figure was reproduced from reference 9. 
AP CFP     TMN C
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labeling proceeds through ketone 1.  Cells expressing the Ala-CFP-TM point mutant in 
place of AP-CFP-TM (Figure 12C) show only background levels of staining, 
demonstrating that the labeling is site-specific for the lysine of the AP.  Despite the 
necessity of a two-stage labeling protocol, high levels of labeling were achieved in total 
times as short as 20 minutes, within the timescale necessary for the study of relatively 
fast biological processes, such as receptor trafficking. 
We also used the AP-CFP-TM construct to quantify the sensitivity of BirA-
catalyzed labeling.  On a dish of cells expressing AP-CFP-TM at a range of 
concentrations (< 10 µM to > 1 mM as determined by fluorescence intensity comparison 
to a wedge of purified CFP protein of known concentration), labeling by the BP probe 
was clearly detectable, with a signal-to-background ratio > 4:1, for cells expressing  
> 10 µM AP-CFP-TM.  Based on deconvolution imaging, which shows approximately a 
1:1 ratio of cell-surface to intracellular AP-CFP-TM fluorescence (data not shown), and 
assuming an average cell volume of 1 pL, an expression level of 10 µM corresponds to 
~106 copies of AP on the cell surface.  Thus, our labeling method can detect cell surface 
proteins expressed at 106 copies/cell, and perhaps even less.  This expression level 
corresponds to that of a highly overexpressed protein. 
To demonstrate BirA/ketone 1-mediated labeling on a natural protein, we chose to 
label the epidermal growth factor receptor (EGFR). The trafficking behavior and ligand-
dependent dimerization and possible higher-order oligomerization16 of EGFR are of great 
biological interest. In addition, EGFR has proven to be intractable to study by 
extracellular green fluorescent protein (GFP) fusion, which severely impairs receptor 
expression and trafficking17.  Thus, only minimal-sized probes and tags may be tolerated 
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by the extracellular domain.  We fused the AP to the N-terminus of human EGFR, 
expressed the construct in HeLa cells, and demonstrated both robust surface expression 
and steric accessibility of the AP tag using direct enzymatic biotinylation. We then used 
BirA- and ketone 1-mediated labeling to introduce the BP probe onto AP-EGFR.  Cells 
cotransfected with AP-EGFR and cytoplasmic CFP (used as a transfection marker) 
display surface staining, whereas neighboring untransfected cells do not (Figure 13A). 
Negative controls with ketone 1 omitted (Figure 13B) and AP-EGFR replaced by Ala-
EGFR (Figure 13C) gave no labeling. 
 
AP EGFRN C  
 
Figure 13.  Site-specific labeling of AP-EGFR expressed on the surface of live HeLa cells with 
BP.  Cells expressing the construct were labeled with ketone 1 for 60 minutes, followed by BP for 
60 minutes.  The probe was then detected via its biotin handle using streptavidin-Alexa 568. The 
left columns show the CFP images (false-colored cyan) merged with the DIC images. The right 
columns show the Alexa 568 images (false-colored orange).  (A) HeLa cells co-transfected with 
AP-EGFR and a cytoplasmic CFP marker plasmid display BP labeling, while neighboring 
untransfected cells are not labeled.  (B) Negative control with ketone 1 omitted.  (C) Negative 
control with AP-EGFR replaced by the Ala-EGFR point mutant.  Figure was reproduced from 
reference 9. 
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Mark Howarth performed two assays to verify that, in contrast to the GFP tag, the 
15-amino acid AP tag did not alter the expression, trafficking, or function of EGFR.  
First, the distribution of AP-EGFR and untagged wild-type EGFR were compared by  
immunofluorescence staining with anti-EGFR antibody and found to be identical  
(Figure 14A).  Second, we assessed EGFR function by measuring the increase in general 
tyrosine phosphorylation in response to EGF ligand binding18.  EGF treatment elevates 
phosphotyrosine levels at the plasma membrane indistinguishably in wild-type EGFR- 
and AP-EGFR-transfected cells (Figure 14B).  Therefore, the AP tag at the N-terminus 
appears minimally invasive and should allow introduction of a range of probes to study 
EGFR trafficking and function in live cells. 
 
 
 
Figure 14  Analysis of the effect of the AP tag on EGFR distribution and function.  (A) HeLa cells 
were transfected with either wild-type EGFR or AP-EGFR (cytoplasmic CFP was co-introduced as a 
transfection marker), fixed, and then stained with anti-EGFR antibody. The localization patterns of 
EGFR and AP-EGFR are indistinguishable. Note that because CFP-expressing cells consistently display 
higher levels of EGFR staining under these conditions, we conclude that our protocol detects mostly 
EGFR expressed from introduced plasmids rather than endogenous EGFR.  (B) Immunofluorescence 
staining of fixed cells with anti-phosphotyrosine antibody before and after EGF stimulation. EGFR and 
AP-EGFR-expressing cells give the same response to EGF treatment.  Figure was reproduced from 
reference 9. 
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Discussion 
 We have developed new methodology for labeling proteins with biophysical 
probes using the covalent, BirA-catalyzed ligation of a ketone analog of biotin to the 15-
amino acid AP.  Through this ketone handle, we demonstrated that proteins could be 
labeled with a fluorophore in vitro and to a photoaffinity probe when expressed on the 
surface of live cells.  Others have also used our method to conjugate a Raman probe to 
the surface of HeLa cells19.  Our method is highly specific because it capitalizes on the 
excellent sequence specificity of BirA, and in principle the ketone handle allows 
introduction of a wide range of probes.  In these respects, BirA/ketone 1-mediated 
labeling compares favorably to existing labeling approaches using protein recognition 
sequences such as alkylguaninetransferase (AGT)20, dihydrofolate reductase21, FK506 
binding-protein22, HaloTag23, and acyl carrier protein/peptide carrier protein 
(ACP/PCP)24-26, which are larger and hence more sterically invasive tags.  In terms of 
specificity and stability of probe recruitment, our method also compares favorably to 
strategies using peptide tags, such as tetracysteines (FlAsH)27,28, peptide aptamers29, and 
oligohistidines30-32.  
BirA/ketone 1-mediated labeling has its disadvantages, however, and must 
therefore be seen as a complement to, rather than a replacement for, existing 
methodologies.  Most of the limitations of our method result from the use of ketone-
hydrazide conjugation to effect probe attachment via stable hydrazone linkages.  First, we 
performed BP conjugation in slightly acidic pH to accelerate hydrazone formation and at 
16 °C to reduce endocytosis.  While these conditions are milder than Schultz’s reported 
conditions for labeling E. coli, they are still not optimal for cell health.  Next, the use of a 
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ketone handle to mediate probe conjugation restricts our method to the labeling of cell 
surface proteins, even though we and others3 have already shown that BirA retains its 
activity and sequence specificity when expressed inside mammalian cells.  The lower rate 
of hydrazone formation at physiological pH15 and the presence of competing ketone- and 
aldehyde-containing small molecules inside cells would likely prevent efficient and 
specific ligation of hydrazide- or hydroxylamine-functionalized probes to the ketone-
labeled target protein.  Finally, we believe that the mediocre rate of ketone-hydrazide 
ligation (an apparent second order rate constant of 0.8 min-1 has been reported33) is 
primarily responsible for our method’s mediocre sensitivity, mediocre time resolution, 
and inability to label cell surface proteins with small molecule fluorophores. 
Another limitation of our approach is the two-step labeling protocol, which limits 
the timescale of biological processes that can be studied.  We report a minimal labeling 
time of 20 minutes, which is faster than techniques such as FlAsH, but slower than AGT 
or ACP/PCP tagging strategies.  To improve the enzymatic ligation of ketone 1, it may be 
useful to develop a deeper understanding of the kinetics of cell surface probe ligation by 
BirA and to explicitly define a quantitative relationship between the kinetic parameters of 
the enzyme, concentrations of each reactant, and the desired signal-to-noise ratio for 
labeling.  A kinetic model invoking a combination of Langmuir surface adsorption 
kinetics and Michaelis-Menten kinetics could serve as a good approximation for our 
system34.  The labeling timescale and sensitivity of our method would also benefit greatly 
from a faster ketone-hydrazide conjugation.  Strategies to accelerate the hydrazone 
formation may proceed through altering the stereoelectronics of the ketone or the 
hydrazide.  A detailed understanding of how such alterations would affect both the 
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equilibrium concentration of the initial carbinolamine adduct and the rate of acid-
catalyzed dehydration of the carbinolamine will be beneficial15.  
Our preferred approach to addressing the shortcomings of the current 
methodology, however, is through further re-engineering of the BirA active site to 
incorporate more probes.  In the most ambitious approach, we would like to circumvent 
the need of a secondary conjugation reaction by re-engineering BirA to ligate the probe 
directly to the AP.  In a more conservative approach, we would be content to re-engineer 
BirA to accept a biotin analog possessing a more biologically orthogonal functional 
handle than the ketone, such as an azide.  The use of an azide would still require a two-
step labeling approach, but it would enable the application of chemoselective ligation 
reactions with potentially better kinetics and cell compatibility than the ketone-hydrazide 
ligation, such as the Huisgen ligation between an azide and a cyclooctyne35.  Our efforts 
to develop azide analogs of biotin for site-specific labeling are chronicled in Chapter 4. 
Further re-engineering efforts of the BirA active site may proceed through 
rational and/or combinatorial designs.  In this chapter, we had tried to rationally design 
BirA mutants that would bind better to ketone 1 than the wild-type enzyme.  However, 
our introduced mutations all led to enzymes with reduced ketone 1 ligation activity, 
suggesting that our understanding of the determinants of biotin analog binding in the 
active site is still limited.  It might also be possible that our mutational efforts resulted in 
enzymes that actually bind ketone 1 too well for efficient catalytic turnover.  Given our 
incomplete understanding of the relationship between sequence and catalytic function of 
BirA, in vitro evolution will play a major role in all of our future efforts to re-engineer 
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the BirA active site.  Our efforts in developing a platform for in vitro evolution of BirA 
are described in Chapter 5. 
Since the publication of the paper describing our BirA/ketone 1-mediated labeling 
method, several other strategies have been reported that utilize enzymes to mediate the 
covalent attachment of small molecules to a peptide recognition sequence.  In an 
approach very similar to this method, Bertozzi and co-workers have shown that an 
aldehyde can be site-specifically introduced within a six-amino acid peptide tag using the 
formylglycine-generating enzyme36.  The resulting aldehyde can be derivatized in the 
same fashion as ketone 1, but this method has not yet been demonstrated on live cells.  
The natural sequence specificities of lipoic acid ligase,37, transglutaminase38, and 
phosphopantetheinyl transferase39 have also been harnessed by our laboratory and the 
laboratories of Walsh and Yin to label cell surface proteins of live cells.  Lipoic acid 
ligase-mediated labeling is a two-step process consisting of enzymatic ligation of an 
azide and its subsequent chemoselective reaction with cyclooctyne-conjugated probes.  
On the other hand, transglutaminase and phosphopantetheinyl transferase are able to 
directly incorporate probes onto their peptide substrates in a single step.  None of these 
enzymatic strategies have yet been applied to intracellular labeling, however.  A unique 
advantage of all of these enzyme-mediated methods is that labeling can be spatially 
controlled through the genetic targeting of the labeling enzyme.  For example, we are 
working on targeting BirA to the presynaptic surface of neurons, in order to specifically 
label the subpopulation of proteins that traffic to the postsynaptic surface.  This degree of 
spatial control is not attainable with other labeling methods where the probe recruitment 
is independent of a protein catalyst.  
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While BirA/ketone 1-mediated labeling was originally conceived for live cell 
imaging, the ability to site-specifically and efficiently introduce a ketone handle into a 
protein has many important in vitro applications.  In contrast to live cell imaging, the 
mediocre kinetics of ketone-hydrazide ligation can be overcome with higher reactant 
concentrations and extended reaction times for in vitro applications.  The high specificity 
of our method is well suited for lysate detection applications, and we even showed that 
our two-step fluorescent labeling procedure was more sensitive than antibody binding for 
protein detection in lysate.  We expect that the high specificity of our method can also be 
exploited to synthesize homogeneous and well-defined protein conjugates, with important 
applications in the total chemical synthesis of therapeutic proteins40, the synthesis of 
glycoprotein mimics41,  and the conjugation of therapeutic agents to antibodies42.   
 
Conclusions  
In conclusion, we have developed new protein labeling methodology that 
combines the specificity of GFP fusion with the minimal invasiveness of a small peptide.  
This method is based on our discovery that E. coli biotin ligase (BirA) ligates an isosteric 
ketone analog of biotin to a 15-amino acid acceptor peptide (AP), without compromising 
the excellent sequence specificity of the native reaction.  We demonstrated the labeling 
on a synthetic peptide, on purified protein, on mammalian cell lysate, and on both an 
artificial construct and EGFR expressed on the surface of living mammalian cells.  
Benzophenone attachment to EGFR should permit the non-invasive study of receptor 
trafficking and oligomerization in live cells.  Future efforts will focus on extending the 
methodology to intracellular labeling and improving the timescale of labeling through re-
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engineering the active site of BirA, as well as exploiting the enzyme dependence to 
spatially restrict labeling to interesting protein subpopulations. 
 
Experimental 
 
HPLC assay for probe ligation to synthetic AP (Figure 5 and Table 1) 
The synthetic AP with sequence KKKGPGGLNDIFEAQKIEWH was 
synthesized by the Tufts University Core Facility.  The crude peptide was purified by 
reverse-phase HPLC (Microsorb-MV 300 C18, 10-39% acetonitrile/water with 0.1% 
trifluoroacetic acid (TFA) over 35 minutes, flow rate 4.7 mL/min); the desired peak had a 
retention time of 25.5 minutes.  Following lyophilization, the peptide was redissolved in 
water, and the concentration was determined from the absorbance at 280 nm using the 
calculated extinction coefficient of 5690 M-1cm-1.   
Reaction conditions for the probe ligation to the AP were as follows:  50 mM 
bicine pH 8.3, 5 mM magnesium acetate, 4 mM ATP, 100 µM AP, 1-2 µM BirA, and 1 
mM probe (either biotin or racemic ketone 1).  Reactions were incubated at 30 °C for 1-2 
hours, then quenched with the addition of 45 mM ethylenediamine tetraacetic acid 
(EDTA).  Reactions were analyzed on a reverse-phase HPLC column (Microsorb-MV 
300 C18).  Biotin ligation reactions were analyzed using a gradient of 10-43% 
acetonitrile/water with 0.1% TFA over 20 minutes (flow rate 1.0 mL/min).  Retention 
times were 8.2 minutes for biotin, 16.3 minutes for the AP, and 17.7 minutes for the AP-
biotin conjugate.  Ketone 1 ligation reactions were analyzed using a gradient of 10-46% 
acetonitrile/water with 0.1% TFA over 25 minutes (flow rate 1.0 mL/min).  Retention 
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times were 16.4 minutes for ketone 1, 17.9 minutes for the AP, and 22.0 minutes for the 
AP-ketone 1 conjugate.  For MALDI-TOF analysis, the product peak was collected, 
diluted with matrix solution (saturated α-cyano 4-hydroxycinnamic acid in 50% 
acetonitrile/water with 0.05% TFA), and spotted onto the sample target.  Positive-ion 
MALDI-TOF data were acquired in reflector mode with external calibration. 
 
Measurement of probe ligation kinetics (Figure 6) 
For kinetic measurements, the reaction conditions were the same as above, except 
that 0.091 µM BirA was used, and for the ketone ligation reactions, 2 mM of racemic  
ketone 1 was used.  A 400 µL reaction was initiated by addition of BirA and incubated at 
30 °C.  At various timepoints, a 40 µL aliquot was removed and quenched with EDTA.  
Reactions were analyzed by reverse-phase HPLC as described above.  The area ratios of 
AP and AP-probe conjugate peaks were converted to concentrations of AP-probe 
conjugate using a calibration curve generated by mixing known ratios of AP and AP-
probe conjugate.  The concentration of AP-probe conjugate was plotted versus time, and 
the reported initial rate was the slope of the line fit to the linear region of product 
synthesis. 
 
Fluorescent labeling of CFP-AP (Figure 7) 
The reaction conditions for enzymatic ligation of ketone 1 to CFP-AP were as 
follows:  50 mM bicine pH 8.3, 5 mM magnesium acetate, 4 mM ATP, 10-20 µM CFP-
AP, 1.3 µM BirA, and 100 µM racemic ketone 1.  The reaction was incubated at 30 °C 
for 3 hours, and then 0.1 M HCl was added to adjust the pH to 6.2.  Fluorescein 
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hydrazide (FH, Molecular Probes C-356) was added to a final concentration of 1 mM, 
and the reaction was incubated at 30 °C for 12-16 hours.  Sodium cyanoborohydride  
(15 mM) was added to reduce the hydrazone for 1.5 hours at 4 °C.   The total protein was 
precipitated by the addition of trichloroacetic acid (TCA) to a final v/v ratio of 10%.  The 
protein pellet was redissolved in SDS-PAGE loading buffer and resolved on SDS-PAGE.  
The gel was visualized with the STORM 860 instrument (Amersham Biosciences) and 
stained with Coomassie Blue afterwards. 
 
Fluorescent labeling of CFP-AP spiked into HeLa cell lysates (Figure 8)   
HeLa were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37 °C under 
5% CO2.  Lysates were generated from HeLa cells at 90-100% confluence by hypotonic 
lysis (to minimize protease release) as follows.  HeLa cells in a 10 cm2 dish were 
suspended by trypsinization and concentrated by centrifugation.  The cell pellet was 
resuspended in 100 µL of 1 mM HEPES pH 7.5, 5 mM MgCl2 supplemented with 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 1 µM pepstatin, and protease inhibitor cocktail 
(Calbiochem).  The cells were allowed to swell for 10 minutes at 4 °C before vigorous 
vortexing for two minutes at room temperature.  The lysates were clarified by 
centrifugation, divided into aliquots, and stored at -80 °C.  The reaction conditions for the 
enzymatic ligation of ketone 1 to CFP-AP in the presence of HeLa lysate were as 
follows:  50 mM bicine pH 8.3, 5 mM magnesium acetate, 4 mM ATP, 1 µM BirA, 1 µM 
CFP-AP, 200 µM ketone 1, and lysate to a final v/v ratio of 77%.  The reactions were 
incubated at 30 °C for 4 hours, then 0.1 M HCl was added to adjust the pH to 6.2.  
129 
Conjugation with FH and analysis of the reactions on SDS-PAGE were performed as 
described above for the Figure 7 experiments.   
 
Fluorescent labeling of lysates from HEK cells expressing CFP-AP (Figure 9) 
Human embryonic kidney 293T (HEK) cells were cultured in DMEM containing 
10% FBS and 1% penicillin-streptomycin at 37 °C under 5% CO2.  HEK cells at 90% 
confluence in a 10 cm2 dish were transfected with 1 µg of a pcDNA3 plasmid containing 
the CFP-AP gene (has an N-terminal hexahistidine tag, see the Supporting Electronic 
Information) using 4 µL Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions.  Lysates were generated after 24-48 hours using the 
hypotonic lysis protocol described above.  Lysate labeling and reaction analysis were 
performed as described above, except without spiking in additional CFP-AP protein.   
 
Comparison of BirA/ketone and antibody detection of CFP-AP in HEK cell lysate 
(Figure 10) 
The HEK cell lysate used in the Figure 9 experiments was also used in this 
experiment.  HEK cell lysate was fluorescently labeled as described above for Figures 8 
and 9.  This reaction was loaded into one lane of an SDS-PAGE gel (Figure 10, left).  
Untreated lysate was loaded into a separate lane on the same gel (Figure 10, right).  After 
resolution by SDS-PAGE and transfer to a nitrocellulose membrane, the membrane was 
cut in half between the two lanes.  The half of the membrane containing the labeled lysate 
lane was stored in Tris-buffered saline until imaging with the Storm 860 instrument.  The 
other half of the membrane containing the untreated lysate lane was blotted with an anti-
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pentahistidine mouse antibody (1:1000, Qiagen), followed by a fluorescein-conjugated 
anti-mouse antibody (1:20, Calbiochem), to detect CFP-AP.  Following antibody 
application, the two halves of the membrane were reconstituted and imaged 
simultaneously with the Storm 860 instrument.  
 
Labeling of cell surface AP-CFP-TM and AP-EGFR expressed in HeLa cells with 
Benzophenone-biotin hydrazide (Figures 12 and 13) 
HeLa cells at 70-80% confluency in a 10 cm2 dish were transfected with 1 µg of 
the AP-CFP-TM or AP-EGFR plasmid using 4 µL of Lipofectamine 2000 according to 
the manufacturer’s instructions.  The AP-EGFR plasmid was also co-transfected with  
0.3 µg of a cytoplasmic CFP construct to serve as a transfection marker.  After 12-24 
hours at 37 °C, the cells were washed twice with Dulbecco's phosphate buffered saline 
(DPBS) pH 7.4.  Enzymatic ligation of ketone 1 to AP-CFP-TM was performed in DPBS 
pH 7.4 with 5 mM magnesium chloride, 0.2 µM recycled BirA, 1 mM racemic ketone 1, 
and 1 mM ATP for 10-60 minutes at 32 °C.  Cells were then washed twice with DPBS 
pH 6.2 and incubated for 10-60 minutes at 16 °C (to reduce endocytosis) with 1 mM 
benzophenone-biotin hydrazide (BP) in DPBS pH 6.2.  The cells were washed twice with 
DPBS pH 7.4 and incubated with streptavidin-Alexa 568 (1:300 dilution, Molecular 
Probes) in DPBS pH 7.4 and 1% dialyzed bovine serum albumin (dBSA) for 5 minutes at 
room temperature.  The cells were washed twice with DPBS pH 7.4 and imaged in the 
same buffer on a Zeiss Axiovert 200M inverted epifluorescence microscope using a 40× 
oil-immersion lens. CFP (420DF20 excitation, 450DRLP dichroic, 475DF40 emission), 
Alexa 568 (560DF20 excitation, 585DRLP dichroic, 605DF30 emission), and DIC 
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images (630DF10 emission) were collected and analyzed using OpenLab software 
(Improvision).  Acquisition times ranged from 0.2-2 seconds. 
 
Determination of labeling sensitivity using AP-CFP-TM 
We used the wedge method to estimate the concentration of CFP in single cells 
expressing the AP-CFP-TM construct27,43.  A wedge-shaped microchamber was 
constructed from three glass coverslips.  The length along the x-direction was 7 mm and 
the height of the chamber (z-direction) increased linearly from 0 to 175 µm.  The 
chamber was filled with a solution of 27 µM purified CFP in PBS pH 7.4.  The 
fluorescence of the wedge was imaged under conditions identical to those used for 
cellular imaging.  We assumed an average cell thickness of 5 µm and therefore 
interpolated to the region of the wedge with thickness 5 µm.  We used the fluorescence 
intensity measured there as a reference standard for CFP concentration measured in 
single cells.  Using the wedge for comparison, we imaged a sample of HeLa cells 
expressing AP-CFP-TM that had been labeled with the BP probe.  Examination of the 
CFP channel images for cells that displayed clear BP labeling (signal to background 
>4:1) showed that the CFP concentrations ranged from 10 µM to >1 mM.  We therefore 
concluded that cells expressing as little as 10 µM AP-CFP-TM could be labeled by our 
method.  We also performed deconvolution imaging to estimate the amount of cell 
surface AP-CFP-TM as opposed to internal AP-CFP-TM.  We acquired 20 µm image 
stacks with a 0.2 µm step size.  The stacks were deconvoluted using Volocity software 
(Improvision), and analysis showed that approximately half of the total CFP fluorescence 
was inside the cell, and the other half was at the plasma membrane.  Based on this 
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observation, and the estimate that a typical HeLa cell has a volume of 1 pL, the number 
of cell surface AP tags is ~106 for a cell expressing 10 µM of AP-CFP-TM.  This 
represents an upper limit to the labeling sensitivity of our methodology. 
 
Immunofluorescence detection of AP-EGFR localization and EGF-induced tyrosine 
phosphorylation (Figure 14) 
HeLa cells were co-transfected with a cytoplasmic CFP marker plasmid and either 
wild-type EGFR or AP-EGFR in pcDNA3, in a 1:8 ratio, using Lipofectamine 2000. 
After 24 hours of expression at 37 °C, the cells were fixed at 4 ºC for 5 minutes, then  
25 ºC for 10 minutes, using 4% paraformaldehyde, 4% sucrose, and 1 mM sodium 
orthovanadate.  After two rinses with PBS, the cells were incubated at 25 ºC for 10 
minutes with 0.1% Triton X-100, 1 mM sodium orthovanadate, and PBS to permeabilize 
the membranes. Treatment with an anti-EGFR antibody (1 µg/mL, Oncogene GR01L), 
followed by a fluorescein-conjugated goat anti-mouse IgG (5 µg/mL, Calbiochem 
401244) was used to stain the EGFR.  After mounting, the cells were imaged on the Zeiss 
Axiovert 200M microscope using a 40× lens and a fluorescein filter set (495DF10 
excitation, 515DRLP dichroic, 530DF30 emission).  Because we consistently observed 
higher levels of staining for cells expressing CFP, we concluded that the majority of 
EGFR staining on transfected cells resulted from introduced EGFR plasmid rather than 
endogenous EGFR.  
To detect tyrosine phosphorylation, transfected cells were serum-starved for 7-24 
hours, then EGF (100 ng/mL) was added for 10 minutes at room temperature. The cells 
were fixed and stained with an anti-phosphotyrosine antibody (2.5 µg/mL, BD 
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Transduction Laboratories PY20B).  Fluorescein-conjugated goat anti-mouse antibody 
was used to detect the primary antibody, and the cells were imaged using the same 
fluorescein filter set as above at 40× magnification. 
 
General plasmid constructions 
Cloning of pRSETB-CFP-AP for bacterial expression (appends an N-terminal 
hexahistidine tag), pCDNA3-CFP-AP for mammalian cytoplasmic expression (appends 
an N-terminal hexahistidine tag), and pDisplay-AP-CFP-TM for mammalian cell surface 
expression was performed using standard PCR subcloning techniques.  The pCDNA3-
AP-EGFR plasmid for expression of AP-tagged EGFR in mammalian cells was 
constructed in a different manner and its construction is described below.  Ala point 
mutations of each of these plasmids were constructed using Quikchange™ site-directed 
mutagenesis with the AP plasmids as templates.     
The pBTac2 plasmid containing the gene for wild-type E. coli BirA with a C-
terminal hexahistidine tag was a gift from D. Beckett (University of Maryland, College 
Park).  The plasmids encoding the BirA single mutants and Thr90 double mutants used in 
this chapter were constructed using Quikchange™ of the pBTac2-wild-type BirA plasmid 
or the Thr90 single mutant plasmids.  For higher-yielding bacterial overexpression of 
wild-type BirA, the pET21-BirA plasmid was cloned by Marta Fernandez-Suarez.   
For the sequences of all mentioned constructs, please see the Supporting 
Electronic Information.   
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Construction of AP-tagged EGFR   
The human EGFR gene in pcDNA3 (Invitrogen) was a gift from K. D. Wittrup 
(MIT). The acceptor peptide (GLNDIFEAQKIEWHE) was introduced at the NheI site 
between residues A21 and S22 of the EGFR signal sequence using the primers 5'-CTA 
GTC GGG CTG GCC TGA ACG ATA TCT TCG AGG CCC AGA AGA TCG AGT GGC ACG AGG 
and 5'- CTA GCC TCG TGC CAC TCG ATC TTC TGG GCC TCG AAG ATA TCG TTC AGG CCA 
GCC CGA.  These primers were annealed, phosphorylated with T4 polynucleotide kinase 
(New England Biolabs), and ligated into NheI-digested EGFR plasmid.  Ala-EGFR with 
a lysine to alanine mutation in the AP was constructed using the QuikChange™ kit (see 
the Supporting Electronic Information). 
 
Bacterial expression and purification of E. coli biotin ligase (BirA) and mutants 
Expression of pBTac2 plasmids in JM109   
The pBTac2 plasmid containing the gene for wild-type or mutant BirA with a C-
terminal hexahistidine tag was introduced into E. coli strain JM109 by heat-shock 
transformation.  The cells were cultured in Luria Bertani (LB) media supplemented with 
ampicillin (100 µg/mL) at 37 °C until OD600 0.9.  Enzyme expression was induced with 
the addition of isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 
0.4 mM.  After incubation with shaking at 30 °C for three hours, the cells were harvested 
by centrifugation.  The cells were lysed by sonication at 4 °C (three 10-second pulses at 
half-maximal power with 1 minute between each pulse) in lysis buffer (50 mM Tris pH 
7.8, 300 mM NaCl) containing 1 mM PMSF and protease inhibitor cocktail 
(Calbiochem).  The hexahistidine-tagged enzyme was purified from the lysate using Ni-
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NTA agarose (Qiagen).  Fractions containing the enzyme were consolidated and dialyzed 
against PBS pH 7.4.   
 
Expression of pET21 plasmids in BL21(DE3) 
The pET21 plasmid containing the gene for wild-type BirA with a C-terminal 
hexahistidine tag was introduced into E. coli strain BL21(DE3) by heat-shock 
transformation.  The cells were cultured in LB supplemented with ampicillin (100 
µg/mL) at 37 °C until OD600 0.5 and induced for three hours at 30 ° with 0.4 mM IPTG.  
The cell pellet was lysed by sonication (see above for JM109 expression) or resuspension 
in bacterial protein extraction reagent (B-PER, Pierce) supplemented with 1 mM PMSF, 
1 µM pepstatin, and protease inhibitor cocktail (Calbiochem).  The supernatant was 
loaded onto a Ni-NTA agarose column and purified as described above for JM109 
expression.   
 
“Recycling” BirA 
To remove the biotin-AMP ester that co-purified with BirA, the enzyme was 
incubated with three molar equivalents of synthetic AP at 25 °C for three hours and then 
re-purified using Ni-NTA chromatography. 
 
Bacterial expression and purification of CFP-AP 
The pRSETB plasmid containing the CFP-AP gene was introduced into E. coli 
strain BL21(DE3) by heat-shock transformation.  The cells were cultured in LB 
supplemented with ampicillin (100 µg/mL) at 22-37 °C until OD600 0.5.  The volume of 
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the culture was expanded four-fold, and protein expression was induced by the addition 
of IPTG to a final concentration of 0.4 mM.  After incubation at 30 °C for three hours, 
the cells were harvested by centrifugation.  The cells were lysed by resuspension in B-
PER as described above for BirA purification.  Following Ni-NTA chromatography, the 
fractions containing CFP-AP were collected and consolidated.  Biotinylated CFP-AP (a 
result of endogenous BirA activity in the BL21(DE3) strain) was removed using a 
streptavidin-agarose column (Novagen).  Following debiotinylation, the protein was 
concentrated by buffer exchange into pure water by gel filtration and lyophilizing to 
dryness.  The solid protein was redissolved in 50 mM bicine pH 8.3 with 5 mM 
magnesium acetate.  The concentration of protein was determined from its absorbance at 
434 nm using the extinction coefficient for enhanced CFP (34,000 M-1cm-1). 
 
Synthesis of benzophenone-biotin hydrazide (BP) (Figure 11) 
General Synthetic Methods 
All chemicals were purchased from Sigma-Aldrich or Alfa Aesar and used 
without further purification, unless otherwise stated. Analytical thin-layer 
chromatography (TLC) was performed using 0.25 mm silica gel 60 F254 plates and 
visualized with ultraviolet light, potassium permanganate, phosphomolybdic acid, or 
ninhydrin.  Flash chromatography was carried out using 70-230 mesh silica gel (ICN 
SiliTech 32-63D).  Solvents for chromatography are described as percent by volume.   
Infrared (IR) spectra were recorded on a Perkin-Elmer Model 2000 FT-IR 
spectrometer.  Proton nuclear magnetic resonance (1H NMR) spectra were recorded using 
a Varian Unity 300, Mercury 300 (300 MHz) spectrometer, or Bruker Avance 400 (400 
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MHz) spectrometer.  Chemical shifts are reported in delta (δ) units, parts per million 
(ppm) referenced to the deuterochloroform (CDCl3) singlet at 7.27 ppm or the center 
peak of the deuterated methanol (CD3OD) quintet at 3.31 ppm.  The following 
abbreviations for multiplicities are used:  s, singlet; bs, broad singlet; d, doublet; t, triplet; 
dd, doublet of doublets; m, multiplet.  High resolution mass spectra (HRMS) were 
obtained on a Bruker Daltonics APEXII 3 Tesla Fourier Transform Mass Spectrometer 
using electrospray ionization.   
  
O
MeO2C NH2  
para-benzoylphenylalanine methyl ester (3) 
para-benzoylphenylalanine (2)44 (2.3 g, 8.5 mmol) was suspended in 2,2-
dimethoxypropane (120 mL) and concentrated hydrochloric acid (10 mL) was added.  
The mixture was stirred at room temperature overnight. The volatile components were 
removed under reduced pressure. The residue was purified by silica gel column 
chromatography (20% methanol/ethyl acetate + 1% N,N-diisopropylethylamine  
(DIPEA) ) to afford a colorless oil (1.8 g, 75%).  1H NMR (CDCl3, 300 MHz) δ 7.33-
7.80 (m, 9H), 3.80 (t, 1H), 3.76 (s, 3H), 3.18 (dd, 1H), 2.94 (dd, 1H), 1.58 (s, 2H). 
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3-(4-Benzoyl-phenyl)-2-[5-(2-oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-
pentanoylamino]-propionic acid methyl ester (4) 
To a stirred solution of 3 (0.97 g, 3.5 mmol) in N,N-dimethylformamide (50 mL) 
were added biotin-N-hydroxysuccinimidyl ester (1.2 g, 3.5 mmol) and DIPEA (3 mL, 
17.5 mmol). After stirring at room temperature overnight, the solvent was removed under 
vacuum. The residue was purified by silica gel column chromatography (10% 
methanol/ethyl acetate) to afford a slightly yellow solid (0.86 g, 48%).  1H NMR 
(CD3OD, 300 MHz) δ 7.40-7.78 (m, 9 H), 4.78 (t, 1H), 4.42 (m, 1H), 4.22 (m, 1H), 3.74 
(s, 3H), 3.34 (m, 2H), 3.08 (m, 2H), 2.82 (m, 1H), 2.20 (t, 2H), 1.20-1.62 (m, 6H). 
 
O
N
H
O
S
HN NH
O
O
NHH2N
 
Benzophenone-biotin hydrazide (BP) 
Compound 4 (90 mg, 177 µmol) was added to a solution of hydrazine (2 mL) in 
ethanol (5 mL). After heating at reflux for 10 hours, the volatile components were 
removed under reduced pressure.  The residue was triturated in diethyl ether. The 
precipitate was removed by filtration, washed with diethyl ether, and dried under vacuum 
to afford a white solid (70 mg, 78%). IR (KBr): 3275, 1684 cm-1.  1H NMR (CD3OD, 400 
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MHz) δ 7.20-7.78 (m, 9H), 4.56-4.78 (m, 2H), 4.24-4.34 (m, 1H), 3.10 (m, 2H), 2.88 (m, 
2H), 2.72 (m, 1H), 2.18 (m, 2H), 1.22-1.60 (m, 6H).  HRMS (found) 510.2157 [M+H]+.  
Required for  C26H31N5O4S:  510.2170. 
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Chapter 4:  Rational design and synthesis of azide analogs of biotin and 
mutants of E. coli biotin ligase for site-specific protein labeling 
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incorporation of structural analogs of biotin onto the synthetic acceptor peptide.  Alice Y. 
Ting assisted in the development of the thin-layer chromatography assay for azide 
decomposition.  Sarah Slavoff performed the screening of biotin ligases from different 
species for incorporation of structural analogs of biotin onto the p67 polypeptide.   
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Introduction  
In this chapter, we describe the development of novel analogs of biotin to 
generalize our two-step labeling scheme to intracellular proteins.  Because ketones are 
absent from endogenous cell surfaces, we successfully demonstrated the site-specific 
labeling of cell surface proteins by E. coli biotin ligase-mediated conjugation of ketone 1 
and its subsequent chemoselective derivatization with hydrazide-bearing probes1.  
However, the use of ketone 1 to mediate intracellular probe conjugation is undesirable 
because ketones and aldehydes are found in various small molecule metabolites inside the 
cell.  The presence of these competing functional groups would not only interfere with 
the efficiency of the desired probe conjugation, but also cause high background labeling 
in imaging experiments.  Furthermore, the rate of ketone-hydrazide ligation is 
significantly slower at physiological pH (7.4) than the slightly acidic pH (6-7) employed 
for our cell surface labeling experiments2.  To extend biotin ligase-mediated labeling to 
intracellular applications, we would need a new substrate for biotin ligase in lieu of 
ketone 1.  The new substrate should possess a more biologically orthogonal functional 
handle that can be derivatized with a chemoselective reaction with superior kinetics than 
the ketone-hydrazide conjugation.   
 We targeted the development of an azide analog of biotin for the following 
reasons.  Due to the small size of the azide group, precedents exist for the incorporation 
of azides into biomolecules by natural and engineered enzymes involved in sugar 
metabolism3 and protein translation4,5.  Next, the organic azide is a functional group that 
is absent from natural biomolecules and chemically inert towards existing functionalities 
within cells.  Finally, under physiological conditions, azides react chemoselectively with 
145 
phosphines and alkynes, functionalities that are also absent from and unreactive towards 
natural biomolecules.     
The Staudinger reaction between an azide and a phosphine has classically been 
used to reduce an azide to an amine, proceeding through an aza-ylide intermediate and 
generating a phosphine oxide byproduct.  The Bertozzi and Raines groups have 
independently modified the reaction so that the aza-ylide intermediate is intercepted 
intramolecularly by an electrophilic group on the phosphine3,6.  Thus, the substituents on 
the azide and the phosphine become covalently ligated via a stable amide bond.  In the 
Bertozzi version of the “Staudinger ligation,” the phosphine oxide byproduct is 
incorporated into the final adduct (Figure 1A), whereas the Raines version is traceless 
and generates a freely diffusible phosphine oxide (Figure 1B).  
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Because of the mutual and unique reactivity of the azide and triarylphosphine, the 
Staudinger ligation has emerged as a powerful tool for bioconjugation.  Traceless 
versions of the Staudinger ligation have been particularly effective for in vitro  protein 
semi-synthesis and immobilization of small molecules or proteins on microarrays7.  In the 
field of chemical proteomics, the Bertozzi group have applied their Staudinger ligation to 
Figure 1.  Bioconjugation using the Staudinger ligation between an azide-labeled protein (black oval) 
and a phosphine-conjugated probe (green circle).  (A) In the Bertozzi version the phosphine oxide 
byproduct is incorporated as part of the final adduct.  (B) Raines’s traceless version generates a freely 
diffusible phosphine oxide byproduct.  
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detect and identify specific proteins harboring a particular glycosylation pattern.  Azide-
bearing analogs of galactosamine8 or glucosamine9 are metabolically incorporated by the 
endogenous protein glycosylation machinery.  The entire cell lysate is then treated with a 
triarylphosphine conjugated to an epitope tag.  Proteins that are covalently modified with 
the unnatural, azide-containing sugar are then detected by Western blot analysis with an 
antibody against the conjugated epitope.  The Bertozzi group have also demonstrated that 
their Staudinger ligation can be used to derivatize the cell surfaces of living mammalian 
cells that display an azide analog of sialic acid, either in cell culture or in a living 
mouse3,10.  Azides were metabolically incorporated onto the cell surfaces by feeding the 
cells an azide analog of mannosamine and capitalizing on the inherent substrate 
promiscuity of the sialic acid biosynthetic and post-translational transfer enzymes.  As a 
proof of principle, Bertozzi and co-workers demonstrated that the azide-tagged cell 
surfaces could be labeled with phosphine-conjugated epitope tags and stained with 
fluorescent antibodies for flow cytometry analysis, but the ability to modify cell surfaces 
with reactions such as the Staudinger ligation offers exciting new strategies for targeted 
cell killing, virus-based gene therapy, and remodeling of existing glycosylation patterns.   
 Under physiological conditions, azides also undergo a copper(I)-catalyzed 
Huisgen [3+2] cycloaddition with terminal alkynes to afford 1,2,3-triazole adducts in 
high yields and with complete 1,4-regioselectivity11 (Figure 2A).  This bioconjugation 
reaction developed by Sharpless and co-workers (also known as “click chemistry”) was 
used in vitro to fluorescently label recombinant proteins where azides or alkynes were 
introduced site-specifically through unnatural amino acid mutagenesis12.   The selectivity 
and sensitivity of click chemistry is showcased in lysate applications, such as the 
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detection of enzymes in lysates for activity-based protein profiling13 and studying their 
inhibition14.  In these approaches, enzymes expressed in living cells were covalently 
labeled with membrane-permeable, active-site probes bearing an azide or alkyne reporter 
functionality.  Following cell lysis, the enzymes were then fluorescently labeled using 
click chemistry, to the exclusion of all other proteins in the cell lysate. 
 
N3 + NNN
N3 +
CuI
N
N
N
A
B
 
 
A version of the azide-alkyne cycloaddition that is not dependent on copper(I) 
was also recently developed by the Bertozzi group (Figure 2B).  In the absence of the 
copper(I) catalyst, ring strain was used as an alternative strategy to lower the kinetic 
barrier towards cycloaddition.  By employing a massively strained cyclooctyne (18 
kcal/mol ring strain), the ground state is destabilized enough relative to the transition 
state to enable the reaction with an azide to proceed under physiological conditions.  The 
reaction of unstrained alkynes with azides, by contrast, typically requires elevated 
temperatures, high pressures, or a copper(I) catalyst, which are all unsuitable for 
biocompatibility.  This reaction (also called the “Huisgen ligation”) can be accelerated 
Figure 2.  Bioconjugation using the cycloaddition between an azide-labeled protein (black oval) and 
an alkyne-conjugated probe (green circle).  (A) In Sharpless’s “click chemistry” version, copper(I) is 
necessary to enable the reaction between an azide and an unstrained terminal alkyne to proceed at 
physiological conditions.  (B) Bertozzi’s Huisgen ligation between an azide and a strained 
cyclooctyne proceeds at physiological conditions in the absence of copper..   
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further by using a mono-15 or difluorinated cyclooctyne (Jeremy M. Baskin and Carolyn 
R. Bertozzi, personal communication).     
Of the four reactions shown in Figures 1 and 2, only Bertozzi’s versions of the 
Staudinger ligation and the Huisgen ligation are suitable for our purposes of live cell 
labeling.  Raines’s current version of the Staudinger ligation has only been reported with 
organic co-solvents, although in theory it should be possible to develop water-soluble 
phosphino-thioester reagents for traceless probe conjugation to azides.  Despite its 
superior kinetics and sensitivity of detection15, click chemistry is incompatible with cell 
viability, due to the demonstrated toxicity of the copper (I) catalyst to bacteria16 and 
mammalian cells15.  On the other hand, the Bertozzi versions of the Staudinger and 
Huisgen ligations have been used on cultured cells and even in laboratory mice without 
noticeable toxicity10,15. 
Our proposed reaction scheme to achieve the site-specific labeling of intracellular 
recombinant proteins is shown in Figure 3.  An AP fusion protein is co-expressed inside 
the cell with an engineered biotin ligase enzyme that is capable of utilizing an azide 
analog of biotin as a substrate.  Then, the azide analog of biotin is fed to the cells, 
probably in the form of a membrane-permeable ester.  After penetrating the plasma 
membrane, the ester is hydrolyzed to the free acid by endogenous esterases.  The 
expressed biotin ligase enzyme can then site-specifically ligate the azide to the AP fusion 
protein.  Following washout of the unreacted azide, a membrane-permeable small 
molecule probe (green circle) bearing either a triarylphosphine or a cyclooctyne is added 
to derivatize the azides via the Staudinger or Huisgen ligations.   
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 In this chapter we describe the synthesis of four azide analogs of biotin (Figure 4).  
To aid in the design of the azide analogs, we also synthesized several structural analogs 
of biotin to probe the active site tolerance of E. coli biotin ligase (BirA).  We designed 
several BirA mutants that could possibly better accommodate the azide functional group, 
using the crystal structure of BirA bound to biotin as a guide17.  We assayed for azide 
incorporation with the HPLC assay described in Chapter 3 and a Western blot assay for 
detecting azide attachment to an AP fusion protein.  We determined that neither wild-type 
BirA nor any of our designed mutants incorporated any of the synthesized azides onto the 
AP.  We also assayed for azide 3 utilization by biotin ligases from different organisms.  
Interestingly, we found that the biotin ligase from Pyrococcus horikoshii could ligate 
azide 3 to a 67-amino acid polypeptide derived from a natural biotin acceptor domain 
found in humans18.  
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Figure 3.   Proposed method for intracellular labeling of acceptor peptide (AP)-tagged recombinant 
proteins with biophysical probes using azides.  A biotin ligase is co-expressed inside the cell along 
with the AP fusion.  This biotin ligase catalyzes the ligation of an azide analog of biotin to the AP 
(blue); a subsequent bio-orthogonal ligation between azide and triarylphosphine or cyclooctyne 
introduces the probe (green circle) 
Figure 4.  Structures of the azide probes synthesized in this chapter. 
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Results and Discussion 
 
Synthesis of azide 1 by acylation of a single ureido nitrogen of biotin 
Biotin analogs have been synthesized as inhibitors of biotin-dependent 
carboxylases19, inhibitors of HIV proteases20, and probes of the streptavidin binding 
pocket21.  The sites on the biotin scaffold that have been modified are shown in Figure 5.   
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The most obvious strategies for appending functional groups to the biotin scaffold are 
alkylation and acylation of the ureido nitrogens 1′-N and 3′-N.  To impose a smaller steric 
demand on the active site and retain hydrogen bonding, we preferred derivatization at a 
single ureido nitrogen over modification at both sites.  We also preferred modification at 
the 1′-N over the 3′-N, to avoid deleterious interactions with the backbone of BirA.  The 
hydrogen bonds at the 1′-N are made with oxygen atoms from the sidechains of Thr90 
and Gln112, whereas the 3′-N hydrogen bonds to the backbone carbonyl group at 
Arg11622.  We hypothesized that it would be easier to accommodate the steric intrusion 
of the azide by changing the size and hydrophobicity/hydrophilicity of the sidechains, 
rather than drastically altering the conformation of the backbone.   
While alkylation of a single ureido nitrogen generally results in a mixture of 
regioisomers, acylation has been demonstrated to be specific for the 1′-N19.  Without any 
Figure 5.  Biotin scaffold derivatization.  The reported sites of modification are indicated by the arrows.
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prior empirical knowledge of the tolerance of the BirA active site, we first targeted the 
acylimidazolidinone azide 1 because we could synthesize the desired 1′-N regioisomer 
starting from a known synthetic sequence.  Azide 1 was synthesized in four steps from  
d-biotin, following the strategy employed to synthesize a phosphate analog of biotin as an 
inhibitor of acetyl CoA carboxylase (Figure 6)19. 
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First, d-biotin was quantitatively converted to its methyl ester 4 by stirring in a solution 
of methanolic hydrogen chloride, generated in situ by the addition of acetyl chloride to 
methanol (MeOH).  The methyl ester was then selectively acylated at the 1′-N by the 
careful addition of chloroacetyl chloride in the presence of N,N-diisopropylethylamine 
(DIPEA).  The acylimidazolidinone chloride 5 was heated with sodium azide to afford 
the azide methyl ester 6 in good yield. 
Hydrolysis of compound 6 to yield azide 1 proved to be tricky.  We first tried 
basic hydrolysis with sodium or lithium hydroxide, but the only isolated products were 
biotin and biotin methyl ester (4), suggesting that the acylimidazolidinone linkage was 
more labile than the methyl ester under these conditions.  In the model synthesis of the 
phosphate analog of biotin, the neighboring negatively charged phosphate may have 
disguised the latent lability of the acylimidazolidinone moiety19.  We next tried 
hydrolysis under acidic conditions.  Heating azide methyl ester 6 at 70 °C in a mixture of 
Figure 6.  Synthesis of azide 1.  a.  acetyl chloride, MeOH.  b.  chloroacetyl chloride, DIPEA, 
DCM, -78 °C to rt.  c.  NaN3, DMF, 70 °C.  d.  50% dioxane/0.5 M HCl, 80 °C, 30 minutes. 
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dioxane and hydrochloric acid produced three products after one hour:  the desired  
azide 1, biotin methyl ester (4), and biotin.  When the reaction time was shortened to 30 
minutes, azide 1 was the only product observed by analytical thin-layer chromatography 
(TLC), in addition to the starting material.  Purification of the reaction on silica gel 
afforded 83 mg of azide 1 (30% yield, 77% based on recovered starting material) and 
recovered 177 mg of azide methyl ester 6 (61 % recovery).  The difficulties we 
encountered in the final hydrolysis reaction foreshadowed that decomposition of azide 1 
to biotin could be a potential problem, even at the neutral pH employed for cellular 
labeling.  
 
Screening for azide 1 incorporation by HPLC and Western blot analysis 
 By examining the crystal structure of BirA bound to biotin17, we anticipated that 
the binding of azide 1 in the wild-type active site would lead to severe steric clashing 
with the sidechain atoms of Ser89, Thr90, Asn91, Gln112, and Ser134 (Figure 7).  Thus, 
to better accommodate the 1′-N sidechain, we designed some single and double mutants 
of BirA by substituting amino acids with smaller sidechains for Thr90, Asn91, Gln112, 
and Ser134.  With the help of Jeremy Baskin and Karen Riesenburger, we constructed the 
genes for the single and double mutants Thr90Gly, Gln112Gly, Ser134Gly,  
Thr90Gly + Asn91Gly, Thr90Gly + Asn91Ala, and Thr90Ala + Asn91Ala, using 
Quikchange™ site-directed mutagenesis.   
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We overexpressed and purified each enzyme from E. coli JM109.  Because we 
thought it unlikely that a single point mutant would completely abolish biotin binding, we 
used our HPLC assay for biotinylation of the synthetic AP (Chapter 3) to test for properly 
folded enzymes (Table 1).  At a catalyst loading of 1-2 mol%, the Thr90Gly and 
Thr90Ala + Asn91Ala mutants were able to fully biotinylate 100 µM of synthetic AP 
within six hours at room temperature.  Under the same conditions we observed only 50-
70% conversion to biotinylated product by the Thr90Gly + Asn91Ala double mutant.  
While the Thr90Gly and Thr90Gly + Asn91Ala reactions showed only one product peak, 
the Thr90Ala + Asn91Ala reaction showed multiple product peaks, which we confirmed 
by MALDI-TOF mass spectrometry to be AP conjugates with multiple biotin molecules 
attached.  This nonspecific biotinylation was also observed with the double mutants 
designed for ketone 1 (Chapter 3).  We hypothesize that these alterations to the active site 
lead to poor binding of the biotin adenylate ester intermediate, which is subsequently 
released and trapped locally by the additional lysines of our synthetic AP peptide.  The 
Gln112Gly, Ser134Gly, and Thr90Gly + Asn91Gly mutants were inactive, even after 
longer reaction times.  Many of our proposed mutations to create more space in the active 
Figure 7.  Amino acids targeted for mutagenesis to accommodate azide 1.  Amino acids 
that contain atoms within 4 Å of the 1′-N in the crystal structure (PDB:  1HXD) are 
shown.  Carbon atoms are colored grey, oxygen atoms are colored red, nitrogen atoms are 
colored blue, and sulfur atoms are colored orange.   
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site yielded either inactive enzymes or enzymes with enhanced nonspecific biotin transfer 
activity, thus illustrating the challenge of rational design.   
 
 
 
 We next assayed for the incorporation of azide 1 onto the AP by our collection of 
active biotin ligases:  the three active mutants designed above, the mutants designed for 
ketone 1, and the wild-type enzyme.  The results of our screening of BirA mutants using 
the HPLC assay are summarized in Table 1.  In the traces from all of the enzymatic 
reactions, we observed two new peaks in addition to the starting AP peptide.  One peak, 
with a retention time longer than that of the AP, was not present in the negative control 
reactions with ATP omitted, which strongly suggested that it corresponded to an AP-
small molecule conjugate.  The other peak had the same retention time as biotin and its 
presence was not dependent on the presence of ATP.  Thus, azide 1 partially decomposed 
Mutant Designed for Conversion to AP-biotin Conversion to AP-azide 1 
Thr90Gly azide 1 100% 0% 
Gln112Gly azide 1 0% not tested 
Ser134Gly azide 1 0% not tested 
Thr90Gly + Asn91Gly azide 1 0% not tested 
Thr90Gly + Asn91Ala azide 1 50-70% 0% 
Thr90Ala + Asn91Ala azide 1 100%, but nonspecific biotinylation 0% 
Thr90Ala ketone 1 100% 0% 
Thr90Val ketone 1 100% 0% 
Gln112Met ketone 1 100% 0% 
Gly115Ala ketone 1 100% 0% 
Thr90Ala + Asn91Leu ketone 1 100%, but nonspecific biotinylation 0% 
Thr90Val + Asn91Leu ketone 1 100%, but nonspecific biotinylation 0% 
wild-type  100% 0% 
Table 1.  Summary of biotin and azide 1 incorporation onto the AP by the BirA mutants used in 
this study.  The reaction conditions were as follows:  50 mM bicine pH 8.3 containing 5 mM 
magnesium acetate, 1 mM azide 1 or biotin, 100 µM AP peptide, and 4 mM ATP.  Biotin reactions 
were incubated at room temperature for six hours.  Azide 1 reactions were incubated at room 
temperature for longer than 12 hours. 
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to biotin under the reaction conditions.  MALDI-TOF mass spectrometry confirmed our 
suspicions that the new enzymatic product peak was the AP-biotin conjugate and not the 
AP-azide 1 conjugate.  Therefore, we did not detect any azide 1 incorporation, but instead 
we observed enzymatic ligation of the biotin generated from hydrolytic decomposition of 
azide 1 in situ.     
 We turned to a more sensitive Western blot assay to detect levels of azide 
incorporation below the threshold for the HPLC (~5% conversion, 135 pmol of product).   
We used the azide incorporation assay developed by the Bertozzi and Tirrell groups, 
which relies on the Staudinger ligation of an azide-functionalized protein with a 
phosphine-FLAG peptide conjugate (pFLAG) and detection of the FLAG epitope with 
immunoblot using an anti-FLAG antibody4.  The pFLAG peptide was synthesized by 
Alice Y. Ting and the Tufts Core Facility according to the literature proceduret4.  We 
validated the assay on our model protein substrate, the C-terminal AP fusion to the cyan 
fluorescent protein (CFP-AP, Chapter 3).  Azide 1 was nonspecifically conjugated to the 
lysines of CFP-AP using 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
(EDC) and sulfo-N-hydroxysuccinimide activation of the carboxylic acid.  Following size 
exclusion chromatography to remove excess azide 1, the collected azide-protein 
conjugate was mixed with 250 µM pFLAG and incubated for at least 12 hours at room 
temperature.  The reactions were analyzed by SDS-PAGE and blotted with anti-FLAG-
horseradish peroxidase (HRP) conjugate.  Figure 8 shows that a strong chemiluminesence 
signal was observed when azide-conjugated CFP-AP protein was treated with pFLAG 
(lane 1), but no signal was observed when pFLAG was omitted (lane 2).  Mock-treated 
CFP-AP, where azide 1 was omitted in the chemical conjugation, gave no signal when 
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similarly treated with pFLAG (lane 3).  These results confirmed that the chemoselectivity 
of the Staudinger ligation could be used to detect the covalent attachment of azide 1 onto 
CFP-AP.   
+   - + pFLAG
azide 1+   +   -
1       2       3  
 
 
 We then assayed for enzymatic attachment of azide 1 onto CFP-AP using Western 
blot.  The reaction conditions were the same as those employed for the HPLC assays, 
except the concentration of AP substrate was 10-15 µM.  Without any intermediate 
purification of excess azide 1, the individual reactions were treated with pFLAG as 
described above.  We had confirmed by Western blotting that pFLAG conjugation to 
azide 1-conjugated CFP-AP is not inhibited in the presence of 1 mM of azide 1.  The 
reactions were then analyzed by SDS-PAGE and immunoblot with anti-FLAG-HRP.  We 
observed no chemiluminescence signal above background from any of the reactions with 
our BirA mutants, even though similarly treated azide 1-conjugated CFP-AP yielded a 
strong signal as the positive control.  Therefore, we could not detect any azide 1 
incorporation by any of our collection of rationally designed enzymes, even with this 
more sensitive assay.  On the other hand, when we analyzed the same reactions for biotin 
incorporation by streptavidin-HRP blotting, we observed strong chemiluminescence 
signals for all reactions that included ATP, which is consistent with what we observed in 
the HPLC assays.   
Figure 8..  Western blot detection of azide 1-conjugated CFP-AP via Staudinger ligation of a 
FLAG epitope.  CFP-AP was nonspecifically labeled with azide 1, conjugated to pFLAG, and the 
FLAG epitope was detected using an anti-FLAG-HRP conjugate.  The chemiluminescence signal is 
dependent on both the presence of azide 1 and phosphine-FLAG conjugate.    
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 Before we could definitively conclude that azide 1 is not utilized as a substrate by 
our BirA mutants, we had to consider the faint possibility that the strong biotinylation 
signal could have arisen from hydrolytic decomposition of azide 1 after enzymatic 
ligation to CFP-AP.  We investigated the extent of decomposition of azide 1 to biotin 
using an analytical thin-layer chromatography (TLC) assay.  Following incubation of 5 
mM azide 1 for twelve hours at 37 °C in the reaction buffer only, we observed less than 
10% decomposition to biotin (Alice Y. Ting, unpublished results).  We did not perform 
the more relevant experiment of monitoring the decomposition of protein-conjugated 
azide 1.  This could have been accomplished through comparing the changes in the 
chemiluminesence signals from anti-FLAG and streptavidin blotting of azide 1-
conjugated CFP-AP after various intervals of incubation under the same reaction 
conditions.  Nevertheless, from the TLC analysis of the decomposition of the free azide 
1, we believe that if there were any azide 1 molecules attached to protein, most of them 
would still have retained the azide functional group, allowing for detection by pFLAG 
Staudinger ligation.   
Through our HPLC and Western blot assays, we concluded that azide 1 is not 
incorporated by any of our collection of biotin ligase mutants.  Rather than pursuing 
further mutagenesis experiments to find a mutant capable of utilizing this probe, we 
decided to synthesize a new azide probe that would not decompose under the conditions 
of our assays.  Although the extent of decomposition to biotin is less than 10%, it is still 
significant enough to make azide 1 a problematic probe for protein labeling.  We 
typically employed a large excess of (60-100 fold) of azide 1 to compensate for an 
anticipated high Km value for its enzymatic ligation.  As a result, decomposition of only a 
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small fraction (< 1.5%) of azide 1 is enough to deplete all of the CFP-AP through 
enzymatic biotinylation.  For in vitro labeling experiments, we can address this problem 
by using more CFP-AP in each reaction and adding avidin to sequester the generated 
biotin, but the implementation of similar strategies for live cell intracellular labeling will 
not be straightforward.     
 
Probing the active site of BirA with structural analogs of biotin 
 To design an azide analog with the maximum probability of being incorporated, 
we now decided to explore the structural limits of the tolerance of the BirA active site.  
We chose to test the reaction of BirA with the following analogs of biotin because they 
were either commercially available or easily accessed in two to three steps from biotin 
methyl ester (4) (Figure 9).  Table 2 at the end of this section summarizes the results of 
our probing of the BirA active site. 
 
N N
S
O
CO2H
HN NH
O
HO CO2H
HN NH
S
O
CO2H
R1 R2
HN NH
S
O
CO2HHO
O
HN NH
S
O
CO2H
O O
HN NH
O
CO2H
HN NH
S
NH
CO2H
H2N NH2
S CO2H
iminobiotin
diaminobiotin
desthiobiotin
cis-7: R1 = H, R2 = Me
trans-7:  R1 = Me, R2 = H
cis-8:  R1 = H, R2 = CH2CCH
trans-8:  R1 = CH2CCH, R
2 = H
9
10
11
12
 
 
 
Figure 9.  Structures of biotin analogs used to explore the tolerance of the BirA active site. 
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We first tested whether the commercially available biotin analogs iminobiotin, 
diaminobiotin, and desthiobiotin could be utilized by any of our collection of BirA 
mutants.  These analogs can bind to other biotin-binding proteins such as streptavidin23 
and the biotin transporter24.  Using our standard HPLC assay, we found that none of our 
biotin ligases ligated diaminobiotin or iminobiotin to the AP (Table 2).  On the other 
hand, we confirmed that desthiobiotin was an efficient substrate for wild-type BirA25, and 
we found that Gly115Ala, Gln112Met, and Thr90Gly also utilized desthiobiotin with 
similar efficiency, achieving > 90% conversion to product within four hours of reaction 
(Table 2).  Thr90Ala catalyzed desthiobiotin ligation less efficiently (70% conversion 
under the same conditions), while the other BirA mutants tested did not catalyze any 
product formation.  From our studies with these analogs of biotin and ketone 1, we 
concluded that the carbonyl of the ureido group seems to be especially important for 
recognition by BirA.   
We next explored the range of derivatization at the ureido nitrogens tolerated by 
the BirA active site.  To this end, we targeted the synthesis of N-methylbiotin (7) and N-
propargylbiotin (8) (Figure 10).   
HN NH
S
O
CO2Me
N NH
S
O
CO2R
N NH
S
O
CO2R
13:  R = Me
7:  R = H
14:  R = Me
8: R = H
+ cis
+ cis4
a.
b.
38%
38%
c.
95%
c.
62%  
 
Figure 10.  Synthesis of N-alkylated analogs of biotin.  a.  NaH, THF, then iodomethane, rt.  b.  NaH, 
THF, then propargyl bromide, rt.  c.  LiOH, THF/MeOH/water, 4 °C. 
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Biotin methyl ester (4) was treated with sodium hydride and then either iodomethane or 
propargyl bromide to obtain the N-alkylated methyl esters 13 and 14 as an inseparable 
mixture of regioisomers in favor of the trans isomer (alkylation at 1′-N, trans to the 
valeric acid sidechain).  The corresponding acids 7 and 8 were obtained following 
hydrolysis with lithium hydroxide.  The cis- and trans- regioisomers could be resolved at 
this stage using reverse-phase HPLC on a semipreparative C18 column, but we used the 
mixture to screen for incorporation by our enzymes.   
We found that none of our biotin ligases incorporated 8, but wild-type BirA and 
Gly115Ala were able to sluggishly effect ~30% conversion to an AP-7 conjugate after 
6.5 hours of reaction.  These findings suggest that the BirA active site is not very 
accommodating of additional substitution at the ureido nitrogens; thus, it is not surprising 
that azide 1 was not incorporated.  We re-screened the wild-type enzyme and Gly115Ala 
with the individual regioisomers of 7.  Surprisingly, cis-7 was incorporated but not trans-
7, which suggested we had incorrectly assumed from the crystal structure that 
derivatization at the 1′-N would be better accommodated by the enzyme than at the 3′-N.  
It is not immediately obvious from re-examining the crystal structure why the wild-type 
and Gly115Ala enzymes could tolerate the methyl substitution at 3′-N or why Thr90Gly 
and Thr90Ala could not tolerate the methyl substitution at the 1′-N. 
 In search of more sites for derivatization, we next looked at the thiophane ring of 
the biotin scaffold because previous work in the literature suggested that substitution 
within the thiophane ring is tolerated by biotin ligase enzymes.  Experiments by Lane and 
co-workers demonstrated that oxybiotin (where the sulfur atom is replaced with an 
oxygen atom) is a substrate for the biotin ligase of Propionibacterium shermanii26.  
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Previous work by Wormser et al. showed that the biotin derivative carbobiotin (where the 
sulfur atom is replaced with a methylene group) has about 15% of the growth-promoting 
activity as d-biotin in three microorganism test systems, suggesting that this analog may 
also be a substrate for the endogenous biotin ligases of these organisms27.   
We first tested whether the conservative addition of one or two oxygen atoms 
would be tolerated by BirA.  Biotin sulfoxide (9) and biotin sulfone (10) are two naturally 
occurring byproducts of biotin metabolism with significantly different biological 
properties.  The sulfoxide has been shown to be a strong promoter of yeast growth28, 
whereas the sulfone is only a very weak promoter of growth29.  We were curious whether 
differences in utilization by biotin ligase could partially explain the difference in the 
biological properties of the two closely related compounds.  We synthesized 9 and 10 
from biotin methyl ester (4) following the reaction sequence shown in Figure 11.   
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Oxidation of 4 with a slight excess of sodium metaperiodate yielded primarily the 
sulfoxide methyl ester 15, as well as the sulfone methyl ester 16 as a minor contaminant 
that could be purified out using silica gel chromatography.  The methyl esters were 
hydrolyzed to the acids using lithium hydroxide, and the crude reaction mixtures were 
added directly to the reactions for screening for enzymatic incorporation onto the AP.   
Using an assay coupling HPLC with electrospray ionization mass spectrometry (ESI-
Figure 11.  Synthesis of biotin sulfoxide (9) and biotin sulfone (10).  a.  NaIO4, 
MeOH/water.  b.  LiOH, THF/MeOH/water, 4 °C. 
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MS), we found that both biotin sulfoxide (9) and biotin sulfone (10) were utilized 
efficiently by wild-type BirA (Hemanta Baruah and Alice Y. Ting, unpublished results, 
Table 2).  Both of these probes also were incorporated more efficiently than 
desthiobiotin.   
We next explored the effects of derivatization at C-5 (see Figure 5 for atom 
numbering) by synthesizing hydroxybiotin (11) and hydroxydesthiobiotin (12).  
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A hydroxyl group can be introduced at C-5 via Pummerer rearrangement of sulfoxide 
methyl ester 1530 (Figure 12).  Following addition of trifluoroacetic anhydride at -60 °C 
and basic workup in a mixture of 50% dioxane/1 M NaOH, we always observed by 
analytical TLC an approximately equimolar amount of hydroxybiotin (11) and the 
byproduct 17.  The byproduct 17 arises from Pummerer rearrangement at C-5 and 
elimination of the trifluoroacetate leaving group.  Despite our attempts to minimize its 
formation, significant amounts of elimination product were formed even at -60 °C.  The 
unusually facile elimination is probably driven by the formation of a conjugated aza-
diene.  After purifying away 17 using silica gel chromatography, hydroxybiotin (11) was 
obtained in 30-50% yield from 15.  Hydroxydesthiobiotin (12) was then synthesized by 
Raney Nickel desulfurization of 11. 
Figure 12.  Synthesis of hydroxybiotin (11) and hydroxydesthiobiotin (12).  a.  trifluoroacetic 
anhydride, -60 °C to 4 °C, then 50% dioxane/1 M NaOH, rt.  b.  Raney nickel, EtOH, reflux. 
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We then tested for incorporation onto the AP by wild-type BirA, Gly115Ala, 
Gln112Met, or Thr90Gly, using the HPLC/ESI-MS assay.  All of these enzymes 
incorporated both probes, with ligation of hydroxybiotin (11) proceeding at least twice as 
efficiently as ligation of hydroxydesthiobiotin (12) under the conditions employed.  
Within 1.5 hours at 30 °C we observed complete conversion of 100 µM of starting AP 
peptide in the presence of 1 mM 11 and 2 µM of wild-type BirA, Gly115Ala, or 
Thr90Gly, but only about 60% conversion by the same amount of Gln112Met (Table 2).  
Under the same conditions, we observed only 25-60% conversion to AP-12, with wild-
type BirA utilizing hydroxydesthiobiotin (12) most efficiently (Table 2.  We also 
compared the ligations of hydroxybiotin (11) and desthiobiotin by the wild-type enzyme 
and found that 11 was utilized slightly more efficiently (Hemanta Baruah and Alice Y. 
Ting, unpublished results).   
A summary of the structure-activity-relationship data generated with the various 
biotin analogs is shown in Table 2 for the four most permissive enzymes tested.  From 
these experiments, we concluded that derivatization of the ureido group is not well-
tolerated by the BirA active site.  Biotin analogs lacking the carbonyl of the ureido 
moiety are not ligated to the AP by BirA or its mutants.  The efficient ligation of ketone 1 
by wild-type BirA had suggested that hydrogen bonding to the ureido nitrogens is not 
critical  for probe recognition, but our new data indicate that the BirA active site cannot 
tolerate much additional substitution at either ureido nitrogen.  Surprisingly, methylation 
at the 3′-N is better accommodated despite its proximity to the protein backbone.   
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Probe wild-type Gly115Ala Gln112Met Thr90Gly 
Diaminobiotin − − − − 
Iminobiotin − − − − 
Desthiobiotin +++ +++ +++ +++ 
cis- 7 + + − − 
trans 7 − − − − 
cis-/trans-8 − − − − 
biotin sufoxide (9) +++ not tested not tested not tested 
biotin sulfone (10) +++ not tested not tested not tested 
hydroxybiotin (11) +++ +++ ++ +++ 
desthiohydroxybiotin (12) ++ ++ ++ ++ 
 
 
The BirA active site seems to be more forgiving in the region surrounding the 
thiophane ring, as desthiobiotin and probes 9-12 are all incorporated onto the AP by wild-
type BirA with much better efficiency than cis-7.  The most immediately applicable 
discovery from this set of experiments was that a hydroxyl substituent at C-5 is well-
tolerated by BirA, suggesting a new site for appending an azide through functional group 
transformation of the hydroxyl group.  By comparing the reactions with hydroxybiotin 
(11) and hydroxydesthiobiotin (12), we also concluded that bicyclic analogs are better 
substrates for BirA, presumably because their greater rigidity reduces the entropic cost of 
binding to the enzyme active site.    
Besides identifying the structural limits of tolerance by the active site of BirA, 
these experiments also illustrated the difficulty of rational design of an enzyme.  The 
wild-type enzyme was the most permissive enzyme we tested.  None of the BirA mutants 
showed an enhanced ability to incorporate any of the analogs (including biotin or ketone 
1) compared to the wild-type enzyme.  The inability of the Thr90Gly or Thr90Ala 
Table 2.  Summary of probe incorporation onto the AP by wild-type BirA, Gly115Ala, Gln112Met, and 
Thr90Gly.  Activities are scored as follows:  +++ for nearly 100% conversion after 4 hours, ++ for 30-80% 
conversion, and + for < 30% conversion. 
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enzymes to enable the incorporation of trans-7 was a particularly humbling result.  
Ironically, our experiments with the BirA double mutants demonstrated that most of the 
additional mutations we introduced to increase the small molecule promiscuity of BirA 
actually reduced the substrate tolerance.        
 
Synthesis of new azide analogs based on structure-activity relationship information
 Based on the structure-activity relationship information above, we targeted the 
following new azide analogs of biotin (Figure 13).   
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Based on the structure-activity relationship data, azides 18 and 3 would be more likely to 
be incorporated than the cis isomer of azide 2.  We were also aware that 2 and 18 could 
potentially decompose through neighboring atom-assisted displacement of the –N3 
leaving group.  
 We first pursued the synthesis of azide 2 because it could be synthesized in the 
fewest number of steps (Figure 14).  Biotin methyl ester (4) was formylated by stirring 
with paraformaldehyde in MeOH containing 1% (vol/vol) 1.25 M NaOH solution, 
quantitatively yielding 19 as a mixture of regioisomers.  We next tried to convert the 
hydroxyl group to a tosylate or chloride, but both strategies for activating the hydroxyl 
group led to complex reaction mixtures.  We found that stirring 19 in the presence of 
Figure 13.  Structures of new azide targets after structure-activity relationship study. 
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excess sodium azide in 50% dioxane/1 M HCl at room temperature could effect the 
displacement of the hydroxyl group, without hydrolysis of the methyl ester, to obtain 20.   
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Hydrolysis of the methyl ester 20 to yield 2 proved to be an insurmountable 
problem.  With acidic hydrolysis we never detected the formation of the desired product 
by TLC or ESI-MS.  We tried basic hydrolysis with lithium, sodium, or barium 
hydroxide, but under these conditions we also observed displacement of the azide by 
hydroxide ion, affording compound 21 instead as the major isolated product.  We even 
tried hydrolysis catalyzed by pig liver esterase, but surprisingly this yielded a complex 
reaction mixture.   
 We eventually successfully obtained azide 2 by switching the order of hydrolysis 
and azide displacement.  Intermediate 19 was first hydrolyzed to its free acid 21 using 
lithium hydroxide.  The hydrolysis reaction was then concentrated and the crude residue 
was taken up 50% dioxane/1 M HCl containing an excess of sodium azide, without any 
intermediate purification.  The desired azide 2 was isolated as a mixture of regioisomers 
Figure 14.  Synthesis of azide 2.  a.  paraformaldehyde, NaOH/MeOH, rt.  b.  NaN3, 50% dioxane/ 
1 M HCl.  c.  LiOH, NaOH, Ba(OH)2, 50 % dioxane/1 M HCl, or pig liver esterase.  d.  LiOH, 
THF/MeOH/water, 4 °C.  e. NaN3, 50% dioxane/1 M HCl.    
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after silica gel chromatography, along with 21.   We also tried to shorten the synthesis by 
directly synthesizing 21 by formylation of biotin, but that reaction failed to proceed.   
 Because we observed displacement of the –N3 leaving group by water (or 
hydroxide ion) under basic conditions, we were wary of subjecting azide 2 to the slightly 
basic pH used in our enzyme assays, especially after our experience with azide 1.   Not 
only would the displacement of the –N3 leaving group result in diminished ability to 
detect azide incorporation through the Staudinger ligation, but it would also release azide 
ion (N3-), an extremely cytotoxic decoupler of oxidative phosphorylation.  Therefore, we 
first tested the stability of 2 under a variety of reaction conditions, using the previously 
mentioned TLC assay.  Azide 2 turned out to be even more unstable than azide 1, 
decomposing almost completely to a new compound with a lower retention factor (Rf) 
within four hours of incubation at 30 °C in 100 mM sodium bicarbonate pH 8.6, Tris-
buffered saline, phosphate-buffered saline, and 50 mM bicine pH 8.3.  Surprisingly, the 
Rf of the byproduct of azide 2 decomposition matched that of biotin and not that of the 
expected byproduct from azide displacement, 21.  We confirmed that biotin was the 
byproduct of azide 2 decomposition by ESI-MS.  The decomposition of azide 2 to biotin 
probably proceeds via an initial neighboring atom-assisted displacement of the –N3 
leaving group by water (or hydroxide ion) to transiently yield 21, followed by collapse of 
the resulting carbinolamine to liberate formaldehyde and biotin.  Despite TLC showing 
nearly quantitative loss of the azide functional handle, we could still detect azide 2-
conjugated CFP-AP following Staudinger ligation of pFLAG and immunoblot with anti-
FLAG-HRP, thus illustrating the sensitivity of this Western blot assay.    
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 We believed that the neighboring atom-assisted displacement of the –N3 leaving 
group contributed greatly to the instability of azide 2, so we decided that azide 18 was no 
longer worth pursuing.  We therefore focused our efforts on the synthesis of azide 3 
according to the scheme shown in Figure 15, which contains a known reaction sequence 
to mesylate 2431.  
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Starting from biotin sulfoxide methyl ester (15), hydroxybiotin methyl ester (22) was 
obtained in only 21% yield after Pummerer rearrangement and aqueous workup in 50% 
tetrahydrofuran (THF)/water.  An approximately equimolar amount of the elimination 
byproduct, the methyl ester of 17, was also isolated.  Conversion of 22 to the mesylate 24 
was accomplished smoothly by Raney Nickel desulfurization and mesylation of the 
resulting alcohol 23.  After heating mesylate 24 in the presence of sodium azide, we were 
able to obtain azide methyl ester 25 in high yield (80% in two steps from 23).  Basic 
hydrolysis of 25 with lithium hydroxide under our standard conditions afforded the 
desired azide 3 without the complications observed in the syntheses of azides 1 and 2.  
The presence of the azide group was further confirmed by Staudinger ligation of pFLAG 
Figure 15.  Synthesis of azide 3.  a.  trifluoroacetic anhydride, -60 °C to 4 °C, then 50% THF / water, 
rt.  b.  Raney nickel, EtOH, reflux.  c.  mesyl chloride, triethylamine, THF, 0 °C to rt.  d.  NaN3, DMF, 
90 °C.  e.  LiOH, THF/MeOH/water, 4 °C. 
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to azide 3-conjugated CFP-AP and chemiluminescence detection with anti-FLAG-HRP 
(data not shown).  As expected, TLC assays also showed no evidence of decomposition 
of azide 3 after prolonged incubation in our standard reaction buffer (data not shown).        
 
Screening for azide 3 incorporation by BirA mutants and other biotin ligases 
 We first assayed using HPLC for azide 3 incorporation onto the AP by the 
collection of BirA mutants we had in hand, even though they were not designed 
specifically for azide 3.  Not surprisingly, none of the enzymes could catalyze the 
detectable formation of AP-azide 3 conjugate (Table 3).  Using a slightly more 
sophisticated analysis of the BirA crystal structure, we next designed some mutants that 
could possibly better accommodate the linear, three-atom protrusion of the azide group.  
We docked in an energy-minimized conformation (obtained using Chem3D, 
Cambridgesoft) of azide 3 into the BirA active site, superimposing the ureido ring and 
valeric acid atoms of azide 3 and biotin.  Analysis of the resulting model revealed a steric 
clash between the terminal nitrogen atom of the azide group and the protein backbone at 
Tyr132 (Figure 16).  We thought that we could alleviate this destabilizing interaction by 
substituting Tyr132 with Ala or Gly, two amino acids that would confer more rotational 
freedom of the backbone and more space to accommodate the azide group.  We also 
created a Tyr132Thr mutant to introduce a sidechain capable of hydrogen bonding to the 
nitrogen atoms of the azide group.   
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The three mutants Tyr132Gly, Tyr132Ala, and Tyr132Thr were expressed from 
E. coli JM109 and assayed for biotinylation activity after purification.  Tyr132Gly and 
Tyr132Ala failed to biotinylate the AP at all, whereas Tyr132Thr showed a modest 
reduction in biotinylation activity relative to the wild-type enzyme, achieving the same 
level of conversion to AP-biotin conjugate in one hour as BirA in five to seven minutes 
(Table 3).  We then assayed for azide 3 incorporation onto the AP by Tyr132Thr, but we 
observed no detectable product formation.   
Mutant Biotin  incorporation 
Azide 3 
incorporation 
Wild-type Yes No 
Ketone 1 mutants Yes No 
Azide 1 mutants Yes No 
Tyr132Gly No No 
Tyr132Ala No No 
Tyr132Thr Yes No 
Figure 16.  Targeted amino acids for mutagenesis to accommodate azide 3.  An energy-minimized 
conformation of azide 3 was docked into the BirA-biotin crystal structure (PDB:  1HXD) by 
superimposition onto biotin.  Amino acids that contain atoms within 4 Å of the nitrogen atoms of the 
azide group in our model are shown.  Carbon atoms are colored grey, oxygen atoms are colored red, 
and nitrogen atoms are colored blue. 
Table 3.  Summary of biotin and azide 3 incorporation onto the AP by the BirA mutants used in 
this study.  For the mutants that were designed for ketone 1 and azide 1, only those that retained the 
ability to biotinylate the AP were used to assay for azide 3 incorporation. 
171 
Our laboratory also cloned biotin ligases from several other organisms and 
explored their small molecule substrate tolerance.  Sarah Slavoff tested several of these 
biotin ligases for azide 3 utilization.  Since these other biotin ligases do not use the AP as 
a substrate, she developed the HPLC and Western blot assays for azide incorporation 
onto p6718, a 67-amino acid polypeptide derived from a biotin acceptor domain found in 
humans that is a common substrate for all of our laboratory’s cloned biotin ligases.  
Using the HPLC assay, azide 3 was found to be utilized weakly by the biotin ligase from 
P. horikoshii (PhBL).  ESI-MS analysis of the collected product peak confirmed that it 
had the expected mass for the azide 3-p67 conjugate (found:  10167 ± 3, expected:  
10167)32.  We also confirmed azide 3 ligation to p67 using Staudinger ligation with 
pFLAG and immunoblot detection with anti-FLAG-HRP.  Figure 17 shows that azide 3 
ligation was dependent on the presence of azide 3 (lanes 5 and 8), PhBL (lanes 4 and 7), 
ATP (lane 6), and the acceptor lysine of p67 (lane 3).  From comparing the structures of 
the biotin-binding sites of BirA and PhBL33, it is not immediately obvious why azide 3 is 
accommodated by PhBL but not by BirA. 
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Conclusions   
 We synthesized four azide analogs of biotin and assayed for their incorporation 
onto the AP by BirA or a closely related mutant.  Azide 1 was synthesized by 
regiospecific acylation of the 1′-N of biotin.  Using our HPLC assay, we found that  
azide 1 was not incorporated onto the AP by wild-type BirA or any designed mutant.  We 
also found that azide 1 partially (< 10%) decomposed to biotin under our reaction 
conditions.  We then adapted a known Staudinger ligation/Western blot assay for azide 
detection to detect levels of azide 1 incorporation below the detection limit of HPLC.  
Figure 17.  Site-specific azide 3 ligation catalyzed by P. horikoshii biotin ligase.  (A) Azide 3 was 
reacted with p67 in the presence of PhBL, and azide attachment was detected using 
chemiluminescence as described in Figure 8.  1. ladder.  2. PhBl reaction with azide 3, all 
components present.  3. minus acceptor lysine negative control.  4. BirA negative control.  5. biotin 
negative control.  6. minus ATP negative control.  7. minus PhBL negative control.  8. minus azide 
negative control.  (B) Coomassie stain of reactions in (A) after Staudiger ligation, demonstrating 
equal loading of protein.  Note that successful conjugation of pFLAG to p67 results in a noticeable 
change in the molecular weight of p67 (land 2, top band).   
173 
However, even with this more sensitive assay, we could not detect any azide 1 
incorporation.   
The decomposition of azide 1 to biotin made it inconvenient for protein labeling, 
so we targeted new azide analogs, azides 2 and 3, based on structure-activity relationship 
data we had obtained from screening several structural analogs of biotin for enzymatic 
incorporation.  Azide 2 was synthesized through nonspecific formylation of the ureido 
nitrogens, while azide 3 was synthesized through functionalization of C-5 by the 
Pummerer rearrangement of biotin sulfoxide methyl ester.  Azide 2 was even more 
unstable than azide 1, decomposing nearly quantitatively to biotin in every aqueous 
buffer that we sampled.  On the other hand, azide 3 did not suffer from the instability 
issues of the other azides.  Using both HPLC and Western blot analysis, we conclusively 
determined that azide 3 was not ligated to the AP by wild-type BirA or any of our 
designed mutants.  However, we discovered that the biotin ligase from the thermophilic 
organism P. horikoshii (PhBL) could catalyze the ligation of azide 3 to a common protein 
substrate of the biotin ligases from various species.  It is not immediately obvious why 
azide 3 is better accommodated by PhBL, as comparison of the published structures of 
PhBL33 and BirA17 shows that the features of the biotin binding pocket are generally 
well-conserved34.   
We synthesized several structural analogs of biotin to probe the substrate 
tolerance of BirA.  From these experiments, we concluded that derivatization of the 
ureido group is not well-tolerated by the BirA active site.  Biotin analogs lacking the 
carbonyl of the ureido moiety are not ligated to the AP by BirA or its mutants.  
Substitution at either ureido nitrogen is not well-tolerated, as shown by the slow rate of 
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cis-N-methylbiotin ligation and the inability of BirA to utilize trans-N-methylbiotin and 
N-propargylbiotin.  Surprisingly, methylation at the 3′-N is better accommodated despite 
its proximity to the protein backbone.  The BirA active site seems to be more forgiving in 
the region surrounding the thiophane ring.  Desthiobiotin, biotin sulfoxide, biotin sulfone, 
hydroxybiotin, and hydroxydesthiobiotin are all incorporated onto the AP by wild-type 
BirA with far better efficiency than cis-N-methylbiotin.  We also found that bicyclic 
analogs are better substrates for BirA, presumably because their greater rigidity reduces 
the entropic cost of binding to the enzyme active site.  Thus, these results, in conjunction 
with the results of our azide screens, indicate that the active site of BirA can only tolerate 
relatively conservative additions (one non-hydrogen atom) to the core scaffold of biotin.  
Using crystal structure-guided rational design, we failed to identify any mutants 
with enhanced small molecule substrate tolerance compared to the wild-type enzyme.  In 
particular, the inability of the Thr90Gly or Thr90Ala enzymes to enable the incorporation 
of trans-N-methylbiotin was a particularly humbling result.  Gly115Ala, Thr90Gly, and 
Gln112Met had similar substrate tolerance as wild-type BirA, but for every structural 
analog tested (including ketone 1), the wild-type enzyme was the best catalyst for its 
ligation.  Ironically, our experiments with the BirA double mutants demonstrated that 
most of the additional mutations we introduced to increase the small molecule 
promiscuity of BirA actually reduced the substrate tolerance.  Another problem we 
encountered when designing mutant enzymes was the propensity to introduce mutations 
that yielded inactive enzymes, presumably because of improper folding.  Therefore, 
because the factors that govern the stable formation of the active site and probe 
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recognition are still not well understood, we embraced a combinatorial, in vitro evolution 
approach to re-engineer the active site to accommodate azide 3 (Chapter 5). 
We synthesized azide analogs exclusively through derivatization of the bicyclic 
core of biotin.  The reason for this was to avoid interference with the network of 
interactions involved in activating the carboxylic acid for adenylate ester formation.  
However, the active site residues that are closest to the sites of derivatization are buried 
in the hydrophobic interior of the enzyme.  As a result, most of the mutations we 
introduced to compensate for the steric crowding of the azide group probably destabilized 
the hydrophobic packing in the interior and yielded inactive enzymes.  The atoms of the 
valeric acid sidechain are closer to the solvent-exposed surface, so derivatization at these 
positions could possibly be better accommodated.  However, appending of azide groups 
at various positions along the valeric acid sidechain is not synthetically straightforward 
from biotin and probably requires an extensive total synthesis.   
           
Experimental 
 
General Synthetic Methods 
All chemicals were purchased from Sigma-Aldrich or Alfa Aesar and used 
without further purification, unless otherwise stated. Analytical thin-layer 
chromatography (TLC) was performed using 0.25 mm silica gel 60 F254 plates and 
visualized with potassium permanganate, phosphomolybdic acid, or 4-dimethylamino-
cinnamaldehyde.  Flash chromatography was carried out using 70-230 mesh silica gel 
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(ICN SiliTech 32-63D).  Solvents for chromatography are described as percent by 
volume.   
Infrared (IR) spectra were recorded on a Perkin-Elmer Model 2000 FT-IR 
spectrometer.  Proton nuclear magnetic resonance (1H NMR) spectra were recorded using 
a Varian Unity 300 or Mercury 300 (300 MHz) spectrometer.  Chemical shifts are 
reported in delta (δ) units, parts per million (ppm) referenced to the center peak of the 
hexadeuterated dimethylsulfoxide (d6-DMSO) quintet at 2.50 ppm.  Coupling constants 
(J) are reported in Hertz (Hz).  The following abbreviations for multiplicities are used:  s, 
singlet; bs, broad singlet; d, doublet; t, triplet; dd, doublet of doublets; m, multiplet.  
Carbon nuclear magnetic resonance (13C NMR) spectra were recorded with broadband 
decoupling using a Varian Mercury 300 (75 MHz) spectrometer.  Chemical shifts are 
reported in δ units, ppm referenced to the center line of the d6-DMSO septet at 39.51 
ppm.  High resolution mass spectra (HRMS) were obtained on a Bruker Daltonics 
APEXII 3 Tesla Fourier Transform Mass Spectrometer using electrospray ionization.  
Low resolution electrospray ionization mass spectra (ESI-MS) were obtained on a Sciex 
Model API 365 triple stage mass spectrometer or an Applied Biosystems 200 QTRAP 
Mass Spectrometer. 
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Synthesis of azide 1 (Figure 6) 
 
HN NH
S
O
CO2Me  
Biotin methyl ester (4) 
Biotin methyl ester was synthesized according to the literature procedure35.  A 
methanolic solution of hydrogen chloride was generated by adding acetyl chloride (4.9 g, 
4.4 mL, 62 mmol) dropwise to 25 mL of ice-cold methanol (MeOH).  After stirring for 
five minutes, the solution was added to a suspension of d-biotin (3.00 g, 14.3 mmol) in 25 
mL MeOH.  The resulting homogeneous mixture was stirred at room temperature for 
three hours.  The reaction was concentrated in vacuo and partitioned between 5% MeOH/ 
dichloromethane (DCM) and saturated sodium bicarbonate solution.  The aqueous layer 
was re-extracted once more with 5% MeOH/DCM.  The combined organic layers were 
dried over sodium sulfate (Na2SO4) and concentrated in vacuo to afford 3.63 g of 4 (98%) 
as a white solid.  1H NMR (d6-DMSO, 300 MHz):  δ 6.46 (s, 1H), 6.38 (s, 1H), 4.30 (m, 
1H), 4.13 (m, 1H), 3.58 (s, 3H), 3.09 (m, 1H), 2.82 (dd, J = 12.4, 5.1, 1H), 2.57  (d,  
J = 12.3, 1H), 2.30 (t, J = 7.4, 2H), 1.23-1.66 (m, 6H). 
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N NH
S
O
CO2Me
O
Cl
 
5-[1-(2-Chloro-acetyl)-2-oxo-hexahydro-thieno[3,4-d]imidazol-4-yl]-pentanoic acid 
methyl ester (5) 
Biotin methyl ester (4) (791 mg, 3.06 mmol) was suspended in 16 mL of DCM.  
Diisopropylethylamine (DIPEA) (1.21 g, 1.63 mL, 9.36 mmol) was added, and the 
reaction mixture was cooled to -78 °C.  Chloroacetyl chloride (528 mg, 0.45 mL, 4.68 
mmol) was added dropwise in three equal portions, with at least 12 hours of stirring at 
room temperature between each addition at -78 °C.  The reaction mixture was filtered, 
and the filtrate was concentrated in vacuo.  Purification of the residue on silica gel (50% 
ethyl acetate/hexanes (EtOAc/Hex) + 2% MeOH) afforded 816 mg (80%) of 5 as an 
orange-yellow solid.  1H NMR (d6-DMSO, 300 MHz):  δ 8.12 (s, 1H), 4.75-4.87 (m, 3H), 
4.20 (m, 1H), 3.58 (s, 3H), 3.22 (m, 1H), 3.00 (dd, J = 13.1, 5.5, 1H), 2.85 (d, J = 13.2, 
1H), 2.31 (t, J = 7.4, 2H), 1.23-1.70 (m, 6H).  ESI-MS (found) 335.40 [M+H]+.  Required 
for C13H20N2O4ClS:  335.08.     
 
N NH
S
O
CO2Me
O
N3
 
5-[1-(2-Azido-acetyl)-2-oxo-hexahydro-thieno[3,4-d]imidazol-4-yl]-pentanoic acid 
methyl ester (6) 
To a solution of chloride 5 (615 mg, 1.84 mmol) in 12 mL of N,N-
dimethylformamide (DMF) was added sodium azide (597 mg, 9.18 mmol).  The mixture 
was heated at 70 °C for 16 hours, and then partitioned between EtOAc and water.  The 
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aqueous layer was re-extracted twice with EtOAc.  The combined organic layers were 
dried over magnesium sulfate (MgSO4) and concentrated in vacuo.  Purification on silica 
gel (50% EtOAc/Hex + 2% MeOH) afforded 479 mg (76%) of azide methyl ester 6 as a 
yellow solid.  IR (neat):  3255 (broad), 2944, 2110, 1735, 1691, 1383, 1251 cm-1.  1H 
NMR (d6-DMSO, 300 MHz):  δ 8.06 (s, 1H), 4.79 (m, 1H), 4.53 (d, J = 17.9, 1H), 4.43 
(d, J = 17.9, 1H) 4.20 (m, 1H), 3.58 (s, 3H), 3.21 (m, 1H), 3.01 (dd, J = 13.2, 5.5, 1H), 
2.89 (d, J = 13.0, 1H), 2.31 (t, J = 7.4, 2H), 1.23-1.71 (m, 6H).  ESI-MS (found) 342.24 
[M+H]+.  Required for C13H20N5O4S:  342.12.     
 
N NH
S
O
CO2H
O
N3
 
5-[1-(2-Azido-acetyl)-2-oxo-hexahydro-thieno[3,4-d]imidazol-4-yl]-pentanoic acid (1) 
A solution of 6 (290 mg, 0.849 mmol) in 8 mL of 50% dioxane / 0.5 M 
hydrochloric acid (HCl) was heated at 80 °C for 30 minutes.  The reaction mixture was 
concentrated in vacuo and the residue was purified on silica gel (2% MeOH/EtOAc + 1% 
acetic acid (AcOH) ) to afford 83 mg (30%) of azide 1 as a slightly off-white solid.  1H 
NMR (d6-DMSO, 300 MHz):  δ 12.01 (s, 1H), 8.07 (s, 1H), 4.80 (m, 1H), 4.53 (d,  
J = 17.9, 1H), 4.44 (d, J = 17.9, 1H), 4.20 (m,  1H), 3.22 (m, 1H), 3.01 (dd, J = 13.2, 5.4, 
1H), 2.89 (d, J = 13.0, 1H), 2.21 (t, J = 7.3, 2H), 1.23-1.71 (m, 6H).  HRMS (found) 
350.0885 [M+Na]+.  Required for C12H17N5O4SNa:  350.0893. 
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Synthesis of structural analogs of biotin (Figures 10-12) 
 
N NH
S
O
CO2Me
+ cis
 
N-Methylbiotin methyl ester (13) 
A round-bottomed flask was charged with sodium hydride (60% in oil, 80 mg, 
2.00 mmol) and 19 mL of tetrahydrofuran (THF).  To this suspension was added biotin 
methyl ester (4) (500 mg, 1.94 mmol) in three portions.  The resulting mixture was stirred 
at room temperature for 30 minutes, and iodomethane (300 mg, 0.13 mL, 2.11 mmol) 
was added dropwise.  The mixture was stirred overnight at room temperature and 
quenched with the addition of 1 mL saturated ammonium chloride.  The reaction mixture 
was concentrated in vacuo and partitioned between DCM and water.  The aqueous layer 
was re-extracted twice with DCM.  The combined organic layers were dried over Na2SO4 
and concentrated in vacuo.  The residue was purified on silica gel (5% MeOH/DCM) to 
afford 200 mg of 13 (38%) as a mixture of regioisomers.   
 
N NH
S
O
CO2H
+ cis
 
N-Methylbiotin (7) 
To an ice-cold solution of methyl ester 13 (132 mg, 0.485 mmol) in 1.4 mL of 
THF and 1.4 mL of MeOH was added 1.4 mL of 0.9 M lithium hydroxide (1.45 mmol).  
The reaction mixture was stirred at 4 °C for three hours and concentrated in vacuo.  The 
residue was purified on silica gel (5% MeOH/DCM + 0.5% AcOH) to afford 119 mg 
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(95%) of N-methylbiotin (7) as a white solid.  The regioisomers of 7 were further 
resolved using semipreparative reverse-phase HPLC to afford two white solids 
(Microsorb-MV 100 C18; 10-30% acetonitrile/water with 0.1% trifluoroacetic acid 
(TFA) over 15 minutes; flow rate 5.0 mL/min; retention time of cis-7:  12.1 minutes; 
retention time of trans-7:  13.1 minutes).  cis-7 1H NMR (d6-DMSO, 300 MHz):  δ 12.02 
(s, 1H), 6.63 (s, 1H), 4.28 (m, 1H), 3.99 (dd, J = 8.3, 4.7, 1H), 3.23 (m, 1H), 2.85 (dd,  
J = 12.2, 5.4, 1H), 2.69 (s, 3H), 2.58 (d, J = 12.3, 1H), 2.21 (t, J = 7.3, 2H), 1.36-1.79 (m, 
6H).  The spectral data are in close agreement with that reported in the literature36. 
trans-7 1H NMR (d6-DMSO, 300 MHz):  δ 12.02 (s, 1H), 6.58 (s, 1H), 4.24 (dd,  
J = 7.7, 4.6, 1H), 4.08 (m, 1H), 3.14 (m, 1H), 2.88 (d, J = 12.8, 1H), 2.73 (dd, J = 12.9, 
4.8, 1H), 2.60 (s, 3H), 2.20 (t, J = 7.3, 2H), 1.23-1.67 (m, 6H). 
 
N NH
S
O
CO2Me
+ cis
 
N-propargylbiotin methyl ester (14) 
Compound 14 was synthesized and purified in the same manner described for 
compound 13, starting from 516 mg (2.00 mmol) of biotin methyl ester (4) and 0.23 mL 
of propargyl bromide (80% in toluene, 250 mg, 2.1 mmol).  A total of 224 mg (38%) of 
cis- and trans- 14 was isolated as a yellow semi-solid following silica gel 
chromatography.   
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N NH
S
O
CO2H
+ cis
 
 N-propargylbiotin (8) 
N-Propargylbiotin (8) was synthesized from the methyl ester 14 (358 mg, 1.21 
mmol) in the same manner described for the synthesis of N-methylbiotin.  A total of 213 
mg (62%) of 8 was isolated as a yellow solid.  The regioisomers were further resolved 
using semipreparative HPLC to afford two white solids (Microsorb-MV 300 C18; 10-
60% acetonitrile/water with 0.1% TFA over 30 minutes; flow rate 4.7 mL/min; retention 
time of cis-8:  14.0 minutes; retention time of trans-8:  15.6 minutes.   cis-8 1H NMR  
(d6-DMSO, 300 MHz):  12.01 (bs, 1H), 6.98 (s, 1H), 4.20-4.34 (m, 3H), 3.60 (dd,  
J = 17.9, 2.0, 1H), 3.22-3.28 (m, 2H), 2.86 (dd, J = 12.7, 5.3, 1H), 2.60 (d, J = 12.2, 1H), 
2.21 (t, J = 7.2, 2H), 1.30-1.81 (m, 6H).  13C NMR (d6-DMSO, 75 MHz):  174.5, 161.2, 
79.4, 75.2, 64.1, 57.3, 55.9, 34.0, 33.5, 28.9, 28.2, 24.4.  HRMS (found) 305.0924 
[M+Na]+.  Required for C13H18N2O3SNa:  305.0930. 
trans-8 1H NMR (d6-DMSO, 300 MHz):  12.06 (bs, 1H), 6.89 (s, 1H), 4.40 (dd,  
J = 7.8, 4.6, 1H), 4.13 (m, 1H), 4.10 (dd, J = 17.9, 2.2, 1H), 3.75 (dd, J = 17.9, 2.2, 1H), 
3.20 (t, J = 2.2, 1H), 3.15 (m, 1H), 2.98 (d, J = 12.7, 1H), 2.77 (dd, J =  12.8, 4.7, 1H), 
2.20 (t, J = 7.3, 2H), 1.18-1.75 (m, 6H).  13C NMR (d6-DMSO, 75 MHz):  174.5, 160.4, 
79.7, 74.3, 62.8, 58.7, 55.0, 36.0, 33.5, 30.5, 28.2, 28.0, 24.6.  HRMS (found) 305.0920 
[M+Na]+.  Required for C13H18N2O3SNa:  305.0930.  
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HN NH
S
O
CO2Me
O  
Biotin sulfoxide methyl ester (15) 
To a suspension of biotin methyl ester (4) (5.19 g, 20.1 mmol) in 250 mL of 
MeOH was added a solution of sodium metaperiodate (4.38 g, 20.5 mmol) in 43 mL of 
water.  The resulting heterogeneous mixture was stirred vigorously overnight.  The 
mixture was filtered, and the filtrate was concentrated in vacuo.  Benzene was added to 
assist in the removal of water using rotary evaporation.  The resulting solid was taken up 
in 200 mL 5% MeOH/DCM.  The mixture was dried over MgSO4, filtered, and 
concentrated in vacuo.  The recovered white solid was redissolved in 200 mL 5% 
MeOH/DCM, and the solution was dried and concentrated to afford 5.00 g (91%) of 
sulfoxide methyl ester 15 as a white solid.  The solid was ~95% pure by 1H NMR and 
used without further purification.  Compound 15 is known in the literature37.  1H NMR 
(d6-DMSO, 300 MHz):  δ 6.82 (s, 1H), 6.71 (s, 1H), 4.44 (m, 1H), 4.32 (m, 1H), 3.59 (s, 
3H), 3.35 (dd, J = 12.8, 1.8, 1H), 2.91 (m, 1H), 2.88 (dd, J = 12.8, 6.6, 1H), 2.32 (t,  
J = 7.4, 2H), 1.37-1.78 (m, 6H). 
 
HN NH
S
O
CO2Me
O O  
Biotin sulfone methyl ester (16) 
Biotin sulfone methyl ester (16) was a trace contaminant in the periodate 
oxidation of biotin methyl ester (4) to make 15.  The white solid isolated above was 
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purified further on silica gel (15-20% MeOH/DCM) to separate the sulfoxide 15 from 
trace amounts of the sulfone 16.  Compound 16 is known in the literature38.  1H NMR 
(d6-DMSO, 300 MHz):  δ 6.60 (s, 1H), 6.55 (s, 1H), 4.60 (m, 1H), 4.47 (m, 1H), 3.59 (s, 
3H), 3.15 (d, J = 14.9, 1H), 2.87 (dd, J = 14.9, 6.9, 1H), 2.69 (m, 1H), 2.35 (t, J = 7.3, 
2H), 1.41-1.96 (m, 6H). 
 
HN NH
S
O
CO2H
O
HN NH
S
O
CO2H
O O
+
 
Biotin sulfoxide (9) and biotin sulfone (10) 
The methyl esters 15 and 16 were hydrolyzed as described for the synthesis of  
N-methylbiotin (7).  The crude reaction mixtures were used directly in the enzymatic 
incorporation assays.   
 
HN NH
S
O
CO2HHO  
Hydroxybiotin (11) 
A suspension of biotin sulfoxide methyl ester (15) (1.49 g, 5.43 mmol) in 50 mL 
chloroform was cooled to -60 °C.  Freshly distilled trifluoroacetic anhydride (4.2 g, 2.8 
mL, 20 mmol) was added dropwise.  The reaction was allowed to warm up gradually 
over thirty minutes, at which time analytical TLC showed that no more starting material 
was present.  The reaction mixture was concentrated in vacuo.  The residue was taken up 
20 mL of dioxane and 20 mL of 0.8M sodium hydroxide and stirred overnight at room 
temperature.  The dioxane was removed in vacuo, and the remaining aqueous layer was 
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washed once with EtOAc.  The aqueous layer was then acidified to pH=1 with 
concentrated HCl and extracted three times with 50% THF/EtOAc.  The combined 
organic layers were dried and concentrated in vacuo.  Analytical TLC revealed that a 
significant portion of the desired product still resided in the aqueous layer.  Therefore, the 
aqueous layer was lyophilized, and the remaining salts were washed liberally with 20% 
MeOH/DCM.  The mixture was filtered, and the filtrate was combined with the residue 
isolated from the first organic extraction and concentrated.  Purification of the residue on 
silica (10-20% MeOH/DCM + 0.5% AcOH) afforded 706 mg (50%) of hydroxybiotin 
(11) as an orange-yellow solid.  1H NMR (d6-DMSO, 300 MHz):  δ 11.98 (bs, 1H), 6.52 
(s, 1H), 4.90 (s, 1H), 4.26 (dd, J = 7.4, 4.1, 1H), 4.07 (d, J = 7.7, 1H), 3.55 (m, 1H), 2.20 
(t, J = 7.3, 2H), 1.23-1.69 (m, 6H).  ESI-MS (found) 261.06 [M+H]+.  Required for 
C10H17N2O4S:  261.09. 
 
HN NH
O
CO2HHO  
Hydroxydesthiobiotin (12) 
Raney nickel (6 g) was washed twice with water and twice with ethanol (EtOH) 
by resuspension and centrifugation (10,000 rpm, 5 minutes).  The washed Raney nickel 
was resuspended in 51 mL EtOH.  A solution of hydroxybiotin (11) (537 mg, 2.06 mmol) 
in 6 mL MeOH was added to the suspension of Raney nickel.  The resulting mixture was 
heated at reflux for one hour, at which time analytical TLC showed that no more starting 
material was present.  The Raney nickel was pelleted by centrifugation (10,000 rpm, 5 
min), and the supernatant was collected.  The pellet was washed twice with 20% 
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MeOH/DCM + 0.5% AcOH, once with MeOH, and once with 50% MeOH/water by 
resuspension and centrifugation.  The combined supernatants were concentrated in vacuo, 
and the residue was purified on silica (10-15% MeOH/DCM + 0.5% AcOH) to afford 
266 mg (56%) of hydroxydesthiobiotin (12) as a green foam.  Compound 12 is known in 
the literature31.  1H NMR (d6-DMSO, 300 MHz):  δ 11.98 (bs, 1H) 6.44 (s, 1H), 6.04 (s, 
1H), 4.66 (t, J = 5.1, 1H), 3.29-3.56 (m, 4H), 2.20 (t, J = 7.4, 2H), 1.15-1.55 (m, 8H). 
 
Synthesis of azide 2 (Figure 14) 
 
HN N
S
O
CO2Me
OH + trans
 
5-(N-Hydroxymethyl-2-oxo-hexahydro-thieno[3,4-d]imidazol-4-yl)-pentanoic acid methyl 
ester (19) 
To a suspension of biotin methyl ester (4) (1.39 g, 5.38 mmol) in 40 mL of MeOH 
was added 0.4 mL of 5% NaOH, followed by paraformaldehyde (164 mg, 5.46 mmol).  
The resulting heterogeneous mixture was stirred overnight at room temperature.  The 
reaction mixture was concentrated in vacuo and the resulting residue was resubjected to 
the same reaction conditions for thirty minutes.  The resulting yellow oil obtained after 
concentration in vacuo was a mixture of regioisomers and used without further 
purification.  trans-19 (major) 1H NMR (d6-DMSO, 300 MHz):  δ 6.82 (s, 1H), 5.58 (t, 
J = 6.7, 1H), 4.68 (dd, J = 10.9, 6.7, 1H), 4.48 (dd, J = 8.0, 4.7, 1H), 4.37 (dd, J = 10.9, 
6.7, 1H), 4.08 (m, 1H), 3.58 (s, 3H), 3.14 (m, 1H), 2.91 (d, J = 12.7, 1H), 2.78 (dd,  
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J = 12.7, 5.0, 1H), 2.30 (t, J = 7.4, 2H), 1.26-1.68 (m, 6H).  ESI-MS (found) 289.0 
[M+H]+.  Required for C12H21N2O4S:  289.1.   
 
HN N
S
O
CO2Me
N3 + trans
 
5-(N-Azidomethyl-2-oxo-hexahydro-thieno[3,4-d]imidazol-4-yl)-pentanoic acid methyl 
ester (20)      
Compound 19 (4.26 mmol) and sodium azide (1.19 g, 21.2 mmol) were taken up 
in 40 mL of 50% dioxane/1 M HCl.  The resulting mixture was stirred at room 
temperature for two hours before quenching with saturated sodium bicarbonate solution 
at 4 °C for two more hours.  The pH was adjusted to 10 with the addition of 5% sodium 
carbonate, and then the product was extracted three times with EtOAc.  The combined 
organic layers were dried over MgSO4 and concentrated.  The crude product was purified 
on silica gel (5% MeOH/DCM) to afford 749 mg (56% in two steps from 4) of 20 as a 
mixture of regioisomers.  trans-20 (major) IR (neat):  3249, 2936, 2111, 1732, 1706, 
1459, 1368, 1226, 1008, 855, 759 cm-1.  1H NMR (d6-DMSO, 300 MHz):  δ 7.19 (s, 1H), 
4.78 (d, J = 12.9, 1H), 4.67 (d, J = 12.9, 1H), 4.47 (dd, J = 8.0, 3.9, 1H), 4.16 (m, 1H), 
3.58 (s, 3H), 3.16 (m, 1H), 2.93 (d, J = 12.9, 1H), 2.81 (dd, J = 13.1, 4.5, 1H), 2.31 (t,  
J = 7.4, 2H), 1.26-1.68 (m, 6H).  ESI-MS (found) 314.0 [M+H]+.  Required for 
C12H20N5O3S:  314.1. 
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HN N
S
O
CO2H
N3 + trans
 
5-(N-Azidomethyl-2-oxo-hexahydro-thieno[3,4-d]imidazol-4-yl)-pentanoic acid (2) 
Compound 19 (121 mg, 0.420 mmol) was hydrolyzed  as described for the 
synthesis of N-methylbiotin (7).  The reaction mixture was stirred at 4 °C for six hours 
and concentrated in vacuo.  The resulting yellow oil was taken up in 4.2 mL 50% 
dioxane/1M HCl.  Sodium azide (118 mg, 2.10 mmol) was added and the resulting 
homogeneous mixture was stirred at room temperature for 24 hours.  The reaction 
mixture was concentrated in vacuo and the residue was purified on silica (4-10%  
MeOH/DCM + 0.5% AcOH) to afford 30 mg (24% over two steps) of the desired azide 2 
and the acid 21.  trans-2 (major) 1H NMR (d6-DMSO, 300 MHz):  δ 7.19 (s, 1H), 4.78 (d,  
J = 12.9, 1H), 4.67 (d, J = 12.9, 1H), 4.47 (m, 1H), 4.16 (m, 1H), 3.16 (m, 1H), 2.92 (d,  
J = 13.2, 1H), 2.81 (dd, J = 12.9, 4.4, 1H), 2.20 (t, J = 7.4, 2H), 1.23-1.70 (m, 6H).  ESI-
MS (found) 299.8 [M+H]+.  Required for C11H18N5O3S:  300.1.  
 
Synthesis of azide 3 (Figure 15) 
 
HN NH
S
O
CO2MeHO  
Hydroxybiotin methyl ester (22) 
A suspension of biotin sulfoxide methyl ester (15) (4.60 g, 16.8 mmol) in 150 mL 
chloroform was cooled to -60 °C.  Freshly distilled trifluoroacetic anhydride (11.6 g, 7.8 
mL, 55 mmol) was added dropwise.  The reaction was allowed to warm up gradually 
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over thirty minutes, at which time analytical TLC showed that no more starting material 
was present.  The reaction mixture was concentrated in vacuo.  The resulting residue was 
taken up in 150 mL of 50% THF/water and stirred overnight at room temperature.  THF 
was removed in vacuo, and the remaining reaction mixture was partitioned between 
saturated bicarbonate and 5% MeOH/DCM.  The aqueous layer was re-extracted twice 
with 5% MeOH/DCM.  The combined organic layers were dried over Na2SO4 and 
concentrated.  Purification of the resulting oil on silica gel (4-10% MeOH/DCM) 
afforded 950 mg of 22 (21%) as a yellow foam.  1H NMR (d6-DMSO, 300 MHz):  δ 6.54 
(bs, 1H), 4.89 (s, 1H), 4.26 (dd, J = 7.4, 4.1, 1H), 4.07 (d, J = 7.6, 1H), 3.58 (s, 3H), 3.55 
(m, 1H), 2.30 (t, J = 7.4, 2H), 1.23-1.66 (m, 6H).  ESI-MS (found) 275.10 [M+H]+. 
Required for C11H19N2O4S:  275.11.      
 
HN NH
O
CO2MeHO  
Hydroxydesthiobiotin methyl ester (23) 
Raney nickel (10.5 g) was washed twice with water and twice with ethanol by 
resuspension and centrifugation (10,000 rpm, 5 minutes).  The washed Raney nickel was 
resuspended in 80 mL of EtOH and added to a solution of 22 (950 mg, 3.46 mmol) in 20 
mL of EtOH.  The resulting mixture was heated at reflux for one hour.  The Raney nickel 
was pelleted by centrifugation (10,000 rpm, 5 min), and the supernatant was collected.  
The pellet was washed three times with 5% MeOH/DCM by resuspension and 
centrifugation.  The combined supernatants were concentrated in vacuo.  The resulting 
residue was purified on silica gel (8-12% MeOH/DCM) to afford 570 mg (67%) of 23 as 
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a white solid.  Compound 23 is known in the literature39.  1H NMR (d6-DMSO,  
300 MHz):  δ 6.44 (s, 1H), 6.04 (s, 1H), 4.66 (t, J = 5.1, 1H), 3.58 (s, 3H), 3.29-3.56 (m, 
4H), 2.29 (t, J = 7.4, 2H), 1.15-1.55 (m, 8H).  ESI-MS (found) 245.16 [M+H]+.  Required 
for C11H21N2O4:  245.15. 
 
HN NH
O
CO2MeMsO  
6-(5-Methanesulfonyloxymethyl-2-oxo-imidazolidin-4-yl)-hexanoic acid methyl ester (24) 
To an ice-cold suspension of 23 (560 mg, 2.29 mmol) and triethylamine (463 mg, 
638 µL, 4.58 mmol) in 23 mL of THF was added mesyl chloride (789 mg, 532 µL, 6.88 
mmol) dropwise.  The resulting mixture was warmed to room temperature and stirred for 
two hours.  The mixture was concentrated in vacuo and partitioned between DCM and 
saturated ammonium chloride.  The aqueous layer was extracted twice with DCM, and 
the combined organic layers were washed with water, dried over Na2SO4, and 
concentrated in vacuo.  The obtained product 24 was used immediately without further 
purification.  Compound 24 is known in the literature31.  1H NMR (d6-DMSO, 300 MHz):  
δ 6.55 (bs, 2H), 4.22 (dd, J = 10.1, 5.2, 1H), 4.09 (dd, J = 10.0, 6.7, 1H), 3.62-3.86 (m, 
2H), 3.58 (s, 3H), 3.21 (s, 3H), 2.30 (t, J = 7.4, 2H), 1.13-1.56 (m, 8H).   
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HN NH
O
CO2MeN3  
6-(5-Azidomethyl-2-oxo-imidazolidin-4-yl)-hexanoic acid methyl ester (25) 
To a solution of mesylate 24 (2.29 mmol) in 20 mL of DMF was added sodium 
azide (1.04 g, 16.0 mmol).  The resulting mixture was heated at 90 °C for five hours.  The 
reaction mixture was diluted with water and the product was extracted three times with 
DCM.  The combined organic layers were washed four times with water, dried over 
Na2SO4, and concentrated.  The resulting crude oil was purified on silica gel (5% 
MeOH/EtOAc) to afford 495 mg (80% over two steps) of the azide methyl ester 25 as a 
red-orange oil.  IR (neat):  3230, 2941, 2861, 2105, 1732, 1708, 1438, 1364, 1265, 1208, 
1175, 1107, 1010, 770 cm-1.  1H NMR (d6-DMSO, 300 MHz):  δ 6.53 (s, 2H), 3.57-3.67 
(m, 2H), 3.58 (s, 3H), 3.47 (dd, J = 12.5, 4.5, 1H), 3.28 (dd, J = 12.5, 6.1, 1H), 2.29 (t,  
J = 7.4, 2H), 1.13-1.56 (m, 8H).  13C NMR (d6-DMSO, 75 MHz):  δ 173.4, 162.5, 54.2, 
53.8, 51.2, 51.0, 33.2, 29.4, 28.4, 25.7, 24.3.  ESI-MS (found) 270.84 [M+H]+.  Required 
for C11H20N5O3:  270.16. 
 
HN NH
O
CO2HN3  
6-(5-Azidomethyl-2-oxo-imidazolidin-4-yl)-hexanoic acid (3) 
The methyl ester 25 (224 mg, 0.831 mmol) was hydrolyzed with lithium 
hydroxide (105 mg, 2.50 mmol) as described above.  After purification on silica gel  
(5-10% MeOH/DCM + 0.25% AcOH), azide 3 (149 mg, 70%) was afforded as a white 
solid.  1H NMR (d6-DMSO, 300 MHz):  δ 12.02 (bs, 1H), 6.52 (s, 2H), 3.58-3.67 (m, 
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2H), 3.47 (dd, J = 12.5, 4.5, 1H), 3.28 (dd, J = 12.5, 6.1, 1H), 2.19 (t, J = 7.4, 2H), 1.12-
1.53 (m, 8H).  13C NMR (d6-DMSO, 75 MHz):  δ 174.6, 162.5, 54.2, 53.8, 51.0, 33.6, 
29.4, 28.5, 25.8, 24.4.  HRMS (found) 278.1227 [M+Na]+.  Required for C10H27N5O3Na:  
278.1224.    
 
Analytical TLC assay for azide probe decomposition 
The azide probe (1-5 mM) was incubated in various aqueous buffers, at 30 °C or 
37 °C.  2 µL was spotted on a 0.25 mm silica gel 60 F254 plates and dried under high 
vacuum for 20 minutes.  The spots were resolved in 10% MeOH/DCM + 0.25% AcOH 
and developed using phosphomolybdic acid stain.  Retention factors:  0.59, azide 1; 0.52, 
azide 2; 0.45, azide 3; 0.27, biotin. 
 
HPLC/MS assay for azide/probe incorporation (Tables 1-3) 
HPLC assay for probe incorporation onto AP peptide or p67 
Synthetic AP peptide (KKKGPGGLNDIFEAQKIEWH, Chapter 3) was reacted 
with biotin or the biotin analogs as follows:  100 µM AP peptide; 1-2 µM BirA or BirA 
mutant; 4 mM ATP, 5 mM magnesium acetate and 1 mM probe in 50 mM bicine pH 8.3 
at room temperature or 30 °C.  Biotin, azide 1, diaminobiotin, iminobiotin, desthiobiotin, 
N-propargybiotin, and N-methylbiotin reactions reactions were incubated with 1 µM 
enzyme at room temperature for 4-6 hours or at 30 °C for up to one hour, and the 
reactions were analyzed on a reverse-phase HPLC column (Microsorb-MV 300 C18) 
using a gradient of 10-60% acetonitrile/water with 0.1% TFA over 30 minutes (flow rate 
1.0 mL/min).  Retention times were 16.3 minutes for unreacted AP, 17.7 minutes for the 
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AP-biotin conjugate, 17.9 minutes for the AP-desthiobiotin conjugate, and 18.0 minutes 
for the AP-cis-N-methylbiotin- conjugate.  Biotin sulfoxide, biotin sulfone, 
hydroxybiotin, and hydroxydesthiobiotin, and azide 3 reactions were incubated with  
2 µM enzyme at 30 °C for two to twelve hours and analyzed using a gradient of 10-40% 
acetonitrile/water with 0.1% TFA over 25 minutes (flow rate 1.0 mL/min).  Retention 
times were 21.1 minutes for unreacted AP, 21.4 minutes for the AP-biotin sulfoxide 
conjugate, 22.0 minutes for the AP-biotin sulfone conjugate, 22.2 minutes for the AP-
hydroxybiotin conjugate, and 22.2 minutes for the AP-hydroxydesthiobiotin conjugate.   
The p67 polypeptide was reacted with azide 3 as follows:  100 µM p67, 1 µM 
PhBL, 5 mM ATP, 5 mM magnesium acetate, and 1 mM azide 3 in 50 mM bicine pH 8.3 
at 30 °C for 14 hours.  The reaction was analyzed using a gradient of 10-60% 
acetonitrile/water with 0.1% TFA over 40 minutes (flow rate 1.0 mL/min).  Retention 
times were 29.0 minutes for unreacted p67 and 30.5 minutes for the p67-azide 3 
conjugate. 
 
Mass spectrometry (MS) confirmation of product peaks 
Product peaks were collected and analyzed with ESI-MS or MALDI-TOF (as 
described in Chapter 3) under positive ion mode.  ESI-MS unmodified AP:  found, 
1148.6 [M+2H]2+, 766.1 [M+3H]3+; calculated, 1148.1, 765.7.  AP-biotin sulfoxide 
conjugate:  found, 1269.2 [M+2H]2+, 847.1 [M+3H]3+; calculated, 1269.1, 846.4.  AP-
biotin sulfone conjugate:  found, 1277.2 [M+2H]2+, 852.1 [M+3H]3+; calculated, 1277.1, 
851.7.  AP-hydroxybiotin conjugate:  found, 1269.7 [M+2H]2+, 846.7 [M+3H]3+; 
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calculated, 1269.1, 846.4.  AP-hydroxydesthiobiotin conjugate:  found 1254.7 [M+2H]2+, 
837.1 [M+3H]3+; calculated, 1254.2, 836.4.   
ESI-MS Unmodified p67:  found, 1419 [M+7H]7+, 1242 [M+8H]8+, 1104 
[M+9H]9+, 994 [M+10H]10+; calculated, 1420, 1242, 1104, 994.  p67-azide 3 conjugate:  
found, 1453 [M+7H]7+, 1272 [M+8H]8+, 1131 [M+9H]9+, 1018 [M+10H]10+; calculated,  
1453, 1272, 1131, 1018. 
MALDI-TOF unmodified AP: found, 2296.5; calculated [M+H]+ 2295.2.  AP-
desthiobiotin conjugate:  found, 2942.8; calculated, [M+H]+ 2491.3.  AP-cis-N-
methylbiotin conjugate:  found, 2537.0; calculated, [M+H]+ 2535.3.  
 
Western blot assay for azide incorporation (Figures 8 and 17) 
Chemical conjugation of azide to CFP protein (positive control for Western blot) 
In a 20 µL reaction, 10 mM azide was combined with 50 mM EDC and 50 mM 
sulfo-N-hydroxysuccinimide (sulfo-NHS) in 50 mM 2-(N-morpholino)ethanesulfonic 
acid (MES) pH 6.2.  After 20 minutes, β-mercaptoethanol (0.35 µL) was added to quench 
the excess EDC.  Then, 17 µL of this solution of azide sulfo-NHS ester was added to a 
solution of CFP protein in 100 mM sodium bicarbonate pH 8.1 or 100 mM potassium 
phosphate buffer pH 8.0 (total volume 280 µL, [CFP] > 15 µM).  The reaction was 
incubated at room temperature for three hours.  The protein was purified from excess  
azide using size-exclusion chromatography on SephadexTM  G-25.  
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Synthesis of pFLAG 
The N-terminal triarylphosphine carboxylic acid residue was synthesized by Alice 
Y. Ting according to the published procedure3.  The triarylphosphine was coupled to a 
synthetic FLAG peptide (sequence:  DYKDDDDK) by the Tufts University Core Facility 
according to the published procedure4. 
 
Western blot assay for azide incorporation 
CFP-AP was reacted with the azide probes as follows: 5-15 µM CFP-AP, 1-2 µM 
enzyme, > 4 mM ATP, > 1 mM azide probe, > 5 mM magnesium acetate in 50 mM 
bicine pH 8.3.  After incubation at 30 °C for longer than eight hours, pFLAG was added 
to each reaction to a final concentration of 250 µM, and the resulting reaction was 
incubated at room temperature for > 12 hours.  The samples were analyzed by 12% SDS-
PAGE and blotted with anti-FLAG-HRP conjugate (1:1000 dilution, Sigma).  The HRP-
generated chemiluminescence signal was visualized with Supersignal West Pico (Pierce).     
 p67 was reacted with azide 3 under the following conditions:  100 uM p67, 5 µM 
PhBL, 5 mM ATP, 500 µM azide 3, 5 mM magnesium acetate in 50 mM bicine pH 8.3.  
After incubation for twelve hours at 30 °C, pFLAG was added to a final concentration of 
1.2 mM, and the resulting reaction was incubated at room temperature for 16 hours.  The 
reactions were analyzed by SDS-PAGE and anti-FLAG immunoblotting as described 
above.   
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Expression of BirA mutants 
Genes for the single mutants of BirA were constructed using the Quikchange™ 
kit (Stratagene) using pBTAc2-wild-type BirA (a gift from D. Beckett, University of 
Maryland, College Park, MD) as the template.  The Thr90 + Asn91 double mutants were 
constructed using the Thr90 single mutant genes as the template.  For the sequences of all 
genes constructed, please see the Supporting Electronic Information.  BirA mutants were 
expressed in E. coli JM109 and purified via their hexahistidine tags as described in 
Chapter 3.     
 
References 
 
 
 1.  Chen,I., Howarth,M., Lin,W. & Ting,A.Y. Site-specific labeling of cell surface 
proteins with biophysical probes using biotin ligase. Nat. Methods 2, 99-104 (2005). 
 2.  Jencks,W.P. Studies on the mechanism of oxime and semicarbazone formation. J. 
Am. Chem. Soc. 61, 475-481 (1959). 
 3.  Saxon,E. & Bertozzi,C.R. Cell surface engineering by a modified Staudinger 
reaction. Science 287, 2007-2010 (2000). 
 4.  Kiick,K.L., Saxon,E., Tirrell,D.A. & Bertozzi,C.R. Incorporation of azides into 
recombinant proteins for chemoselective modification by the Staudinger ligation. 
Proc. Natl. Acad. Sci. U. S. A 99, 19-24 (2002). 
 5.  Chin,J.W. et al. Addition of p-azido-L-phenylalanine to the genetic code of 
Escherichia coli. J. Am. Chem. Soc. 124, 9026-9027 (2002). 
 6.  Nilsson,B.L., Kiessling,L.L. & Raines,R.T. Staudinger ligation: a peptide from a 
thioester and azide. Org. Lett. 2, 1939-1941 (2000). 
 7.  Kohn,M. & Breinbauer,R. The Staudinger ligation-a gift to chemical biology. 
Angew. Chem. Int. Ed Engl. 43, 3106-3116 (2004). 
 8.  Hang,H.C., Yu,C., Kato,D.L. & Bertozzi,C.R. A metabolic labeling approach 
toward proteomic analysis of mucin-type O-linked glycosylation. Proc. Natl. Acad. 
Sci. U. S. A 100, 14846-14851 (2003). 
197 
 9.  Vocadlo,D.J., Hang,H.C., Kim,E.J., Hanover,J.A. & Bertozzi,C.R. A chemical 
approach for identifying O-GlcNAc-modified proteins in cells. Proc. Natl. Acad. 
Sci. USA 100, 9116-9121 (2003). 
 10.  Prescher,J.A., Dube,D.H. & Bertozzi,C.R. Chemical remodelling of cell surfaces in 
living animals. Nature 430, 873-877 (2004). 
 11.  Wang,Q. et al. Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] 
cycloaddition. J. Am. Chem. Soc. 125, 3192-3193 (2003). 
 12.  Deiters,A. et al. Adding amino acids with novel reactivity to the genetic code of 
Saccharomyces cerevisiae. J. Am. Chem. Soc. 125, 11782-11783 (2003). 
 13.  Speers,A.E. & Cravatt,B.F. Profiling enzyme activities in vivo using click 
chemistry methods. Chem. Biol. 11, 535-546 (2004). 
 14.  Cohen,M.S., Hadjivassiliou,H. & Taunton,J. A clickable inhibitor reveals context-
dependent autoactivation of p90 RSK. Nat. Chem. Biol. 3, 156-160 (2007). 
 15.  Agard,N.J., Baskin,J.M., Prescher,J.A., Lo,A. & Bertozzi,C.R. A comparative study 
of bioorthogonal reactions with azides. ACS Chem. Biol. 1, 644-648 (2006). 
 16.  Link,A.J., Vink,M.K. & Tirrell,D.A. Presentation and detection of azide 
functionality in bacterial cell surface proteins. J. Am. Chem. Soc. 126, 10598-10602 
(2004). 
 17.  Weaver,L.H., Kwon,K., Beckett,D. & Matthews,B.W. Corepressor-induced 
organization and assembly of the biotin repressor: a model for allosteric activation 
of a transcriptional regulator. Proc. Natl. Acad. Sci. U. S. A 98, 6045-6050 (2001). 
 18.  Leon-Del-Rio,A. & Gravel,R.A. Sequence requirements for the biotinylation of 
carboxyl-terminal fragments of human propionyl-CoA carboxylase alpha subunit 
expressed in Escherichia coli. J Biol. Chem. 269, 22964-22968 (1994). 
 19.  Amspacher,D.R. et al. Synthesis of a reaction intermediate analogue of biotin-
dependent carboxylases via a selective derivatization of biotin. Org. Lett. 1, 99-102 
(1999). 
 20.  Han,Q. et al. Synthesis of (+)-biotin derivatives as HIV-1 protease inhibitors. 
Bioorg. Medic. Chem. Lett. 6, 1371-1374 (1996). 
 21.  Dixon,R.W. et al. Theoretical and experimental studies of biotin analogues that 
bind almost as tightly to streptavidin as biotin. J Org. Chem. 67, 1827-1837 (2002). 
 22.  Wilson,K.P., Shewchuk,L.M., Brennan,R.G., Otsuka,A.J. & Matthews,B.W. 
Escherichia coli biotin holoenzyme synthetase/bio repressor crystal structure 
delineates the biotin- and DNA-binding domains. Proc. Natl. Acad. Sci. U. S. A 89, 
9257-9261 (1992). 
198 
 23.  Reznik,G.O., Vajda,S., Sano,T. & Cantor,C.R. A streptavidin mutant with altered 
ligand-binding specificity. Proc. Natl. Acad. Sci. U. S. A 95, 13525-13530 (1998). 
 24.  Zempleni,J. & Mock,D.M. Uptake and metabolism of biotin by human peripheral 
blood mononuclear cells. Am. J. Physiol 275, C382-C388 (1998). 
 25.  Wu,S.C. & Wong,S.L. Development of an enzymatic method for site-specific 
incorporation of desthiobiotin to recombinant proteins in vitro. Anal. Biochem. 331, 
340-348 (2004). 
 26.  Lane,M.D., Young,D.L. & Lynen,F. The enzymatic synthesis of 
holotranscarboxylase from apotranscarboxylase and (+)-biotin. I. purification of the 
apoenzyme and synthetase; characteristics of the reaction. J Biol. Chem. 239, 2858-
2864 (1964). 
 27.  Wormser,H.C., Israsena,S., Heiling,M.S., Williams,C. & Perlman,D. Synthesis and 
growth-promoting activity of dl-cis-hexahydro-4-(4-carboxybutyl)-2-
cyclopentimidazolone: carbobiotin. J Pharm. Sci. 61, 1168-1170 (1972). 
 28.  Melville,D.B. Biotin sulfoxide. J Biol. Chem. 208, 495-501 (1954). 
 29.  Dittmer,K. & du Vigneaud,V. Antibiotins. Science 100, 129-131 (1944). 
 30.  Lett,R. & Kuroki,Y. Pummerer reaction of biotin sulfoxides:  an access to new 
functionalized biotin derivatives. Tetrahedron Lett. 23, 5541-5544 (1982). 
 31.  Even,L., Florentin,D. & Marquet,A. Biotin biosynthesis: preparation of the 
postulated intermediate thiol. Bull. Soc. Chim. Fr. 127, 758-768 (1990). 
 32.  Slavoff,S.A., Chen,I. & Ting,A.Y. Manuscript in preparation (2007). 
 33.  Bagautdinov,B., Kuroishi,C., Sugahara,M. & Kunishima,N. Crystal structures of 
biotin protein ligase from Pyrococcus horikoshii OT3 and its complexes: structural 
basis of biotin activation. J Mol. Biol. 353, 322-333 (2005). 
 34.  Wood,Z.A., Weaver,L.H., Brown,P.H., Beckett,D. & Matthews,B.W. Co-repressor 
induced order and biotin repressor dimerization: a case for divergent followed by 
convergent evolution. J Mol. Biol. 357, 509-523 (2006). 
 35.  Sundberg,S.A. et al. Spatially-Addressable Immobilization of Macromolecules on 
Solid Supports. J Am. Chem. Soc. 117, 12050-12057 (1995). 
 36.  Field,G.F. Synthesis of 3'-N-methylbiotin. J. Org. Chem. 43, 1084-1085 (1978). 
 37.  Hashimoto,M. et al. Preparation and biological properties of biotinylated PhTX 
derivatives. Bioorg. Med. Chem. 7, 1181-1194 (1999). 
199 
 38.  Hofmann,K., Melville,D.B. & du Vigneaud,V. Characterization of the functional 
groups of biotin. J. Biol. Chem. 141, 207-211 (1941). 
 39.  Marquet,A. et al. Biotin biosynthesis: synthesis and biological evaluation of the 
putative intermediate thiols. J Am. Chem. Soc. 115, 2139-2145 (1993). 
 
 
200 
 
 
 
 
 
Chapter 5:  Development of an in vitro compartmentalization platform 
for the in vitro evolution of BirA to accept an azide analog of biotin  
 
 
All of the work discussed in this chapter is unpublished.  The model selections 
were performed in collaboration with Bernard Kelly of the Griffiths laboratory (MRC, 
UK) and Hemanta Baruah and Yoon-Aa Choi of the Ting laboratory.  Lara Collazo 
assisted in the sequencing of individual clones recovered from the rounds of selection.     
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Introduction 
In Chapter 4 we describe the design and synthesis of an unnatural azide analog of 
biotin, azide 3, which we hoped to use for the site-specific labeling of cellular proteins.   
 
HN NH
O
CO2HN3
3  
 
 
However, we found that neither wild-type BirA nor any designed mutant could catalyze 
the ligation of azide 3 to the acceptor peptide substrate (AP).  Our unsuccessful attempts 
at rational redesign of the BirA active site demonstrated a limited understanding of the 
relationship between sequence and catalytic function of BirA (Chapters 3 and 4).  A 
combinatorial approach to engineering new enzymatic function circumvents the need for 
intimate knowledge of the factors governing substrate recognition and active site 
formation.  Thus, we turned to directed evolution to re-engineer BirA to catalyze azide 3 
ligation to the AP. 
Directed evolution is a powerful combinatorial strategy for altering existing 
properties of proteins or even creating new functions.  In this approach, a gene library is 
created that encodes the expression of a collection of different proteins.  Proteins 
possessing the desired properties are selected from the rest of the library, and the genes 
encoding their synthesis are amplified.  The cycle of gene expression, protein selection, 
and gene amplification continues iteratively until the gene library becomes heavily 
enriched in genes that encode for the proteins with the desired properties (phenotypes).  
Figure 1.  Structure of azide 3. 
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Enrichment of the genes through evaluation of the phenotypes of their protein products is 
only possible if a stable link exists between the gene and the protein it encodes 
(genotype-phenotype linkage).  In Nature, the encapsulation of DNA and their expressed 
proteins within a cellular membrane provides the stable genotype-phenotype linkage that 
enables evolution.   
 Methods have been developed to alter the properties of polypeptides through 
directed evolution outside of the confines of the living cell.  The most popular platform 
for in vitro evolution has been M13 phage display.  In this method, the protein to be 
evolved is displayed on the surface of the M13 filamentous phage as a fusion to one of its 
coat proteins, while the gene encoding its expression is packaged within the phage.  The 
stability of the genotype-phenotype linkage provided by the phage particle, the ease of 
phage isolation through affinity chromatography, and the ease of phage amplification 
through infection of E. coli have all enabled phage display to become the most widely 
used evolution platform for optimizing and discovering new binding interactions1.   
Applications of phage display to selections for catalysis have been far less 
prevalent, however2.  Early attempts to select for catalysis have involved indirect 
strategies:  binding of the phage-displayed enzymes (phage-enzymes) to transition state 
analogs3 or trapping of the phage through mechanism-based inhibitors4.  These strategies 
have met with limited success and are not easily generalizable, so more recent attempts to 
apply phage display to select for catalysis have focused on direct selection for product 
formation using anti-product affinity reagents2.  In these strategies, the substrate is 
covalently attached to the surface of the phage before initiating selection for catalysis.  
Attachment of the substrate to the phage accomplishes two things.  First, the product 
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remains attached to the phage after catalytic turnover.  Second, by localizing the substrate 
in close proximity to the enzyme, the effective molarity of the substrate with respect to 
the phage-enzyme is now elevated above millimolar levels.  This ensures that substrate 
conversion is most likely a result of an intramolecular phage-enzyme reaction, provided 
that the linked substrate can access the active site of the phage-enzyme.  An 
intermolecular phage-enzyme reaction is far less likely because the total concentration of 
the substrate in solution is only at nanomolar levels.  Thus, in phage display strategies 
that select directly for product formation, the link between genotype and phenotype is 
strictly maintained through enforcing an intramolecular phage-enzyme reaction and 
preventing product dissociation after turnover. 
One of these recent strategies to select directly for product formation has been 
demonstrated with BirA and the AP.  The display of enzyme-calmodulin fusions to the 
phage coat protein pIII enables enzyme substrate attachment through the strong, but 
noncovalent, interaction between calmodulin and the calmodulin-binding peptide (CBP)5.  
The AP was synthesized as a fusion to the CBP and immobilized on phage displaying a 
BirA-calmodulin fusion protein.  Neri and co-workers demonstrated that the phage-
displayed BirA-calmodulin fusion protein could catalyze the intramolecular biotinylation 
of the AP anchored in this orientation6.  However, when they performed a model 
selection to enrich for phage displaying BirA from a mixture with phage displaying 
glutathione-S-transferase, poor enrichment was observed (enrichment factor ~7), which 
they attributed to the poor display efficiencies of the full-length BirA-calmodulin fusion 
protein.  Elsa Arocho Quinones and Mark Howarth attempted to apply this phage display 
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system for use in our laboratory, but they struggled with the low activity of the phage-
displayed BirA and the difficulties in propagating and cloning into this phage vector.   
Phage display strategies for in vitro evolution of enzymes suffer from several 
inherent drawbacks.  Two drawbacks result from the fact that phage production proceeds 
through a living E. coli host.  First, the transformation efficiency into E. coli limits the 
size of the phage libraries that can be produced (up to 1010 members, but more typically 
108-109).  Second, there is a hidden in vivo selection against library members that are 
toxic to the host or are poorly exported by the host for phage assembly.  Another 
drawback of these phage display strategies is that the selection reaction is intramolecular, 
where the concentration of the substrate is artificially inflated by several orders of 
magnitude.   Therefore, even enzymes with poor substrate recognition properties (high 
Km) are isolated, and there is no way to apply selection pressure for improved substrate 
binding.  As a result, the isolated enzymes often perform poorly in catalyzing the desired 
intermolecular reaction.  Finally, phage display cannot be applied to selections for 
multiple turnover catalysts, because typically only one substrate is tethered to the phage.   
  
An in vitro compartmentalization (IVC) strategy for the in vitro evolution of BirA  
  In 1998, Tawfik and Griffiths unveiled a new method for in vitro evolution 
mimicking the natural compartmentalization strategy employed by Nature7.  In this 
strategy known as in vitro compartmentalization (IVC)8, genes are segregated into 
aqueous droplets within a water-in-oil emulsion, creating cell-like compartments in vitro.  
The emulsification procedure can be controlled so that most compartments contain no 
more than a single gene.  Within each of these compartments, the genes are transcribed 
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and translated by a co-compartmentalized in vitro translation mixture (IVTM).  The 
translated enzymes are active and can only act on substrate molecules present within the 
same compartment.  The segregation of the individual enzymes through these 
compartments thus maintains the link between the genotype and the phenotype.   
IVC addresses many of the deficiencies of phage display for the evolution of 
catalysts.  First, there is no need for a library transformation step because purified PCR 
products are translated by the IVTM.  Because gene expression is done in a cell-free 
environment, none of the biases against toxic or poorly exported proteins exist in IVC.  
More importantly, IVC enables selection for catalysis of intermolecular reactions and for 
multiple turnover.  Finally, evolution of RNA can be performed with IVC, whereas it is 
impossible to perform using phage display.  Since its introduction, IVC has been used for 
the in vitro evolution of DNA methylases9, Taq DNA polymerase10, hydrolytic 
enzymes11-13, and ribozymes14,15.      
 IVC enables selection for multiple turnover catalysts, provided that many copies 
of the enzyme substrate are also encapsulated with the single gene to be transcribed and 
translated.  A large number of substrates are necessary to provide the dynamic range 
required to distinguish between high and low turnover catalysts.  One strategy for stably 
linking thousands of substrate molecules to the gene of an enzyme is microbead display.  
Microbead display was developed by Griffiths and co-workers and has been applied to 
select for binding16 and improving catalysis11.  The microbeads are functionalized with 
substrate molecules and a handle for attaching the gene to be expressed.  The beads have 
a diameter of approximately 1 µm, and thus they are easily encapsulated so that almost 
all of the compartments within the water-in-oil emulsion contain no more than a single 
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bead.  In a typical IVC formulation, ~1010 compartments, typically 2-4 µm in diameter, 
are created for an input of up to 109 beads.  This low ratio of the number of beads to the 
total number of compartments promotes single bead encapsulation and ensures that the 
phenotype of each bead is a consequence of only one translated gene.   
The use of microbeads also enables the use of fluorescence-assisted cell sorting 
(FACS) for the selection of beads exhibiting the desired phenotype.  IVC is particularly 
powerful when used in conjunction with FACS.  The major advantage of FACS lies in its 
ability to query each individual member of a large population in an ultra high-throughput 
manner (> 107 cells per hour).  FACS is technically a screen, but because of its ultra high-
throughput nature, we will refer to it as a “selection” throughout the rest of this chapter.  
Using FACS, we also have precise control over the “selection pressure” by manually 
controlling the sort gate, and this easily allows for segregation of cells exhibiting high 
fluorescence from cells exhibiting only medium and low levels of fluorescence.  Thus, 
FACS is emerging as a useful tool for the isolation of multiple turnover catalysts from 
large protein libraries17,18.     
Figure 2 depicts our new strategy for the in vitro evolution of a BirA mutant 
capable of utilizing azide 3 as a substrate, based on in vitro compartmentalization and 
FACS sorting of microbeads.  Beads are densely functionalized with a substrate for BirA 
(Sub) and sparsely functionalized with streptavidin (SA), which enables the attachment of 
DNA through its high-affinity interaction with biotin conjugates.  A biotinylated BirA 
gene library is bound to the beads in a ratio such that each bead binds only one DNA 
molecule (step 1).  The beads are mixed with in vitro translation mixture (IVTM) 
containing azide 3 and then segregated into individual aqueous compartments within a   
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water-in-oil emulsion (step 2).  Within each compartment, enzymes are expressed from 
the bead-bound gene, are free to diffuse throughout the compartment, and act on the 
substrate molecules immobilized on the co-compartmentalized bead (step 3).  Active 
enzymes (grey) will catalyze the covalent attachment of azide to the bead, whereas beads 
compartmentalized with inactive enzymes (white) will remain unmodified.  The different 
Figure 2.  Proposed IVC selection scheme for BirA mutants that utilize azide 3.  In step 1, a 
biotinylated BirA gene library is bound to beads functionalized with a substrate for BirA (Sub) and 
streptavidin (SA).  The ratio of DNA molecules to beads is adjusted so that most of the beads bind 
only one DNA molecule.  The beads are then mixed with IVTM containing azide 3 (Az) and 
segregated in individual aqueous compartments within a water-in-oil emulsion (step 2).  Within the 
compartments the enzymes are expressed from the bead-bound gene (step 3).  Active enzymes (right, 
grey) catalyze azide attachment to molecules of Sub immobilized on the co-compartmentalized bead, 
whereas inactive enzymes (left, white) do not modify the beads.  The beads are re-pooled after 
breaking of the emulsion.  The azides are detected using epitope derivatization via a chemoselective 
ligation and fluorescent labeling with anti-epitope antibodies (step 4).  The beads exhibiting high 
fluorescent intensities, and thus high levels of azide modification, are separated from the beads 
exhibiting low fluorescence using FACS (step 5).  The genes are recovered from the isolated beads 
through PCR for input into the next round of selection (step 6).       
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azide 3 utilization abilities of the enzymes will be reflected in the varying extent of bead 
modification.  The beads are re-pooled by breaking the emulsion, and the azide groups 
are chemoselectively derivatized with an epitope tag and stained with fluorescent 
antibodies against the epitope (step 4).  The desired highly fluorescent beads are 
separated from the beads exhibiting low fluorescence using FACS (step 5).  Following 
the sort, the DNA is recovered through PCR for input into the next round of selection 
(step 6). 
Hemanta Baruah and Yoon-Aa Choi also worked with me to adapt this selection 
scheme for evolving BirA mutants that could utilize N-propargylbiotin (Chapter 4) and 
BirA mutants that were more efficient for biotin transfer, respectively.  The initial 
groundwork for adapting IVC for use in our laboratory was done in collaboration with 
Bernard Kelly of the Griffiths laboratory (formerly of the MRC Laboratory of Molecular 
Biology, Cambridge, United Kingdom; currently of the Institut de Science et d'Ingénierie 
Supramoléculaires, Strasbourg, France).  In model selections, Kelly demonstrated 
enrichment of the BirA gene by selecting for compartmentalized biotinylation activity 
(Bernard T. Kelly and Andrew D. Griffiths, personal communication).  With the help of 
Kelly, we first sought to reproduce his model selection results in our own laboratory. 
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Results 
 
Model selections demonstrate successful compartmentalization and enrichment for 
biotinylation activity 
We made microbeads covalently functionalized with streptavidin (SA) and the  
P. shermanii transcarboxylase 1.3S subunit (hereon referred to as PSBCCP), which is a 
known substrate for BirA (Figure 3A)19.  Carboxylate-modified microbeads were 
activated using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) 
and sulfo-N-hydroxysuccinimide (sulfo-NHS) and reacted with cystamine.  The 
disulfides within cystamine were then reduced with dithiothreitol (DTT) to liberate the 
free thiols.  The thiols were then reacted with maleimide-conjugated PSBCCP and 
streptavidin to afford the dually functionalized beads.      
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The maleimide-conjugated proteins were made by nonspecific acylation of the lysines of 
the proteins with the bifunctional cross-linker, succinimidyl 4-[N-maleimidomethyl]-
Figure 3.  Synthesis of microbeads for IVC.  (A) Commercially available carboxylate-modified beads 
are converted to thiol-functionalized beads and reacted with substrate- (Sub-) and streptavidin (SA)-
maleimide (Mal) conjugates.  Sub = PSBCCP or HP1-AP.  (B)  Synthesis of protein-maleimide 
conjugates through the reaction with the bifunctional cross-linker SMCC.  (C)  Structure of SMCC. 
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cyclohexane-1-carboxylate (SMCC) (Figures 3B and 3C).  Both PSBCCP and 
streptavidin do not possess any solvent-exposed thiols that could react with the 
maleimide moiety of SMCC. 
We first verified that we could observe compartmentalized biotinylation activity 
when using these beads.  Biotinylated genes encoding BirA and E. coli dihydrofolate 
reductase (DHFR), an enzyme with no biotin transfer activity, were synthesized using 
PCR amplification with biotinylated forward and reverse primers.  The genes also 
possessed a spacer at least 300 basepairs in length between either biotinylated terminus 
and the upstream promoter or downstream terminator region of the gene.  The spacers 
allow for better access of these DNA recognition sequences to the transcription enzymes 
when the gene is bound to the surface of the bead.  The biotinylated genes were then 
bound to separate sets of beads at a ratio of 1:3 gene/bead, to ensure that most of the 
beads bound only one gene.  The beads were then compartmentalized with IVTM 
containing biotin, and the resulting emulsion was incubated for at least eight hours at  
30 °C to allow for enzyme translation and biotinylation of PSBCCP to occur.  Because 
magnesium and ATP are critical components of the IVTM, all of the necessary cofactors 
for BirA-catalyzed biotinylation are present within each compartment.  Following 
breaking of the emulsion and washing, the beads were incubated with streptavidin-
phycoerythrin (PE) to fluorescently label the biotin molecules that had become covalently 
attached to the beads.  The labeled beads were then analyzed by flow cytometry for PE 
fluorescence.   
Dot plots of PE fluorescence and forward scatter (a characteristic used to identify 
single beads from aggregates) for a sample of the beads are shown in Figure 4A.  We 
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observed two distinct bead populations from the BirA emulsion, a larger low-
fluorescence population and a smaller high-fluorescence population of biotinylated beads 
(Figure 4A top, boxed).  As expected, we only observed one low fluorescence population 
for the negative control DHFR emulsion (Figure 4A, top).  The presence of two distinct 
populations from the BirA emulsion is characteristic of compartmentalization, because 
not every compartmentalized bead was bound to a BirA gene.  The observed ratio of the 
high fluorescence and low fluorescence populations is reasonable for a 1:3 gene /bead 
ratio, considering errors in DNA and bead concentration determination. 
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Figure 4.  Model selection results with PSBCCP beads.  (A) Dot plot analysis of the emulsion 
reactions.  For each analyzed bead, phycoerythrin fluorescence (PE) is plotted versus forward scatter 
(FSC).  (top) The high fluorescence population (boxed) in the BirA emulsion is not present in the 
negative control DHFR reaction, indicating that these beads were biotinylated by the enzyme expressed 
from the BirA gene.  (bottom) The high fluorescence population decreases with each successive dilution 
of BirA in the DNA input for model selection.  (B) Agarose gel analysis of the compositions of the 
DNA mixture before one round of model selection and after one round of selection.  Enrichment of the 
BirA gene is observed in all model selection experiments.  Data provided by Hemanta Baruah.   
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We next reproduced the model selections of Kelly to demonstrate enrichment 
through selection for biotinylation activity.  The model selection was performed 
according to the scheme shown in Figure 2, except substituting biotin for azide 3 and 
using streptavidin-PE to fluorescently label the beads after the breaking of the emulsion.  
We first mixed the BirA and DHFR genes in 1:10, 1:100, and 1:1000 BirA/DHFR ratios 
before binding these gene mixtures to the beads.  The beads were compartmentalized, 
incubated at 30 °C for over eight hours, re-pooled through breaking of the emulsion, and 
labeled with streptavidin-PE as described above.  Flow cytometry analysis of the beads 
from these emulsions showed that the population of high fluorescence beads successively 
decreased with each further dilution of the BirA gene (Figure 4A bottom, boxed), but the 
number of high fluorescence beads remained greater for the 1:1000 dilution than the 
negative control DHFR emulsion.  The beads from each emulsion were sorted using 
FACS, and the high fluorescence beads falling within our defined gate (Figure 4A box) 
were isolated along with their attached genes.  The recovered genes were amplified by 52 
cycles of nested PCR with common primers flanking both of the BirA and DHFR genes.  
The genes from an aliquot of the unsorted beads were also PCR amplified in the same 
manner.   
The compositions of the DNA mixtures both before and after selection were 
analyzed by agarose gel electrophoresis (Figure 4B).  In all experiments we observed 
enrichment of the BirA gene after sorting.  Using densitometry, we estimated the relative 
compositions of BirA and DHFR in the DNA mixture, and we calculated the enrichment 
factor by dividing the BirA/DHFR ratio after selection by the BirA/DHFR ratio before 
selection.  We obtained up to 250-fold enrichment in a single round from the 1:1000 
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BirA/DHFR model selection experiment, which is consistent with that obtained by Kelly.  
However, it still pales in comparison with the 5000-fold enrichment achieved in FACS 
selections for fluorescent ligand binding20.  Possible reasons for the lower enrichment 
factors include binding of more than one DNA molecule per bead, compartmentalization 
of more than one bead, scrambling of the genotype and phenotype linkages as a result of 
the dissociation and re-association of biotinylated DNA from the beads15, and the 
inherently greater difficulty of selecting for catalysis rather than ligand-binding.  Also, 
since the DHFR gene is half the size of the BirA gene, it is amplified more efficiently by 
DNA polymerase, and thus our actual enrichment is probably higher than that suggested 
by this PCR detection assay.   
Paying heed to the adage “you get what you select for,” we preferred to perform 
the selections on beads functionalized with the AP, since our ultimate goal remained to 
isolate enzymes that would be useful for site-specific labeling of AP fusion proteins.  As 
a testament to the different recognition properties of PSBCCP and AP, ketone 1 is not 
ligated to PSBCCP by BirA (data not shown), despite being efficiently ligated to the AP.  
We initially tried to synthesize AP-functionalized beads by conjugating synthetic AP 
peptide or CFP-AP to the beads, but we observed poor conjugation efficiency with the 
peptide and poor compartmentalized biotinylation activity with CFP-AP.  We 
hypothesized that the larger size of CFP-AP compared to PSBCCP sterically prevented 
efficient binding of the genes or transcription of the bead-bound genes.  Thus, we cloned 
and expressed an AP fusion to heterochromatin protein 1 (HP1-AP), which is similar in 
size to PSBCCP.  Because HP1-AP has one surface-exposed cysteine, we first capped the 
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thiol with N-ethyl maleimide before synthesizing HP1-AP beads according to the scheme 
shown in Figure 3.  
With some optimization of the HP1-AP and streptavidin ratios, we were finally 
able to observe compartmentalized biotinylation activity comparable to that observed 
with the PSBCCP beads (Figure 5A).  Phycoerythrin fluorescence (PE or FL2) 
histograms indicated the presence of a high-fluorescence bead population in the BirA 
emulsion that was not present in the negative control DHFR emulsion (starred, Figure 5A 
left).  However, with the HP1-AP beads we observed background biotinylation activity in 
the DHFR emulsion, which we had never observed before with PSBCCP beads (Figure 
5A).  After confirming that the HP1-AP on the beads was fully debiotinylated, we 
identified the source of the background activity to be the IVTM, because we observed the 
same degree of background biotinylation as the DHFR emulsion even when the HP1-AP 
beads were compartmentalized without any bound genes.  We hypothesized that the 
endogenous BirA of the E. coli lysate component of the IVTM was also performing 
compartmentalized biotinylation.  The bead phenotypes observed from the BirA and 
DHFR emulsions in Figure 5A suggest that three types of bead-containing compartments 
are formed after emulsification of BirA gene-bound beads in IVTM:  compartments 
without any BirA, compartments containing only BirA from the IVTM, and 
compartments containing BirA expressed from the bound BirA gene and/or BirA from 
the IVTM.  Because some compartments are formed without any BirA, it follows that the 
number of contaminating BirA molecules from the IVTM must be significantly less than 
the total number of compartments, which is ~1010.  This corresponds to a concentration of 
endogenous BirA in the IVTM of at most 0.5 nM, which we believe to be a reasonable 
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estimate.  The background contribution from the BirA of the IVTM was not observed 
with the PSBCCP beads because PSBCCP is a significantly worse substrate for BirA than 
HP1-AP.  Nevertheless, despite the high background biotinylation activity, the 
appearance of the high-fluorescence population in the BirA emulsion that is absent from 
the DHFR emulsion suggests that we could still select for biotinylation activity resulting 
only from BirA gene expression by using the precise gating capabilities of FACS.  
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Figure 5.  Model selection results with HP1-AP beads.  (A) Fluorescence histogram analysis of the 
BirA and DHFR emulsion reactions on HP1-AP (left) and PSBCCP beads (right).  The histograms 
show the number of beads (y-axis) counted at different PE (FL2) fluorescence intensities (x-axis).  
Higher background biotinylation activity is observed with the HP1-AP beads than PSBCCP beads.   
A high fluorescent population (starred) is still present in the BirA emulsion and absent from the 
negative control DHFR emulsion.  (B) Agarose gel analysis of the DNA compositions before and 
after one round of model selection.  The model selection was performed as described for Figure 6, 
substituting HP1-AP beads for the PSBCCP beads.  Enrichment of the BirA gene is observed in all 
model selection experiments.  
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We performed the same model selection experiments on HP1-AP beads in the 
same manner described for the PSBCCP beads, but we set the collection gate at higher 
PE fluorescence levels to compensate for the higher background.  Figure 5B shows the 
results of the model selection.  We observed enrichment of the BirA gene in all 
experiments.  When compared to the results of the PSBCCP model selections, we 
observed comparable enrichment (~250) in the 1:1000 model selection, better enrichment 
for the 1:100 model selection, and worse enrichment for the 1:10 model selection.  
Therefore, despite the higher background we still achieved high enrichment factors 
because of the precise control over our sort gate.  With this level of background 
biotinylation, it would probably have been impossible to achieve this level of enrichment 
using affinity capture with streptavidin-coated beads.  Also, we note that this background 
biotinylation activity from the contaminating BirA in the IVTM would only be a major 
problem in selection schemes that utilize streptavidin-PE staining as a step in the 
detection of probe incorporation. 
 
Developing a product detection scheme for azide ligation to the beads 
We next turned our attention to developing a reliable product detection scheme to 
distinguish between beads modified with azides and unmodified beads.  Epitope tags can 
be introduced specifically through a chemoselective ligation reaction with the azide 
(Chapter 4), and the epitope tags can then be detected through fluorescent antibody 
staining.  We first tested the efficiency of Staudinger ligation of the phosphine-FLAG 
peptide (pFLAG, Chapter 4) to azide 3-modifed HP1-AP beads (Az-HP1-AP beads).  We 
synthesized these beads by nonspecific chemical acylation of the lysines on the HP1-AP 
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beads with the N-hydroxysuccinimide ester of azide 3.  We then conjugated pFLAG  
(250 µM) to both the Az-HP1-AP beads and unmodified HP1-AP beads.  Following 
pFLAG conjugation, both sets of beads were stained with a mouse anti-FLAG primary 
antibody and a PE-conjugated goat anti-mouse secondary antibody.  The labeled beads 
were analyzed for PE fluorescence using flow cytometry (Figure 6A).  We observed a 
230-fold higher mean fluorescence intensity difference between Az-HP1-AP and 
unmodified HP1-AP beads with this Staudinger ligation-based detection scheme.     
We also tested other conjugation chemistries to maximize the signal-to-noise ratio 
(S/N) between azide-modified and unmodified beads.  Due to its superior sensitivity in 
lysate detection21, we investigated the use of click chemistry to derivatize the azide.  We 
synthesized a biotin-alkyne (BALK) and two fluorescein-alkynes (FITALK and FAALK) 
by acylation of propargyl amine (Figure 7).  Az-HP1-AP and HP1-AP beads were reacted 
with 50 µM biotin-alkyne (BALK) in the presence of Sharpless’s tris-
(benzyltriazolylmethyl) amine ligand22 and a copper(I) catalyst (generated in situ by the 
reduction of copper(II) sulfate with triscarboxyethyl phosphine) and stained with 
streptavidin-PE.  Flow cytometry showed a signal-to-noise ratio of 180 after this 
treatment, which is slightly less than what we observed with pFLAG detection (Figure 
6B).  Although the high-affinity interaction between biotin and streptavidin is attractive 
for minimizing fluorescent signal attenuation during the hours of bead sorting, the use of 
streptavidin staining is complicated by the background biotinylation catalyzed by the 
BirA from the IVTM, especially after we determined that biotin can also be present in the 
IVTM. 
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Figure 6.  Azide detection via Staudinger ligation and click chemistry.  Azide-modified (+Az) and 
unmodified (-Az) beads were both similarly treated and their mean fluorescence intensities after the 
detection procedure were compared and divided to obtain a signal-to-noise ratio (S/N).  (A) Azide 
detection via Staudinger ligation of 250 µM pFLAG, followed by labeling with mouse anti-FLAG 
antibody and PE-conjugated goat anti-mouse antibody.  PE fluorescence (FL2) histograms are shown.  
(B) Azide detection via click chemistry with 50 µM BALK and staining with streptavidin-PE.  PE 
fluorescence (FL2) histograms are shown.  (C) Azide detection via click chemistry with 2 µM FAALK.   
Fluorescein fluorescence (FL1) histograms are shown after no antibody labeling (left), labeling with 
PE-conjugated anti-fluorescein antibody (middle), and antibody labeling with the Alexa 488 Signal 
Amplification kit (right).  
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To avoid possible complications from any residual biotin in the IVTM, we 
investigated an alternative click chemistry product detection scheme using the fluorescein 
alkynes FITALK and FAALK (Figure 7).  The click chemistry reactions with FITALK 
and FAALK proved to be fickle.  By flow cytometry analysis under the fluorescein 
channel (FL1), the reaction with Az-HP1-AP beads failed to proceed under the conditions 
of BALK conjugation, and moreover, we observed severe nonspecific sticking of 
fluorescein to the HP1-AP negative control beads.  We finally were able to observe a 
modest nine-fold difference between Az-HP1-AP and HP1-AP beads when we applied 
these modifications to the FAALK reactions:  (1) lowering the FAALK concentration to  
Figure 7.  Synthesis of alkynes for click chemistry conjugation.  All reactions were performed at room 
temperature.  a. DCC, N-hydroxysuccnimide, DMSO; then propargyl amine.  b. propargyl amine, DMF.  
c. EDC, 10-undecynoic acid, pyridine. 
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2 µM,  (2) switching the copper(I) source to tetrakis(acetonitrile)copper(I) 
hexafluorophosphate (Cu(CH3CN)4PF6)23, (3) switching the buffer from phosphate buffer 
to HEPES buffer, and (4) continuing to use the Sharpless ligand instead of Finn’s 
bathophenanthroline ligands (Figure 6C left)23.  Interestingly, we never observed 
successful conjugation of FITALK, even under these optimized conditions. 
Fortuitously, we discovered that the signal-to-noise ratio was improved 
significantly to 84 by the binding of a phycoerythrin-conjugated anti-fluorescein antibody 
(Figure 6C middle).  Antibody binding simultaneously improved the fluorescein channel 
(FL1) signal and decreased the background stickiness of fluorescein to the beads.  In this 
case it also provided an additional gating parameter for the bead sorts, PE fluorescence.  
Along the same lines, we later discovered that antibody labeling with the AlexFluor488 
Signal Amplification Kit (Invitrogen) after FAALK conjugation yielded a 600-fold 
difference in the fluorescence intensity between the Az-HP1-AP and HP1-AP beads 
(Figure 6C right).   
 In summary, before beginning actual selections for BirA mutants capable of 
catalyzing azide 3 ligation, we needed to develop verify a reliable method for detecting 
the covalent ligation of our unnatural probe.  We demonstrated that Staudinger ligation 
and click chemistry could both be used to detect azide molecules attached to the bead.  
After derivatization of the azide with an epitope tag and fluorescent antibody staining of 
the epitope, we observed a 200-600-fold difference in the mean fluorescence intensity of 
azide 3-conjugated beads and unmodified beads.  A high signal-to-noise ratio for product 
detection is desirable for distinguishing low levels of modification from background and 
for providing the dynamic range necessary to segregate high and mediocre levels of 
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modification.  We also verified that we could enrich for genes on the basis of the 
compartmentalized activity of their expressed enzymes.  We demonstrated in two model 
selections that we could enrich 250-fold for the BirA gene by selecting for its 
biotinylation activity on PSBCCP and HP1-AP.  Thus, the link between enzyme genotype 
and bead phenotype is robust and compartmentalization effectively segregates the action 
of the transcribed enzymes.  
 
Design of a library of BirA mutants for selection with azide 3 
 We next designed a library of mutant BirA enzymes to input into the selection 
with azide 3.  To design the library, we used the same model of the azide 3 interaction 
with the BirA active site that we created to rationally design point mutants (Chapter 4).  
In addition to the residues shown in Figure 16 of Chapter 4, we also targeted Ile108, 
Ala109, Gln112, Ser134, and Ala205 for mutagenesis, because our model predicted that 
these residues contained atoms within 5 Å of the nitrogen atoms of the azide group 
(Figure 8).   
Gln112
Ala205
Leu131
Tyr132
Thr90
Ala109
Ile108
Ser134
Leu133
Cys107
 
 
Figure 8.  Amino acids targeted for saturation mutagenesis to accommodate azide 3.  An energy-
minimized conformation of azide 3 (yellow) was docked into the BirA-biotin crystal structure 
(PDB:  1HXD) by superimposition onto biotin.  Amino acids that contain atoms within 5 Å of the 
nitrogen atoms of the azide group in our model are shown.  Carbon atoms are colored grey, oxygen 
atoms are colored red, nitrogen atoms are colored blue, and sulfur atoms are colored orange.   
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The library we made, library 1, had each of these nine residues fully randomized using 
saturation mutagenesis.  Randomized gene fragments were synthesized by PCR with 
degenerate primers and assembled into the full-length, biotinylated genes using overlap 
extension PCR.      
 
Selections failed to isolate catalysts of azide ligation but highlighted the technical 
challenges of IVC 
We performed two sets of selections for catalysts of azide 3 ligation, 
implementing the selection scheme shown in Figure 2.  One set of selections was 
performed with PSBCCP beads, and the other set was done on HP1-AP beads.  A total of 
1.4×108 and 4×109 DNA molecules from library 1 were input into the PSBCCP and HP1-
AP selections, respectively.  To avoid competition between azide 3 and any residual 
biotin present in the IVTM for the active sites of the expressed enzymes, we first treated 
the IVTM with streptavidin-coated magnetic beads before emulsification with the beads 
and azide 3.  After breaking the emulsions, we used Staudinger ligation in the PSBCCP 
selections and click chemistry in the HP1-AP selections to detect azide incorporation.  In 
the bead sorts, the stringency of selection was gradually increased with each successive 
round.  We collected the top 1% of the beads (as determined by PE fluorescence) in the 
first round, and by the fourth round we only collected the top 0.1% of the beads.   
Following PCR recovery of the DNA from the beads isolated after sorting, the 
recovered product was assembled using overlap extension PCR into the full-length 
biotinylated gene for input into the next round of selection.  The recovered DNA from 
each round was evaluated by sequencing and a functional assay for azide incorporation.  
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In this assay, the recovered pools of DNA were transcribed and translated in solution 
containing IVTM, and the resulting enzyme-containing mixture was then added to 
PSBCCP or HP1-AP beads in the presence of azide 3, magnesium, and ATP.  The beads 
were then conjugated to pFLAG, stained with anti-FLAG antibodies, and analyzed by 
flow cytometry.   
We observed no evidence from either set of selections indicating enrichment for 
genes encoding catalysts of azide 3 ligation.  Within a fixed gate defined in the first 
round, the number of desired high fluorescence beads should gradually increase with 
each successive round of selection, if enrichment for catalysts of azide attachment were 
truly happening.  Instead, in both sets of selections we observed that the number of beads 
within this gate remained constant throughout the selection and did not exceed the 
number observed in the negative control beads from an emulsion reaction omitting azide.  
Our observations from the bead sorts were corroborated by the results of our functional 
assays of the recovered DNA pools.  When these assays were performed on PSBCCP 
beads as described above, the level of azide modification from all of the recovered pools 
was the same as the background from the negative control reaction omitting azide 3, as 
indicated by fluorescent anti-FLAG staining.   
The lack of enrichment for azide ligation activity in the PSBCCP selections can 
be explained by a library contamination problem that dominated the selection quickly.  
Sequencing thirty clones from the first three rounds of selection resulted in no clones 
with the characteristics of library 1.  Instead, clones from other BirA libraries designed in 
our laboratory were isolated.  When nested PCR amplifications were performed in the 
absence of template with common primers shared by members of our laboratory, we 
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observed no visible PCR product after 30 cycles, but a large amount of product after 55 
cycles.  The PCR product was confirmed by molecular weight comparison and 
sequencing to be a BirA library.  The tiny amount of inevitable contamination in the 
primer stocks, which normally is not a problem for routine amplifications employing less 
than 30 cycles, became a serious problem because of the large number of PCR cycles that 
were necessary to recover the DNA from the beads.  Attempts to optimize the PCR 
conditions so that DNA recovery could be consistently accomplished in slightly more 
than 30 cycles were unsuccessful.   
The HP1-AP selections revealed more technical problems of IVC.  We noticed 
that a high background problem persisted in these selections, even in negative control 
emulsion reactions where the azide was omitted.  We determined that the IVTM was 
causing problems with our product detection schemes.  We found that unmodified  
HP1-AP beads that had been pre-incubated in IVTM exhibited very significant 
background staining after our azide detection procedure, in contrast to the low  
background observed with non-IVTM treated HP1-AP beads (Figure 6).  Thus, 
incubation in IVTM caused greater stickiness of the conjugation reagents or the 
antibodies to the beads.  The degree of background stickiness was the same regardless if 
Staudinger ligation or click chemistry was used for azide detection.  Interestingly, we did 
not observe IVTM-induced bead stickiness with the PSBCCP beads.   
In our azide 3 selections, we believed that the residual biotin in the IVTM could 
be a problem because it would compete with azide 3 for the active sites of the expressed 
enzymes.  Furthermore, it would complicate the use of BALK conjugation and 
streptavidin-PE staining for detection of the azide-labeled beads.  To assess the level of 
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biotin contamination in the IVTM, we emulsified HP1-AP beads bound to the BirA gene 
with IVTM without exogenous biotin, and then we detected for biotin incorporation using 
streptavidin-PE.  HP1-AP beads were used instead of PSBCCP beads because of the 
greater sensitivity of detection afforded by using the better substrate for BirA.  Our flow 
cytometry results showed that the level of biotin contamination varied greatly between 
different batches of commercial IVTM (data not shown).  We sometimes observed just a 
single, low-fluorescence bead population, indicating essentially no biotin contamination.  
Other times we observed two distinct populations, with the higher fluorescence 
population comprising up to 25% of the total bead population.  We attempted to deplete 
the contaminating biotin through treatment with streptavidin-coated beads before 
emulsification or to sequester the biotin by emulsification with free streptavidin, but flow 
cytometry showed that neither procedure was particularly effective in eliminating the 
background. 
Besides the variability in the IVTM content, we also encountered inconsistencies 
in the quality of the PSBCCP and HP1-AP beads that we synthesized.  We found that the 
level of compartmentalized biotinylation activity varied widely with each different batch 
of beads synthesized.  The nonspecific nature of the attachment of protein to the bead 
probably precludes consistency in the binding orientation of the biotinylated DNA, the 
access of the DNA to transcription enzymes, and the access of the substrate to the 
translated enzyme.  New strategies to conjugate the substrates to the beads using site-
specific protein labeling reactions could greatly reduce the variability in bead synthesis.  
We also tried to compensate for the variability by making large batches of beads at one 
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time, but the compartmentalized biotinylation activity observed with the beads 
deteriorated significantly within a month of storage at 4 °C.   
 
Discussion of IVC and library design strategies 
 While we still appreciate the concept of IVC, especially for selection of multiple 
turnover enzymes, our experiences illustrate that several technical hurdles remain and 
need to be overcome before IVC can fully realize its potential as the foremost strategy for 
the in vitro evolution of catalysts.  Most of our own problems with IVC stemmed from 
the microbeads themselves.  We had difficulties synthesizing beads displaying consistent 
compartmentalized biotinylation activity.  Also, incubation in IVTM resulted in 
nonspecific sticking of the conjugation and detection reagents to the beads, which 
hampered the effectiveness of our azide product detection strategies.  Furthermore, 
recovery of DNA from the beads was difficult, inconsistent, and spawned serious DNA 
contamination issues.  New microbead synthesis strategies will need to be developed to 
address these problems, making use of site-specific protein labeling technologies and 
maybe even principles of self-assembly and surface passivation used to fabricate 
nanoparticles.  To circumvent the need for microbeads, our laboratory has begun to 
develop bead-less strategies for IVC through the compartmentalization of hybrid AP-
DNA molecules (Hemanta Baruah, Yoon-Aa Choi, and Alice Y. Ting, unpublished 
results).  The Griffiths and Tawfik laboratories have independently demonstrated that 
fluorescent aqueous droplets of a water-in-oil emulsion can be sorted by FACS without 
compromising their content and structural integrity, if the water-in-oil emulsion were 
emulsified further to make a double water-in-oil-in-water emulsion12,13.  However, it is 
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not immediately obvious how BirA-catalyzed probe attachment could be coupled to a 
fluorogenic reaction within the emulsion.   
 Although the use of IVTM has the benefit of allowing the expression of proteins 
that may adversely impact the viability of the expression host, the trade-off is 
significantly reduced yield of expressed protein.  Only 10-100 molecules are typically 
expressed within the compartments, resulting in enzyme concentrations in the nanomolar 
range12.  Tawfik and co-workers have shown that high concentrations of enzyme (>1 µM) 
within the compartments are necessary to detect very weak enzymatic activities (catalytic 
efficiencies on the order of 75 M-1 s-1)13.  Because most of the BirA mutants of library 1 
that display any azide 3 ligation activity would likely utilize it poorly, the expression 
levels of the enzymes within the compartments may not be high enough to enrich for 
these weak catalysts.  Higher levels of enzyme expression could possibly be obtained 
with other cell-free translation mixtures, such as wheat germ or rabbit reticulocyte lysate, 
and complications from BirA biotinylation activity can be eliminated in these other 
systems.  However, the use of IVTM and other cell-free translation mixtures remains 
impractical due to their expense.      
Technical issues aside, other possible reasons for the failure of our selections stem 
from the library design.  To ensure that the input into the selection is as enriched for 
sequences encoding our desired function, we would like the DNA input to represent a 
large fraction (ideally, 100%) of our designed theoretical diversity.  However, a library of 
nine fully randomized residues represents an overwhelming amount of theoretical 
diversity (5.1×1011).  Since we typically input at most 108-109 DNA molecules into the 
selection, only a tiny fraction (at most 0.2%) of the theoretical diversity is represented in 
228 
the initial input in the first round.  We would also like to have multiple copies of each 
member present in the initial input, to compensate for losses during the entire selection 
procedure.  We estimate that we lose about 50% of the beads over the course of one 
entire round of selection.  However, due to the undersampling of the theoretical diversity, 
each library member input into the first round of selection was present in only a single 
copy.  Therefore, beads exhibiting interesting properties had a high probability of being 
lost forever at an early stage of the selection.   
Besides creating a library size that was too large for the practical limitations of 
compartmentalization and FACS sorting, our strategy of simultaneous and full 
diversification of nine residues in the active site was flawed because it most likely 
yielded an extremely high representation of inactive enzymes in the library.  Our own 
studies of the BirA active site through rational mutagenesis (Chapters 3 and 4) indicated 
that many of our targeted residues may be critical for folding into catalytically active 
proteins The Ser134Gly, Tyr132Gly, and Tyr132Ala mutations all resulted in enzymes 
incapable of biotin transfer.  Thus, reducing the mutation rate at the active site will likely 
increase the representation of functional enzymes in the library.  Instead of saturation 
mutagenesis at each position, each position can be randomized using 91-3-3-3 
mutagenesis of the codon nucleotides so that 75% of the sequences in the library would 
retain the wild-type residue at a particular position.  Another method to sample mutations 
from a large number of residues (~16) while keeping the overall mutation rate low (~3 
mutations per gene) is a modified DNA shuffling procedure with spiked-in randomized 
oligonucleotides, as demonstrated by Tawfik and co-workers13.   
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Given the infinitesimal fraction of theoretical sequence space that can be explored 
in a typical directed evolution experiment, there is no question that structural information 
is important in focusing enzyme libraries on the most important residues.  However, 
crystallographic snapshots of a particular enzyme conformation often still paint an 
incomplete picture of enzyme catalysis.  In many instances, residues that are distant from 
the active site play a large role in catalysis.  The use of error-prone PCR to further 
diversify the recovered DNA pools can identify these non-obvious mutations that are 
beneficial to catalysis.  Also, diversification by homology-dependent recombination 
methods can also access beneficial combinations of mutations that were not present in the 
initial library synthesis24. 
Another critical factor in the success of in vitro evolution experiments is the 
choice of an appropriate start point for evolution.  It is generally much easier to enhance 
an existing weak activity through directed evolution than to create an entirely new 
function.  Hence, our expectation to isolate a BirA mutant that could utilize azide 3 was 
probably overly ambitious.  We have recently discovered that the biotin ligase from P. 
horikoshii (PhBL) weakly catalyzes the ligation of azide 3 to the p67 polypeptide 
(Chapter 4).  Our selection scheme in Figure 2 is better suited for a directed evolution 
experiment seeking to improve azide 3 ligation by PhBL rather than to create de novo 
azide 3 recognition by BirA.  It may also be interesting to explore structure-guided, site-
directed recombination of BirA and PhBL to create libraries of hybrid BirA-PhBL 
enzymes with the azide 3 recognition characteristics of PhBL and the AP recognition 
characteristics of BirA25.   
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Conclusions 
 In this chapter, we present our efforts to develop a robust in vitro evolution 
platform for re-engineering the active site of BirA to accommodate novel small molecule 
substrates.  We first considered the use of phage display because of its widespread use, 
particularly in the evolution of novel binding peptide ligand and protein binders.  
However, the use of phage display for the evolution of catalytic activity inherently suffers 
from several limitations.  In vitro compartmentalization (IVC) strategies can address 
many of the deficiencies of phage display, including selection for intermolecular 
substrate recognition and multiple turnover catalysts.  We developed a platform for the in 
vitro evolution of BirA based on the IVC of microbeads displaying a substrate for BirA 
and FACS sorting of the beads labeled with antibodies specific for product formation.  
We validated that we could enrich for the BirA gene by selecting for its biotinylation 
activity in model selections conducted with beads displaying two different substrates for 
BirA, PSBCCP and HP1-AP.  Enrichment factors of up to 250 could be obtained from a 
starting 1:1000 gene mixture of BirA and DHFR, an enzyme without any biotin ligase 
activity.  We next developed reliable detection schemes for azide 3 conjugation.  After 
derivatizing the azides with epitope tags and staining with fluorescent antibodies against 
the conjugated epitope tags, we obtained a 200-600-fold difference in the mean 
fluorescence intensity between beads that were nonspecifically acylated with azide 3 and 
unmodified beads  
We designed a library of BirA mutants through saturation mutagenesis of nine 
amino acid positions.  We input our designed library into our IVC selection scheme, to 
select for BirA mutants capable of utilizing azide 3 as a substrate.  The selections failed 
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to yield any enrichment of azide 3 ligation activity, but instead highlighted the technical 
difficulties of our IVC scheme.  We encountered problems such as inconsistent and 
difficult recovery of genes from the beads, contamination of recovered DNA pools, 
variability in microbead performance in emulsion reactions, and IVTM-induced 
stickiness of the azide detection reagents to the beads.  Future efforts to use IVC to re-
engineer the BirA active site will need to address these technical limitations as well as 
invoke wiser library designs. 
 
Experimental 
 
General bead manipulations 
To “wash” beads with buffer, the beads were resuspended in buffer and pelleted 
by centrifugation (13,200 rpm, 2 min, 20 °C).  The supernatant was then removed from 
the bead pellet.  Unless otherwise stated, the volume of washing buffer was 100 µL.  
When a distinct bead pellet did not form after centrifugation, phosphate-buffered saline + 
0.1% Tween (PBS-T) was added, and the beads were resuspended and repelleted by 
centrifugation. 
Beads were typically sonicated for 30 seconds to break up aggregates in the 
following situations:  (1) immediately before performing a chemical modification (e.g. 
conjugation, reduction), (2) immediately before a blocking step with heparin or bovine 
serum albumin (BSA) solution or a DNA-binding step, (3) immediately before 
emulsification, (4) immediately before antibody application, and (5) immediately before 
flow cytometry or fluorescence-activated “cell” sorting (FACS). 
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To prevent sedimentation during chemical modification, blocking, DNA binding, 
or antibody application, beads were agitated at 300 rpm. 
 
General IVC procedures for compartmentalized biotinylation 
Emulsification of microbeads 
A total of 8×107 beads were blocked in 40 µL PBS-T containing 8 mg/mL heparin 
for one hour.  The beads were washed twice with PBS-T, resuspended in a solution of 
biotinylated BirA DNA in 40 µL PBS-T, and agitated for 30 minutes.  In typical 
experiments, the DNA was bound to the beads in a 1:3 ratio (DNA/bead).  The beads 
were washed twice with TA buffer (5 mM Tris-acetate pH 8.0), resuspended in 27 µLTA, 
and chilled on ice.  To the bead suspension was added 33 µL of chilled 1× in vitro 
translation mixture (IVTM) from the RTS 100 E. coli HY Kit (Roche), additionally 
supplemented with 23 µM of biotin.  Fifty µL of the resulting well-mixed bead 
suspension was then added to a 2 mL Nunc CryoTube vial containing 500 µL of chilled 
mineral oil (Sigma) with 4.5% w/w Span-80 and 0.5% w/w Triton-X-100.  The water-in-
oil emulsions were formed by stirring on ice at 1100 rpm for three minutes and 
homogenizing further on ice at 11,000 rpm for three minutes using an IKA Labortechnik 
Ultra-Turrax T8 homogenizer.  The emulsions were then incubated at 25-30 °C for at 
least eight hours.   
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Breaking the emulsion  
The emulsion was transferred to a 1.5 mL eppendorf tube and centrifuged (13,200 
rpm, 10 minutes, 15 °C).  The less dense oil phase was removed and the remaining 
emulsion was broken by three extractions with 1 mL mineral oil.  One round of extraction 
involves resuspension of the emulsion in oil, centrifugation (13,200 rpm, 5 minutes,  
16 °C), and removal of the oil phase.  After the emulsion was broken to reveal two 
distinct phases, an oil phase on top and an aqueous phase containing the bead pellet, both 
layers were removed carefully, and the pellet was resuspended in 100 µL of PEET buffer 
(PBS-T supplemented with 5 mM ethylenediamine tetraacetic acid (EDTA) and 5 mM 
ethylene glycol tetraacetic acid (EGTA) ).  One mL of mineral oil was added; the mixture 
was vortexed; the beads were pelleted by centrifugation (13,200 rpm, 3 minutes, 16 °C); 
and both phases were removed from the pellet.  The beads were resuspended in 100 µL of 
PEET, and residual oil was removed from the aqueous layer by three extractions 
extracted with 1 mL hexane.  The remaining hexane in the aqueous layer was evaporated 
by heating at 30 °C for 15 minutes.  The beads were pelleted and washed twice with wash 
buffer (10 mM Tris pH 7.4 with 1 mM EDTA and 2 M NaCl). 
 
Streptavidin-PE staining for biotinylated beads 
The beads were stained with streptavidin-PE (1:100 dilution in 0.5× wash buffer, 
Jackson ImmunoResearch) for one hour.  The beads were washed three times with  
PBS-T, and resuspended in 500 µL PBS-T for flow cytometry (FACScan, BD 
Biosciences) or bead sorting. 
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DNA recovery from the beads 
Following a sort, the collected beads were pelleted by centrifugation (13,200 rpm, 
10 minutes, 20 °C) and washed twice in 1× PCR buffer and resuspended in 25 µL of PCR 
buffer.  The beads were input into 100 µL PCR reactions with the primers LMB2-7 (5′-
AAG TTG GGT AAC GCC AGG) and PIVB-7 (5′- TAC GCG ATC ATG GCG AC), and the 
reactions were cycled 22 times (94 °C 0.5 min, 50 °C 0.5 min, 72 °C 2 min) before 
holding at 72 °C for 7 minutes.  Then, 1 µL of this PCR reaction served as the template 
for the next PCR reaction with nesting primers (30 cycles like above).   
 
Model selection for biotinylation activity (Figures 4 and 5) 
The pIVEX plasmid harboring the gene for E. coli biotin ligase (BirA) and the 
biotinylated dihydrofolate reductase (DHFR) gene were a kind gift from A.D. Griffiths 
and B.T. Kelly (MRC Laboratory of Molecular Biology, UK).  The biotinylated BirA and 
DHFR genes were amplified with the biotinylated primers LMB2-1 (5′-biotin-CAG GCG 
CCA TTC GCC ATT) and PIVB1 (5′-biotin-GCG TTG ATG CAA TTT CT). 
The biotinylated genes of BirA and DHFR were mixed in 1:10, 1:1000, and 
1:1000 ratios (BirA/DHFR).  The DNA mixtures were bound to PSBCCP or HP1-AP-
functionalized microbeads and emulsified with IVTM containing biotin as described 
above.  Following incubation at 30 °C for greater than eight hours, the emulsions were 
broken and the beads were stained with streptavidin-PE as described above.  The beads 
were sorted with a BD FACS ARIA at the MIT Center for Cancer Research Core 
Facility, using forward and side scatter for bead gating and a 488 nm argon laser for 
fluorescence excitation.  A positive control compartmentalization reaction (BirA gene 
235 
only) and negative control reaction (DHFR gene only) were used to define the 
appropriate sort gate.  DNA was recovered as described above, using Taq polymerase 
(New England Biolabs) and the nesting primers LMB2-9 (5′-GTA AAA CGA CGG CCA GT) 
and PIVB-9 (5′- TAT CCG GAT ATA GTT CC).  The DNA recovered was analyzed by 
agarose gel electrophoresis. 
 
Azide detection via epitope derivatization and fluorescent antibody labeling  
(Figure 6) 
Chemical conjugation of azide 3 to the microbeads 
Azide 3 (340 mM) was combined with 340 mM dicyclohexylcarbodiimide 
(DCC), and 360 mM N-hydroxysuccinimide (NHS) in 24 µL of dimethylsulfoxide 
(DMSO).  After two hours, the reaction was centrifuged at 13,200 rpm for two minutes, 
and the supernatant was collected and stored at -20 °C. 
A total of 50 µL of HP1-AP beads (1% suspension) were pelleted and 
resuspended in 500 µL of bicarbonate buffer (100 mM NaHCO3 pH 8.6).  To this bead 
suspension was added 1 µL of the azide NHS ester solution synthesized above, and the 
beads were agitated overnight at room temperature.  The beads were pelleted, washed 
twice with PBS-T, and stored in 50 µL PBS-T. 
 
Staudinger ligation of pFLAG and anti-FLAG staining (Figure 6A) 
The beads were suspended in 100 µL of a phosphine-FLAG solution (pFLAG, 
250 µM in PBS) and agitated overnight.  The beads were pelleted and washed twice with 
PBS-T.  The beads were then blocked in 100 µL of 3% BSA/PBS-T for ten minutes at 
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room temperature before application of mouse anti-FLAG antibody (1:1000 dilution in 
3% BSA/PBS-T, Sigma) for 45 minutes at room temperature.  The beads were washed 
three times with PBS-T and labeled with PE-conjugated goat anti-mouse antibody (1:200 
dilution in 3% BSA/PBS-T, Invitrogen) for 45 minutes.  The beads were washed three 
times with PBS-T before flow cytometry or bead sorting. 
 
Click chemistry with Biotin-alkyne (BALK) (Figure 6B) 
The beads were suspended in 50 µL of the following mixture:  50 µM BALK, 200 
µM Sharpless ligand (a gift from K.B. Sharpless, Scripps Research Institute), 200 µM 
triscarboxyethyl phosphine in 100 mM potassium phosphate pH 8.0.  The reaction was 
initiated with the addition of copper(II) sulfate to a final concentration of 100 µM and 
rotated overnight at 4 °C.  We always observed the presence of a large amount of 
precipitate.  The beads were washed twice with wash buffer and stained with 
streptavidin-PE as described above. 
 
Click chemistry with fluoresceinamine-alkyne (FAALK) (Figure 6C) 
The beads were suspended in 50 µL of the following solution:  2 µM FAALK, 
250 µM Sharpless ligand, 100 µM tetrakis(acetonitrile)copper(I) hexafluorophosphate in 
100 mM HEPES pH 8.  The beads were incubated overnight at 4 °C with rotation, 
washed three times with PBS + 0.1% Pluronic (PBS-P), and resuspended in PBS-T for 
flow cytometry analysis using the fluorescein channel. 
The signal-to-noise could be improved with antibody staining.  Following the 
PBS-P washes, the beads were incubated in 3% BSA/TBS-T for 10 minutes, labeled with 
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PE-conjugated rabbit anti-fluorescein antibody (1:100 dilution in 3% BSA/PBS-T, 
Invitrogen) at 4 °C for two hours, and washed three times with PBS-T.   
The Alexa Fluor® 488 Signal Amplification Kit (Invitrogen) was also applied to 
the fluorescein-conjugated beads according to the manufacturer’s instructions.   
 
Selections for a BirA mutant capable of utilizing azide 3 
Synthesis of library 1 by overlap extension PCR (Figure 8) 
Library 1 was assembled from five randomized BirA gene fragments A-E using 
overlap extension PCR.  In a typical overlap extension PCR reaction, 1.7 nM of each 
fragment were mixed in the presence of Roche Expand High FidelityPLUS PCR System 
and the reactions were cycled 10 times (94 °C 0.5 min, 50 °C 0.5 min, 72 °C 3 min) 
without primers.  Then a pair of flanking primers were added, and the reactions were 
cycled 15 more times.  Fragment A was amplified from the pIVEX BirA template using 
the primers LMB2-1 and the BirA89.R (5′-GGA GTC AAT CAC TGG CAG C), using 30 
reaction cycles as described above.  Fragment B was similarly amplified using the 
primers Bir90.F (5′-GCT GCC AGT GAT TGA CTC CNN KAA TCA GTA CCT TCT T, where N = 
A, G, C, or T and K = G or T; randomizes Thr90) and Bir107.R (5′-GCA AGC ATC GCC CGA TTT 
AA).  Fragment C was similarly amplified with the primers Bir108.F (5′-TTA AAT CGG 
GCG ATG CTT GCN NKN NKG AAT CAN NKC AGG CTG GCC G; randomizes Ile108, Ala109, and 
Gln112) and Bir130B.R (5′-GTT TGC GCC AAA AGG CGA AAA CC).  Fragment D was 
similarly amplified with the primers Bir131.F (5′-TTT CGC CTT TTG GCG CAA ACN NKN 
NKN NKN NKA TGT TCT GGC GTC; randomizes Leu131, Tyr132, Leu133, and Ser134) and 
Bir204.R (5′-TCC AAT GAC TAT TTG CGC CG).  Fragment E was similarly amplified with 
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the primers Bir205.R (5′-CGG CGC AAA TAG TCA TTG GAN NKG GGA TCA ACA TGG; 
randomizes Ala205) and PIVB1.   
 
Azide 3 selections on PSBCCP beads 
A total of 1.4×108 DNA molecules from library 1 were bound to 4×108 beads in 
the first round of selection.  In theory, this represents 0.03% of the theoretical diversity of 
library 1, with each input member only present in a single copy.  The beads were then 
emulsified as described above for compartmentalized biotinylation, except the IVTM 
contained 100 µM of azide 3.  Following breaking of the emulsions, we performed azide 
detection using the Staudinger ligation with pFLAG. 
In the first round of bead sorting, we applied a loose gate, collecting the top 1% of 
the beads (as determined by PE fluorescence).  In subsequent rounds, the number of 
collected beads decreased until by the fourth round only the top 0.1% of the beads were 
collected.  After sorting, the DNA was recovered from the beads as described for the 
model selections, except using Pfu Turbo (Stratagene) and the nesting primers 
pIVEXNco.F (5′- GAT ATA CCA TGG GGG GCT CGA GC) and pIVEXSac.R (5′- GCT GCA 
GAG CTC GGT ACC TTA TTA GTG G).  For input into the next round of selection, the 
recovered PCR product was assembled into the full-length biotinylated gene using 
overlap extension PCR, as described above for the library synthesis.  For sequencing 
clones isolated from a round of selection, the purified PCR product was digested with 
NcoI and SacI and ligated into similarly digested pIVEX (Roche) vector. 
In all subsequent rounds after the first, a total of 3.4×107 DNA molecules were 
bound to 1.0×108 beads.  As a result of the hundred-fold reduction in diversity produced 
239 
by the gating in the first round of selection (only the top 1% were collected, and in 
principle each input DNA is only present in a single copy), this number of DNA 
molecules ensured that at least 24 copies of each DNA molecule recovered from the 
previous round were input into the next round. 
 
Azide 3 selections on HP1-AP beads 
The selections were performed as described above for the PSBCCP beads, except 
with the following modifications:  (1) 4×109 DNA molecules were incubated with 4×108 
HP1-AP beads in the first round, (2) 1×108 DNA molecules were bound to 1×108 beads 
in the second round, (3) click chemistry with BALK was used for azide detection in the 
first round, and (4) click chemistry with FAALK was used for azide detection in all 
rounds after the first.  By binding more than one DNA to the beads in the initial rounds, 
we sought to increase the number of library members input into the first round of 
selection, although we do not know the DNA binding capacity of these beads.   
 
Synthesis of microbeads functionalized with HP1-AP or PSBCCP (Figure 3) 
A.  Bacterial expression of HP1-AP and PS-BCCP 
The pET23d plasmid for bacterial expression of P. shermanii transcarboxylase 
1.3S subunit (“PSBCCP”) was a kind gift from A.D. Griffiths and B.T. Kelly (MRC 
Laboratory of Molecular Biology, UK).  The pET21 plasmid for bacterial expression of 
HP1-AP was constructed by standard PCR subcloning techniques (see the Supporting 
Electronic Information).   
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The expression in E. coli BL21 DE3 and purification of hexahistidine-tagged 
PSBCCP or HP1-AP was performed as described for pET21a-BirA in Chapter 3.  
Removal of biotinylated PSBCCP or HP1-AP was performed with streptavidin-agarose 
beads as described for CFP-AP in Chapter 3.  The cysteine residue on HP1-AP was 
capped by incubating with 4 mM N-ethylmaleimide for 30 minutes at room temperature, 
and excess N-ethylmaleimide was removed by dialysis.  
 
B.  Synthesis of thiol-modified beads 
A total of 25 µL of carboxylate-modified microbeads (10% suspension, ~4×109 
beads, Bangs laboratories) were pelleted and washed twice with 500 µL of MES buffer 
(50 mM 2-(N-morpholino)ethanesulfonic acid pH 6.2) and resuspended in 400 µL MES 
buffer.  To the bead suspension was added sulfo-N-hydroxysuccinimide to a final 
concentration of 100 mM and then 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) to a final concentration of 100 mM.  The beads were agitated for 
twenty minutes at room temperature and then washed twice with 500 µL MES buffer.  
The beads were resuspended in 500 µL of a solution of 100 mM cystamine in bicarbonate 
buffer (0.1 M NaHCO3 pH 8.2) and agitated for 2.5 hours.  The beads were washed twice 
with 500 µL PBS-T (phosphate-buffered saline + 0.1% Tween), resuspended in 500 µL 
of PBS containing 20 mM dithiothretiol (DTT), and then agitated at room temperature for 
1.5 hours.  The beads were washed three times with 500 µL PBS-T prior to conjugation 
to protein. 
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C.  Synthesis of protein-SMCC conjugates 
In the meantime, both streptavidin and the protein substrate were reacted with 
succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (SMCC).  To make 
PSBCCP-functionalized beads, SMCC was added to 50 µL of PSBCCP solution (20 
mg/mL in PBS) and 50 µL of streptavidin solution (1.5 mg/mL in PBS) to final 
concentrations of 4.8 mg/mL and 0.7 mg/mL, respectively.  The reactions were incubated 
at room temperature for 45 minutes and the protein-SMCC conjugates were purified from 
excess SMCC using size-exclusion chromatography on a NAP-5 (SephadexTM  G-25 
resin, GE Healthcare) column.  The proteins were eluted from the column in 10×100 µL 
fractions in PBS supplemented with 1 mM EDTA.  The four most concentrated fractions 
of PSBCCP-SMCC conjugate were combined with the two most concentrated fractions 
of streptavidin-SMCC.  
To make HP1-AP-functionalized beads, SMCC was added to 120 µL of HP1-AP 
solution (1.0 mg/mL in PBS) and 50 µL of streptavidin (1.5 mg/mL in PBS) to final 
concentrations of 0.2 mg/mL and 0.3 mg/mL, respectively.  Following 45 minutes, the 
reactions were purified on a NAP-5 column as described above for PSBCCP.  The  
HP1-AP-and streptavidin-SMCC conjugates were mixed as described above for 
PSBCCP. 
 
D.  Conjugation of protein-SMCC to thiol-functionalized beads  
The thiol-functionalized beads synthesized in (B) were resuspended in the 
streptavidin-/protein substrate-SMCC mixtures synthesized in (C) and agitated at room 
temperature overnight.  The beads were washed three times with 500 µL of PBS-T and 
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resuspended in 225 µL of PBS-T to make a 1% suspension, assuming a 90% recovery of 
the beads.  This corresponds to 1.6×107 beads/µL, or a concentration of 27 pM. 
 
Synthesis of alkyne conjugation reagents (Figure 7) 
General synthetic methods   
All chemicals were purchased from Sigma-Aldrich or Alfa Aesar and used 
without further purification.  Analytical thin-layer chromatography (TLC) was performed 
using 0.25 mm silica gel 60 F254 plates and visualized with phosphomolybdic acid or 
ultraviolet light.  Flash chromatography was carried out using 70-230 mesh silica gel 
(ICN SiliTech 32-63D).  Solvents for chromatography are described as percent by 
volume.   
Proton nuclear magnetic resonance (1H NMR) spectra were recorded using a 
Varian Mercury 300 spectrometer.  Chemical shifts are reported in delta (δ) units, parts 
per million (ppm) referenced to the deuterochloroform (CDCl3) singlet at 7.27 ppm or the 
deuterated methanol (CD3OD) quintet at 3.31 ppm.  Coupling constants (J) are reported 
in Hertz (Hz).  The following abbreviations for multiplicities are used:  s, singlet; broad 
singlet; t, triplet; dd, doublet of doublets; m, multiplet.  Low resolution electrospray 
ionization mass spectra (ESI-MS) were obtained on an Applied Biosystems 200 QTRAP 
Mass Spectrometer. 
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Biotin-alkyne (BALK) 
Biotin (1.00 g, 4.09 mmol), DCC (1.10 g, 5.34 mmol), and NHS (0.600, 5.22 
mmol) were dissolved in 10 mL of DMSO.  The resulting clear solution was stirred at 
room temperature for two hours, at which time it had become a heterogeneous mixture.  
The precipitated dicyclohexylurea was filtered off and was washed with 2 mL of  
N,N-dimethylformamide (DMF).  The combined filtrate was dried extensively under high 
vacuum to yield a concentrated solution of biotin NHS ester.  To 4 mL of this solution 
was added propargylamine (169 mg, 0.21 mL, 3.07 mmol).  The reaction mixture was 
stirred at room temperature for one hour and then poured into dichloromethane (DCM) 
and water.  The layers were separated and the organic layer was dried over sodium 
sulfate.  Purification on silica (0-10% methanol / ethyl acetate + 0.2% ammonium 
hydroxide) afforded biotin-alkyne (BALK) as an off-white solid.  1H NMR (10% 
CD3OD/CDCl3, 300 MHz):  δ 4.44 (dd, J = 7.4, 4.7, 1H), 4.24 (dd, J = 8.0, 4.4, 1H), 3.91 
(d, J = 2.5, 2H), 3.08 (m, 1H), 2.84 (dd, J = 12.9, 4.95, 1H), 2.65 (d, J = 12.9, 1H), 2.19 
(t, J = 2.6, 1H), 2.13 (t, J = 7.0, 2H), 1.48-1.70 (m, 4H), 1.30-1.40 (m, 2H).  ESI-MS 
(found) 282.30 [M+H]+.  Required for C13H21N3O2S:  282.13. 
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Fluorescein isothiocyanate-alkyne (FITALK) 
To a solution of propargyl amine (26 mg, 32 µL, 0.464 mmol) in 1.4 mL of DMF 
was added a solution of fluorescein isothiocyanate (100 mg, 0.232 mmol) in 1.4 mL of 
DMF.  The reaction was stirred at room temperature for two hours and concentrated.  
Purification on silica gel (10% methanol/dichloromethane) afforded 33 mg (32%) of pure 
FITALK.  1H NMR (CD3OD, 300 MHz):  δ 8.21 (s, 1H), 7.69 (dd, J = 8.3, 1.7, 1H), 7.11 
(d, J = 8.3, 1H), 6.69 (d, J = 2.2, 2H), 6.66 (d, J = 8.5, 2H), 6.56 (dd, J = 8.8, 2.5, 2H), 
5.31 (d, J = 1.4, 1H), 5.22 (d, J = 1.4, 1H), 4.81 (s, 2H), 2.35 (s, 1H).  ESI-MS (found) 
443.16 [M-H]-.  Required for C24H14N2O5S:  443.07. 
 
HO O O
CO2H
HN
O  
Fluoresceinamine-alkyne (FAALK) 
FAALK was synthesized according to the literature procedure26,27.  To a stirring 
solution of fluoresceinamine (150 mg, 0.432 mmol) and 10-undecynoic acid (79 mg, 0.43 
mmol) in 2 mL of pyridine was added 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC) (83 mg, 0.43 mmol).  The resulting solution was stirred overnight at 
room temperature and poured into 15 mL of water.  The pH of the mixture was adjusted 
to pH=1 by the addition of concentrated hydrochloric acid, and the precipitate was 
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collected by filtration.  The isolated solid was further purified on silica gel (5-10% 
methanol/dichloromethane) to yield 73 mg (33%) of FAALK as orange crystals.  1H 
NMR (CD3OD, 300 MHz):  δ 8.36 (d, J = 1.7, 1H), 7.88 (dd, J = 8.3, 1.9, 1H), 7.17 (d,  
J = 8.3, 1H), 6.70 (d, J = 2.2, 2H), 6.65 (d, J = 8.8, 2H), 6.56 (dd, J = 8.7, 2.3, 2H), 2.47 
(t, J = 7.4, 2H), 2.16-2.20 (m, 3H), 1.77 (m, 2H), 1.31-1.54 (m, 10H).  ESI-MS (found) 
510.36 [M-H]-.  Required for C31H27NO6:  510.19. 
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Chapter 6:  Phage display evolution of a peptide substrate for  
yeast biotin ligase and application to two-color  
quantum dot labeling of cell surface proteins  
 
 
The majority of the work described in this chapter has been published in:    
Chen, I., Choi, Y. A., and Ting, A. Y.  Phage display evolution of a peptide substrate for 
yeast biotin ligase and application to two-color quantum dot labeling of cell surface 
proteins.  J. Am. Chem. Soc. 129, 6619-6625 (2007).  Lara Collazo, an undergraduate 
researcher working in the Ting laboratory, assisted in the mutagenesis and protein 
expression experiments for the rational design of a BL2-AP2 pair.  Yoon-Aa Choi cloned 
the yAP fusions to cyan fluorescent protein and heterochromatin protein 1 and 
demonstrated their ATP-dependent biotinylation by Western blot.  Yeast display 
experiments were performed in collaboration with Yoon-Aa Choi, with consultation from 
Shaun Lippow and K. Dane Wittrup.  Two-color imaging experiments on live HeLa cells 
were performed in collaboration with Yoon-Aa Choi.       
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Introduction 
Quantum dots (QDs) are semiconductor nanoparticles that are extremely useful 
for fluorescence imaging of live cells and animals1.  Their intense fluorescence emission, 
complete resistance to photobleaching, and narrow emission spectra make them much 
better probes for single molecule2 and multicolor imaging3 than small molecule dyes.   
QDs, which themselves are about the same size as fluorescent proteins, are often targeted 
to the protein of interest with a three-layer strategy: primary antibody, followed by 
biotinylated secondary antibody, followed by streptavidin-QD (Figure 1A).  This strategy 
has several limitations.  The size of this QD complex (~50 nm) can affect membrane 
protein trafficking by reducing mobility and preventing accessibility to crowded locations 
on the cell surface4.  The linkage between QD and the protein of interest is not permanent 
due to dissociation of the antibody from its antigen.  Furthermore, antibody binding can 
lead to cross-linking of membrane proteins and unintentional triggering of cell signaling 
pathways.  
Mark Howarth of our laboratory developed a novel labeling method that targets 
QDs only to the protein of interest, reduces the size of the QD conjugate, and provides a 
more stable linkage to the protein of interest (Figure 1B)5.  This method makes use of the 
enzyme E. coli biotin ligase (BirA), which catalyzes the sequence-specific and ATP-
dependent transfer of biotin to the lysine sidechain of a 15-amino acid acceptor peptide 
(AP)6.  Following site-specific biotinylation of the AP fusion proteins expressed on the 
cell surface, imaging can be performed using streptavidin conjugates to fluorophores or 
quantum dots5.   This method eliminates the need for bulky antibodies and provides a 
significantly more stable linkage in the form of the biotin-streptavidin binding  
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interaction, which has a Kd of ~10-13 M and an off-rate on the order of days7.  To 
eliminate cross-linking induced by streptavidin, which is a tetramer containing four 
biotin-binding sites, Howarth has also developed a monovalent streptavidin to which QDs 
can be conjugated8. 
Our laboratory has used the biotin ligase technology to target QDs specifically to 
glutamate receptors, neuroligin, and epidermal growth factor receptors expressed on the 
surface of living cells, in order to image their single molecule trafficking behavior5,8.  We 
also found that BirA can accept a ketone analog in place of biotin (Chapters 2 and 3)9,10.  
Site-specific ligation of the ketone to AP fusion proteins allows derivatization with 
Figure 1.  Strategies for targeting QDs to cell surface proteins. (A) The size of GFP is compared with 
unconjugated QD605 and the QD605-streptavidin-secondary antibody-primary antibody complex used 
to label a cell surface protein. (B)  Targeting strategy developed by Howarth, Ting, and co-workers.  An 
AP fusion protein is expressed on the cell surface.  Biotin ligase (BirA) catalyzes the ligation of biotin 
to the AP (purple). Streptavidin-conjugated QDs are added to label the biotinylated surface proteins.  
Biotin-AMP is the activated adenylate ester of biotin, which can be used in place of biotin + ATP for 
the enzymatic biotinylation.  Figure reproduced from reference 5.  
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hydrazide- or hydroxylamine-functionalized biophysical probes (e.g. QDs), bypassing the 
need for bulky streptavidin conjugates.   
To expand the utility of enzymatic protein biotinylation for live cell imaging, we 
sought to discover a new biotin ligase-acceptor peptide pair, which we would call BL2-
AP2.  This new pair would possess specificity and kinetics similar to the original BirA-
AP pair, but it would represent an orthogonal system.  The new BL2 would not recognize 
the original AP, and conversely, BirA would not biotinylate the new AP2 (Figure 2A).  If 
such specificity requirements were met, we envisioned using the BL2-AP2 pair in 
conjunction with BirA-AP to perform site-specific labeling of two different proteins on 
the surface of the same cell as shown in Figure 2B.   
 
 
 
An AP fusion protein and an AP2 fusion protein are co-expressed on the surface 
of the same cell.  In the first labeling step, BirA is used to site-specifically biotinylate the 
AP, followed by detection of the introduced biotin molecules at the cell surface with a 
streptavidin conjugate to a green fluorophore.  Provided that all of the biotin molecules 
introduced by BirA are saturated by the first streptavidin binding step, a second labeling 
step can then be performed using BL2 to biotinylate the AP2 fusions and a streptavidin-
Figure 2.  Two-color labeling enabled by a new orthogonal biotin ligase-acceptor peptide pair.  (A) 
Specificity requirements for two orthogonal biotin ligase-acceptor peptide pairs. (B) Site-specific 
labeling of two different cell surface proteins (an AP fusion and an AP2 fusion), using two orthogonal 
biotin ligase enzymes (BirA and BL2).  Streptavidin (SA)-fluorophore conjugates bind to the site-
specifically introduced biotin molecules.  Biotin-AMP is the activated adenylate ester of biotin, which 
can be used in place of biotin + ATP for the enzymatic biotinylation. 
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red fluorophore conjugate to detect the newly introduced biotin molecules.  We have 
previously shown in pulse-chase labeling experiments that it is straightforward to saturate 
biotin molecules at the cell surface with streptavidin conjugates5.    
Two-color imaging of orthogonal carrier protein and O6-alkylguanine-DNA 
alkyltransferase fusions has previously been demonstrated on yeast cell surfaces11 and 
inside mammalian cells12.  The use of orthogonal peptide tags should be less structurally 
and functionally invasive due to their much smaller size compared to protein tags.  In an 
approach similar to ours, orthogonal substrates for the Sfp and AcpS phosphopantetheinyl 
transferases were recently developed, and the orthogonal enzyme/peptide substrate pairs 
were used for two-color imaging of transferrin and epidermal growth factor receptors in 
fixed mammalian cells13. 
In this chapter, we describe the creation of a new orthogonal biotin ligase-
acceptor peptide pair for protein labeling (BL2-AP2) through two approaches.  In our 
first approach, we designed an AP2 through mutagenesis of the AP, but we failed to 
rationally design a BirA mutant that could restore its biotinylation.  We then adopted the 
converse approach of first identifying a BL2 and discovering a matching AP2 substrate 
through phage display evolution.   Using two generations of selection from 15-mer 
peptide libraries, we discovered a novel substrate for yeast (Saccharomyces cerevisiae) 
biotin ligase (yBL), which we have named the “yeast acceptor peptide” (yAP).  We 
characterized the kinetics of yAP biotinylation and found that the yAP sequence is 
transposable and can be fused to many different proteins.  We demonstrated labeling of 
the yAP with streptavidin-probe conjugates on the surface of living yeast cells and 
mammalian cells. The yBL-yAP system is orthogonal to the BirA-AP pair, and thus we 
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were able to label yAP and AP fusion proteins expressed in the same cell selectively with 
differently colored quantum dots.  Like BirA, yBL is extremely sequence-specific, as 
endogenous proteins on the surface of yeast and HeLa cells are not biotinylated. This new 
methodology expands the scope of biotin ligase labeling to two-color imaging and yeast-
based applications.  It also establishes a general approach to engineer new biotin ligase-
peptide substrate pairs, for multiplexing all applications of site-specific biotinylation.  
The majority of the work in this chapter has been described in a recent publication by 
Chen, Choi, and Ting14. 
 
Results and Discussion 
 
Identification of an AP2 and rational design of a matching BL2  
We considered two possible approaches to developing the new BL2-AP2 pair. 
The first approach was to design an AP2 sequence, and then engineer a matching BL2 
enzyme through rational design or in vitro evolution.  Conversely, we could rationally 
design a BL2 enzyme, and then use in vitro evolution to discover a matching AP2 
substrate.  Although peptide evolution is generally more straightforward than enzyme 
evolution, we initially explored the first approach because at the time it dovetailed with 
our efforts to develop a robust platform for the in vitro evolution of BirA (Chapter 5).  A 
crystal structure of BirA bound to the AP does not exist, so to design an AP2 we assumed 
that mutation of the amino acids surrounding the acceptor lysine would have the greatest 
impact on biotin transfer.  Gln(-1) and Ile(+1) were thus targeted for extensive 
mutagenesis (Figure 3A).  The mutations Glu119Lys and Glu147Lys in biotin carboxyl 
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carrier protein (BCCP), BirA’s only natural substrate, resulted in impaired biotin transfer 
by BirA (especially Glu119Lys).  Thus, we also investigated whether charge reversal at 
Glu(-3) and Glu(+2) could significantly impair recognition by BirA.  With the help of 
Lara Collazo, the AP mutants shown in Figure 3C were constructed by Quikchange™ 
site-directed mutagenesis using the AP-CFP-TM gene as the template (Chapter 3).  This 
enabled us to qualitatively evaluate biotinylation activity by a cell surface biotinylation 
imaging assay.  In separate dishes, the AP mutants were expressed on the surface of 
HeLa cells.  The cells were biotinylated under one fixed set of conditions (1 mM biotin,  
1 mM ATP, 5 mM magnesium chloride, 0.7 µM BirA in Dulbecco’s phosphate-buffered 
saline pH 7.4 (DPBS) for 20 minutes at room temperature) and stained with a 
streptavidin-Alexa 568 conjugate.  Imaging of all samples was then done under the same 
settings.    
Representative results from the imaging assay are shown in Figure 3B.  Through 
imaging of the cyan fluorescent protein (CFP) fluorescence, we verified that all of the 
point mutants showed the same expression level and degrees of cell surface localization.  
The AP mutants were biotinylated to different extents by BirA under the conditions 
employed (Figure 3B and 3C).  Some mutants showed the same degree of labeling as the 
wild-type AP, although the signal from BirA biotinylation of AP saturates after 10 
minutes of reaction5.  Other mutants, such as Gln(-1)Ile, showed depressed biotinylation 
by BirA.  Four Ile(+1) mutants showed no detectable biotinylation by BirA under the 
conditions of this assay.  Because for quantum dot labeling experiments we typically only 
biotinylate the cells for less than five minutes under the same conditions, these four 
mutants are sufficiently unreactive with BirA to serve as AP2 candidates.  Interestingly, 
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we observed that the charge reversal mutations did not impact AP biotinylation the same 
way similar charge-reversal mutations affected BCCP biotinylation. 
 
wt
(++)
Ile(+1)Met
(++)
CFP Alexa
Gln(-1)Ile
(+)
Ile(+1)Asp
(-)
CFP Alexa
G L N D I  F  E A  Q K  I E W  H  E
-3    -2    -1             +1   +2
A
B
AP TMCFP
 
 
AP mutant Biotinylation by BirA   AP mutant Biotinylation by BirA  
wild-type ++  Ile(+1)Thr + 
Ile(+1)Val ++  Gln(-1)Glu + 
Ile(+1)Met ++  Gln(-1)Thr + 
Ile(+1)Leu +  Gln(-1)Ile + 
Ile(+1)Asn –  Glu(-3)Lys ++ 
Ile(+1)Asp –  Glu(-3)Arg ++ 
Ile(+1)Ala –  Glu(+2)Lys ++ 
Ile(+1)Ser –  Glu(+2)Arg ++ 
 
 
 
 
   
Figure 3.  Biotinylation of AP mutants expressed on the cell surface of live HeLa cells using BirA.  (A)  
Residue numbering scheme used for the AP.  (B)  Representative images of cells biotinylated by BirA and 
labeled with streptavidin-Alexa 568, viewed under the CFP (left) and Alexa (right) channels.  The AP 
mutants displayed varying extents of biotinylation by BirA.  Conversion was scored as follows:  (++) similar 
conversion as wild-type AP, (+) similar conversion as the Gln(-1)Ile mutant, and (-) no detectable 
biotinylation under our conditions.  (C)  The complete results are tabulated in this table.    
C 
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 We were particularly interested in the Ile(+1)Ala and Ile(+1)Asp mutants because 
we thought that we could restore biotinylation activity by engineering a complementary 
mutation in BirA.  We made an assumption that Ile(+1) corresponded to Met123 on 
BCCP (the site of biotinylation is Lys122) and used a proposed model of the BirA-BCCP 
interaction (Figure 4A) to identify the residues in BirA that likely interact with Ile(+1) 
(Figure 4B)15.  We hypothesized that the “hole” resulting from mutation of isoleucine to 
the smaller alanine residue could be complemented with a corresponding hydrophobic 
“bump” at residues 150, 174, and 189 of BirA.  Accordingly, we constructed the genes 
for the BirA mutants Pro174Val, Pro174Leu, Ser150Phe, Ser150Ile, Ser150Val, 
Ser150Thr, Val189Phe, and Val189Met.  We also constructed the Asn175Lys and 
Asn174Arg mutants to introduce a favorable electrostatic interaction with the carboxylate 
group of AP Ile(+1)Asp mutant.  
 
A
Val189
Ser150
Asn175
Pro174
B
 
 
Figure 4.  Amino acids on BirA targeted for mutagenesis to restore biotinylation of the AP Ile(+1) 
mutants.  (A) The model of the BirA-BCCP interaction proposed by Weaver et al. (PDB:  1K67, 
reference 15) was used as an approximation of the BirA-AP interaction.  BirA is shown in blue, and 
BCCP is shown in orange.  Biotin is shown in yellow, and the site of BCCP biotinylation, Lys122, is 
shown in green.  We hypothesized that AP Ile(+1) corresponded to Met123 of BCCP (white).  (B)  
Amino acids of BirA (blue) that contain atoms within 4 Å of the Met123 sidechain (white) in the 
proposed model are shown.   
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 With the assistance of Lara Collazo, we expressed and purified each of these 
enzymes from E. coli.  We then tested each mutant for its ability to modify any of the 
four AP2 candidates using the cell surface biotinylation assay.  Unfortunately, we did not 
observe any biotinylation of any of the AP Ile(+1) mutants, even after one hour of the 
enzymatic reaction (data not shown).  To verify that the mutant enzymes were properly 
folded, we assayed each enzyme for biotinylation of synthetic AP by HPLC (Chapters 3 
and 4) using a fixed set of conditions:   1 mM biotin, 1 µM enzyme, 100 µM AP, 4 mM 
ATP, 5 mM magnesium acetate in 50 mM bicine pH 8.3 for one hour at 30 °C.  All of the 
enzymes displayed varying degrees of AP biotinylation activity (Table 1). 
 
BirA mutant Percent conversion to biotinylated AP 
 BirA mutant Percent conversion to biotinylated AP 
Ser150Thr 100 %  Pro174Leu 50% 
Ser150Val < 10%  Asn175Lys 100% 
Ser150Ile < 10%  Asn175Arg 100% 
Ser150Phe < 10%  Val189Met 100% 
Pro174Val 50%  Val189Phe 100% 
 
 
 We realize that since the mutations were introduced along the purported BirA-
BCCP binding interface, it is highly possible that the low AP biotinylation activity of the 
Ser150Ile, Ser150Val, and Ser150Phe mutants result from impaired AP recognition rather 
than improper folding of the enzyme.  Thus, to distinguish between the two scenarios we 
require another independent assay for folding.  Xu and Beckett have reported that the 
intrinsic tryptophan fluorescence of BirA decreases 15% upon binding biotin and almost 
40% upon binding the biotin adenylate ester intermediate (biotin-AMP).  This drop in 
Table 1.  AP biotinylation by the BirA mutants constructed in this study.  Reactions were incubated for 
one hour at 30 °C under the following conditions:  100 µM AP, 1 µM enzyme, 1 mM biotin, 4 mM 
ATP, and 5 mM magnesium acetate in 50 mM bicine pH 8.3.  The reactions were analyzed using 
reverse-phase HPLC.   
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fluorescence can be used to monitor the kinetics of biotin-AMP formation catalyzed by 
BirA16.  Mutant enzymes that catalyze biotin-AMP formation and show low biotin 
transfer activity to the AP are most likely defective in AP recognition, whereas 
improperly folded enzymes most likely would not be able to synthesize the biotin-AMP 
intermediate.  We tried to adapt this assay for use in our lab, but we never consistently 
observed the expected decrease in tryptophan fluorescence upon binding of recycled 
BirA (Chapter 3) to either ligand.  Another possible way to assay for proper folding, 
independent of biotin transfer to the AP, would be to compare the circular dichroism 
spectra of BirA and each of its mutants.     
 As a result of our AP mutagenesis studies, we identified four possible AP2 
candidates, all possessing a mutation at Ile(+1).  We attempted to rationally design 
complementary mutations in BirA using a “bump-hole” strategy or by introducing 
favorable electrostatic interactions.  Since no crystal structure exists showing the 
interaction of BirA and AP, we used the proposed model for the BirA-BCCP interaction 
as an approximation.  While some of our designed mutant enzymes displayed reduced 
ability to catalyze AP biotinylation, none could rescue biotinylation of the AP mutants.  
Because of the lack of available information about AP binding to BirA, a combinatorial 
search for a new BL2-AP2 pair seems to be the most prudent approach.  Given our 
difficulties in developing a reliable platform for the in vitro evolution of BirA (Chapter 
5), we made no attempt to use any of the four identified AP2 candidates to evolve a 
matching BL2 mutant.  
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Identification of BL2 candidates for phage display evolution of AP2 
We now embraced the converse approach of first identifying a BL2 enzyme and 
then evolving an AP2 peptide substrate for it.  Our previous studies suggested that a BirA 
point mutant could serve as the BL2.  By HPLC, the Ser150Val, Ser150Ile, and 
Ser150Phe enzymes all showed significantly impaired biotin transfer to the AP, and we 
confirmed that all of these enzymes showed no detectable biotinylation of AP-CFP-TM 
after 20 minutes of reaction under our standard cell surface biotinylation assay 
conditions.  The impaired ability of the BL2 enzymes to catalyze biotinylation of the AP 
must be a result of defects in AP recognition but not in biotin-AMP synthesis.  We 
hypothesized that this was likely the case for Ser150Ile and Ser150Val because 
Ser150Thr, which has an amino acid substitution similar in size to isoleucine and valine, 
did not show significantly impaired AP biotinylation activity (Table 1).  However, we 
were hesitant to adopt Ser150Ile and Ser150Val as candidates for BL2 due to their 
incomplete orthogonality with the AP and our inability to establish a tryptophan 
fluorescence assay to confirm biotin-AMP formation by these mutants.   
Our laboratory’s explorations of biotin ligase enzymes from different species 
revealed better candidates for BL2 enzymes.  Using HPLC and Western blot assays we 
discovered that S. cerevisiae (yeast), Bacillus subtilis, and Methanococcus jannaschii 
biotin ligases (yBL, bsBL, mjBL) do not biotinylate the AP. (Sarah A. Slavoff and Alice 
Y. Ting, unpublished results).  Peterson and co-workers have also reported that AP fusion 
proteins can be expressed in yeast cells without becoming biotinylated by the endogenous 
yBL17.  These observations are particularly interesting in light of the fact that these three 
enzymes all efficiently biotinylate the BCCP substrate of BirA18,19 (Sarah A. Slavoff and 
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Alice Y. Ting, unpublished results).  This suggests that the AP interacts with the BirA 
active site in a different manner than BCCP.  Like BirA, these other biotin ligases exhibit 
high sequence-specificity, only biotinylating between one and five endogenous protein 
substrates within their respective organisms20,21.   
As candidates for BL2, we preferred yBL, bsBL, and mjBL over the BirA Ser150 
mutants for two primary reasons.  First, they displayed complete orthogonality with the 
AP; we observed no biotinylation of the AP, even with the more sensitive Western blot 
assay.  Furthermore, because it is well known that biotin ligases can biotinylate the 
natural acceptor domains from a wide variety of species22, we can confirm their proper 
folding and ability to catalyze biotin-AMP synthesis by an activity assay on a common 
protein substrate, the P. shermanii transcarboxylase 1.3S subunit (Chapter 5).  A caveat 
to using these enzymes is the observed contamination by endogenous BirA following 
overexpression and purification from E. coli.  We have developed an effective procedure 
to remove or inactivate the contaminating BirA using a rabbit anti-BirA antibody.       
 Starting from yBL, bsBL, and mjBL as our candidate BL2s, we used phage 
display to identify a new AP2 substrate.  The original AP was discovered by in vivo 
panning from a peptide library fused to the lacI DNA-binding protein6, but we decided 
against this method because it is not straightforward to replace the endogenous BirA 
activity with the activity of our candidate BL2s, and in vivo selection does not permit fine 
control over the specific selection conditions.  In general, phage display has been used 
more often to discover new binding partners than catalytic substrates, but precedents exist 
for using this technique to discover new substrates for proteases23, kinases24, and 
transglutaminases25.  In addition, phage display has already been used to identify the 
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minimal BirA recognition elements for the biotin acceptor domains of K. pneumoniae 
oxaloacetate decarboxylase26 and yeast pyruvate carboxylase27. 
To perform the selection, we used the scheme shown in Figure 5.  An AP2 library 
of 15-mer peptides is displayed as a fusion to the pIII coat protein of M13 bacteriophage.  
Because the phage are exposed to endogenous BirA during production in E. coli, the 
scheme permits facile incorporation of a negative selection step.  A fraction of the phage 
that display peptide substrates for BirA will emerge from the bacteria already “pre-
biotinylated,” and these phage can be removed with streptavidin-coated beads.  
Thereafter, the remaining phage are treated with the BL2 enzyme, and the biotinylated 
phage are isolated using streptavidin-coated beads, and amplified in E. coli for another 
round of selection. 
1. Streptavidin beads to remove
pre-biotinylated phage
3. Streptavidin beads to
retain biotinylated phage 
2. BL2, biotin, ATP
4. Amplify in 
E. coli ER2738
AP2 library
B
B
B
Phage B
+
+
Negative
Selection
Positive
Selection
 
 
 
Figure 5.  Phage display selection scheme. The AP2 library (blue) is fused to the pIII coat protein. B 
represents biotin. After phage production in E. coli strain ER2738, a fraction of the phage pool is pre-
biotinylated by endogenous BirA. In step 1 of the selection, streptavidin-coated beads are used to remove 
these pre-biotinylated phage (negative selection). In step 2, the remaining phage are treated with the BL2 
enzyme. In step 3, streptavidin-coated beads are used to isolate the biotinylated phage from this mixture 
(positive selection). Finally (step 4), the recovered biotinylated phage are amplified in ER2738 for another 
round of selection.  Figure reproduced from reference 14.
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Model selections give 2000-fold enrichment in a single round of selection.  
Before beginning selections with peptide libraries, we wished to determine the 
enrichment factor that could be obtained using our selection protocol.  We prepared two 
phage constructs: an AP-phage displaying the AP sequence28, and an Ala-phage 
displaying an AP mutant where the acceptor lysine is mutated to alanine.  To perform the 
model selection, we combined the AP-phage and Ala-phage in a 1:100 ratio and then 
implemented steps 2 to 4 of the selection scheme shown in Figure 5, using 0.65 nM BirA 
enzyme.  To compare the composition of the phage pools before and after selection, we 
isolated and sequenced the single-stranded DNA packaged within the phage.  Figure 6 
shows that in the initial mixture, Ala-phage dominates and AP-phage is undetectable.  
After selection, however, the AP-phage dominates the mixture by about 20:1.  Thus, we 
estimate an enrichment factor of ~2000 in a single round of selection. 
 
 
Figure 6.  Results of model selection. A 1:100 mixture of AP phage to Ala mutant phage was enriched 
>2000-fold in a single round of selection. Sequence chromatograms of the phage mixtures 
(complementary strand) before and after selection are shown. We introduced a silent mutation (starred 
A) into the Ala phage sequence. While AP phage was undetectable in the initial mixture (arrow), it is 
the predominant species after selection (>20:1).  The enrichment factor was calculated by dividing the 
AP/Ala ratio after selection by the AP/Ala ratio before selection.  Figure reproduced from reference 14. 
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Design of the AP2 library for first-generation phage display selections.  
Having verified the ability to enrich for biotinylatable peptide substrates using our 
selection scheme, we next turned our attention to designing an AP2 library.  All 
characterized biotin ligase enzymes biotinylate between one and five endogenous protein 
substrates within their respective organisms29.  These biotin acceptor proteins exhibit 
some degree of sequence overlap, especially in the residues that immediately surround 
the lysine biotinylation site30  Structures of three of these acceptor proteins suggest a 
conserved tertiary structure, in which the lysine biotinylation site is presented at the tip of 
a tight hairpin loop31-33  It is difficult to recapitulate such a three-dimensional structure in 
a peptide sequence, and it is probably for this reason that the AP most likely interacts 
with the BirA active site in a different manner than BCCP does.  
To design an AP2 library to be used in selections with our three BL2 candidates, 
we aligned the sequences of their natural biotin acceptor proteins (Figure 7).  Aside from 
the lysine biotinylation site, five residues flanking the lysine appear to be highly 
conserved.  We noticed that these residues are well-conserved in the biotin ligase 
substrate proteins of other organisms as well.  Thus, in a manner analogous to Schatz6, 
we fixed these five positions and the lysine biotinylation site, and randomized the 
remaining positions of the 15-mer by saturation mutagenesis to create an AP2 library of 
diversity 4.2×107 (Figure 7).  Because our library also resembles the sequence of BirA’s 
BCCP substrate, we recognized the importance of performing negative selections to 
remove any sequences still recognized by BirA.  
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First generation selections produce a conserved M(T/E)F motif 
In our first attempts at selection, we suffered setbacks due to inadvertent 
amplification of AP phage.  Although the AP was only a minor contaminant (< 0.01%) in 
the construction of the AP2 library, incomplete removal during the negative selection 
step, coupled with the low extent of biotinylation of desired AP2 sequences under the 
selection conditions used (0.65 nM of BL2 enzymes), may have led to the complete 
dominance of AP-phage by the third round of selection.  In our next attempt, we made 
two key changes in the protocol to avoid unintentional enrichment of AP-phage.  First, to 
increase the biotinylation extent of desired AP2 substrates, the BL2 enzyme 
concentration was increased 150-fold to 100 nM.  Second, for the first two rounds of 
selection, the phage were produced in the E. coli strain BM4092F′ in biotin-depleted 
media.  This strain lacks the ability to biosynthesize biotin, and it expresses a mutant of 
BirA with higher Km value for biotin34.  Thus, even phage that display the AP dol not 
become pre-biotinylated when produced in BM4092F′.  For the third and fourth rounds, 
we returned to the original E. coli ER2738 strain and performed negative selections to 
remove substrates of BirA.  
Figure 7.  Design of the first-generation AP2 library.  Sequences of the AP and biotin ligase substrate 
proteins from four different species. The lysine biotinylation sites are underlined. BCCP is the biotin 
carboxyl carrier protein; ACC is acetyl-CoA carboxylase; ODC is oxaloacetate decarboxylase; and PC1 
is pyruvate carboxylase 1. Red positions are completely randomized by saturation mutagenesis.  Figure 
modified from reference 14. 
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With these two modifications in the selection protocol, we observed strikingly 
different results when we re-selected from the same library using a mixture of yBL, 
bsBL, and mjBL enzymes (100 nM of each).  Using a phage ELISA (enzyme-linked 
immunosorbent assay), we assayed the recovered phage pools from each round of 
selection for biotinylation by both the BL2 mixture and BirA.   
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We observed a steady increase in the extent of biotinylation by the BL2 mixture, but no 
increase in the biotinylation extent by BirA (Figure 8A).  Deconvolution of the mixture 
Figure 8.  Results of the first generation selections.  (A) ELISAs showing the biotinylation of 
recovered phage from different rounds of selection by BirA, and by a BL2 mix consisting of yBL, 
bsBL, and mjBL.  For each reaction, 1×1011 pfu phage were incubated with 100 nM of each enzyme at 
30 °C for one hour.  (B)  Deconvolution of the enzyme mixture revealed that yBL was solely 
responsible for the BL2 activity towards phage recovered from the third round.  For each reaction, 
1×1011 pfu phage from the third round of selection were incubated with 100 nM of each enzyme at  
30 °C for one hour.  Measurements for three phage dilutions are shown.  (C) Sequences of eight clones 
isolated from the first generation selections (clone nomenclature: generation-round-clone#).  The 
M(T/E)F motif observed in all of these clones is highlighted and the lysine biotinylation site is 
underlined.  Figure reproduced from reference 14. 
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revealed that yBL was solely responsible for the biotinylation activity (Figure 8B).  
Interestingly, we did not observe any enrichment of mjBL substrates, even though the 
fixed amino acids in the AP2 library exactly match those of mjBL’s natural protein 
substrate (Figure 7). 
Evaluating individual clones from the third and fourth rounds by sequencing and 
phage ELISA revealed that all peptides biotinylated by yBL contained an M(T/E)F motif 
immediately following the lysine (Figure 8C).  The enrichment of this motif is 
remarkable because the two amino acids following the methionine were completely 
randomized in the design of the initial library, suggesting that these two amino acids are 
crucial for peptide recognition by yBL.  It was also striking that the isolated yBL-active 
peptides bore little resemblance to the natural acceptor domains in yeast, or to the AP, 
suggesting that these substrates may all bind to yBL in a different manner.  
Unfortunately, no crystal structure of yBL is yet available to provide insight into the 
mechanism of peptide or protein substrate recognition.  By phage ELISA the best peptide 
isolated from the first generation selections was biotinylated by yBL roughly 90-fold 
worse than the AP was biotinylated by BirA, under identical conditions.  Thus, we sought 
to improve the kinetics of this peptide by constructing a new library and performing a 
second generation set of selections.   
 
Second generation selections with an improved AP2.2 library  
We designed a new library for the second generation selections that was biased to 
include the MTF motif that emerged from the first generation selections.  We completely 
randomized seven positions by saturation mutagenesis.  Instead of rigidly fixing the 
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residues at the remaining positions, we decided to mutate each of them (besides the lysine 
biotinylation site, which remained completely fixed) so that 34% of the sequences would 
contain the designed amino acid, while the remaining 66% would contain any of the other 
19 amino acids or stop codons (Figure 9).  This design enabled us to explore sequence 
space previously unavailable to us in the first generation selections, and yet the designed 
amino acid was represented in >10-fold excess over any other amino acid at the indicated 
positions. 
 
 
 
We constructed two libraries for the second generation selection: a smaller library 
of diversity 1.2×108 and a larger library of diversity 7.1×108.  In one set of selections 
(generation 2) we performed four rounds of selection with the smaller library using ten-
fold less yBL (10 nM) in order to isolate peptides with improved kinetics.  In another set 
of selections (generation 2′), we performed six rounds of selection with the larger library, 
progressively decreasing the yBL concentration from 100 nM to 0.1 nM over the rounds 
of selection.  In the first two rounds, it was necessary again to produce the phage in the 
BM4092F′ strain to minimize pre-biotinylation by BirA and prevent enrichment of 
peptides that were better substrates for BirA than yBL.  As in the first generation 
selections, we observed a steady increase in the biotinylation extent of recovered phage 
Figure 9.  Design of the second-generation AP2.2 library.  The sequences of the AP, biotin ligase 
substrate proteins from four different species, and the first-generation AP2 library are shown for 
comparison.  The lysine biotinylation sites are underlined. Red positions are completely randomized, 
while blue positions are partially randomized (~34% the indicated amino acid).  Figure modified from 
reference 14. 
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after yBL treatment but not after treatment with BirA (results for generation 2′ are shown 
in Figure 10A).  The extent of biotinylation by yBL did not increase beyond the fourth 
round, as streptavidin-binding peptides (identifiable by the HPQ tripeptide motif35) began 
to dominate the selection.  We also observed that the extent of biotinylation by yBL was 
higher for the second generation phage pools than from the first (Figure 10A), suggesting 
that we had selected for more kinetically competent peptides by lowering the yBL 
concentration during selection. 
 
 
 
Figure 10.  Results from the second generation selections.  (A) ELISAs showing the extent of 
biotinylation by BirA and yBL of recovered phage from different rounds of selection. For each 
reaction, 1×1011 pfu phage were incubated with 10 nM enzyme at 30 °C for one hour. (B) Ten of the 
best clones isolated from different rounds of selection (clone nomenclature: generation-round- 
clone #). The MTF motif observed in all clones is highlighted. The clones span a twenty-fold window 
of activity towards yBL, by phage ELISA.  The top clone was named “yeast acceptor peptide” (yAP) 
and characterized further.  Figure reproduced from reference 14. 
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Sequences of best clones and identification of the yAP (yeast acceptor peptide).   
Figure 10B shows the sequences of the best peptides isolated from both of the 
second generation selections (ranked in order of activity towards yBL).  The best peptide 
from the first generation selections is also shown for comparison.  Despite randomization 
in the design of the second generation library, the AMKMTF motif re-emerged largely 
intact, although some of the best peptides possessed M→F mutations in the position 
preceding the lysine.  Again, KMTF emerged as an immutable sequence shared by all of 
the substrates.  By contrast, there was less preference for the original VL motif, 
particularly in the best peptides.  We did not notice any pattern to the amino acid 
preferences at either end of the 15-mer, other than the presence of a large number of polar 
residues.  By phage ELISA, the best peptide we isolated was biotinylated by yBL nine-
fold worse than the AP was biotinylated by BirA, under identical conditions.  This 
represents a ten-fold improvement over the best peptide isolated from the first generation 
selection.  We named this sequence the “yeast acceptor peptide” (yAP), and all 
subsequent characterizations were performed with this peptide.   
 
Characterization of yAP kinetics and transposability 
We fused the yAP sequence to the N- and C-terminal ends of two different 
proteins, cyan fluorescent protein (CFP) and heterochromatin protein 1 (HP1), and tested 
whether it could be biotinylated by yBL in these different contexts.  Yoon-Aa Choi 
demonstrated ATP-dependent biotinylation of both CFP and HP1 fusions by Western blot 
with a streptavidin-horseradish peroxidase conjugate (Figure 11A).  We also compared 
the biotinylation efficiency of all four fusion proteins by a [3H]-biotin incorporation 
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assay.  The yAP is preferentially biotinylated at the C-terminus of CFP, while it is 
preferred at the N-terminus of HP1 (Figure 11B).  Thus, yAP biotinylation by yBL does 
exhibit some context-dependence, but the yAP sequence is recognized by yBL at both 
ends of fusion proteins. 
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 We measured the biotinylation kinetics of one of the fusion proteins, yAP-HP1, 
using the [3H]-biotin incorporation assay (Figure 12).  We determined a kcat of 0.10 ± 
0.01 min-1 and a Km of 130 ± 25 µM, which gives a catalytic efficiency about 780-fold 
lower than that of the BirA-AP pair36.  The discrepancy between yAP and AP 
biotinylation is larger than predicted by phage ELISA, but this may reflect the different 
kinetic behaviors observed under single turnover and multiple turnover conditions.  The 
Figure 11.  Biotinylation of yAP fusion proteins. (A) N- and C-terminal yAP fusions to CFP and HP1 
were biotinylated with yBL and analyzed by blotting with streptavidin-horse radish peroxidase (HRP) 
conjugate. Coomassie staining confirms equal loading of protein.  (B) yBL biotinylation of four 
different yAP fusion proteins were compared using the [3H]-biotin incorporation assay. Reactions 
containing 12 µM yAP fusion protein and 1 µM yBL were incubated for three hours at room 
temperature. Measurements were performed in triplicate (error bars, std).  Figure reproduced from 
reference 14. 
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inferiority of the current yAP is largely due to a poor kcat, which reflects the limitations of 
our phage display system for selecting for multiple turnover substrates.   
 
 
 
Orthogonality of the yBL-yAP pair  
We tested the orthogonality of the new yBL-yAP pair by biotinylating yAP and 
AP fusion proteins displayed on the surfaces of phage and yeast cells.  First, we 
demonstrated that phage displaying the yAP are not biotinylated by BirA, and conversely 
that phage displaying the AP are not biotinylated by yBL (Figure 13).   
Figure 12.  Kinetics of yAP biotinylation. The Michaelis-Menten curve shows the initial rates of 
biotinylation of a yAP-HP1 fusion protein by yBL, as a function of yAP-HP1 concentration. 
Measurements of initial rates at each concentration were performed in triplicate (error bars, std).  Figure 
reproduced from reference 14. 
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Next, Yoon-Aa Choi performed the same set of experiments on yAP and AP fusions to 
the Aga2p mating protein of yeast37, which are expressed at much higher levels (about 
10,000-fold) than the pIII fusions on phage (Figure 14A).  When yeast cells displaying 
the yAP or AP were biotinylated, stained with streptavidin-phycoerythrin, and analyzed 
by flow cytometry, we observed the presence of a highly fluorescent population only 
when the yAP fusions were biotinylated by yBL and the AP fusions were biotinylated by 
BirA (Figure 14B).  By staining the myc-tag of each construct, we verified that both 
fusion proteins were displayed at the same levels on yeast cell surfaces (Figure 14D), 
indicating that the observed orthogonality was not due to diminished availability of either 
peptide.  We also observed that yBL biotinylation was site-specific for the lysine of the 
yAP (Figure 14C). 
     
Figure 13.  Phage ELISA demonstrating the orthogonality of the yBL-yAP pair compared to the BirA-AP 
pair.  A total of 1.8×1010 yAP-phage or AP-phage were incubated with 10 nM enzyme (BirA or yBL) at 
30 °C for one hour. Measurements for three phage dilutions are shown.  Figure reproduced from reference 
14. 
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Application to two-color quantum dot labeling on live cells 
We then demonstrated that the new orthogonal pair enables two-color imaging of 
two distinct mammalian cell surface proteins when used in conjunction with BirA-AP.  
First, we created a yAP-YFP-TM construct where we fused the yAP and the yellow 
fluorescent protein (YFP) marker to the extracellular side of the transmembrane helix 
(TM) of the platelet-derived growth factor receptor (Figure 15).  We then biotinylated 
human HeLa fibroblasts transfected with the yAP-YFP-TM construct with yBL and 
Figure 14.  Orthogonal labeling on yeast cell surface.  (A) Constructs used for peptide display on 
yeast surface. The Aga2p fusions were anchored to the yeast cell surface via disulfide bonds to the 
Aga1p protein.  (B) Yeast cells expressing the yAP or AP on their surface were biotinylated with 
either yBL or BirA. After staining with streptavidin-phycoerythrin conjugate, yeast cells were 
analyzed by flow cytometry. The histograms show the number of cells (y-axis) counted at different 
fluorescence intensities (FL2, x-axis).  (C) The alanine mutant of yAP (yAla) was used as a negative 
control.  The fluorescence histogram is shown after treament with yBL as in (B).  (D) To verify 
similar levels of surface expression, the yeast cells were stained with an anti-myc antibody, followed 
by anti-mouse antibody conjugated to phycoerythrin.  Typically, 20-25% of the yeast cells did not 
display any Aga2p fusion, and thus did not become labeled (*).  Figure reproduced from reference 14.
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observed that the labeling with a streptavidin-QD conjugate was specific for the 
transfected cells (Figure 15).  Negative controls showed that the biotinylation was ATP-
dependent and site-specific for the lysine of the yAP (Figure 15).  Thus, yBL exhibits the 
same high degree of specificity for the yAP that BirA exhibits for the AP.  
We next performed two-color labeling on HeLa cells.  HeLa cells transfected with 
the yAP-YFP-TM plasmid were plated in the same dish together with HeLa cells stably 
expressing the AP-CFP-TM construct5,9.  The cells were biotinylated with yBL for one 
hour at 32 °C, then labeled with streptavidin-QD655.  Next, the cells were biotinylated 
with BirA for four minutes at room temperature and labeled with streptavidin-QD565.  
YFP + DIC QD655
-ATP
negative
control
yAla
negative
control
yAP TMYFP QD655
 
 
Figure 15.  Site-specific biotinylation of yAP expressed on the surface of live HeLa cells.  HeLa 
expressing the yAP-YFP-TM construct were biotinylated with yBL for one hour at 32 °C and 
detected by staining with streptavidin-QD655 for five minutes.  Negative controls with ATP omitted, 
or yAP-YFP-TM replaced by its yAla-YFP-TM point mutant (lysine biotinylation site mutated to 
alanine), are shown.  YFP images were merged and overlaid with the differential interference contrast 
(DIC) image.  Figure reproduced from reference 14. 
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Figure 16 shows that yAP-displaying cells were labeled only with QD655, and the AP 
cells were selectively labeled with QD565.  This demonstrates that the orthogonality of 
the yBL-yAP pair is also preserved on the mammalian cell surface. 
AP and yAP fusion proteins could also be selectively labeled when co-expressed 
in the same cell.  In the same culture dish we plated together HeLa expressing only the 
yAP, HeLa expressing only the AP, and HeLa expressing both the yAP and AP.  We used 
yBL biotinylation to selectively label the yAP fusion proteins with QD655.  Then BirA 
biotinylation was used to target QD565 to the AP fusion proteins.  Figure 17 shows that 
cells co-expressing AP and yAP (white arrows) exhibit both QD655 and QD565 staining. 
Neighboring cells expressing only AP or only yAP exhibit single-color QD staining.   
  
Figure 16.  Selective labeling of live HeLa cells expressing yAP or AP fusion proteins (domain 
structures shown at top) with quantum dots. First, yAP-expressing cells (indicated by YFP 
fluorescence) were selectively labeled with streptavidin-QD655 conjugate, using yBL biotinylation. 
Then, AP-expressing cells (indicated by CFP fluorescence) in the same dish were labeled with 
streptavidin-QD565 conjugate, using BirA biotinylation. CFP and YFP images were merged and 
overlaid with the DIC image.  Figure reproduced from reference 14. 
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Conclusions 
We have evolved a new peptide substrate for yeast biotin ligase, called the yAP. 
Our first set of phage display selections identified an M(T/E)F motif which appeared to 
be crucial for yBL recognition.  In the second set of phage display selections using a 
more focused library, we isolated peptides with ten-fold improved biotinylation kinetics 
by yBL.  Our yAP peptide is only the second peptide substrate ever reported for a biotin 
ligase.  Our phage display approach is more general than the lacI repressor panning 
method previously used to find the AP6 and should enable the engineering of more 
orthogonal biotin ligase-peptide substrate pairs. 
We showed that the yAP sequence could be recognized and biotinylated by yBL 
when fused to the N-terminus, C-terminus, or an internal position of a variety of 
recombinant proteins.  yBL is extremely specific for the yAP, as endogenous proteins on 
the surface of yeast and HeLa mammalian cells were not biotinylated.  We measured the 
Figure 17.  Selective labeling of live HeLa cells co-expressing yAP and AP fusion proteins.  HeLa 
expressing the yAP-YFP-TM construct shown in Figure 16, the AP-CFP-TM construct shown in 
Figure 16, or both constructs simultaneously (white arrows) were plated together and labeled as in 
Figure 16.  Figure reproduced from reference 14. 
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kcat and Km for a yAP-HP1 fusion protein, and determined a catalytic efficiency of  
13 M-1 s-1, approximately 780-fold lower than that of the BirA-AP pair. 
As expected based on our choice of a BL2 enzyme, and on the implementation of 
negative selections, the yAP-yBL pair was orthogonal to the BirA-AP pair.  We 
demonstrated the lack of cross-reactivity between yBL and the AP, and BirA and the 
yAP, using phage ELISA and a yeast cell surface display assay.  The orthogonality of 
these two pairs allowed us to selectively target quantum dots to HeLa cells co-expressing 
yAP and AP fusion proteins in the same cell.  
 The relatively poor kcat of our yAP reflects the limitations of phage display, where 
it is impossible to discriminate between high-turnover peptide substrates and low-
turnover substrates.  We confirmed this limitation by performing a model selection 
attempting to enrich for the yAP sequence over the sequence of the 2-3-5 peptide (Figure 
10B), which is biotinylated by yBL about ten-fold worse than the yAP.  When we 
performed the model selection on a 1:20 mixture of yAP-phage to 2-3-5-peptide-phage, 
we observed no enrichment, suggesting that our selection and product capture schemes 
did not provide the necessary dynamic range to discriminate between these two substrates 
for yBL.  On the other hand, yeast cell surface display37, in which thousands of copies of 
each peptide are displayed on each cell, would allow for highly biotinylated yeast to be 
separated from moderately biotinylated yeast by fluorescence-activated cell sorting 
(FACS).  Yoon-Aa Choi confirmed the ability of yeast display and FACS to provide this 
degree of discrimination, as she observed 100-fold enrichment of the AP in a model 
selection performed on a mixture of yeast displaying the AP and yeast displaying the AP 
Gln(-1)Glu mutant (Yoon-Aa Choi and Alice Y. Ting, unpublished results).  The 
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adoption of this evolution platform should provide access to yAP sequences with 
improved kinetics.  
Despite sampling only a tiny fraction (~0.02%) of the theoretical diversity of the 
AP2 and AP2.2 libraries, we were still able to isolate a yAP that was kinetically 
competent enough for our cell labeling experiments.  The designs of the AP2 and AP2.2 
libraries, which incorporated features that we thought a yeast acceptor peptide should 
possess, were probably critical to our success.  Because of the limitations in library size 
imposed by transformation into bacteria (or yeast), it is important that the initial library is 
already highly enriched in peptides that are substrates for yBL.  As demonstrated here, 
structure-activity relationships gleaned from previous rounds of selection are helpful 
ways to reduce the theoretical diversity for next generation library designs.  In the 
absence of crystallographic data, an alanine scan at each position of the yAP (besides the 
acceptor lysine) may also be helpful to quickly identify key determinants of yAP 
recognition by yBL.  Investigating new library designs will also be important to improve 
the properties of the yAP.  The AP2 and AP2.2 libraries used here were arbitrarily 
designed to resemble the AP.  It may be beneficial to move the lysine biotinylation site to 
different positions along the 15-mer.  Investigating different lengths of yAP may also be 
helpful; the length of the yAP was arbitrarily designed to match that of the AP.  We have 
shown that the yAP can be truncated by three N-terminal residues without loss of 
recognition by yBL, at least in the context of fusion to phage coat protein pIII.  In 
addition, because truncation of the AP by more than one residue at either end greatly 
reduced the value for kcat36, slightly longer peptide libraries may result in improved yAP 
biotinylation rates.   
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We showed that improved peptide substrates can be obtained through strategic 
adjusting of the kinetics of the yBL biotinylation reaction used for each round of 
selection.  By successively reducing the concentration of yBL used in each round of 
selection, we were able to obtain more kinetically competent peptides in the second 
generation selections.  Although we did not investigate this in our own selections, the 
amount of input phage (or yeast) can also be successively decreased to reduce the 
effective concentration of the peptides.  This strategy, which was implemented by Yin, 
Walsh, and co-workers13, may be particularly effective in improving the Km value of the 
yAP. 
Previous efforts to truncate the natural biotin acceptor proteins have led to 
minimal domains 70-80 amino acids in length22, because biotin ligases recognize a stably 
folded structure.  The three-dimensional structure of this fold is likely to be highly 
evolutionarily conserved, given the ability of biotin ligases from different species to 
recognize acceptor domains from other organisms22  The fact that the AP and yAP are 
substrates only for their respective biotin ligases suggests that these peptides bind to their 
enzymes in a different mode than the natural acceptor protein substrates.  While we failed 
to create a BL2-AP2 through rational design, we discovered several mutations in BirA 
and AP that severely hampered the biotin transfer reaction.  We initiated collaborations 
with the protein crystallography laboratory of Cathy Drennan at MIT to eventually 
provide a structural basis for these observations, as well as to understand the critical 
nature of the MTF motif observed in our yAP selections.   
Quantum dots are extremely useful probes for single-molecule imaging in living 
cells. The yBL-yAP technology, in conjunction with BirA-AP, can be used to image and 
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study the trafficking and localization of two different cellular proteins at once.  This can 
be used to investigate, for example, how different isoforms of a particular protein (e.g., 
neuroligin) traffic to excitatory versus inhibitory synapses during development, or how 
two different receptors diverge in the endosomal pathway after internalization (e.g., 
transferrin receptor and epidermal growth factor receptor). 
In addition to two-color imaging applications, yAP technology should also be 
useful for protein detection, labeling, and purification, especially in S. cerevisiae cells, 
where it may be possible to rely upon endogenous yBL activity.  In many cases, 
expression of recombinant proteins in yeast is superior to expression in E. coli, due to the 
opportunities for glycosylation, disulfide bond formation, and folding/assembly of multi-
domain complexes.  We are currently working on demonstrating the in vivo pre-
biotinylation of yAP fusion proteins expressed in yeast.  With this successful 
demonstration, we envision that the yAP can also make a significant impact in yeast cell 
biology and the production of eukaryotic proteins. 
 
Experimental 
 
Methods for rational design of BL2-AP2 
General DNA and protein methods 
The AP mutants were constructed with Quikchange™ site-directed mutagenesis 
using the pDisplay-AP-CFP-TM plasmid as the template (Chapter 3).  The genes for all 
BirA mutants were also constructed by Quikchange™ site-directed mutagenesis using the 
pBTac2-BirA plasmid as the template.  The enzymes were expressed and purified from 
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E. coli JM109 as described in Chapter 3.  Biotinylation of the synthetic AP peptide was 
assessed using the HPLC assay described in Chapters 3 and 4.  For the sequences of all 
constructs, please see the Supporting Electronic Information.   
 
Cell surface BirA biotinylation assay for evaluating AP mutants (Figure 3) 
HeLa were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37 °C under 
5% CO2.  HeLa at 70-80% confluency in a 10 cm2 dish were transfected with 1 µg of the 
plasmid for AP-CFP-TM or its point mutant using 4 µL of Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions.  After 24 hours, the cells were 
rinsed once with DPBS and then biotinylated for 20 minutes at room temperature with  
1 mM biotin, 1 mM ATP, 0.7 µM BirA, and 5 mM magnesium chloride in Dulbecco’s 
phosphate-buffered saline pH 7.4 (DPBS).  Following biotinylation, the cells were rinsed 
with DPBS and then labeled with streptavidin-Alexa 568 (1:300 dilution in DPBS 
containing 1% dialyzed bovine serum albumin (dBSA), Molecular Probes) for ten 
minutes at room temperature.  The cells were washed three times with DPBS before 
imaging on a Zeiss Axiovert 200M inverted epifluorescence microscope using a 40× oil-
immersion lens.  CFP (420DF20 excitation, 450DRLP dichroic, 475DF40 emission), 
Alexa 568 (560DF20 excitation, 585DRLP dichroic, 605DF30 emission), and DIC 
images (630DF10 emission) were collected and analyzed using OpenLab software 
(Improvision).  Acquisition time for all images was 500 milliseconds. 
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Yeast biotin ligase methods 
Expression and purification of yeast biotin ligase 
The pET16b plasmid containing the gene for yeast biotin ligase was a kind gift 
from J.C. Wallace (University of Adelaide, Australia). Yeast biotin ligase (yBL) was 
expressed in E. coli BL21(λDE3) pLysS according to the literature procedure18.  The 
cells were lysed by resuspension in bacterial protein extraction reagent (B-PER, Pierce) 
supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF), protease inhibitor 
cocktail (Calbiochem), and DNase I (Roche).  The clarified lysate was purified by nickel-
nitrilotriacetic acid (Ni-NTA) chromatography.  Fractions containing the enzyme were 
consolidated and dialyzed against storage buffer (50 mM Tris·HCl pH 8.0, 1 mM 
ethylenediamine tetraacetic acid (EDTA), 0.1 mM dithiothreitol (DTT), 5% glycerol).  
Because of the known toxicity of Tris to mammalian cells, the yBL used for cellular 
labeling was dialyzed against 0.75× DPBS supplemented with 1 mM EDTA, 0.1 mM 
DTT, and 5% glycerol.   
 
Removal or inactivation of contaminating BirA 
During the course of our orthogonality experiments, we discovered that our stocks 
of yBL were contaminated with endogenous BirA from the host E. coli, and that the 
amount of contamination varied widely from batch to batch, greatly affecting the 
reproducibility of our data.  Further fractionation of yBL on a Q-Sepharose anion-
exchange column did not completely remove the contaminating BirA.  We eventually 
found a reliable method to remove BirA by using a combination of rabbit anti-BirA 
antibody and anti-rabbit antibody-coated agarose beads.  Briefly, 8 µL of anti-BirA 
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antibody (supplied as serum, 21st Century Biochemicals, Marlboro, MA) was added to 
3.2 µL of agarose immobilized anti-Rabbit antibody (Rockland).  The suspension was 
incubated at 4 °C for one hour, then the agarose beads were pelleted by centrifugation, 
and the supernatant was removed.  The beads were resuspended in a solution containing 
seven nanomoles of yBL and incubated at 4 °C for one hour. The beads were pelleted and 
the supernatant containing yBL was collected.  Alternatively, the anti-BirA antibody 
could be added directly to the yBL stock solution in a 1:100 ratio to inhibit BirA activity 
without affecting the activity of yBL. 
 
Methods for phage display selections 
General phage methods 
M13KE bacteriophage were propagated, purified, and titered according to the 
manufacturer’s instructions (included in the Supporting Electronic Information) for the 
Ph.D.-12TM Phage Display Peptide Library Kit (New England Biolabs).  E. coli strains 
used for phage amplification were ER2738 (New England Biolabs), TOP10F′ 
(Invitrogen), and BM4092F′.  BM4092F′ was derived from BM409234 (a kind gift from 
J.E. Cronan, Jr., University of Illinois at Urbana-Champaign) by bacterial conjugation 
with ER2738.   
Phage were precipitated by the addition of ¼ volume of PEG solution (20% 
polyethylene glycol 8000 containing 2.5 M NaCl), incubation on ice for at least ten 
minutes, and centrifugation at 13,200 rpm for ten minutes at 4 °C.   
Single-stranded DNA for sequencing was isolated also according to the 
instructions for the Ph.D.-12TM Phage Display Peptide Library Kit.  Double-stranded 
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replicative form DNA (for M13KE vector digestion) was isolated from phage-infected 
ER2738 using Qiaprep spin columns (Qiagen) and quantified by comparison to λ-HindIII 
digest (New England Biolabs) after agarose gel electrophoresis.  
 
General phage ELISA protocol 
Individual wells of 96-well polystyrene plates or polystyrene Microlon 200 plates 
(Greiner Bio-One) were coated with 100 µL of streptavidin in 100 mM sodium 
bicarbonate pH 8.6 (10 µg/mL for polystyrene wells, 5 µg/mL for polystyrene Microlon 
200 wells) for two hours at room temperature.  Then, each well was blocked with 300 µL 
blocking buffer (BB, 3% bovine serum albumin (BSA) in Tris-buffered saline (TBS) 
supplemented with 10 mM EDTA) for two hours at room temperature.  The coated wells 
were rinsed twice with BB immediately before phage capture. Following a biotinylation 
reaction (see below), phage were precipitated three times with PEG to remove excess 
biotin before redissolving in BB to a final concentration of 8.3×1011 pfu/mL.  Serial 
dilutions of the phage in BB were then applied to the blocked streptavidin-coated wells 
for one hour.  The number of input phage ranged from 1.1×108 to 2.8×1010 pfu when 
using polystyrene plates or 1.3×106 to 3.3×108 pfu when using polystyrene Microlon 200 
plates.  The wells were incubated for four minutes with 100 µM biotin to remove 
streptavidin-binding peptides, washed eight times with TBS + 0.1% Tween (TBS-T) and 
three times with BB.  Then, 100 µL of horseradish peroxidase (HRP)-conjugated anti-
M13 antibody (Pharmacia) solution (1:5000 dilution in BB) was applied to each well for 
one hour.  The wells were washed three times with TBS-T and three times with TBS 
before developing with o-phenylenediamine solution (0.5-1.0 mg/mL in 1× Stable 
Peroxide Substrate Buffer (Pierce) or citrate phosphate buffer pH 5.0 containing 0.03% 
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v/v hydrogen peroxide). The absorbance at 492 nm was recorded following addition of 
2.5M sulfuric acid to quench the HRP-catalyzed reaction. 
 
Model selection (Figure 6) 
A 1:100 mixture of AP-phage (debiotinylated as described below) and Ala-phage 
(1×1011 pfu total) was pre-blocked in 3% dBSA (dialyzed BSA, to remove biotin) in TBS 
for one hour at 30 °C.  After precipitation with PEG, the phage were redissolved in 40 µL 
of 50 mM bicine pH 8.3 containing 5 mM magnesium acetate, 4 mM ATP, 50 µM biotin, 
and 100 µg/mL BSA.  Biotinylation was initiated by the addition of BirA to a final 
concentration of 0.65 nM.  After incubation at 30 °C for one hour, the reaction was 
quenched with 45 mM EDTA.  The phage were precipitated with PEG three times to 
remove excess biotin, then redissolved in 40 µL 3% dBSA/TBS.  Meanwhile, 5 µL of 
streptavidin-coated magnetic beads (Roche) was blocked in 50 µL 3% dBSA/TBS at  
37 °C for 30 minutes.  The beads were pelleted with a magnet, resuspended in 40 µL  
3% dBSA/TBS, added to the phage solution, and incubated at room temperature for 30 
minutes.  The beads were washed five times with TBS-T, three times with TBS, and once 
with water before resuspending in 22 µL water.  The captured phage were eluted by 
heating at 80 °C for five minutes38 and 1 µL of the bead suspension was used to infect a  
1 mL culture of ER2738 (1:100 dilution of a saturated culture in LB supplemented with 
10 µg/mL tetracycline).  Another 1 mL ER2738 culture was also infected with a diluted 
solution of the phage mixture before selection.  Both cultures were incubated at 37 °C for 
4.5 hours, then the single-stranded DNA was isolated and sequenced.    
 
  
286 
First generation phage display selections (Figure 8) 
Yeast biotin ligase was expressed and purified as described above.  B. subtilis and 
M. jannaschii biotin ligase were generously provided by Sarah Slavoff of the Ting 
laboratory.  In the manner described above for the model selection, 2×1011 pfu phage 
displaying the AP2 library were biotinylated with a mixture of BL2 enzymes, consisting 
of 100 nM each of yeast biotin ligase, B. subtilis biotin ligase, and M. jannaschii biotin 
ligase.  After incubating the reaction for one hour at 30 °C and quenching with 45 mM 
EDTA, the phage were precipitated with PEG three times to remove excess biotin and 
then redissolved in 40 µL 3% dBSA/TBS. 
A total of 10 µL of streptavidin-coated magnetic beads (Roche) were blocked in 
100 µL 3% dBSA/TBS at 37 °C for 30 minutes.  The beads were pelleted with a magnet, 
resuspended in 40 µL 3% dBSA/TBS, added to the phage solution, and incubated at room 
temperature with the phage for 30 minutes.  The beads were washed once with 100 µM 
biotin to remove streptavidin-binding peptides, then five times with TBS -T, three times 
with TBS, and once with water before resuspending in 22 µL water.  The captured phage 
were eluted from the beads by heating at 80 °C for five minutes38 and mixed with 2.5 µL 
of 10× TBS and 0.5 µL of 100 µM biotin.  For the first two rounds of selection, the phage 
were re-amplified by adding 24 µL of the bead suspension to 20 mL of BM4092F′ E. coli 
(1:100 dilution of a saturated culture in Luria Broth (LB) supplemented with 100 µg/mL 
avidin (Rockland) ).  For the third and fourth rounds, 13 µL of the bead suspension was 
used to infect 20 mL of ER2738 E. coli (New England Biolabs) in LB.  Negative 
selections were performed on phage produced from ER2738, by removing pre-
biotinylated phage with streptavidin-coated polystyrene beads as described below.   
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Second generation phage display selections (Figure 10) 
Selections performed with the AP2.2 libraries were identical to those of the first 
generation with the following modifications: (1) in the generation 2 selections, 10 nM 
yBL was used for each round; (2) and in the generation 2′ selections, the yBL 
concentration was decreased successively over rounds, from 100 nM in the first round, to 
10 nM in the second and third rounds, to 1 nM in the fourth and fifth rounds, and to  
0.1 nM in the sixth round.  As before, phage were prepared from the BM4092F′ strain for 
the first two rounds and then from the ER2738 strain for all subsequent rounds.  Negative 
selections were performed when ER2738 was used for phage amplification.  
 
Negative selections (removal of pre-biotinylated phage) 
Recovered phage were propagated in 20 mL ER2738 culture (1:100 dilution of a 
saturated culture in LB supplemented with 10 µg/mL tetracycline) and purified by two 
precipitations with PEG.  The phage pellet was redissolved in 300 µL of 3% dBSA in 
TBS-T.  Streptavidin-coated polystyrene beads (Bangs Laboratories, 1% suspension) 
were pre-blocked by incubation in 3% dBSA/TBS at 37 °C for 30 minutes.  The beads 
were pelleted by centrifugation, resuspended thoroughly in the solution of phage, and 
incubated for 30 minutes.  The debiotinylated phage were removed from the beads by 
centrifugation and collection of the supernatant.  The supernatant was treated with pre-
blocked streptavidin-coated polystyrene beads once more.  On average, we estimate that 
30-50% of the AP-phage are pre-biotinylated by the endogenous BirA in ER2738, by 
comparing the titer of phage before and after depletion with streptavidin-coated beads.  
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By phage ELISA, we estimate that > 90% of the biotinylated phage are removed by this 
treatment 
 
Construction of the AP2 phage library (Figure 7) 
The DNA encoding the phage library was constructed following the 
manufacturer’s instructions for the Ph.D. Peptide Display Cloning System (New England 
Biolabs, see Supporting Electronic Information).  Briefly, the oligonucleotides 
M13KEExtend.F (5'-CAT GCC CGG GTA CCT TTC TAT TCT C; incorporates an Acc65I site) and 
AP2Lib.R (5'-CAT GTT TCG GCC GAM NNM NNM NNM NNC ATC TTC ATG GCM NNG AGC 
ACM NNM NNM NNM NNA GAG TGA GAA TAG AAA GGT ACC CGG G, where M=A,C and  
N= A,G,C,T; the primer incorporates an EagI site) were annealed, and the 5' overhangs were 
made double-stranded with Klenow fragment.  The insert was digested with Acc65I and 
EagI and purified by PAGE.  M13KE vector was prepared by digestion of replicative 
form (RF) DNA with Acc65I and EagI and purified by gel extraction from low melt 
agarose.  For maximum recovery, 5 µg RF DNA was loaded per eight-well lane, and the 
vector was recovered using digestion with β-agarase (New England Biolabs) and ethanol 
precipitation.  Four equivalents of insert were then ligated to 4.4 µg of M13KE vector in 
a reaction containing 5 ng vector/µL and 1 unit T4 DNA ligase (New England Biolabs) 
per ng vector.  The DNA was purified using the Qiaquick PCR purification kit (Qiagen) 
or phenol/chloroform extraction, divided into 12 aliquots, and used to transform  
12× 40 µL electrocompetent TOP10F′ cells (commercially available from Invitrogen, but 
better electrocompetencies can be achieved if prepared according to the protocol in the 
Supporting Electronic Information).  Following 30 minutes of rescue in SOC media, the 
number of transformants was determined by titering the outgrowth.  The remaining cells 
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were diluted with a 600 mL culture of TOP10F′ (1:100 dilution of a saturated culture in 
LB supplemented with 10 µg/mL tetracycline) and incubated at 37 °C for 5 hours.  
Following two rounds of PEG precipitation, the recovered phage were resuspended 
thoroughly in 3 mL of TBS supplemented with 3 mM sodium azide to produce a library 
with diversity 4.2×107.  
 
Construction of the AP2.2 phage libraries (Figure 9) 
The insert was constructed as described above for the AP2 library, using the 
primer AP2.2Lib.R (5'-CAT GTT TCG GCC GAM NNM NNA AAC GTC ATC TTC ATA GCM 
NNA AGA ACM NNM NNM NNM NNA GAG TGA GAA TAG AAA GGT ACC CGG G where M=A,C 
and N= A,G,C,T; A represents 70% A and 10% each of the other bases, G represents 70% G and 10% each 
of the other bases, and so forth; the primer incorporates an EagI site).  Ligation of the PAGE-
purified insert and M13KE vector and transformation into electrocompetent TOP10F′ for 
phage production were performed as described above for the AP2 library. The generation 
2 library with diversity of 1.2×108 was constructed from a ligation reaction with 4 µg 
vector.  The generation 2′ library was obtained by combining the generation 2 library 
with a sub-library obtained from a ligation reaction with 8 µg vector, giving a total 
diversity of 7.1×108. 
 
Construction of AP and Ala phage 
The DNA encoding the AP-phage and Ala-phage were constructed as described 
above  for the AP2 phage library using the oligonucleotides AP.R (5'-CAT GTT TCG GCC 
GAC TCG TGC CAC TCG ATC TTC TGG GCC TCG AAG ATG TCG TTC AGG CCA GAG TGA 
GAA TAG AAA GGT ACC CGG G; incorporates the AP sequence (GLNDIFEAQKIEWHE) and an EagI 
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site) and Ala.R (5'-CAT GTT TCG GCC GAC TCG TGC CAC TCG ATC GCC TGG GCC TCG AAG 
ATA TCG TTC AGG CCA GAG TGA GAA TAG AAA GGT ACC CGG G; incorporates the Ala 
sequence (GLNDIFEAQAIEWHE), an EagI site, and a silent mutation (bold) to facilitate interpretation of 
the sequencing data generated from mixtures of AP- and Ala-phage). 
 
Methods for yAP biotinylation in vitro 
General DNA and protein methods 
The pET21 plasmids for bacterial expression of yAP fusions to HP1 or CFP were 
constructed by standard PCR subcloning techniques.  For the sequences of these 
construct, please see the Supporting Electronic Information.  The yAP fusion proteins 
were expressed in E. coli BL21 (DE3) as described for pET21-BirA in Chapter 3.   
 
Western blot assays for yAP biotinylation (Figure 11A) 
Proteins were biotinylated in vitro as follows: 20 µM yAP-CFP, CFP-yAP, yAP-
HP1, or HP1-yAP protein was combined with 1 µM yBL, 4 mM ATP, 50 µM biotin, and 
5 mM magnesium acetate in 50 mM bicine buffer pH 8.3 overnight at 30 °C.  Eight hours 
into the reaction, supplemental ATP (final concentration 8 mM) was added. The samples 
were resolved on 12% SDS-PAGE and blotted with streptavidin-HRP conjugate (1:1000 
dilution, Pierce) or stained with Coomassie Brilliant Blue. The HRP signal was visualized 
using Supersignal West Pico (Pierce). 
 
[3H]-biotin labeling of yAP fusion proteins (Figure 11B) 
The reaction conditions were as follows:  50 mM bicine pH 8.3, 5 mM 
magnesium acetate, 4 mM ATP, 50 µM biotin, 81 nM [3H]-biotin (37 µCi/nmol), 1 µM 
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yBL, and 12 µM yAP fusion protein.  A 30 µL reaction was initiated by the addition of 
ATP and incubated at ambient temperature (18.5 °C) for three hours.  Aliquots of the 
reaction (9 µL) were quenched by spotting onto dry phosphocellulose circles that were 
pretreated successively with 50 µM biotin and 10% trichloroacetic acid (TCA).  The air-
dried circles were then washed twice with cold 10% TCA, once with ethanol, and dried.  
The acid-insoluble radioactivity spotted on the circles was measured by liquid 
scintillation counting.  To calibrate for the lower counting efficiency of [3H]-biotin on the 
circles (typically five to seven-fold worse), the maximum amount of [3H]-biotin that 
could be incorporated onto HP1 was determined by simultaneously running a 
biotinylation reaction of HP1-AP by BirA.  Negative control reactions omitting ATP 
were used for background correction.   
 
Measurement of kcat and Km for yAP biotinylation by yBL (Figure 12) 
Kinetic measurements were performed with saturating concentrations of biotin 
and ATP as described previously18,39.  The reaction conditions were the same as above, 
and the concentration of yAP-HP1 ranged from 20 µM to 400 µM.  A 30 µL reaction was 
initiated by the addition of ATP and incubated at room temperature (18.5 °C) for up to 
one hour, during which time the reaction rate was still linear.  Aliquots of the reaction  
(9 µL) were quenched by spotting onto dry phosphocellulose circles that were treated as 
described above.  To calibrate for the lower counting efficiency of [3H]-biotin on the 
circles (typically five to seven-fold worse), the maximum amount of [3H]-biotin that 
could be incorporated onto HP1 was determined by running a BirA biotinylation reaction 
of HP1-AP at the same concentration.  Negative control reactions omitting ATP were 
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used for background correction.  The circles were washed and counted as above.  Kinetic 
data points were plotted and fitted against the Michael-Menten equation using ORIGIN 
software.  
We attempted to measure the kinetics of biotinylation of yAP-HP1 by BirA.  
However, no significant signal above background could be detected, even when we 
incubated the maximum possible amount of yAP-HP1 protein (260 µM) with 2 µM BirA 
for three hours.  Assuming that these are Vmax reaction conditions, this suggests that the 
kcat for yAP-HP1 biotinylation by BirA is less than 0.001 min-1, which is about 100-fold 
lower than the kcat for biotinylation by yBL.  We also attempted to measure the kinetics of 
biotinylation of HP1-AP by yBL, but our measurements were confounded by the 
background activity of BirA in the yBL stock (see above, “Yeast biotin ligase methods”).         
 
Methods for yeast cell surface biotinylation 
Cloning of yAP and AP fusions to Aga2p for yeast cell surface display 
The plasmid expressing Aga2p-AP was constructed by yeast homologous 
recombination40.  The insert was made in two steps.  First, the oligonucleotides APRev.R 
(5′-AAA TAA GCT TTT GTT CGG ATC CCT CGT GCC ACT CGA TCT TCT GGG CCT CGA AGA 
TGT CGT TCA GGC CTC CGC TAG CCG ACC CTC C; incorporates the AP) and Con2For.F (5′-
CTA GTG GTG GAG GAG GCT CTG GTG GAG GCG GTA GCG GAG GCG GAG GGT CGG CTA 
GCG GA; incorporates ~40 bp of overlap with pCTCon2 5′ of the AP sequence) were annealed and 
the 5' overhangs were made double-stranded with Klenow fragment.  Next, the annealed 
product was then amplified with the primers Con2For.F and Con2Rev.R (5′-TAT CAG ATC 
TCG AGC TAT TAC AAG TCC TCT TCA GAA ATA AGC TTT TGT TCG GAT CC; incorporates ~50 
bp of overlap with pCTCon2 3′ of the AP).  The insert and pCTcon2 vector (a kind gift from S. 
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Lippow and K.D. Wittrup (MIT) ), triply digested with NheI/SalI/BamHI, were 
transformed together into S. cerevisiae EBY100 (Invitrogen)40 using the Frozen-EZ Yeast 
Transformation IITM kit (Zymo Research) according to the manufacturer’s instructions.  
DNA was isolated from yeast colonies using the ZymoprepTM Yeast Plasmid 
Minipreparation Kit (Zymo Research) and amplified in E. coli. 
The plasmids expressing Aga2p-yAP and Aga2p-yAla were constructed using 
standard directional cloning.  The insert for Aga2p-yAP was constructed by annealing the 
oligonucleotides NheyAP.F (5'-GGG TCG GCT AGC GGA GGC ACG ACT AAT TGG GTT GCT 
CAG GCT TTC; incorporates an NheI site and part of the yAP) and BamyAP.R (5'-TTT TTT GGA 
TCC CGG ATC AAA CGT CAT CTT GAA AGC CTG AGC AAC CCA ATT; incorporates a BamHI site 
and the rest of the yAP), and the 5' overhangs were made double-stranded with Klenow 
fragment.  The insert was digested with NheI and BamHI and ligated in-frame to 
similarly digested pCTCon2 vector.  The Aga2p-yAla insert was similarly constructed 
using BamyAla.R (5'-TTT TTT GGA TCC CGG ATC AAA CGT CAT CGC GAA AGC CTG AGC 
AAC CCA ATT incorporates a BamHI site and the rest of the yAla sequence). 
 
yAP expression and labeling on yeast cell surface (Figure 14) 
The plasmids for yeast display of Aga2p-AP and Aga2p-yAP (construction 
described above) were transformed into S. cerevisiae EBY100 using the Frozen-EZ Yeast 
Transformation IITM kit (Zymo Research). After transformation, the cells were grown in 
synthetic minimal defined media lacking tryptophan and uracil (SD –W –U; 0.67% yeast 
nitrogen base (Difco), 2% glucose, 0.01% of adenine, arginine, cysteine, leucine, lysine, 
threonine and 0.005% of aspartic acid, glutamic acid, histidine, isoleucine, methionine, 
phenylalanine, proline, serine, tyrosine, valine) at 30 °C with shaking for 24 hours.  The 
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culture was diluted to a cell density of 2×107 cells/mL in 10% SD –W –U / SG –W –U 
media (same as SD –W –U but substituting galactose for glucose), and  protein 
expression and cell surface display were induced for 24 hours at room temperature with 
shaking.  The induced cells were harvested and washed with PBS-B (PBS+1% BSA).  
2×106 cells in 100 µL PBS-B were taken out for labeling experiments.  
For BirA reactions, the cells were incubated for three hours at room temperature 
with 50 µM biotin, 0.3 µM BirA, 4 mM ATP.  For yBL reactions, the cells were 
incubated for three hours at room temperature with 10 µM biotin, 4.7 µM yBL, 1 mM 
ATP, and 1.4 mM magnesium acetate.  Following the biotinylation reaction, the cells 
were washed once with PBS-B, and biotin incorporation was detected with streptavidin-
phycoerythrin (1:100 dilution, Jackson ImmunoResearch) for one hour at 4 °C.  For 
detection of the myc-tag as an expression marker, mouse anti-myc antibody (1:100 
dilution, Calbiochem) was added separately to the cells at room temperature. After one 
hour, cells were washed once with PBS-B and incubated with phycoerythrin-conjugated 
anti-mouse antibody (1:100 dilution, Invitrogen) for one hour at 4 °C.  Following 
antibody application, the cells were rinsed once with PBS-B and resuspended in 600 µL 
of PBS-B for flow cytometry analysis (FACScan, BD Biosciences). 
 
Methods for cell surface labeling on mammalian cells with yBL-yAP 
Labeling of yAP fusion proteins with QDs on the surface of living HeLa cells  
(Figure 15) 
HeLa were transfected with the pDisplay-yAP-YFP-TM plasmid (see the 
Supporting Electronic Information for sequence information) as described above in “Cell 
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surface BirA biotinylation assay for evaluating AP mutants.”  After 36-48 hours, the cells 
were rinsed once with DPBS and then biotinylated for one hour at 32 °C with 10 µM 
biotin, 1 mM ATP, 4.7 µM yBL, and 5 mM magnesium chloride in 0.75× DPBS 
containing 10% FBS.  The reaction also contained 0.2 mM EDTA, 20 µM DTT, and  
1% glycerol from the yBL storage buffer.  The cells were rinsed with DPBS containing 
6% bovine serum (DPBS+BS), then labeled with 10 nM streptavidin-QD655 conjugate 
(Invitrogen) in DPBS containing 1% dBSA for five minutes at room temperature. The 
cells were washed once with DPBS+BS and twice with DPBS before imaging on a Zeiss 
Axiovert 200M inverted epifluorescence microscope using a 40× oil-immersion lens.  
YFP (495DF10 excitation, 515DRLP dichroic, 530DF30 emission), QD655 (405DF20 
excitation, 585DRLP dichroic, 655DF20 emission), and DIC (630DF10 emission) images 
were collected and analyzed using Slidebook software (Intelligent Imaging Innovations).  
Acquisition times ranged from 100-400 milliseconds. 
 
Two-color labeling and imaging of yAP and AP fusions on the surface of living HeLa 
cells (Figures 16 and 17) 
HeLa transfected with the yAP-YFP-TM plasmid were plated together on the 
same dish with HeLa stably expressing AP-CFP-TM5,9 or HeLa stably expressing AP-
CFP-TM that had also been transiently transfected with yAP-YFP-TM.  After 40-48 
hours of protein expression, the cells were washed with DPBS, then biotinylated with 
yBL and labeled with streptavidin-QD655 as described above. Then, the AP tag was 
labeled by incubating the cells with 0.5 µM BirA, 10 µM biotin, 1 mM ATP, and 5 mM 
magnesium chloride in DPBS for four minutes at room temperature. After washing with 
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DPBS+BS, the biotin molecules were detected with 10 nM streptavidin-QD565 conjugate 
(Invitrogen) in DPBS+1% dBSA, incubated for four minutes at room temperature, then 
washed three times with DPBS.  Imaging was performed as above, with additional CFP 
(420DF20 excitation, 450DRLP dichroic, 475DF40 emission) and QD565 (405DF20 
excitation, 565DRLP dichroic, 565DF20 emission) filter sets.  
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Appendix:  Spectral characterization of ketone 1 and azides 1-3 
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Figure 1.  IR spectrum of ketone 1. 
 
 
 
Figure 2.  1H NMR spectrum of ketone 1. 
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Figure 3.  13C NMR spectrum of ketone 1. 
 
 303 
 
 
 
 
Figure 4.  IR spectrum of the methyl ester of azide 1. 
 
 
Figure 5.  1H NMR of azide 1. 
 304 
 
 
Figure 6.  IR spectrum of the methyl ester of azide 2. 
 
 
 
Figure 7.  1H NMR spectrum of azide 2 
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Figure 8.  IR spectrum of the methyl ester of azide 3. 
 
 
 
Figure 9.  1H NMR spectrum of azide 3. 
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Figure 10.  13C NMR spectrum of azide 3.  
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